<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Taxotere, INN-docetaxel</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ZapfDingbats;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\(Utiliser une police de caract\00E8";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:+mn-ea;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-name:"Heading 1\,Info rubrik 1\,titel 1";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-name:"Heading 2\,titel 2";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
h3
	{mso-style-name:"Heading 3\,OLD Heading 3\,Titre 31\,titel 3";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h4
	{mso-style-name:"Heading 4\,titel 4";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;
	font-style:italic;}
h5
	{mso-style-name:"Heading 5\,titel 5";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
h6
	{margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:.25in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:24.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:48.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:24.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:48.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-name:"Footer\,Pied de page1";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:141.75pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoEndnoteReference
	{color:black;
	vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:12.0pt;
	margin-right:-1.4pt;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:12.0pt;
	margin-right:-1.4pt;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-align:justify;
	text-indent:-14.15pt;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-indent:-.25in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-align:justify;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	layout-grid-mode:line;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:12.0pt;
	margin-right:26.95pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	layout-grid-mode:line;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	layout-grid-mode:line;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:-.05pt;
	margin-bottom:0in;
	margin-left:27.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#606420;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
address
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.References, li.References, div.References
	{mso-style-name:References;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TextBullet, li.TextBullet, div.TextBullet
	{mso-style-name:TextBullet;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Protokollsrubrik1, li.Protokollsrubrik1, div.Protokollsrubrik1
	{mso-style-name:"Protokollsrubrik 1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Format-Listepuces, li.Format-Listepuces, div.Format-Listepuces
	{mso-style-name:"Format-Liste \00E0 puces";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Titre0, li.Titre0, div.Titre0
	{mso-style-name:"Titre 0";
	margin-top:30.0pt;
	margin-right:0in;
	margin-bottom:24.0pt;
	margin-left:0in;
	text-align:center;
	page-break-before:always;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
p.TextTi11, li.TextTi11, div.TextTi11
	{mso-style-name:"Text\:Ti11";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Authors, li.Authors, div.Authors
	{mso-style-name:Authors;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MDSnormalsectionstyle, li.MDSnormalsectionstyle, div.MDSnormalsectionstyle
	{mso-style-name:"MDS normal section style";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Normaltitre3, li.Normaltitre3, div.Normaltitre3
	{mso-style-name:"Normal titre 3";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.Questiontext, li.Questiontext, div.Questiontext
	{mso-style-name:"Question text";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Normal2, li.Normal2, div.Normal2
	{mso-style-name:Normal2;
	margin:0in;
	text-align:justify;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TblTextCenter, li.TblTextCenter, div.TblTextCenter
	{mso-style-name:"Tbl Text Center";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
p.Text, li.Text, div.Text
	{mso-style-name:Text;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Heading41, li.Heading41, div.Heading41
	{mso-style-name:"Heading 41";
	margin:0in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableTextCenter, li.TableTextCenter, div.TableTextCenter
	{mso-style-name:"Table Text Center";
	mso-style-link:"Table Text Center Char1";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
p.Header1, li.Header1, div.Header1
	{mso-style-name:Header1;
	margin:0in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.paragraph, li.paragraph, div.paragraph
	{mso-style-name:paragraph;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Heading51, li.Heading51, div.Heading51
	{mso-style-name:"Heading 51";
	margin-top:0in;
	margin-right:2.85pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Retrait1, li.Retrait1, div.Retrait1
	{mso-style-name:Retrait1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.Heading31, li.Heading31, div.Heading31
	{mso-style-name:"Heading 31";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BodyText21, li.BodyText21, div.BodyText21
	{mso-style-name:"Body Text 21";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	line-height:13.0pt;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Heading21, li.Heading21, div.Heading21
	{mso-style-name:"Heading 21";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading11, li.Heading11, div.Heading11
	{mso-style-name:"Heading 11";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.65pt;
	text-indent:-212.65pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldCharacter
	{mso-style-name:"Bold Character";
	font-weight:bold;}
p.TblTextLeft, li.TblTextLeft, div.TblTextLeft
	{mso-style-name:"Tbl Text Left";
	mso-style-link:"Tbl Text Left Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.TblTextLeftChar
	{mso-style-name:"Tbl Text Left Char";
	mso-style-link:"Tbl Text Left";
	font-family:"Arial Narrow",sans-serif;}
p.TableTextLeft, li.TableTextLeft, div.TableTextLeft
	{mso-style-name:"Table Text Left";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.BlueReplace
	{mso-style-name:"Blue Replace";
	color:blue;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.xCover2Answ, li.xCover2Answ, div.xCover2Answ
	{mso-style-name:"xCover 2 Answ";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.Event, li.Event, div.Event
	{mso-style-name:Event;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times",serif;}
p.BalloonText1, li.BalloonText1, div.BalloonText1
	{mso-style-name:"Balloon Text1";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.CommentSubject1, li.CommentSubject1, div.CommentSubject1
	{mso-style-name:"Comment Subject1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEA1, li.EMEA1, div.EMEA1
	{mso-style-name:EMEA1;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEA2, li.EMEA2, div.EMEA2
	{mso-style-name:EMEA2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:27.0pt;
	text-indent:-27.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Normal11pt, li.Normal11pt, div.Normal11pt
	{mso-style-name:"Normal + 11pt";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEA10, li.EMEA10, div.EMEA10
	{mso-style-name:"EMEA 1";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEA20, li.EMEA20, div.EMEA20
	{mso-style-name:"EMEA 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:27.0pt;
	text-indent:-27.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Normal11ptCar
	{mso-style-name:"Normal + 11pt Car";}
p.Normal11ptGauche0, li.Normal11ptGauche0, div.Normal11ptGauche0
	{mso-style-name:"Normal + 11pt + Gauche\00A0\:  0\,30 cm";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:9.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TableHeadCenter, li.TableHeadCenter, div.TableHeadCenter
	{mso-style-name:"Table Head Center";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial Narrow",sans-serif;
	font-weight:bold;}
span.TableTextCenterChar1
	{mso-style-name:"Table Text Center Char1";
	mso-style-link:"Table Text Center";
	font-family:"Arial Narrow",sans-serif;}
span.msoins0
	{mso-style-name:msoins;}
p.ListBulletLevel1, li.ListBulletLevel1, div.ListBulletLevel1
	{mso-style-name:"List Bullet Level 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-17.85pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TextTi10, li.TextTi10, div.TextTi10
	{mso-style-name:"Text\:Ti10";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.xCoverDocTitle, li.xCoverDocTitle, div.xCoverDocTitle
	{mso-style-name:xCoverDocTitle;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.ReplaceText
	{mso-style-name:"Replace Text";
	color:fuchsia;}
p.00-Paragraph, li.00-Paragraph, div.00-Paragraph
	{mso-style-name:00-Paragraph;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.45pt 841.7pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:595.45pt 841.7pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:595.45pt 841.7pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:595.45pt 841.7pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection5
	{page:WordSection5;}
@page WordSection6
	{size:595.45pt 841.7pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection6
	{page:WordSection6;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#606420" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>&nbsp;</span></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=EMEA1><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=EMEA1><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:yellow'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE 20 mg/0.5&nbsp;ml
concentrate and solvent for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each single&#8209;dose
vial of TAXOTERE 20 mg/0.5&nbsp;ml concentrate contains docetaxel (as
trihydrate) corresponding to 20 mg of docetaxel (anhydrous). The viscous
solution contains 40&nbsp;mg/ml docetaxel (anhydrous).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Excipients with
known effect: </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each single&#8209;dose
vial of solvent contains 13% (w/w) ethanol 95% v/v &nbsp;in water for injection
</span><span style='font-size:11.0pt'>(252&nbsp;mg of ethanol 95% v/v)</span><span
lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB>For the
full list of excipients, see section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Concentrate and
solvent for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The concentrate is
a clear viscous, yellow to brown-yellow solution.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;layout-grid-mode:both'>The solvent is a colourless solution.</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Breast cancer</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>TAXOTERE
in combination with doxorubicin and cyclophosphamide is indicated for the
adjuvant treatment of patients with:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;positive
breast cancer</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node-negative
breast cancer</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients with
operable node</span><span lang=EN-GB style='font-size:11.0pt'>&#8209;negative
breast cancer, adjuvant treatment should be restricted to patients eligible to
receive chemotherapy according to internationally established criteria for primary
therapy of early breast cancer (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin is indicated for the treatment of patients with
locally advanced or metastatic breast cancer who have not previously received
cytotoxic therapy for this condition.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE
monotherapy is indicated for the treatment of patients with locally advanced or
metastatic breast cancer after failure of cytotoxic therapy. Previous
chemotherapy should have included an anthracycline or an alkylating agent.</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'> in combination with trastuzumab is indicated for the
treatment of patients with metastatic breast cancer whose tumours over express
HER2 and who previously have not received chemotherapy for metastatic disease.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>TAXOTERE in combination with
capecitabine is indicated for the treatment of patients with locally advanced
or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous
therapy should have included an anthracycline.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE is indicated for the treatment of patients
with locally advanced or metastatic non-small cell lung cancer after failure of
prior chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with cisplatin is indicated for the treatment of patients with
unresectable, locally advanced or metastatic non-small cell lung cancer, in
patients who have not previously received chemotherapy for this condition.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with prednisone or prednisolone is indicated
for the treatment of patients with metastatic castration-resistant prostate
cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with androgen-deprivation therapy (ADT),
with or without prednisone or prednisolone, is indicated for the treatment of patients
with metastatic hormone-sensitive prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>TAXOTERE in
combination with cisplatin and 5&#8209;fluorouracil is indicated for the
treatment of patients with metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction, who have not received prior
chemotherapy for metastatic disease.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with cisplatin and 5&#8209;fluorouracil is
indicated for the induction treatment of patients with locally advanced
squamous cell carcinoma of the head and neck.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>The use of docetaxel should be confined to units
specialised in the administration of cytotoxic chemotherapy and it should only
be administered under the supervision of a physician qualified in the use of
anticancer chemotherapy (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For breast, non-small cell lung, gastric, and head and
neck cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can be used (see section 4.4). </span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For metastatic castration-resistant prostate cancer,
given the concurrent use of prednisone or prednisolone the recommended
premedication regimen is oral dexamethasone 8&nbsp;mg, 12&nbsp;hours,
3&nbsp;hours and 1&nbsp;hour before the docetaxel infusion (see section 4.4).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For metastatic hormone-sensitive prostate cancer,
irrespective of the concurrent use of prednisone or prednisolone, the
recommended premedication regimen is oral dexamethasone 8&nbsp;mg 12 hours, 3
hours, and 1 hour before docetaxel infusion (see section 4.4).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Prophylactic G&#8209;CSF may be used to mitigate the
risk of haematological toxicities.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
administered as a one-hour infusion every three weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the adjuvant
treatment of operable node&#8209;positive and </span><span lang=EN-GB
style='font-size:11.0pt'>node&#8209;negative </span><span lang=EN-GB
style='font-size:11.0pt'>breast cancer, the recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour after doxorubicin
50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> every
3&nbsp;weeks for 6&nbsp;cycles (TAC regimen) (see also Dose adjustments during
treatment). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For the treatment
of patients with locally advanced or metastatic breast cancer, the recommended
dose of docetaxel is 100&nbsp;mg/m<sup>2</sup> in monotherapy. In first&#8209;line
treatment, docetaxel 75&nbsp;mg/m<sup>2 </sup>is given in combination therapy
with doxorubicin<sup> </sup>(50&nbsp;mg/m<sup>2</sup>).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with trastuzumab the recommended dose of docetaxel is 100&nbsp;mg/m<sup>2</sup>
every three weeks, with trastuzumab administered weekly. In the pivotal study
the initial docetaxel infusion was started the day following the first dose of
trastuzumab. The subsequent docetaxel doses were administered immediately after
completion of the trastuzumab infusion, if the preceding dose of trastuzumab
was well tolerated. For trastuzumab dose and administration, see trastuzumab
summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with capecitabine, the recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>
every three weeks, combined with capecitabine at 1250&nbsp;mg/m<sup>2</sup>
twice daily (within 30&nbsp;minutes after a meal) for 2&nbsp;weeks followed by a
1&#8209;week rest period. For capecitabine dose calculation according to body
surface area, see capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In chemotherapy
na&iuml;ve patients treated for non-small cell lung cancer, the recommended
dose regimen is docetaxel 75&nbsp;mg/m<sup>2 </sup>immediately followed by
cisplatin 75&nbsp;mg/m<sup>2 </sup>over 30&#8209;60&nbsp;minutes. For treatment
after failure of prior platinum-based chemotherapy, the recommended dose is
75&nbsp;mg/m&sup2; as a single agent.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer </span></u></i></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic </span></i><i><span
style='font-size:11.0pt;color:black'>castration-resistant</span></i><i><span
style='font-size:11.0pt;color:black'> prostate cancer</span></i><span
style='font-size:11.0pt;color:black'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>. Prednisone or prednisolone
5&nbsp;mg orally twice daily is administered continuously </span><span
lang=EN-GB style='font-size:11.0pt'>(see section 5.1)</span><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><i><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic
hormone-sensitive prostate cancer</span></i></p>

<p class=Heading41 style='text-align:justify;page-break-after:auto'><span
style='color:black;font-weight:normal'>The recommended dose of </span><span
lang=EN-GB style='font-weight:normal'>docetaxel</span><span lang=EN-GB> </span><span
style='color:black;font-weight:normal'>is 75&nbsp;mg/m<sup>2</sup> every 3
weeks for 6 cycles. Prednisone or prednisolone 5&nbsp;mg orally twice daily may
be administered continuously.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1&#8209;hour infusion,
followed by cisplatin 75&nbsp;mg/m<sup>2</sup>, as a 1&#8209; to 3&#8209;hour
infusion (both on day&nbsp;1 only), followed by 5&#8209;fluorouracil
750&nbsp;mg/m<sup>2</sup> per day given as a 24&#8209;hour continuous infusion
for 5&nbsp;days, starting at the end of the cisplatin infusion. Treatment is
repeated every three weeks. Patients must receive premedication with
antiemetics and appropriate hydration for cisplatin administration.
Prophylactic G&#8209;CSF should be used to mitigate the risk of haematological
toxicities (see also Dose adjustments during treatment).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients must
receive premedication with antiemetics and appropriate hydration (prior to and
after cisplatin administration). </span><span lang=EN-GB style='font-size:11.0pt'>Prophylactic
G&#8209;CSF may be used to mitigate the risk of haematological toxicities. </span><span
lang=EN-GB style='font-size:11.0pt'>All patients on the docetaxel-containing
arm of the TAX&nbsp;323 and TAX&nbsp;324 studies, received prophylactic
antibiotics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by radiotherapy (TAX&nbsp;323)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of inoperable locally advanced squamous
cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel
is 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion followed by cisplatin
75&nbsp;mg/m<sup>2</sup> over 1&nbsp;hour, on day one, followed by 5&#8209;fluorouracil
as a continuous infusion at 750&nbsp;mg/m<sup>2</sup> per day for five days.
This regimen is administered every 3&nbsp;weeks for 4&nbsp;cycles. Following
chemotherapy, patients should receive radiotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by chemoradiotherapy (TAX&nbsp;324)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of patients with locally advanced
(technically unresectable, low probability of surgical cure, and aiming at
organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1 hour
intravenous infusion on day&nbsp;1, followed by cisplatin 100&nbsp;mg/m<sup>2 </sup>administered
as a 30&#8209;minute to 3&#8209;hour infusion, followed by 5&#8209;fluorouracil
1000&nbsp;mg/m<sup>2</sup>/day as a continuous infusion from day&nbsp;1 to
day&nbsp;4. This regimen is administered every 3&nbsp;weeks for 3&nbsp;cycles.&nbsp;
Following chemotherapy, patients should receive chemoradiotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For cisplatin and
5&#8209;fluorouracil dose modifications, see the corresponding summary of
product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Dose adjustments during treatment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>General </span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel should
be administered when the neutrophil count is </span><span
lang=EN-GB style='font-size:11.0pt'>&sup3;</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;1,500&nbsp;cells/mm<sup>3</sup>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"(Utiliser une police de caract&egrave;",serif'>
</span><span lang=EN-GB style='font-size:11.0pt'>who experienced either febrile
neutropenia, neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for more
than one week, severe or cumulative cutaneous reactions or severe peripheral
neuropathy during docetaxel therapy, the dose of docetaxel should be reduced
from 100&nbsp;mg/m<sup>2</sup> to 75&nbsp;mg/m<sup>2</sup> and/or from 75 to
60&nbsp;mg/m&sup2;. If the patient continues to experience these reactions at
60&nbsp;mg/m&sup2;, the treatment should be discontinued. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Adjuvant therapy for breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Primary G&#8209;CSF
prophylaxis should be considered in patients who receive docetaxel, doxorubicin
and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who
experience febrile neutropenia and/or neutropenic infection should have their
docetaxel dose reduced to 60&nbsp;mg/m&sup2; in all subsequent cycles (see
sections 4.4 and 4.8). Patients who experience Grade&nbsp;3 or 4 stomatitis
should have their dose decreased to 60&nbsp;mg/m&sup2;.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with cisplatin</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients who
are dosed initially at docetaxel 75&nbsp;mg/m<sup>2</sup> in combination with
cisplatin and whose nadir of platelet count during the previous course of
therapy is &lt;&nbsp;25,000&nbsp;cells/mm<sup>3</sup>, or<sup> </sup>in
patients who experience febrile neutropenia, or in patients with serious non&#8209;haematologic
toxicities, the docetaxel dose in subsequent cycles should be reduced to
65&nbsp;mg/m<sup>2</sup>. For cisplatin dose adjustments, see the corresponding
summary of product characteristics.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with capecitabine</span></u></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For capecitabine dose modifications, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the first
appearance of Grade&nbsp;2 toxicity, which persists at the time of the next
docetaxel/capecitabine treatment, delay treatment until resolved to
Grade&nbsp;0&#8209;1, and resume at 100% of the original dose.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the second
appearance of Grade&nbsp;2 toxicity, or the first appearance of Grade&nbsp;3
toxicity, at any time during the treatment cycle, delay treatment until
resolved to Grade&nbsp;0&#8209;1 and then resume treatment with docetaxel
55&nbsp;mg/m&sup2;.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For any subsequent appearances of
toxicities, or any Grade&nbsp;4 toxicities, discontinue the docetaxel dose.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>For
trastuzumab dose modifications, see trastuzumab summary of product
characteristics.</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with cisplatin and 5&#8209;fluorouracil</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If an episode of
febrile neutropenia, prolonged neutropenia or neutropenic infection occurs
despite G&#8209;CSF use, the docetaxel dose should be reduced from 75 to
60&nbsp;mg/m<sup>2</sup>. If subsequent episodes of complicated neutropenia
occur the docetaxel dose should be reduced from 60 to 45&nbsp;mg/m<sup>2</sup>.
In case of Grade&nbsp;4 thrombocytopenia the docetaxel dose should be reduced
from 75 to 60&nbsp;mg/m<sup>2</sup>. Patients should not be retreated with
subsequent cycles of docetaxel until neutrophils recover to a level
&gt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup> and platelets recover to a level
&gt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>. Discontinue treatment if these
toxicities persist see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Recommended dose
modifications for toxicities in patients treated with docetaxel in combination
with cisplatin and 5&#8209;fluorouracil (5&#8209;FU):</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Toxicity</span></b></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Dose adjustment</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce 5&#8209;FU dose by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: then reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce docetaxel and 5&#8209;FU doses
  by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis/mucositis grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce 5&#8209;FU dose by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: stop 5&#8209;FU only, at all
  subsequent cycles.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Third episode: reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis/mucositis
  grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>First episode:
  stop 5&#8209;FU only, at all subsequent cycles.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second episode:
  reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
</table>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=Questiontext align=left style='margin:0in;text-align:left;page-break-after:
auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:
normal'>For cisplatin and 5&#8209;fluorouracil dose adjustments, see the
corresponding </span><span style='font-family:"Times New Roman",serif;
font-weight:normal'>summary of product characteristics</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the pivotal
SCCHN studies patients who experienced complicated neutropenia (including
prolonged neutropenia, febrile neutropenia, or infection), it was recommended
to use G&#8209;CSF to provide prophylactic coverage (eg, day&nbsp;6&#8209;15)
in all subsequent cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Special populations:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'>Patients with hepatic impairment</span></u></i></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Based on pharmacokinetic data with docetaxel at
100&nbsp;mg/m&sup2; as single agent, patients who have both elevations of
transaminase (ALT and/or AST) greater than 1.5&nbsp;times the upper limit of
the normal range (ULN) and alkaline phosphatase greater than 2.5&nbsp;times the
ULN, the recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> (see sections
4.4 and 5.2). For those patients with serum bilirubin &gt;&nbsp;ULN and/or ALT
and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN associated with alkaline
phosphatase &gt;&nbsp;6&nbsp;times the ULN, no dose&#8209;reduction can be
recommended and docetaxel should not be used unless strictly indicated. </span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>with gastric adenocarcinoma, the pivotal
clinical study excluded patients with <span class=BlueReplace><span
style='color:windowtext'>ALT and/or</span></span></span><span lang=EN-GB
style='font-size:11.0pt'> </span><span class=BlueReplace><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span><span
lang=EN-GB style='font-size:11.0pt'>bilirubin &gt;&nbsp;1&nbsp;x&nbsp;ULN<span
class=BlueReplace><span style='color:windowtext'>; for these patients,</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>no dose-reductions can be recommended and docetaxel should not be used
unless strictly indicated.</span><span lang=EN-GB style='font-size:11.0pt'> No
data are available in patients with hepatic impairment treated by docetaxel in
combination </span><span lang=EN-GB style='font-size:11.0pt'>in the other
indications</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of TAXOTERE in nasopharyngeal carcinoma in children aged 1 month to
less than 18 years have not yet been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There is no
relevant use of TAXOTERE in the paediatric population in the indications breast
cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head
and neck cancer, not including type II and III less differentiated
nasopharyngeal carcinoma. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'>Older people</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Based on a
population pharmacokinetic analysis, there are no special instructions for use
in the older people.</span></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>In combination with capecitabine, for patients
60&nbsp;years of age or more, a starting dose reduction of capecitabine to 75%
is recommended (see capecitabine summary of product characteristics).</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>For instructions on preparation and administration of
the product, see section</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;6.6.</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel must not
be used in patients with baseline neutrophil count of
&lt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel must not
be used in patients with severe liver impairment since there is no data
available (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>Contraindications for other medicinal products also
apply, when combined with docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For breast and non&#8209;small
cell lung cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can reduce the incidence and severity of fluid retention as well as the
severity of hypersensitivity reactions. For prostate cancer, the premedication is
oral dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour
before the docetaxel infusion (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Haematology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenia is the
most frequent adverse reaction of docetaxel. Neutrophil nadirs occurred at a
median of 7&nbsp;days but this interval may be shorter in heavily pre&#8209;treated
patients. Frequent monitoring of complete blood counts should be conducted on
all patients receiving docetaxel. Patients should be retreated with docetaxel
when neutrophils recover to a level </span><span
lang=EN-GB style='font-size:11.0pt'>&sup3;</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;1,500&nbsp;cells/mm<sup>3</sup> (see section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the case of
severe neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for seven days or
more) during a course of docetaxel therapy, a reduction in dose for subsequent
courses of therapy or the use of appropriate symptomatic measures are
recommended (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
(TCF), febrile neutropenia and neutropenic infection occurred at lower rates
when patients received prophylactic G&#8209;CSF. Patients treated with TCF
should receive prophylactic G&#8209;CSF to mitigate the risk of complicated
neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic
infection). Patients receiving TCF should be closely monitored (see sections
4.2 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with doxorubicin and cyclophosphamide
(TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates
when patients received primary G&#8209;CSF prophylaxis. Primary G&#8209;CSF
prophylaxis should be considered in patients who receive adjuvant therapy with
TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile
neutropenia, prolonged neutropenia or neutropenic infection). Patients
receiving TAC should be </span><span lang=EN-GB style='font-size:11.0pt'>closely
monitored (see sections 4.2 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Gastrointestinal reactions</span></u></p>

<p class=MsoNormal style='margin-left:15.85pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Caution is recommended for
patients with </span><span style='font-size:11.0pt'>neutropenia,</span><span
style='font-size:11.0pt'> particularly at risk for developing gastrointestinal
complications</span><span style='font-size:11.0pt'>. Although majority of cases
occurred during the first or second cycle of docetaxel containing regimen, e</span><span
lang=EN-GB style='font-size:11.0pt'>nterocolitis could develop at any time, and
could lead to death as early as on the first day of onset. Patients should be
closely monitored for early manifestations of serious gastrointestinal toxicity
(see sections 4.2, 4.4 Haematology, and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Hypersensitivity reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients should be
observed closely for hypersensitivity reactions especially during the first and
second</span><span lang=EN-GB style='font-size:11.0pt'> infusions.
Hypersensitivity reactions may occur within a few minutes following the
initiation of the infusion of docetaxel, thus facilities for the treatment of
hypotension and bronchospasm should be available. If hypersensitivity reactions
occur, minor symptoms such as flushing or localised cutaneous reactions do not
require interruption of therapy. However, severe reactions, such as severe
hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation
of docetaxel and appropriate therapy. Patients who have developed severe
hypersensitivity reactions should not be re-challenged with docetaxel.</span><span
lang=EN-GB style='font-size:11.0pt'> Patients who have previously experienced a
hypersensitivity reaction to paclitaxel may be at risk to develop hypersensitivity
reaction to docetaxel, including more severe hypersensitivity reaction. These
patients should be closely monitored during initiation of docetaxel therapy</span><span
style='font-size:11.0pt'>.</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Cutaneous reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Localised skin erythema of the extremities (palms of
the hands and soles of the feet) with oedema followed by desquamation has been
observed. Severe symptoms such as eruptions followed by desquamation which lead
to interruption or discontinuation of docetaxel treatment were reported (see
section 4.2).</span></p>

<p class=00-Paragraph><span lang=EN-GB>Severe Cutaneous Adverse Reactions
(SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis</span><sup><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial Narrow",sans-serif'> </span></sup><span
lang=EN-GB>(TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have
been reported with docetaxel treatment. Patients should be informed about the
signs and symptoms of serious skin manifestations and closely monitored</span><strong><span
lang=EN-GB style='font-family:"Segoe UI",sans-serif;color:#444444;font-weight:
normal'>. </span></strong><span lang=EN-GB>If signs and symptoms suggestive of
these reactions appear discontinuation of docetaxel should be considered.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Fluid retention</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Patients with severe fluid retention such as pleural
effusion, pericardial effusion and ascites should be monitored closely.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Respiratory
disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung
disease, pulmonary fibrosis and respiratory failure have been reported and </span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>may be associated </span></span><span
lang=EN-GB style='font-size:11.0pt'>with fatal outcome. </span><span
class=BlueReplace><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Cases
of radiation pneumonitis have been reported in patients receiving concomitant
radiotherapy.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If new or
worsening pulmonary symptoms develop, patients should be closely monitored,
promptly investigated, and appropriately treated. Interruption of docetaxel
therapy is recommended</span><span style='font-size:11.0pt'> until diagnosis is
available</span><span lang=EN-GB style='font-size:11.0pt'>. Early use of
supportive care measures may help improve the condition. The benefit of
resuming docetaxel treatment must be carefully evaluated.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Patients with liver impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel at 100&nbsp;mg/m<sup>2</sup> as single agent who have
serum transaminase levels (ALT and/or AST) greater than 1.5&nbsp;times the ULN
concurrent with serum alkaline phosphatase levels greater than 2.5&nbsp;times
the ULN, there is a higher risk of developing severe adverse reactions such as
toxic deaths including sepsis and gastrointestinal haemorrhage which can be
fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and
asthenia. Therefore, the recommended dose of docetaxel in those patients with
elevated liver function test (LFTs) is 75&nbsp;mg/m<sup>2</sup> and LFTs should
be measured at baseline and before each cycle (see section 4.2).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For patients with serum bilirubin levels &gt;&nbsp;ULN
and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN concurrent with serum
alkaline phosphatase levels &gt;&nbsp;6&nbsp;times the ULN, no dose-reduction
can be recommended and docetaxel should not be used unless strictly indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with cisplatin and 5&#8209;fluorouracil for the treatment of patients</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>with gastric adenocarcinoma, the pivotal clinical study excluded
patients with <span class=BlueReplace><span style='color:windowtext'>ALT and/or</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span class=BlueReplace><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span><span
lang=EN-GB style='font-size:11.0pt'>bilirubin &gt;&nbsp;1&nbsp;x&nbsp;ULN<span
class=BlueReplace><span style='color:windowtext'>; for these patients,</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>no dose-reductions can be recommended and docetaxel should not be used
unless strictly indicated.</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>No data are available in patients with
hepatic impairment treated by docetaxel in combination </span><span lang=EN-GB
style='font-size:11.0pt'>in the other indications</span><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Patients with renal impairment</span></u></p>

<p class=TblTextCenter align=left style='margin:0in;text-align:left;page-break-after:
avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There are no data
available in patients with severely impaired renal function treated with
docetaxel. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Nervous system</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The development of
severe peripheral neurotoxicity requires a reduction of dose (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Cardiac toxicity</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Heart failure has
been observed in patients receiving docetaxel in combination with trastuzumab,
particularly following anthracycline (doxorubicin or epirubicin)&#8209;containing
chemotherapy. This may be moderate to severe and has been associated with death
(see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>When patients are
candidates for treatment with docetaxel in combination with trastuzumab, they
should undergo baseline cardiac assessment. Cardiac function should be further
monitored during treatment (e.g. every three months) to help identify patients
who may develop cardiac dysfunction. For more details see summary of product
characteristics of trastuzumab.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including
ventricular tachycardia (sometimes fatal) has been reported in patients treated
with docetaxel in combination regimens including doxorubicin, 5-fluorouracil
and/ or cyclophosphamide (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>Baseline cardiac assessment is
recommended.&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Eye</span></u><u><span
lang=EN-GB style='font-size:11.0pt'> disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cystoid macular
oedema (CMO) has been reported in patients treated with docetaxel. Patients
with impaired vision should undergo a prompt and complete ophthalmologic
examination. In case CMO is diagnosed, docetaxel treatment should be
discontinued and appropriate treatment initiated (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies have been reported when docetaxel was given in combination with
anticancer treatments known to be associated with second primary malignancies. Second
primary malignancies (including acute myeloid leukaemia, myelodysplastic
syndrome and non-Hodgkin lymphoma) may occur several months or years after
docetaxel-containing therapy. Patients should be monitored for second primary
malignancies (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Tumour Lysis
Syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tumour lysis
syndrome has been reported with docetaxel after the first or the second cycle
(see section 4.8). Patients at risk of tumour lysis syndrome (e.g. with renal impairment,
hyperuricemia, bulky tumour, rapid progression) should be closely monitored.
Correction of dehydration and treatment of high uric acid levels are
recommended prior to initiation of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Others</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Contraceptive measures must be
taken by both men and women during treatment and for men at least 6&nbsp;months
after cessation of therapy (see section 4.6).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><a
name="OLE_LINK5"></a><a name="OLE_LINK6"><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></a></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The concomitant use of docetaxel
with strong CYP3A4 inhibitors </span><span style='font-family:"Times New Roman",serif;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole)
should be avoided (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Additional cautions for use in adjuvant
treatment of breast cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Complicated neutropenia</span></u></i></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For patients who experience complicated neutropenia
(prolonged neutropenia, febrile neutropenia or infection), G&#8209;CSF and dose
reduction should be considered (see section 4.2).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastrointestinal reactions</span></u></i></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Symptoms such as early abdominal pain and tenderness,
fever, diarrhoea, with or without neutropenia, may be early manifestations of
serious gastrointestinal toxicity and should be evaluated and treated promptly.</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Congestive heart failure (CHF)</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients should be monitored for symptoms
of congestive heart failure during therapy and during the follow up period. In
patients treated with the TAC regimen for node positive breast cancer, the risk
of CHF has been shown to be higher during the first year after treatment (see
sections 4.8 and 5.1). </span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Patients with 4+ nodes</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>As the benefit observed in patient
with 4+ nodes was not statistically significant on disease&#8209;free survival
(DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in
patients with 4+ nodes was not fully demonstrated at the final analysis (see
section 5.1).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Elderly</span></u></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in adjuvant treatment
of breast cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There are limited data available in
patients &gt;&nbsp;70&nbsp;years of age on docetaxel use in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in castration-resistant
prostate cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Of the 333&nbsp;patients treated
with docetaxel every three weeks in a prostate cancer study (TAX 327),
209&nbsp;patients were 65&nbsp;years of age or greater and 68&nbsp;patients
were older than 75&nbsp;years. In patients treated with docetaxel every three
weeks, the incidence of related nail changes occurred at a rate </span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;10% higher in patients who
were 65&nbsp;years of age or greater compared to younger patients. The
incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred
at rates </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;10% higher </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>in patients who were
75&nbsp;years of age or greater versus less than 65&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in hormone-sensitive
prostate cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>Of the
</span><span style='font-size:11.0pt;color:black'>545 </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>patients treated with docetaxel every 3
weeks</span><span style='font-size:11.0pt;color:black'> in a hormone-sensitive
prostate cancer study (STAMPEDE)</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>, </span><span style='font-size:11.0pt;color:black'>296 patients
were 65 years of age or older, and 48 patients were 75 years of age or older</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>More patients aged &#8805;65 years in the
docetaxel arm reported hypersensitivity reaction, neutropenia, anaemia, fluid
retention, dyspnea, and nail changes when compared to the patients aged less
than 65 years. None of these increases in frequency reached 10% difference with
the control arm.</span><span style='font-size:11.0pt'> </span><span lang=EN-GB
style='font-size:11.0pt'>In patients who were 75&nbsp;years of age or older,
when compared to younger patients,</span><span style='font-size:11.0pt'>
neutropenia, anaemia, diarrhea, dyspnea and upper respiratory tract infection
were reported</span><span style='font-size:11.0pt'> </span><span
style='font-size:11.0pt'>with a greater incidence (at least 10% higher)</span><span
lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in gastric
adenocarcinoma cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Among the 300 (221&nbsp;patients in
the phase&nbsp;III part of the study and 79&nbsp;patients in the phase&nbsp;II
part) patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
in the gastric cancer study, 74 were 65&nbsp;years of age or older and
4&nbsp;patients were 75&nbsp;years of age or older. </span><span
style='font-family:"Times New Roman",serif'>The incidence of serious adverse
events was higher in older people compared to younger patients. The incidence
of the following adverse events (all grades): lethargy, stomatitis, neutropenic
infection occurred at rates </span><span style='font-family:Symbol'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;10% higher in patients who
were 65&nbsp;years of age or older compared to younger patients. </span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'>Older people
treated with TCF should be closely monitored.</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>13 % (w/w) ethanol 95% v/v (alcohol), i.e.
up to 252&nbsp;mg ethanol 95% v/v per solvent vial, equivalent to 6&nbsp;ml of
beer or 2.6&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, in children and in high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>Consideration
should be given to possible effects on the central nervous system.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'> studies have shown that the metabolism of docetaxel may be modified by
the concomitant administration of compounds which induce, inhibit or are
metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450&#8209;3A
such as ciclosporine, ketoconazole and erythromycin. As a result, caution
should be exercised when treating patients with these medicinal products as
concomitant therapy since there is a potential for a significant interaction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In case of
combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse
reactions may increase, as a result of reduced metabolism. If the concomitant
use of a strong CYP3A4 inhibitor </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) </span><span
lang=EN-GB style='font-size:11.0pt'>cannot be avoided, a close clinical
surveillance is warranted and a dose-adjustment of docetaxel may be suitable
during the treatment with the strong CYP3A4 inhibitor (see section 4.4). </span><span
lang=EN-GB style='font-size:11.0pt'>In a pharmacokinetic study with 7 patients,
the co-administration of docetaxel with the strong CYP3A4 inhibitor
ketoconazole leads to a&nbsp;significant decrease in docetaxel clearance by
49%.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Docetaxel pharmacokinetics in the
presence of prednisone was studied in patients with metastatic prostate cancer.
Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4. No
statistically significant effect of prednisone on the pharmacokinetics of
docetaxel was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
highly protein bound (&gt;&nbsp;95%). Although the possible <i>in vivo</i>
interaction of docetaxel with concomitantly administered medicinal product has
not been investigated formally, <i>in vitro</i> interactions with tightly
protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did
not affect protein binding of docetaxel. In addition, dexamethasone did not
affect protein binding of docetaxel. Docetaxel did not influence the binding of
digitoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not
influenced by their co&#8209;administration. Limited data from a single
uncontrolled study were suggestive of an interaction between docetaxel and
carboplatin. When combined to docetaxel, the clearance of carboplatin was about
50% higher than values previously reported for carboplatin monotherapy.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and
lactation</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>There is no information on the use of docetaxel in
pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic
in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic
medicinal products, docetaxel may cause foetal harm when administered to
pregnant women. Therefore, docetaxel must not be used during pregnancy unless
clearly indicated.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Women of childbearing age receiving docetaxel should
be advised to avoid becoming pregnant, and to inform the treating physician
immediately should this occur.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is a
lipophilic substance but it is not known whether it is excreted in human milk.
Consequently, because of the potential for adverse reactions in nursing
infants, breast feeding must be discontinued for the duration of docetaxel
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Contraception
in males and females</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>An effective
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In non clinical
studies, docetaxel has genotoxic effects and may alter male fertility (see
section 5.3). Therefore, men being treated with docetaxel are advised not to
father a child during and up to 6&nbsp;months after treatment and to seek
advice on conservation of sperm prior to treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No studies on the
effects on the ability to drive and use machines have been performed. The
amount of alcohol in this </span><span lang=EN-GB style='font-size:11.0pt'>medicinal
product </span><span style='font-size:11.0pt'>and the side effects</span><span
lang=EN-GB style='font-size:11.0pt'> of the product may impair the ability to
drive or use machines (see sections 4.4</span><span style='font-size:11.0pt'>
and 4.8</span><span lang=EN-GB style='font-size:11.0pt'>). Therefore, patients
should be warned of the potential impact of the amount of alcohol and the side
effects of this medicinal product on the ability to drive or use machines, and
be advised not to drive or use machines if they experience these side effects
during treatment.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Summary of the safety profile for all
indications</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The adverse reactions
considered to be possibly or probably related to the administration of
docetaxel have been obtained</span><span lang=EN-GB style='font-size:11.0pt'>
in: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1312 and
     121&nbsp;patients who received 100&nbsp;mg/m&sup2;<sup> </sup>and
     75&nbsp;mg/m&sup2; of docetaxel as a single agent respectively.</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>258&nbsp;patients
     who received docetaxel in combination with doxorubicin. </span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>406&nbsp;patients
     who received docetaxel in combination with cisplatin. </span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>92&nbsp;patients
treated with </span><span style='font-family:"(Utiliser une police de caract&egrave;",serif'>docetaxel</span><span
style='font-family:"Times New Roman",serif;text-transform:uppercase'> </span><span
style='font-family:"Times New Roman",serif'>in combination with </span><span
style='font-family:"Times New Roman",serif'>trastuzumab. </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>255&nbsp;patients
     who received docetaxel in combination with capecitabine.</span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>332&nbsp;patients
(TAX327) who received docetaxel in combination with prednisone or prednisolone
(clinically important treatment related adverse events are presented).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1276&nbsp;patients
     (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received
     docetaxel in combination with doxorubicin and cyclophosphamide (clinically
     important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>300&nbsp;gastric
     adenocarcinoma patients (221&nbsp;patients in the phase&nbsp;III part of
     the study and 79&nbsp;patients in the phase&nbsp;II part) who received docetaxel
     in combination with cisplatin and 5&#8209;fluorouracil (clinically
     important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>174 and
     251&nbsp;head and neck cancer patients who received docetaxel in
     combination with cisplatin and 5&#8209;fluorouracil (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>545 patients (STAMPEDE
     study) who received docetaxel in combination with prednisone or
     prednisolone and ADT.</span></li>
</ul>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>These reactions were described using the NCI Common
Toxicity Criteria (grade&nbsp;3&nbsp;=&nbsp;G3; grade&nbsp;3&#8209;4&nbsp;=&nbsp;G3/4;
grade&nbsp;4&nbsp;=&nbsp;G4), the COSTART and the MedDRA terms. Frequencies are
defined as: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to
&lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from available data).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>The most commonly reported adverse reactions of
docetaxel alone are: neutropenia (which was reversible and not cumulative; the
median day to nadir was 7&nbsp;days and the median duration of severe
neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) was 7&nbsp;days), anaemia,
alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The severity of
adverse events of docetaxel may be increased when docetaxel is given in
combination with other chemotherapeutic agents.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with </span><span lang=EN-GB style='font-size:11.0pt'>trastuzumab, </span><span
lang=EN-GB style='font-size:11.0pt'>adverse events (all grades) reported in
&#8805;&nbsp;10% are displayed. There was an increased incidence of SAEs (40%
vs. 31%) and Grade&nbsp;4 AEs (34% vs. 23%) in the trastuzumab combination arm
compared to docetaxel monotherapy.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For combination with capecitabine,
the most frequent treatment-related undesirable effects (&#8805;&nbsp;5%)
reported in a phase&nbsp;III study in breast cancer patients failing
anthracycline treatment are presented (see capecitabine summary of product
characteristics).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring
over the 6 cycles of treatment with docetaxel and having at least 2% higher
incidence in the docetaxel treatment arm by comparison to the control arm, are
presented, using the CTCAE grading scale.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The following
adverse reactions are frequently observed with docetaxel:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Immune system disorders</span></u></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity reactions have
generally occurred within a few minutes following the start of the infusion of
docetaxel and were usually mild to moderate. The most frequently reported
symptoms were flushing, rash with or without pruritus, chest tightness, back
pain, dyspnoea and fever or chills.&nbsp; Severe reactions were characterised
by hypotension and/or bronchospasm or generalized rash/erythema (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></u></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The development of severe
peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and
4.4). Mild to moderate neuro-sensory signs are characterised by paresthesia,
dysesthesia or pain including burning. Neuro-motor events are mainly
characterised by weakness.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Reversible
cutaneous reactions have been observed and were generally considered as mild to
moderate. Reactions were characterised by a rash including localised eruptions
mainly on the feet and hands (including severe hand and foot syndrome), but
also on the arms, face or thorax, and frequently associated with pruritus.
Eruptions generally occurred within one week after the docetaxel infusion. Less
frequently, severe symptoms such as eruptions followed by desquamation which
rarely lead to interruption or discontinuation of docetaxel treatment were
reported (see sections 4.2 and 4.4). Severe nail disorders are characterised by
hypo- or hyperpigmentation and sometimes pain and onycholysis. &nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
reactions were generally mild and consisted of hyper pigmentation,
inflammation, redness or dryness of the skin, phlebitis or extravasation and
swelling of the vein.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Fluid retention includes events
such as peripheral oedema and less frequently pleural effusion, pericardial
effusion, ascites and weight gain. The peripheral oedema usually starts at the
lower extremities and may become generalised with a weight gain of 3&nbsp;kg or
more. Fluid retention is cumulative in incidence and severity (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 100&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA system
   organ classes</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Very common
   adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections
  (G3/4: 5.7%; including sepsis and pneumonia, fatal in 1.7%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection
  associated with G4 neutropenia (G3/4: 4.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  76.4%); <br>
  Anaemia (G3/4: 8.9%); <br>
  Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Thrombocytopenia
  (G4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (G3/4: 5.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3: 4.1%); <br>
  Peripheral motor neuropathy (G3/4: 4%); <br>
  Dysgeusia (severe: 0.07%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension;
  Hypertension;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Haemorrhage</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dyspnoea
  (severe: 2.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 5.3%); </span></p>
  <p class=MsoDate><span lang=EN-GB>Diarrhoea (G3/4: 4%); <br>
  Nausea (G3/4: 4%); <br>
  Vomiting (G3/4: 3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (severe: 0.2%); <br>
  Abdominal pain (severe: 1%); <br>
  Gastrointestinal haemorrhage (severe: 0.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oesophagitis
  (severe: 0.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  <br>
  Skin reaction (G3/4: 5.9%); <br>
  Nail </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders
  (severe: 2.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (severe:
  1.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arthralgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (severe: 6.5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 11.2%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
  reaction; </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Non-cardiac
  chest pain (severe: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  alkaline phosphatase increased (&lt;&nbsp;4%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 AST increased
  (&lt;&nbsp;3%);<br>
  G3/4 ALT increased (&lt;&nbsp;2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for TAXOTERE 100 mg/m<sup>2</sup>
single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare: bleeding episodes
associated with grade&nbsp;3/4 thrombocytopenia.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>Reversibility data are available among 35.3% of
patients who developed neurotoxicity following docetaxel treatment at
100&nbsp;mg/m&sup2; as single agent. The events were spontaneously reversible
within 3&nbsp;months.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Very rare: one
case of alopecia non-reversible at the end of the study. 73% of the cutaneous
reactions were reversible within 21&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The</span><span
lang=EN-GB style='font-size:11.0pt'> median cumulative dose to treatment
discontinuation was more than 1,000&nbsp;mg/m<sup>2 </sup>and the median time
to fluid retention reversibility was 16.4&nbsp;weeks (range 0 to
42&nbsp;weeks). The onset of moderate and severe retention is delayed (median
cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in patients with premedication
compared with patients without premedication (median cumulative dose:
489.7&nbsp;mg/m<sup>2</sup>); however, it has been reported in some patients
during the early courses of therapy.</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Tabulated list of adverse reactions in non-small
cell lung cancer for TAXOTERE 75&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA <span
   style='color:black'>system organ classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections
  (G3/4: 5%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  54.2%); </span></p>
  <p class=MsoDate><span lang=IT>Anaemia (G3/4: 10.8%); Thrombocytopenia (G4:
  1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (no severe)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 2.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia (no
  severe) </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  3.3%); <br>
  Stomatitis (G3/4: 1.7%); <br>
  Vomiting (G3/4: 0.8%); <br>
  Diarrhoea (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  <br>
  Skin reaction (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nail disorders
  (severe: 0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 12.4%); <br>
  Fluid retention (severe: 0.8%);<br>
  Pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;2%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Tabulated list of adverse reactions in breast cancer
for TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA <span
   style='color:black'>system organ classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection (G3/4:
  7.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  91.7%);<br>
  Anaemia (G3/4: 9.4%); <br>
  Febrile neutropenia;<br>
  Thrombocytopenia (G4: 0.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cardiac failure;
  </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia (no
  severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  5%); Stomatitis (G3/4: 7.8%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  6.2%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  5%); Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  disorders (severe: 0.4%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
  reaction (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 8.1%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (severe: 1.2%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
  reaction</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;2.5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  alkaline phosphatase increased (&lt;&nbsp;2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 AST
  increased (&lt;&nbsp;1%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 ALT
  increased (&lt;&nbsp;1%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in non-small
cell lung cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with cisplatin</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 5.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Neutropenia (G4: 51.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Anaemia (G3/4: 6.9%); Thrombocytopenia (G4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>N</span><span lang=EN-GB style='font-size:11.0pt'>ervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3: 3.7%); Peripheral
  motor neuropathy (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypotension (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 9.6%); Vomiting (G3/4: 7.6%); <br>
  Diarrhoea (G3/4: 6.4%); <br>
  Stomatitis (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Skin and subcutaneous tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia; </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  (severe: 0.7%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin reaction
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia (severe: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia (severe: 9.9%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fluid retention (severe: 0.7%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fever (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infusion site reaction; Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood bilirubin increased (2.1%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 ALT increased (1.3%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 AST increased (0.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood alkaline phosphatase increased (0.3%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 100&nbsp;mg/m&sup2; in combination with trastuzumab</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Neutropenia (G3/4: 32%); Febrile
  neutropenia (includes neutropenia associated with fever and antibiotic use)
  or neutropenic sepsis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Psychiatric disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Insomnia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Paresthesia; Headache; Dysgeusia; Hypoaesthesia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased; Conjunctivitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif;background:yellow'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vascular disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lymphoedema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Epistaxis; Pharyngolaryngeal pain; Nasopharyngitis;
  Dyspnoea; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cough; Rhinorrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea; Diarrhoea; Vomiting; Constipation;
  Stomatitis; Dyspepsia; Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  Erythema; Rash; Nail disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia; Arthralgia; Pain in extremity; Bone pain;
  Back pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia; Oedema peripheral; Pyrexia; Fatigue;
  Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lethargy</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Weight increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions in breast cancer for TAXOTERE 100&nbsp;mg/m&sup2;
in combination with trastuzumab</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Symptomatic
cardiac failure was reported in 2.2% of the patients who received docetaxel
plus trastuzumab compared to 0% of patients given docetaxel alone. In the
docetaxel plus trastuzumab arm, 64% had received a prior anthracycline as
adjuvant therapy compared with 55% in the docetaxel arm alone.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>Very common: Haematological toxicity was increased
in patients receiving trastuzumab and docetaxel, compared with docetaxel alone
(32% grade&nbsp;3/4 neutropenia versus 22%, using NCI-CTC criteria). Note that
this is likely to be an underestimate since docetaxel alone at a dose of
100&nbsp;mg/m<sup>2</sup> is known to result in neutropenia in 97% of patients,
76% grade&nbsp;4, based on nadir blood counts. The incidence of febrile
neutropenia/neutropenic sepsis was also increased in patients treated with
Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel
alone).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with capecitabine</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Oral candidiasis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neutropenia (G3/4: 63%); Anaemia (G3/4: 10%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Thrombocytopenia (G3/4: 3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Anorexia (G3/4: 1%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Decreased appetite </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dehydration (G3/4: 2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dysgeusia (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pareaesthesia (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dizziness; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Headache (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neuropathy peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pharyngolaryngeal pain (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspnoea (G3/4:
  1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cough (G3/4:
  &lt;&nbsp;1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Epistaxis (G3/4:
  &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis (G3/4: 18%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea (G3/4: 14%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vomiting (G3/4: 4%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Constipation (G3/4: 1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Abdominal pain (G3/4: 2%); Dyspepsia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal pain
  upper; </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Hand-foot syndrome (G3/4: 24%);</span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Alopecia (G3/4: 6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nail disorders (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dermatitis;
  </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rash
  erythematous (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  discolouration; </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Onycholysis
  (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Myalgia (G3/4: 2%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Arthralgia (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pain in extremity (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Back pain (G3/4:
  1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia (G3/4: 3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pyrexia (G3/4: 1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fatigue/weakness (G3/4: 5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Oedema peripheral (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lethargy;<br>
  Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Weight decreased;<br>
  G3/4 Blood bilirubin increased (9%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in metastatic
castration-resistant prostate cancer for</span></u><u><span lang=EN-GB
style='font-weight:normal'> TAXOTERE 75&nbsp;mg/m&sup2; in combination with
prednisone or prednisolone</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 3.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); </span></p>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Anaemia
  (G3/4: 4.9%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Thrombocytopenia (G3/4: 0.6%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia (G3/4: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3/4: 1.2%);</span></p>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral motor neuropathy (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac left ventricular function decrease (G3/4:
  0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Epistaxis (G3/4:
  0%);</span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspnoea (G3/4:
  0.6%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 2.4%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea (G3/4: 1.2%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis/Pharyngitis (G3/4: 0.9%);&nbsp; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vomiting (G3/4: 1.2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia; </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> (no
  severe)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Exfoliative rash (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective bone disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arthralgia (G3/4: 0.3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fatigue (G3/4: 3.9%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fluid retention (severe: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt style='page-break-after:avoid'><span style='font-size:9.0pt;
font-family:"Arial Narrow",sans-serif;color:black'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in high-risk locally advanced or metastatic
hormone-sensitive prostate cancer for TAXOTERE 75 mg/m&sup2; in combination
with prednisone or prednisolone and ADT (STAMPEDE study) </span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:458.65pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:35.4pt'>
   <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA system organ
   classes</span></b></p>
   <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
   115%;page-break-after:avoid'><b><span style='font-size:11.0pt;line-height:
   115%'>&nbsp;</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Very common adverse reactions</span></b></p>
   </td>
   <td width=211 valign=top style='width:158.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Common adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:37.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Neutropenia (G3-4: 12 %) Anaemia
  </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Febrile
  neutropenia </span><span style='font-size:11.0pt'>(G3-4: 15%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Immune
  system disorders</span><span lang=EN-GB style='font-size:11.0pt;line-height:
  115%;color:black'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Hypersensitivity (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.2pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><s><span style='font-size:11.0pt'><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diabetes (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Anorexia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt' style='page-break-inside:
  avoid !msorm;height:20.45pt !msorm'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Psychiatric
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Insomnia (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Nervous
  system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Peripheral sensory
  neuropathy (&#8805;G3: 2%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Headache<br>
  <br>
  </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.5pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Eye disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Blurred vision</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.1pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Cardiac
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension </span><span
  style='font-size:11.0pt'>(G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:43.05pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Respiratory,
  thoracic and mediastinal disorders</span><span style='font-size:11.0pt;
  line-height:115%'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dyspnea (G3: 1%)<br>
  Coughing (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Upper respiratory tract
  infection (G3: 1%) </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Pharyngitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'><br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:64.3pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%'>Gastrointestinal
  disorders </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diarrhea (G3: 3%)<br>
  Stomatitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Constipation (G3: 0%)<br>
  Nausea (G3: 1%)<br>
  Dyspepsia<br>
  Abdominal pain (G3: 0%)<br>
  Flatulence</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Vomiting (G3: 1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.7pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Alopecia (G3: 3%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Nail changes (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  lang=FR style='font-size:11.0pt;line-height:115%'>Rash</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Myalgia </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Lethargy (G3-4: 2%)<br>
  Flu-like symptoms (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Asthenia (G3: 0%)<br>
  Fluid retention</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Fever (G3: 1%)<br>
  Oral candidiasis </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypocalcaemia (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypophosphataemia (G3-4:
  1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypokalaemia (G3: 0%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif;
color:black'>&nbsp;</span></p>

<p class=Normal11pt><sup><span style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'>a</span></sup><span
style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'> </span><span
style='font-size:9.0pt;color:black'>From the GETUG AFU15 study</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions for
adjuvant therapy with TAXOTERE 75&nbsp;mg/m&sup2; in combination with
doxorubicin and cyclophosphamide<b> </b>in patients with node&#8209;positive </span><span
lang=EN-GB>(TAX 316) </span></u><u><span lang=EN-GB>and node&#8209;negative </span><span
lang=EN-GB>(GEICAM 9805) </span></u><u><span lang=EN-GB>breast cancer<b> </b></span><span
lang=EN-GB>- pooled data</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA
   System Organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Very common
   adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection (G3/4:
  2.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
  infection </span><span lang=NL style='font-size:11.0pt'>(G3/4: 2.</span><span
  style='font-size:11.0pt'>6</span><span lang=NL style='font-size:11.0pt'>%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Anaemia (G3/4: 3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Neutropenia (G3/4: 59.2%); Thrombocytopenia (G3/4:
  1.6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Febrile neutropenia (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia (G3/4: 1.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dysgeusia (G3/4: 0.6%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral motor neuropathy (G3/4: 0%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Syncope (G3/4: 0%); Neurotoxicity (G3/4: 0%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Somnolence (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Conjunctivitis (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased (G3/4: &lt;0.1%) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arrhythmia (G3/4: 0.2%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hot flush (G3/4:
  0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phlebitis (G3/4:
  0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lymphoedema
  (G3/4: 0%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  5.0%); Stomatitis (G3/4: 6.0%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  4.2%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  3.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (G3/4: 0.5%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Abdominal pain
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia
  (persisting: &lt;3%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
  disorder (G3/4: 0.6%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  disorders (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.7%); Arthralgia (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Reproductive system and breast disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Amenorrhoea </span><span lang=NL style='font-size:
  11.0pt'>(G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia (G3/4:
  10.0%);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Pyrexia (G3/4: NA);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Oedema peripheral
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight increased
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight decreased
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions for adjuvant therapy with TAXOTERE
75&nbsp;mg/m&sup2; in combination with doxorubicin and cyclophosphamide<b> </b>in
patients with node&#8209;positive </span><span lang=EN-GB>(TAX 316) </span></u><u><span
lang=EN-GB>and node&#8209;negative </span><span lang=EN-GB>(GEICAM 9805) </span></u><u><span
lang=EN-GB>breast cancer</span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Nervous system
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>peripheral sensory neuropathy </span><span style='font-size:11.0pt'>started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 84&nbsp;patients (11.3%) in TAC arm and 15
patients (2&nbsp;%) in FAC arm. At the end of the follow-up period (median
follow-up time of 8 years), p</span><span style='font-size:11.0pt'>eripheral
sensory neuropathy</span><span lang=EN-GB style='font-size:11.0pt'> was
observed to be ongoing in 10 patients (1.3</span><span style='font-size:11.0pt'>%)
in TAC arm, and in 2</span><span lang=EN-GB style='font-size:11.0pt'> patients
(0.3%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In GEICAM 9805 study peripheral sensory neuropathy that
started during the treatment period persisted into the follow-up period in
10&nbsp;patients (1.9%) in TAC arm and 4 patients (0.8&nbsp;%) in FAC arm. At
the end of the follow-up period (median follow-up time of 10 years and 5
months), peripheral sensory neuropathy was observed to be ongoing in 3 patients
(0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316,
26 patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm
experienced congestive heart failure. All except one patient in each arm were
diagnosed with CHF more than 30 days after the treatment period. Two patients
in the TAC arm and 4&nbsp;patients in the FAC arm died because of cardiac
failure.</span></p>

<p class=MsoHeader style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In GEICAM 9805
study, 3</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
patients (0.6&nbsp;%) in TAC arm and 3 </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>patients </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(0.6&nbsp;%)
in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>FAC
arm developed congestive heart failure during the follow-up period. At the end
of the follow-up period (actual median follow-up time of 10 years and 5
months), no patients&nbsp; had CHF in TAC arm and 1 patient in TAC arm died
because of dilated cardiomyopathy, and CHF was observed to be ongoing in
1&nbsp;patient (0.2%) in FAC arm.</span></p>

<p class=MsoHeader style='text-align:justify'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders </span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In study
TAX316 alopecia persisting into the follow-up period after the end of
chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC
patients (87.6%).<br>
At the end of the follow-up period (actual median follow-up time of</span><span
lang=EN-GB style='font-size:14.0pt;font-family:"Cambria",serif;color:#00B0F0'> </span><span
lang=EN-GB style='font-size:11.0pt'>8 years), alopecia was observed to be
ongoing in 29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In
GEICAM 9805 study alopecia </span><span style='font-size:11.0pt'>that started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period was observed to be ongoing in 49&nbsp;patients
(9.2&nbsp;%) in TAC arm and 35 patients (6.7&nbsp;%) in FAC arm. Alopecia
related to study drug started or worsened during the follow-up period in
42&nbsp;patients (7.9&nbsp;%) in TAC arm and 30 patients (5.8&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm,
and in 1 patient (0.2%) in FAC arm.&nbsp; </span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Reproductive system and breast disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In TAX316 </span>amenorrhoea <span lang=EN-GB>that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%)
and 125 of 736 FAC patients (17.0%). Amenorrhea </span>was observed to be
ongoing <span lang=EN-GB>at the end of the </span>follow-up <span lang=EN-GB>period
(median follow-up time of 8 years) </span>in 121&nbsp;<span lang=EN-GB>of 744
TAC </span>patients <span lang=EN-GB>(16.3%) and 86 FAC patients (11.7%)</span>.</p>

<p class=Text style='margin-top:0in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>In GEICAM 9805 study</span><span lang=EN-GB
style='font-size:11.0pt'> amenorrhoea </span><span style='font-size:11.0pt'>that
started during the treatment period and </span><span lang=EN-GB
style='font-size:11.0pt'>persisted into the follow-up period was observed to be
ongoing in 18&nbsp;patients (3.4&nbsp;%) in TAC arm and 5 patients (1.0&nbsp;%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10 years
and 5 months), amenorrhoea was observed to be ongoing in 7 patients (1.3%) in
TAC arm, and in 4 patients (0.8%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316 peripheral
oedema </span><span style='font-size:11.0pt'>that started during the treatment
period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted into the
follow-up period after the end of chemotherapy was observed in 119 of 744 TAC
patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the follow-up
period (actual median follow-up time of 8 years), peripheral oedema was ongoing
in19&nbsp;TAC<u> </u>patients (2.6%) and 4 FAC<u> </u>patients (0.5%). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
lymphoedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was reported in 11 of
744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), lymphoedema was
observed to be ongoing in 6&nbsp;TAC patients (0.8%) and 1 FAC patient (0.1%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In study TAX316 asthenia that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%)
and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual
median follow-up time of 8 years), asthenia was observed to be ongoing in
29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study GEICAM
9805 peripheral oedema </span><span style='font-size:11.0pt'>that started
during the treatment period </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it
was observed to be ongoing in 1 patient (0.2%) in FAC arm.<u> </u>Lymphoedema </span><span
style='font-size:11.0pt'>that started during the treatment period </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period in
5&nbsp;patients (0.9%) in TAC arm and 2 patients (0.4&nbsp;%) in FAC arm. At
the end of the follow-up period, lymphoedema was observed to be ongoing in 4
patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia </span><span
style='font-size:11.0pt'>that started during the treatment period and </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period was
observed to be ongoing in 12&nbsp;patients (2.3&nbsp;%) in TAC arm and 4
patients (0.8&nbsp;%) in FAC arm. At the end of the follow-up period, asthenia
was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients
(0.4%) in FAC arm.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Acute leukaemia / Myelodysplastic
syndrome.</span></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After 10 years of follow up in study
TAX316, acute leukaemia was reported in 3 of 744 TAC patients </span><span
style='font-weight:normal'>(0.4%)</span><span style='font-weight:normal'> <span
lang=EN-GB>and in 1 of 736 FAC patients </span></span><span style='font-weight:
normal'>(0.1%).</span><span style='font-weight:normal'> </span><span
style='font-weight:normal'>One TAC patient (0.1%) and 1 FAC patient (0.1%) died
due to AML during the follow-up period (median follow-up time of 8 years)</span><span
lang=EN-GB style='font-weight:normal'>. Myelodysplastic syndrome was reported in
2 of 744 TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%). </span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-weight:normal'>10 years of follow-up </span><span
lang=EN-GB style='font-weight:normal'>in GEICAM 9805 study</span><span
lang=EN-GB style='font-weight:normal'>,</span><span lang=EN-GB
style='font-weight:normal'> acute leukaemia occurred in 1</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>of 532 (0.2%)</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>patients in </span><span
lang=EN-GB style='font-weight:normal'>TAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No cases were reported in patients in FAC arm. No
patient was diagnosed with myelodysplastic syndrome in either treatment groups.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Neutropenic complications</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Table below shows that the incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in
patients who received primary G&#8209;CSF prophylaxis after it was made
mandatory in the TAC arm - GEICAM study. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Neutropenic complications in patients receiving TAC with or without
primary G&#8209;CSF prophylaxis (GEICAM 9805)</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=PT-BR style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Without
  primary</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF
  prophylaxis (n&nbsp;=&nbsp;111)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n&nbsp;(%)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>With primary </span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF </span><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>prophylaxis</span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(n&nbsp;=&nbsp;421)
  </span></p>
  <p class=TableHeadCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>n&nbsp;(%)</span></p>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=PT-BR style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenia&nbsp;(Grade&nbsp;4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>104 (93.7)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>135 (32.1)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=IT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Febrile
  neutropenia </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>28 (25.2)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>23 (5.5)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenic infection </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>14 (12.6)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>21 (5.0)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection (Grade&nbsp;3-4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (1.8)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5 (1.2)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
gastric adenocarcinoma cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination
with cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
   infestations</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Neutropenic infection;</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Infection
   (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
   style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Anaemia (G3/4:
   20.9%);</span></p>
   <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G3/4:
   83.2%); </span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=IT>Thrombocytopenia (G3/4: 8.8%);</span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Febrile neutropenia </span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
   disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity (G3/4: 1.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
   nutrition disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anorexia
   (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:40.75pt'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
   disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
   sensory neuropathy (G3/4: 8.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Dizziness (G3/4: 2.3%); </span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'>Peripheral <span lang=EN-GB>motor </span>neuropathy<span
   lang=EN-GB> (G3/4: 1.3%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:
   "Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
   increased (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ear and
   labyrinth disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:
   "Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Hearing impaired (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
   style='font-size:11.0pt'>Cardiac disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
   (G3/4: 1.0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
   disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea
   (G3/4: 19.7%); </span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nausea
   (G3/4: 16%); </span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Stomatitis
   (G3/4: 23.7%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vomiting
   (G3/4: 14.3%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Constipation
   (G3/4: 1.0%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
   pain (G3/4: 1.0%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Oesophagitis/dysphagia/odynophagia
   (G3/4: 0.7%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
   subcutaneous tissue disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
   4.0%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rash pruritus
   (G3/4: 0.7%); </span></p>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nail disorders
   (G3/4: 0.7%); </span></p>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
   exfoliation (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
   disorders and administration site conditions</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Lethargy (G3/4: 19.0%);</span></p>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fever </span><span
   lang=EN-GB style='font-size:11.0pt'>(G3/4: 2.3%);<br>
   Fluid retention (severe</span><span lang=EN-GB style='font-size:11.0pt'>/life&#8209;threatening</span><span
   lang=EN-GB style='font-size:11.0pt'>: 1%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Description of selected adverse reactions in gastric
adenocarcinoma cancer for TAXOTERE 75&nbsp;mg/m<sup>2</sup> in combination with
cisplatin and 5-fluorouracil</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Febrile
neutropenia and neutropenic infection occurred in 17.2% and 13.5% of patients
respectively, regardless of G&#8209;CSF use. G&#8209;CSF was used for secondary
prophylaxis in 19.3% of patients (10.7% of the cycles). Febrile neutropenia and
neutropenic infection occurred respectively in 12.1% and 3.4% of patients when
patients received prophylactic G&#8209;CSF, in 15.6% and 12.9% of patients
without prophylactic G&#8209;CSF (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
head and neck cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with
cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
radiotherapy (TAX 323)</span></p>

<p class=Authors style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>Infection (G3/4: 6.3%);</p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
  infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neoplasms
  benign, malignant and unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cancer pain (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Neutropenia (G3/4: 76.3%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Anaemia (G3/4: 9.2%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Thrombocytopenia (G3/4: 5.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.75pt'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Dysgeusia/Parosmia;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Peripheral sensory
  neuropathy (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dizziness</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
  increased;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Conjunctivitis </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ear and
  labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hearing impaired</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myocardial
  ischemia (G3/4:1.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Venous disorder
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  2.9%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Constipation;</span></p>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Esophagitis/dysphagia/
  odynophagia (G3/4: 0.6%);</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  pain;</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspepsia;</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
  haemorrhage (G3/4: 0.6%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
  10.9%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>Rash pruritic;</p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=FR>Dry skin; </span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=FR>Skin exfoliative (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lethargy (G3/4:
  3.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pyrexia (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oedema</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
chemoradiotherapy (TAX 324)</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB>MedDRA
   <span style='color:black'>system organ classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Very
   common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Common
   adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>Infection (G3/4: 3.6%)</p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Neoplasms
  benign, malignant and unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Cancer
  pain (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Blood
  and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Neutropenia (G3/4: 83.5%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Anaemia (G3/4: 12.4%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Thrombocytopenia (G3/4:&nbsp;4.0%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  12.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Dysgeusia/Parosmia
  (G3/4:&nbsp;0.4%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Peripheral sensory neuropathy (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dizziness (G3/4:
  2.0%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Peripheral
  </span><span lang=EN-GB>motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
  increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Conjunctivitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Ear
  and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hearing impaired
  (G3/4:&nbsp;1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Arrhythmia
  (G3/4: 2.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Ischemia
  myocardial</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Venous
  disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  13.9%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 20.7%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  8.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  6.8%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Esophagitis/dysphagia/
  odynophagia (G3/4: 12.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspepsia
  (G3/4: 0.8%);</span></p>
  <p class=Header1><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.2%);</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
  haemorrhage (G3/4: 0.4%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Skin
  and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
  4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rash pruritic</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dry
  skin&nbsp;;</span></p>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Desquamation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Musculoskeletal,
  connective tissue bone disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myalgia
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lethargy (G3/4:
  4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pyrexia (G3/4:
  3.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (G3/4: 1.2%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Oedema
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Weight
  decreased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Post-marketing experience</span></u></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Neoplasms benign, malignant and unspecified (incl
cysts and polyps)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S</span><span
style='font-size:11.0pt'>econd primary malignancies (</span><span lang=EN
style='font-size:11.0pt'>frequency not known)</span><span style='font-size:
11.0pt'>, including non-Hodgkin lymphoma have been reported in association with
docetaxel when used in combination with other anticancer treatments known to be
associated with second primary malignancies</span><span lang=EN-GB
style='font-size:11.0pt'>. </span><span style='font-size:11.0pt'>Acute myeloid
leukaemia and myelodysplastic syndrome have been reported (frequency uncommon)
in pivotal clinical studies in breast cancer with TAC regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Bone marrow
suppression and other haematologic adverse reactions have been reported.
Disseminated intravascular coagulation (DIC), often in association with sepsis
or multi-organ failure, has been reported.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Immune system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Some cases of anaphylactic
shock, sometimes fatal, have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
reactions (frequency not known) have been reported with docetaxel in patients
who previously experienced hypersensitivity reactions to paclitaxel.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Rare
cases of convulsion or transient loss of consciousness have been observed with
docetaxel administration. These reactions sometimes appear during the infusion
of the medicinal product.</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Eye disorders</span></i></p>

<p class=MsoNormalIndent style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:
11.0pt;layout-grid-mode:line'>Very rare cases of transient visual disturbances
(flashes, flashing lights, scotomata) typically occurring during infusion of
the medicinal product and in association with hypersensitivity reactions have
been reported. These were reversible upon discontinuation of the infusion. </span><span
lang=EN-GB style='font-size:11.0pt'>Cases of lacrimation with or without
conjunctivitis, as cases of lacrimal duct obstruction resulting in excessive
tearing have been rarely reported. </span><span lang=EN-GB style='font-size:
11.0pt'>Cases of cystoid macular oedema (CMO) have been reported in patients
treated with docetaxel.&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Ear and labyrinth disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Rare cases of ototoxicity, hearing impaired and/or hearing loss have been
reported.</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Rare cases of myocardial infarction have been
reported.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Ventricular
arrhythmia including ventricular tachycardia (frequency not known), sometimes
fatal, has been reported in patients treated with docetaxel in combination
regimens including doxorubicin, 5-fluorouracil and/ or cyclophosphamide.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Vascular disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>Venous
thromboembolic events have rarely been reported.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Respiratory, thoracic and mediastinal disorders</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Acute respiratory distress syndrome and cases of<b><i>
</i></b>interstitial pneumonia</span><span lang=EN-GB style='font-size:11.0pt'>/
pneumonitis,</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>interstitial lung</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>disease,</span><span
lang=EN-GB style='font-size:11.0pt'> pulmonary fibrosis and </span><span
lang=EN-GB style='font-size:11.0pt'>respiratory failure</span><span lang=EN-GB
style='font-size:11.0pt'> sometimes fatal have rarely been reported. </span><span
style='font-size:11.0pt'>Rare cases of radiation pneumonitis have been reported
in patients receiving concomitant radiotherapy.</span><span lang=EN-GB
style='font-size:11.0pt'> </span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Gastrointestinal disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare cases of enterocolitis, including
colitis, ischemic colitis, and neutropenic enterocolitis, have been reported
with a potential fatal outcome (frequency not known).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rare occurrences
of dehydration have been reported as a consequence of gastrointestinal events
including enterocolitis and gastrointestinal perforation.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rare cases of ileus
and intestinal obstruction have been reported.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Hepatobiliary disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Very rare cases of
hepatitis, sometimes fatal primarily in patients with pre&#8209;existing liver
disorders, have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Skin and subcutaneous tissue disorders&nbsp; </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cases of cutaneous
lupus erythematosus</span><span lang=EN-GB>, </span><span lang=EN-GB
style='font-size:11.0pt'>bullous eruptions such as erythema multiforme and </span><span
lang=EN-GB>severe cutaneous adverse reactions such as </span><span lang=EN-GB
style='font-size:11.0pt'>Stevens&#8209;Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
(TEN) and </span><span lang=EN-GB style='font-size:11.0pt'>Acute Generalized Exanthematous
Pustulosis (AGEP)</span><span lang=EN-GB style='font-size:11.0pt'> have been
reported with docetaxel. Scleroderma&#8209;like changes usually preceded by
peripheral lymphoedema have been reported with docetaxel. Cases of </span><span
lang=EN-GB style='font-size:11.0pt'>permanent</span><span lang=EN-GB
style='font-size:11.0pt'> alopecia (frequency not known) have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41><i><span lang=EN-GB style='font-weight:normal'>Renal and
urinary disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Renal
insufficiency and renal failure have been reported. In about 20% of these cases
there were no risk factors for acute renal failure such as concomitant
nephrotoxic medicinal products and gastro-intestinal disorders.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>General disorders and administration site conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Radiation recall
phenomena have rarely been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Injection site
recall reaction (recurrence of skin reaction at a site of previous
extravasation following administration of docetaxel at a different site) has
been observed at the site of previous extravasation (frequency not known).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention has
not been accompanied by acute episodes of oliguria or hypotension. Dehydration
and pulmonary oedema have rarely been reported.</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>&nbsp;</span></i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><i>Metabolism and nutrition disorders</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB style='color:windowtext'>Cases of electrolyte imbalance
have been reported. </span><span lang=EN-GB>Cases of hyponatraemia have been
reported, mostly associated with dehydration, vomiting and pneumonia. </span><span
lang=EN-GB style='color:windowtext'>Hypokalaemia, hypomagnesaemia, and
hypocalcaemia were observed, usually in association with gastrointestinal disorders
and in particular with diarrhoea. </span><span lang=EN-GB>Tumour lysis
syndrome, potentially fatal, has been reported (frequency not known).</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin-left:0in;text-indent:0in'><i>Musculoskeletal
disorder</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Myositis has been reported with docetaxel <span lang=EN-GB>(frequency not
known)</span>.</p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via <span style='background:#BFBFBF'>the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>There were a
few reports of overdose. There is no known antidote for docetaxel overdose. In
case of overdose, the patient should be kept in a specialised unit and vital
functions closely monitored. </span><span lang=EN-GB style='font-size:11.0pt'>In
cases of overdose, exacerbation of adverse events may be expected. </span><span
lang=EN-GB style='font-size:11.0pt'>The primary anticipated complications of
overdose would consist of bone marrow suppression, peripheral neurotoxicity and
mucositis. Patients should receive therapeutic G&#8209;CSF as soon as possible
after discovery of overdose. Other appropriate symptomatic measures should be
taken, as needed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pharmacotherapeutic
group: Taxanes, ATC Code: L01CD&nbsp;02</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Mechanism of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is an
antineoplastic agent which acts by promoting the assembly of tubulin into
stable microtubules and inhibits their disassembly which leads to a marked
decrease of free tubulin. The binding of docetaxel to microtubules does not
alter the number of protofilaments.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel has been
shown <i>in vitro</i> to disrupt the microtubular network in cells which is
essential for vital mitotic and interphase cellular functions. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel was
found to be cytotoxic <i>in vitro</i> against various murine and human tumour
cell lines and against freshly excised human tumour cells in clonogenic assays.
Docetaxel achieves high intracellular concentrations with a long cell residence
time. In addition, docetaxel was found to be active on some but not all cell lines
over expressing the p&#8209;glycoprotein which is encoded by the multidrug
resistance gene. <i>In vivo</i>, docetaxel is schedule independent and has a
broad spectrum of experimental anti-tumour activity against advanced murine and
human grafted tumours.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><u><span lang=EN-GB
style='font-weight:normal'>Breast cancer</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><i><span style='font-family:
"Times New Roman",serif'>TAXOTERE in combination with doxorubicin and
cyclophosphamide: adjuvant therapy</span></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><u><span lang=EN-GB>Patients
with operable node&#8209;positive breast cancer </span></u><span lang=EN-GB>(TAX
316)</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Data
from a multi-centre open label randomised study support the use of docetaxel
for the adjuvant treatment of patients with operable node-positive breast
cancer and KPS&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;80%, between 18 and 70&nbsp;years of age. After stratification
according to the number of positive lymph nodes (1&#8209;3, 4+), 1491&nbsp;patients
were randomised to receive either docetaxel 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (TAC arm), or doxorubicin
50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (FAC arm). Both regimens were
administered once every 3&nbsp;weeks for 6&nbsp;cycles. Docetaxel was
administered as a 1&#8209;hour infusion, all other medicinal products were
given as intravenous bolus on day one. G&#8209;CSF was administered as
secondary prophylaxis to patients who experienced complicated neutropenia (febrile
neutropenia, prolonged neutropenia, or infection). Patients on the TAC arm
received antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice
daily for 10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. In
both arms, after the last cycle of chemotherapy, patients with positive eostrogen
and/or progesterone receptors received tamoxifen 20&nbsp;mg daily for up to
5&nbsp;years. Adjuvant radiation therapy was prescribed according to guidelines
in place at participating institutions and was given to 69% of patients who received
TAC and 72% of patients who received FAC. Two interim analyses and one final
analysis were performed. The first interim analysis was planned 3 years after
the date when half of study enrolment was done. The second interim analysis was
done after 400 DFS events had been recorded overall, which led to a median
follow-up of 55 months. The final analysis was performed when all patients had
reached their 10-year follow-up visit (unless they had a DFS event or were lost
to follow-up before). Disease-free survival (DFS) was the primary efficacy
endpoint and Overall survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>A final
analysis was performed with an actual median follow up of 96&nbsp;months.
Significantly longer disease-free survival for the TAC arm compared to the FAC
arm was demonstrated. Incidence of relapses at 10&nbsp;years was reduced in
patients receiving TAC compared to those who received FAC (39% versus 45%,
respectively) i.e. an absolute risk reduction by 6% (p&nbsp;=&nbsp;0.0043).
Overall survival at 10&nbsp;years was also significantly increased with TAC
compared to FAC (76% versus 69%, respectively) i.e. an absolute reduction of
the risk of death by 7% (p&nbsp;=&nbsp;0.002).</span><span lang=EN-GB> As the
benefit observed in patients with 4+ nodes was not statistically significant on
DFS and OS, the positive benefit/risk ratio for TAC in patients with 4+ nodes
was not fully demonstrated at the final analysis.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'>&nbsp;</p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Overall,
the study results demonstrate a positive benefit risk ratio for TAC compared to
FAC.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>TAC-treated patient subsets according to prospectively defined major
prognostic factors were analysed:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='width:104.4%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.92%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Disease free survival</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.6%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Overall survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>Patient subset</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Number of patients</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>p&nbsp;=</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>p&nbsp;=</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>No of positive nodes</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>Overall</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>745</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.80</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.68-0.93</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0043</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.74</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.61-0.90</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0020</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>1-3</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>467</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.72</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.58-0.91</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0047</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.62</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.46-0.82</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0008</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>4+</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>278</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.87</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.70-1.09</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.2290</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.67-1.12</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.2746</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>*a hazard ratio of less than 1 indicates that TAC is associated with
a longer disease&#8209;free survival and overall survival compared to FAC</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Patients with
operable node</span><span lang=EN-GB>&#8209;</span></u><u><span lang=EN-GB
style='font-size:11.0pt'>negative breast cancer eligible to receive
chemotherapy </span></u><span lang=EN-GB style='font-size:11.0pt'>(GEICAM 9805)<u>
</u></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Data from a multi-centre
open label randomised trial support the use of TAXOTERE for the adjuvant
treatment of patients with operable node&#8209;negative breast cancer eligible
to receive chemotherapy.<u> </u></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1060&nbsp;patients
were randomised to receive either TAXOTERE 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (539 patients in TAC arm), or
doxorubicin 50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup>
and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (521 patients in FAC arm), as
adjuvant treatment of operable node-negative breast cancer patients with high
risk of relapse according to 1998 St. Gallen criteria (tumour size
&gt;2&nbsp;cm and/or negative ER and PR and/or high histological/nuclear grade
(grade 2 to 3) and /or age &lt;35&nbsp;years). Both regimens were administered
once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1&#8209;hour
infusion, all other medicinal products were given intraveinously on day 1 every
three weeks. Primary prophylactic G&#8209;CSF was made mandatory in TAC arm
after 230&nbsp;patients were randomised. The incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in patients
who received primary G&#8209;CSF prophylaxis (see section 4.8). In both arms,
after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours
received tamoxifen 20&nbsp;mg once a day for up to 5 years. Adjuvant radiation
therapy was administered according to guidelines in place at participating institutions
and was given to 57.3% of patients who received TAC and 51.2% of patients who
received FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>One
primary analysis and one updated analysis were performed. The primary analysis
was done when all patients had a follow-up of greater than 5 years (median
follow-up time of 77 months). The updated analysis was performed when all
patients had reached their 10-year (</span><span lang=EN-GB>median follow up
time of 10 years and 5&nbsp;months) </span><span lang=EN-GB>follow-up visit
(unless they had a DFS event or were lost to follow-up previously). Disease-free
survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was
the secondary efficacy endpoint.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, significantly longer disease-free survival for the
TAC arm compared to the FAC arm was demonstrated. TAC&#8209;treated patients
had a 32% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.68, 95% CI (0.49-0.93), p&nbsp;=&nbsp;0.01). At the
median follow up time of 10 years and 5&nbsp;months, TAC&#8209;treated patients
had a 16,5% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.84, 95% CI (0.65-1.08), p=0.1646). DFS data were not
statistically significant but were still associated with a positive trend in favour
of TAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median follow-up
time of 77 months, overall survival (OS) was longer in the TAC arm with
TAC-treated patients having a 24% reduction in the risk of death compared to
FAC (hazard ratio&nbsp;=&nbsp;0.76, 95% CI (0.46-1.26, p&nbsp;=&nbsp;0.29).
However, the distribution of OS was not significantly different between the 2
groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow up time of 10 years and 5&nbsp;months, TAC-treated patients had a 9%
reduction in the risk of death compared to FAC-treated patients (hazard
ratio&nbsp;=&nbsp;0.91, 95% CI (0.63-1.32)). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The survival rate
was 93.7% in the TAC arm and 91.4&nbsp;% in the FAC arm, at the 8-year
follow-up time point, and 91.3&nbsp;% in the TAC arm and 89&nbsp;% in the FAC
arm, at the 10-year follow-up time point.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The positive benefit risk ratio for TAC compared to
FAC remained unchanged<b>. </b>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAC&#8209;treated
patient subsets according to prospectively defined major prognostic factors
were analysed in the primary analysis (at the median follow-up time of 77
months) (see table below):</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Subset Analyses-Adjuvant Therapy in Patients with Node&#8209;negative
Breast Cancer Study </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>(Intent&#8209;to&#8209;Treat Analysis)</span></u></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=558
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=258 colspan=2 valign=top style='width:193.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Disease Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  subset</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of patients in TAC group</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio*</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Overall</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>539</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.49-0.93</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Age
  category 1</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&lt;50
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>260</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&#8805;50
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>279</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Age
  category 2</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&lt;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.31</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.11-0.89</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&#8805;35
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>497</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.52-1.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Hormonal
  receptor</span></b><span lang=EN-GB> <b>status</b></span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.6pt'>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Negative</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>195</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.7</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.45-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Positive</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>344</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4-0.97</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Tumour
  size </span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:Symbol'>&pound;</span><span lang=EN-GB>2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.69</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&gt;2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.45-1.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Histological
  grade</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade1
  (includes grade not assessed)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.79</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.24-2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade 2</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>216</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.77</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.46-1.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade 3</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>259</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.59</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.39-0.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Menopausal
  status</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pre-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.64</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.40-1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Post-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.47-1.12</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>*a hazard ratio (TAC/FAC) of less than 1 indicates
that TAC is associated with a longer disease free survival compared to FAC.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Exploratory
subgroup analyses for disease-free survival for patients who meet the 2009 St. Gallen
chemotherapy criteria &#8211; (ITT population) were performed and presented
here below:</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=607
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>TAC</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>FAC</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(TAC/FAC)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Subgroups</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(n=539)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(n=521)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(95%
  CI)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><b><span
  lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Meeting relative indication for
  chemotherapy <sup>a</sup></span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt><span lang=EN-GB>No</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>18/214</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(8.4%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>26/227</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(11.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.796
  (0.434 - 1.459)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.4593</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>48/325</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(14.8%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>69/294</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(23.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.606
  (0.42 - 0.877)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0072</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>TAC = docetaxel, doxorubicin
and cyclophosphamide</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>FAC =
5-fluorouracil, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>CI = confidence
interval; ER = eostrogen receptor</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PR = progesterone
receptor</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:10.0pt;font-family:
"(Utiliser une police de caract&egrave;",serif'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> ER/PR-negative or Grade 3 or tumour size &gt;5&nbsp;cm</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The estimated
hazard ratio was using Cox proportional hazard model with treatment group as
the factor.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
as single agent</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'>Two randomised phase&nbsp;III comparative studies,
involving a total of 326&nbsp;alkylating or 392&nbsp;anthracycline failure
metastatic breast cancer patients, have been performed with docetaxel at the
recommended dose and regimen of 100&nbsp;mg/m&sup2; every 3&nbsp;weeks.</p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In
alkylating-failure patients, docetaxel was compared to doxorubicin
(75&nbsp;mg/m&sup2; every 3&nbsp;weeks). Without affecting overall survival time
(docetaxel 15&nbsp;months vs. doxorubicin 14&nbsp;months, p&nbsp;=&nbsp;0.38)
or time to progression (docetaxel 27&nbsp;weeks vs. doxorubicin 23&nbsp;weeks,
p&nbsp;=&nbsp;0.54), docetaxel increased response rate (52% vs. 37%,
p&nbsp;=&nbsp;0.01) and shortened time to response (12&nbsp;weeks vs.
23&nbsp;weeks, p&nbsp;=&nbsp;0.007). Three docetaxel patients (2%) discontinued
the treatment due to fluid retention, whereas 15&nbsp;doxorubicin patients (9%)
discontinued due to cardiac toxicity (three cases of fatal congestive heart
failure).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In
anthracycline-failure patients, docetaxel was compared to the combination of
mitomycin&nbsp;C and vinblastine (12&nbsp;mg/m&sup2; every 6&nbsp;weeks and
6&nbsp;mg/m&sup2; every 3&nbsp;weeks). Docetaxel increased response rate (33%
vs. 12%, p&nbsp;&lt;&nbsp;0.0001), prolonged time to progression (19&nbsp;weeks
vs. 11&nbsp;weeks, p&nbsp;=&nbsp;0.0004) and prolonged overall survival
(11&nbsp;months vs. 9&nbsp;months, p&nbsp;=&nbsp;0.01).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>During these two
phase&nbsp;III studies, the safety profile of docetaxel was consistent with the
safety profile observed in phase&nbsp;II studies (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB>An open-label, multi-centre, randomised phase&nbsp;III
study was conducted to compare docetaxel monotherapy and paclitaxel in the
treatment of advanced breast cancer in patients whose previous therapy should
have included an anthracycline. A total of 449&nbsp;patients were randomised to
receive either docetaxel monotherapy 100&nbsp;mg/m&sup2; as a 1&nbsp;hour infusion
or paclitaxel 175&nbsp;mg/m&sup2; as a 3&nbsp;hour infusion. Both regimens were
administered every 3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Without affecting
the primary endpoint, overall response rate (32% vs 25%, p&nbsp;=&nbsp;0.10),
docetaxel prolonged median time to progression (24.6&nbsp;weeks vs 15.6&nbsp;weeks;
p&nbsp;&lt;&nbsp;0.01) and median survival (15.3&nbsp;months vs
12.7&nbsp;months; p&nbsp;=&nbsp;0.03).</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext;
layout-grid-mode:both'>More grade&nbsp;3/4 adverse events were observed for
docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with doxorubicin</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><b><i><s><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></s></i></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>One large randomised phase&nbsp;III study, involving
429 previously untreated patients with metastatic disease, has been performed
with doxorubicin (50&nbsp;mg/m&sup2;) in combination with docetaxel
(75&nbsp;mg/m&sup2;) (AT arm) versus doxorubicin (60&nbsp;mg/m&sup2;) in
combination with cyclophosphamide (600&nbsp;mg/m&sup2;) (AC arm). Both regimens
were administered on day&nbsp;1 every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Time to progression
(TTP) was significantly longer in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.0138. The median TTP was 37.3&nbsp;weeks (95%&nbsp;CI:
33.4&nbsp;&#8209;&nbsp;42.1) in AT arm and 31.9&nbsp;weeks (95%&nbsp;CI: 27.4&nbsp;&#8209;&nbsp;36.0)
in AC arm.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Overall response rate
(ORR) was significantly higher in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.009. The ORR was 59.3% (95%&nbsp;CI: 52.8&nbsp;&#8209;&nbsp;65.9)
in AT arm versus 46.5% (95%&nbsp;CI: 39.8&nbsp;&#8209;&nbsp;53.2) in AC arm.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><s><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>In this study, AT arm showed a higher incidence of
severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%),
infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus
2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed
a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in
addition, a higher incidence of severe cardiac toxicity: congestive heart failure
(3.8% versus 2.8%), absolute LVEF decrease </span><span
style='font-family:"Times New Roman",serif'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;20% (13.1% versus 6.1%),
absolute LVEF decrease </span><span
style='font-family:"Times New Roman",serif'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;30% (6.2% versus 1.1%). Toxic
deaths occurred in 1&nbsp;patient in the AT arm (congestive heart failure) and
in 4&nbsp;patients in the AC arm (1 due to septic shock and 3 due to congestive
heart failure).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In both arms, quality
of life measured by the EORTC questionnaire was comparable and stable during
treatment and follow&#8209;up.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with trastuzumab</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'>Docetaxel in combination
with trastuzumab was studied for the treatment of patients with metastatic breast
cancer whose tumours over express HER2, and who previously had not received
chemotherapy for metastatic disease. One hundred eighty six patients were randomised
to receive docetaxel (100&nbsp;mg/m<sup>2</sup>) with or without trastuzumab;
60% of patients received prior anthracycline-based adjuvant chemotherapy.
Docetaxel plus trastuzumab was efficacious in patients whether or not they had
received prior adjuvant anthracyclines. The main test method used to determine
HER2 positivity in this pivotal study was immunohistochemistry (IHC). A
minority of patients were tested using fluorescence in&#8209;situ hybridization
(FISH). In this study, 87% of patients had disease that was IHC 3+, and 95% of
patients entered had disease that was IHC 3+ and/or FISH positive. Efficacy
results are summarized in the following table:</p>

<p class=MDSnormalsectionstyle style='margin-left:0in'>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Parameter</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'>Docetaxel <span lang=EN-GB>plus
  trastuzumab<sup>1</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>n&nbsp;=&nbsp;92</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'>Docetaxel<sup><span lang=EN-GB>1</span></sup></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=FR>n&nbsp;=&nbsp;94</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=FR>Response rate </span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=FR>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>61%</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(50-71)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>34%</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(25-45)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median duration of response (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>11.4</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(9.2-15.0)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>5.1</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(4.4-6.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median TTP (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>10.6</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(7.6-12.9)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>5.7</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(5.0-6.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median survival (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>30.5<sup>2</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(26.8-ne)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>22.1<sup>2</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(17.6-28.9)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify;
page-break-after:avoid'><span lang=EN-GB>TTP&nbsp;=&nbsp;time to progression;
&#8220;ne&#8221; indicates that it could not be estimated or it was not yet
reached.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify;
page-break-after:avoid'><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>Full
analysis set (intent-to-treat)</span></p>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify'><sup><span
lang=EN-GB>2 </span></sup><span lang=EN-GB>Estimated median survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with capecitabine</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Data
from one multi-centre, randomised, controlled phase&nbsp;III clinical study
support the use of docetaxel in combination with capecitabine for treatment of
patients with locally advanced or metastatic breast cancer after failure of
cytotoxic chemotherapy, including an anthracycline. In this study,
255&nbsp;patients were randomised to treatment with docetaxel (75&nbsp;mg/m<sup>2</sup>
as a 1&nbsp;hour intravenous infusion every 3&nbsp;weeks) and capecitabine
(1250&nbsp;mg/m<sup>2</sup> twice daily for 2&nbsp;weeks followed by 1&#8209;week
rest period). 256&nbsp;patients were randomised to treatment with docetaxel
alone (100&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour intravenous infusion every
3&nbsp;weeks). Survival was superior in the docetaxel&nbsp;+ capecitabine combination
arm (p&nbsp;=&nbsp;0.0126). Median survival was 442&nbsp;days (docetaxel&nbsp;+
capecitabine) vs. 352&nbsp;days (docetaxel alone). The overall objective
response rates in the all&#8209;randomised population (investigator assessment)
were 41.6% (docetaxel&nbsp;+ capecitabine) vs. 29.7% (docetaxel alone);
p&nbsp;=&nbsp;0.0058. Time to progressive disease was superior in the
docetaxel&nbsp;+ capecitabine combination arm (p&nbsp;&lt;&nbsp;0.0001). The
median time to progression was 186&nbsp;days (docetaxel&nbsp;+ capecitabine)
vs. 128&nbsp;days (docetaxel alone).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Patients
previously treated with chemotherapy with or without radiotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In a
phase&nbsp;III study, in previously treated patients, time to progression
(12.3&nbsp;weeks versus 7&nbsp;weeks) and overall survival were significantly
longer for docetaxel at 75&nbsp;mg/m&sup2; compared to Best Supportive Care. The
1&#8209;year survival rate was also significantly longer in docetaxel (40%)
versus BSC (16%).</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>There was less use of
morphinic analgesic (p&nbsp;&lt;&nbsp;0.01), non&#8209;morphinic analgesics
(p&nbsp;&lt;&nbsp;0.01), other disease-related medications (p&nbsp;=&nbsp;0.06)
and radiotherapy (p&nbsp;&lt;&nbsp;0.01) in patients treated with docetaxel at
75&nbsp;mg/m&sup2; compared to those with BSC.</p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The overall
response rate was 6.8% in the evaluable patients, and the median duration of
response was 26.1&nbsp;weeks.</span></p>

<p class=MsoHeading7 style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
page-break-after:auto'><b><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with platinum agents in chemotherapy-na&iuml;ve patients</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In a
phase&nbsp;III study, 1218&nbsp;patients with unresectable stage&nbsp;IIIB or
IV NSCLC, with KPS of 70% or greater, and who did not receive previous
chemotherapy for this condition, were randomised to either docetaxel&nbsp;(T)
75&nbsp;mg/m<sup>2 </sup>as a 1&nbsp;hour infusion immediately followed by
cisplatin&nbsp;(Cis) 75&nbsp;mg/m<sup>2 </sup>over </span><span lang=EN-GB
style='font-size:11.0pt'>30&#8209;60&nbsp;minutes every 3&nbsp;weeks (TCis),
docetaxel 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion in combination
with</span><span lang=EN-GB style='font-size:11.0pt'> carboplatin (AUC
6&nbsp;mg/ml.min) over 30&#8209;60&nbsp;minutes every 3&nbsp;weeks, or
vinorelbine&nbsp;(V) 25&nbsp;mg/m<sup>2</sup> administered over 6&#8209;10&nbsp;minutes
on days&nbsp;1, 8, 15, 22 followed by cisplatin 100&nbsp;mg/m<sup>2</sup>
administered on </span><span lang=EN-GB style='font-size:11.0pt'>day&nbsp;1 of
cycles repeated every 4&nbsp;weeks (VCis).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Survival data, median time to progression and response
rates for two arms of the study are illustrated in the following table:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=584
 style='margin-left:17.5pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>TCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;408</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>VCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;404</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Statistical analysis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Overall
  survival </span></p>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(Primary
  end-point):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>10.1</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hazard
  ratio: 1.122</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[97.2% CI: 0.937; 1.342]*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>1-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>41</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 5.4%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: -1.1; 12.0]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>2-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>21</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 6.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.2; 12.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Median
  time to progression</span></p>
  <p class=Authors align=right style='margin-top:0in;text-align:right;
  punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(weeks):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.0</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>23.0</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Hazard ratio: 1.032</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.876; 1.216]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (%):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.6</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.5</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 7.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.7; 13.5]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>*: Corrected for multiple comparisons and adjusted for
stratification factors (stage of disease and region of treatment), based on
evaluable patient population.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Secondary end&#8209;points
included change of pain, global rating of quality of life by EuroQoL-5D, Lung
Cancer Symptom Scale, and changes in Karnosfky performance status. Results on
these end-points were supportive of the primary end-points results.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For
docetaxel/carboplatin combination, neither equivalent nor non-inferior efficacy
could be proven compared to the reference treatment combination VCis.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Metastatic castration-resistant prostate cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left;
page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
font-style:normal'>The safety and efficacy of docetaxel in combination with
prednisone or prednisolone</span><span style='font-size:11.0pt'> </span><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>in patients with
metastatic castration-resistant prostate cancer were evaluated in a randomised
multi-centre phase&nbsp;III study (TAX 327). A total of 1006&nbsp;patients with
KPS&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol;font-weight:
normal;font-style:normal'>&sup3;</span><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;60 were randomised to the following
treatment groups:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 75&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 30&nbsp;mg/m<sup>2</sup>
administered weekly for the first 5&nbsp;weeks in a 6&nbsp;week cycle for
5&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mitoxantrone
12&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>All
3&nbsp;regimens were administered in combination with </span><span lang=EN-GB
style='font-size:11.0pt'>prednisone or prednisolone 5&nbsp;mg twice daily,
continuously.</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>Patients who
received docetaxel every three weeks demonstrated significantly longer overall
survival compared to those treated with mitoxantrone. The increase in survival
seen in the docetaxel weekly arm was not statistically significant compared to
the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus
the control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=587
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Endpoint</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Docetaxel every 3 weeks </span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Docetaxel every week</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Mitoxantrone </span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>every 3 weeks</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Number of
  patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Median survival
  (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>Hazard
  ratio</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value<sup>&#8224;</sup>*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>335</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>18.9</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(17.0-21.2)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.761</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(0.619-0.936)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0094</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>334</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>17.4</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(15.7-19.0)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.912</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(0.747-1.113)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.3624</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>337</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>16.5</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(14.4-18.6)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Number of patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>PSA** response rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span lang=FR style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>291</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>45.4</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(39.5-51.3)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0005</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>282</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>47.9</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(41.9-53.9)<br>
  &lt;0.0001</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>300</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>31.7</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(26.4-37.3)<br>
  --</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Number of patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Pain response rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>153</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>34.6</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(27.1-42.7)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0107</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>154</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>31.2</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(24.0-39.1)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0798</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>157</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>21.7</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(15.5-28.9)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.7pt'>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Number of
  patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Tumour response
  rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>141</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>12.1</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(7.2-18.6)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.1112</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>134</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>8.2</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(4.2-14.2)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.5853</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>137</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>6.6</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(3.0-12.1)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoBodyText3 align=left style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:12.25pt;margin-bottom:.0001pt;text-align:left;
page-break-after:avoid'><sup><span style='font-size:11.0pt;font-weight:normal;
font-style:normal'>&#8224;</span></sup><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Stratified log-rank test<br>
*Threshold for statistical significance&nbsp;=&nbsp;0.0175</span></p>

<p class=MsoNormal style='margin-left:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>**PSA: Prostate-Specific Antigen<br>
<br>
</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Given the fact
that docetaxel every week presented a slightly better safety profile than
docetaxel every 3&nbsp;weeks, it is possible that certain patients may benefit
from docetaxel every week.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No statistical
differences were observed between treatment groups for Global Quality of Life.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Metastatic
hormone-sensitive prostate cancer</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>STAMPEDE </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered concomitantly with standard of care (ADT)<b> </b>in
patients with high-risk locally advanced or metastatic hormone-sensitive
prostate cancer were evaluated in a <span style='color:black'>randomised multi-centre,
multi-arm multi-stage (MAMS) study </span></span><span style='color:black'>with
a seamless phase II/III design</span><span style='font-size:11.0pt'> (STAMPEDE
&#8211; MRC PR08). A total of 1776 male patients were allocated to the treatment
arms of interest: </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>+ docetaxel
75 mg/m&sup2;, administered every 3 weeks for 6 cycles&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>alone </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Docetaxel regimen was administered
in combination with prednisone or prednisolone 5 mg twice daily continuously. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Among the 1776 randomised
patients 1086 (61%) had metastatic disease, 362 were randomised to docetaxel in
combination with standard of care, 724 received standard of care<b> </b>alone. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In these metastatic prostate
cancer patients, the median overall survival was significantly longer in
docetaxel treatment groups than in the standard of care<b> </b>alone group,
with a median overall survival 19 months longer with the addition of docetaxel
to standard of care<b> </b>(HR = &nbsp;0.76, 95% </span><span lang=EN-GB
style='font-size:11.0pt'>CI = 0.62-0.92,</span><span lang=EN-GB
style='font-size:11.0pt'> </span><span style='font-size:11.0pt'>p=0.005). </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Efficacy results in
metastatic prostate cancer patients for </span><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span><span style='font-size:11.0pt'> arm
versus control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in combination with prednisone
or prednisolone and standard of care in the treatment of patients with
metastatic hormone-sensitive prostate cancer </span><span style='font-size:
11.0pt'>(STAMPEDE)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:maroon'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
   3.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:11.0pt;
   color:black'>Endpoint</span></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span><span
   style='font-size:11.0pt;color:black'>+</span><span style='font-size:11.0pt;
   color:black'> standard of care</span></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></p>
   </td>
   <td width=167 valign=top style='width:125.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
   style='font-size:11.0pt;color:black'>Standard of care </span><span
   style='font-size:11.0pt;color:black'>alone</span></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:59.1pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.1pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of metastatic prostate cancer
  patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months) </span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>362</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>51-73</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>724</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>43</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>40-48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='color:black'>Adjusted h</span><span style='font-size:11.0pt;
  color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>(0.62&#8209;0.92)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.005</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Failure-Free survival<i><span style='position:relative;
  top:-3.0pt'>b</span></i>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:31.65pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.65pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.8-25.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.65pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>9.6-12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.57&#8209;0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&lt; 0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.3pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>a </span></sup></i><span
  style='color:black'>p-value calculated from the likelihood ratio test and
  adjusted for all stratification factors (except center and planned hormone
  therapy) and stratified by trial period</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>b</span></sup></i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>
  Failure-free survival: time from randomization to first evidence of at least
  one of: biochemical failure (defined as a rise in PSA of 50% above the
  within-24-week nadir and above 4 ng/mL and confirmed by retest or treatment);
  progression either locally, in lymph nodes, or in distant metastases; skeletal-related
  event; or death from prostate cancer.</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>CHAARTED </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered at the beginning of androgen-deprivation therapy (ADT) in
patients with metastatic hormone-sensitive prostate cancer were evaluated in a randomised
Phase III multi-centre study (CHAARTED). A total of 790 male patients were
allocated to the 2 treatment groups. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT + docetaxel
75 mg/m&sup2; given at the beginning of ADT, administered every 3 weeks for 6
cycles</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT alone<sup> </sup>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'><br>
The median overall survival was significantly longer in docetaxel treatment
group than in the ADT alone group, with a median overall survival 13.6
months&nbsp; longer with the addition of docetaxel to ADT (hazard ratio (HR) =
0.61, 95% </span><span lang=EN-GB style='font-size:11.0pt'>confidence interval
(CI)&nbsp;= 0.47-0.80, </span><span style='font-size:11.0pt'>p=0.0003). <br>
<br>
Efficacy results or the </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> arm versus the control arm are summarized in the
following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Efficacy
of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> and ADT in the treatment of patients with metastatic
hormone-sensitive prostate cancer (CHAARTED)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>Endpoint</span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=178 valign=top style='width:133.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span></b><b><span
   style='font-size:11.0pt;color:black'>+ADT </span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=112 valign=top style='width:83.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>ADT alone</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months)</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>All patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><i><span
  lang=IT style='font-size:11.0pt;color:black'>95% CI</span></i></b></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='color:black'>Adjusted </span><span style='font-size:11.0pt;color:black'>hazard
  ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>397</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>57.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>49.1-72.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>393</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>44.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>34.4-49.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.47&#8209;0.80)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.0003</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Progression Free Survival</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value*</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.7-22.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.60</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.51-0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>P&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.6</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>10.8-14.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 6 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>127 (32.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>77 (19.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 12 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>110 (27.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>66 (16.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to castration-resistant prostate cancer<i><span
  style='position:relative;top:-3.0pt'>b</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months) </span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.2&#8209;23.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(10.8-14.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.51&#8209;0.72)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to clinical progression</span><i><span style='font-size:
  11.0pt;color:black;position:relative;top:-3.0pt'>c</span></i><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)<i><span style='position:relative;top:-3.0pt'> </span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>33.0</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(27.3-41.2)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.9-22.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.50-0.75)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.3pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>a</span></i><span style='font-size:11.0pt;color:black'>&nbsp;</span><span
  style='font-size:11.0pt;color:black'>Time to event variables: Stratified
  log-rank test. <br>
  &nbsp; Response rate variables: Fisher's Exact test</span><i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> </span></i></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>* p-value for
  descriptive purpose.</span></p>
  <p class=MsoCommentText><span style='font-size:11.0pt;color:black'>** </span><span
  lang=EN-GB style='color:black'>PSA r</span><span style='font-size:11.0pt;
  color:black'>esponse</span><span lang=EN-GB style='font-size:11.0pt;
  color:black'>: Prostate-Specific Antigen response: </span><span
  style='font-size:11.0pt;color:black'>PSA level &lt;0.2 ng/mL measured for two
  consecutive measurements at least 4 weeks apart.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>b </span></i><span style='font-size:11.0pt;color:black'>Time
  to castration-resistant prostate cancer = time from randomization to PSA progression
  </span><span lang=EN-GB style='color:black'>or clinical progression (i.e.,
  increasing symptomatic bone metastases, progression per </span><span
  style='font-size:11.0pt;color:black'>Response Evaluation Criteria in Solid
  Tumours (</span><span lang=EN-GB style='color:black'>RECIST) criteria, or
  clinical deterioration due to cancer per the Investigator&#8217;s opinion),
  whichever occurred first.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>c</span></i><span style='font-size:11.0pt;color:black'>&nbsp;The
  time to clinical progression = the time from randomization until clinical
  progression (i.e., increased symptoms of bone metastases; progression
  according to RECIST; or clinical deterioration due to cancer according to the
  investigator&#8217;s opinion).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>A multi-centre,
open-label, randomised study was conducted to evaluate the safety and efficacy
of docetaxel for the treatment of patients with metastatic gastric
adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who
had not received prior chemotherapy for metastatic disease. A total of
445&nbsp;patients with KPS&nbsp;&gt;&nbsp;70 were treated with either
docetaxel&nbsp;(T) (75&nbsp;mg/m<sup>2</sup> on day&nbsp;1) in combination with
cisplatin&nbsp;(C) (75&nbsp;mg/m<sup>2</sup> on day&nbsp;1) and 5&#8209;fluorouracil&nbsp;(F)
(750&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days) or cisplatin (100&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) and 5&#8209;fluorouracil (1000&nbsp;mg/m<sup>2</sup> per day for
5&nbsp;days). The length of a treatment cycle was 3&nbsp;weeks for the TCF arm
and 4&nbsp;weeks for the CF arm. The median number of cycles administered per
patient was 6 (with a range of 1&#8209;16) for the TCF arm compared to 4 (with
a range of 1&#8209;12) for the CF arm. Time to progression (TTP) was the
primary endpoint. The risk reduction of progression was 32.1% and was
associated with a significantly longer TTP (p&nbsp;=&nbsp;0.0004) in favour of
the TCF arm. Overall survival was also significantly longer
(p&nbsp;=&nbsp;0.0201) in favour of the TCF arm with a risk reduction of
mortality of 22.7%. Efficacy results are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Efficacy of docetaxel in the treatment of
patients with gastric adenocarcinoma </span></u></p>

<p align=center style='margin:0in;text-align:center;page-break-after:avoid'><b><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=477
 style='width:357.55pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>TCF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;221</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;224</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median TTP (months)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>5.6</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>3.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(4.86-5.91)</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(3.45-4.47)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>1.473</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.189-1.825)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.2</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(8.38-10.58)</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(7.16-9.46)</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>2-year estimate (%)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18.4</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.293</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.041-1.606)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0201</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (CR+PR) (%)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36.7</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0106</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progressive disease as best overall Response (%)</span></p>
  </td>
  <td width=103 style='width:77.55pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.7</span></p>
  </td>
  <td width=110 style='width:82.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.9</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>*Unstratified
logrank test</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;layout-grid-mode:both'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext;
layout-grid-mode:both'>Subgroup analyses across age, gender and race
consistently favoured the TCF arm compared to the CF arm.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>A survival update analysis
conducted with a median follow-up time of 41.6&nbsp;months no longer showed a
statistically significant difference although always in favour of the TCF
regimen and showed that the benefit of TCF over CF is clearly observed between
18 and 30&nbsp;months of follow up.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Overall, quality
of life (QoL) and clinical benefit results consistently indicated improvement
in favour of the TCF arm. Patients treated with TCF had a longer time to 5%
definitive<b> </b>deterioration of global health status on the QLQ&#8209;C30
questionnaire (p&nbsp;=&nbsp;0.0121) and a longer time to definitive worsening<b>
</b>of Karnofsky performance status (p&nbsp;=&nbsp;0.0088) compared to patients
treated with CF.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction</span><span lang=EN-GB
style='font-size:11.0pt'> chemotherapy followed by radiotherapy (TAX323)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and efficacy
of docetaxel in the induction treatment of patients with squamous cell
carcinoma of the head and neck (SCCHN) was evaluated in a phase&nbsp;III, multi-centre,
open-label, randomised study (TAX323). In this study, 358&nbsp;patients with
inoperable locally advanced SCCHN, and WHO performance status&nbsp;0 or 1, were
randomised to one of two treatment arms.&nbsp; Patients on the docetaxel arm
received docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2</sup> followed by
cisplatin&nbsp;(P) 75&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
750&nbsp;mg/m<sup>2</sup> per day as a continuous infusion for 5&nbsp;days.
This regimen was administered every three weeks for 4&nbsp;cycles in case at
least a minor response (&#8805;&nbsp;25% reduction in bidimensionally measured
tumour size) was observed after 2&nbsp;cycles. At the end of chemotherapy, with
a minimal interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks,
patients whose disease did not progress received radiotherapy (RT) according to
institutional guidelines for 7&nbsp;weeks (TPF/RT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days. This regimen was administered
every three weeks for 4&nbsp;cycles in case at least a minor response
(&#8805;&nbsp;25% reduction in bidimensionally measured tumour size) was
observed after 2&nbsp;cycles. At the end of chemotherapy, with a minimal
interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks, patients whose
disease did not progress received radiotherapy&nbsp;(RT) according to
institutional guidelines for 7&nbsp;weeks (PF/RT). Locoregional therapy with
radiation was delivered either with a conventional fraction (1.8&nbsp;Gy&nbsp;&#8209;&nbsp;2.0&nbsp;Gy
once a day, 5&nbsp;days per week for a total dose of 66 to 70&nbsp;Gy), or
accelerated/hyperfractionated regimens of radiation therapy (twice a day, with
a minimum interfraction interval of 6&nbsp;hours, 5&nbsp;days per week). A
total of 70&nbsp;Gy was recommended for accelerated regimens and 74&nbsp;Gy for
hyperfractionated schemes. Surgical resection was allowed following
chemotherapy, before or after radiotherapy. Patients on the TPF arm received
antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice daily for
10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. The primary
endpoint in this study, progression-free survival (PFS), was significantly
longer in the TPF arm compared to the PF arm, p&nbsp;=&nbsp;0.0042 (median PFS:
11.4 vs. 8.3&nbsp;months respectively) with an overall median follow up time of
33.7&nbsp;months. Median overall survival was also significantly longer in favour
of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5&nbsp;months
respectively) with a 28% risk reduction of mortality, p&nbsp;=&nbsp;0.0128.
Efficacy results are presented in the table below:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in the induction treatment of
patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 style='margin-top:0in'><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
  text-transform:none'>Endpoint</span></h1>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;177</span></b></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;181</span></b></p>
  </td>
 </tr>
 <tr style='height:22.0pt'>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median progression free survival (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>11.4</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>(10.1-14.0)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>8.3</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>(7.4-9.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.70</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.55-0.89)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0042</span></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>18.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(15.7-24.0)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>14.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(11.6-18.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.56-0.93)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0128</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Best overall response to chemotherapy (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>67.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(60.4-74.6)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>53.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(46.0-61.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Best overall response to study treatment
  [chemotherapy +/- radiotherapy] (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>72.3</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.1-78.8)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(51.0-65.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median duration of response to chemotherapy&nbsp;</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&plusmn;</span><span
  lang=EN-GB style='font-size:11.0pt'> radiotherapy (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;128</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>15.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(13.4-24.6)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;106</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(10.2-17.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.52-0.99)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0457</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>A hazard ratio of less than&nbsp;1 favours
docetaxel&nbsp;+ cisplatin&nbsp;+ 5&#8209;FU</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>*Cox model (adjustment for Primary tumour site, T and
N clinical stages and PSWHO)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>**Logrank test</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>*** Chi-square
test</span></p>

<p class=MsoNormal style='margin-left:.5in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Quality
of life parameters</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Patients treated with TPF experienced significantly
less deterioration of their Global health score compared to those treated with
PF (p&nbsp;=&nbsp;0.01, using the EORTC QLQ&#8209;C30 scale). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Clinical
benefit parameters</span></i></p>

<p class=Authors style='margin-top:0in;line-height:12.0pt;page-break-after:
auto;text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
performance status scale, for head and neck (PSS&#8209;HN) subscales designed
to measure understandability of speech, ability to eat in public, and normalcy
of diet, was significantly in favour of TPF as compared to PF.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Median time to
first deterioration of WHO performance status was significantly longer in the
TPF arm compared to PF.</span><span lang=EN-GB style='font-size:11.0pt;
layout-grid-mode:line'> Pain intensity score improved during treatment in both
groups indicating adequate pain management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:
line'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Induction
</span><span lang=EN-GB style='font-size:11.0pt'>chemotherapy</span><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'> followed by
chemoradiotherapy (TAX324)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of docetaxel in the induction
treatment of patients with locally advanced squamous cell carcinoma of the head
and neck (SCCHN) was evaluated in a randomised, multi-centre open-label,
phase&nbsp;III study (TAX324). In this study, 501&nbsp;patients, with locally
advanced SCCHN, and a WHO performance status of 0 or 1, were randomised to one
of two arms. The study population comprised patients with technically
unresectable disease, patients with low probability of surgical cure and patients
aiming at organ preservation. The efficacy and safety evaluation solely
addressed survival endpoints and the success of organ preservation was not
formally addressed. Patients on the docetaxel arm received docetaxel&nbsp;(T)
75&nbsp;mg/m&sup2; by intravenous infusion on day 1 followed by
cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; administered as a 30&#8209;minute to
three&#8209;hour intravenous infusion, followed by the continuous intravenous
infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day from
day&nbsp;1 to day&nbsp;4. The cycles were repeated every 3 weeks for 3 cycles.
All patients who did not have progressive disease were to receive
chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; as a 30&#8209;minute to
three&#8209;hour intravenous infusion on day&nbsp;1 followed by the continuous
intravenous infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day
from day&nbsp;1 to day&nbsp;5. The cycles were repeated every 3&nbsp;weeks for
3&nbsp;cycles. All patients who did not have progressive disease were to
receive CRT as per protocol (PF/CRT).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients in both
treatment arms were to receive 7&nbsp;weeks of CRT following induction
chemotherapy with a minimum interval of 3&nbsp;weeks and no later than
8&nbsp;weeks after start of the last cycle (day&nbsp;22 to day&nbsp;56 of last
cycle). During radiotherapy, carboplatin (AUC&nbsp;1.5) was given weekly as a
one&#8209;hour intravenous infusion for a maximum of 7&nbsp;doses. Radiation
was delivered with megavoltage equipment using once daily fractionation
(2&nbsp;Gy per day, 5&nbsp;days per week for 7&nbsp;weeks, for a total dose of
70&#8209;72&nbsp;Gy). Surgery on the primary site of disease and/or neck could
be considered at any time following completion of CRT. </span><span lang=EN-GB
style='font-size:11.0pt'>All patients on the docetaxel-containing arm of the
study received prophylactic antibiotics. </span><span lang=EN-GB
style='font-size:11.0pt'>The primary efficacy endpoint in this study, overall
survival (OS) was significantly longer (log-rank test, p&nbsp;=&nbsp;0.0058)
with the docetaxel&#8209;containing regimen compared to PF (median OS: 70.6
versus 30.1&nbsp;months respectively), with a 30% risk reduction in mortality
compared to PF (hazard ratio (HR)&nbsp;=&nbsp;0.70, 95% confidence interval
(CI)&nbsp;=&nbsp;0.54&#8209;0.90) with an overall median follow up time of
41.9&nbsp;months. The secondary endpoint, PFS, demonstrated a 29% risk
reduction of progression or death and a 22&nbsp;month improvement in median PFS
(35.5&nbsp;months for TPF and 13.1 for PF). This was also statistically
significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test
p&nbsp;=&nbsp;0.004. Efficacy results are presented in the table below:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in the induction treatment of
patients with locally advanced SCCHN (Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=162 colspan=2 valign=bottom style='width:121.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+
  Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  255</span></b></p>
  </td>
  <td width=153 valign=bottom style='width:114.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+
  5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  246</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median overall survival (months) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=162 colspan=2 valign=top style='width:121.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>70.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(49.0-NA)</span></p>
  </td>
  <td width=153 valign=top style='width:114.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>30.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(20.9-51.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 style='width:187.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value </span></p>
  </td>
  <td width=316 colspan=3 valign=top style='width:236.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.70</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.54-0.90)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0058</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 style='width:187.4pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median PFS (months) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=162 colspan=2 valign=top style='width:121.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>35.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(19.3-NA)</span></p>
  </td>
  <td width=153 valign=top style='width:114.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>13.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(10.6 - 20.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Hazard ratio:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value </span></p>
  </td>
  <td width=316 colspan=3 valign=bottom style='width:236.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.71</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.56 - 0.90)</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Best overall response (CR + PR) to
  chemotherapy (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=158 valign=top style='width:118.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>71.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.8-77.2)</span></p>
  </td>
  <td width=158 colspan=2 valign=top style='width:118.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>64.2</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(57.9-70.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=316 colspan=3 style='width:236.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.070</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Best overall response (CR + PR) to study
  treatment [chemotherapy +/- chemoradiotherapy] (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%CI)</span></p>
  </td>
  <td width=158 valign=top style='width:118.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>76.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(70.8-81.5)</span></p>
  </td>
  <td width=158 colspan=2 valign=top style='width:118.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>71.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.5-77.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=316 colspan=3 style='width:236.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.209</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=250 style='border:none'></td>
  <td width=158 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=153 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>A hazard ratio of less than 1 favours
docetaxel&nbsp;+ cisplatin&nbsp;+ fluorouracil</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>*un-adjusted log-rank test</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>**un-adjusted log-rank test, not adjusted for multiple
comparisons</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>***Chi square test, not adjusted for multiple
comparisons</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>NA-not applicable</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The European
Medicines Agency has waived the obligation to submit the results of studies
with TAXOTERE in all subsets of the paediatric population in breast cancer,
non-small cell lung cancer, prostate cancer, gastric carcinoma and head and
neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel have been evaluated in cancer patients after
administration of 20&#8209;115&nbsp;mg/m<sup>2</sup> in phase&nbsp;I studies.
The kinetic profile of docetaxel is dose independent and consistent with a
three-compartment pharmacokinetic model with half-lives for the </span><span lang=EN-GB style='font-size:11.0pt'>a</span><span lang=EN-GB style='font-size:
11.0pt'>, </span><span
lang=EN-GB style='font-size:11.0pt'>b</span><span lang=EN-GB style='font-size:
11.0pt'> and </span><span
lang=EN-GB style='font-size:11.0pt'>g</span><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;phases of 4&nbsp;min, 36&nbsp;min and 11.1&nbsp;h, respectively.
The late phase is due, in part, to a relatively slow efflux of docetaxel from
the peripheral compartment. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Distribution</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Following the
administration of a 100&nbsp;mg/m<sup>2</sup> dose given as a one&#8209;hour
infusion a mean peak plasma level of 3.7&nbsp;&micro;g/ml was obtained with a
corresponding AUC of 4.6&nbsp;h.&micro;g/ml. Mean values for total body
clearance and steady-state volume of distribution were 21&nbsp;l/h/m<sup>2</sup>
and 113&nbsp;l, respectively. Inter individual variation in total body
clearance was approximately 50%. Docetaxel is more than 95% bound to plasma
proteins.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>A study of <sup>14</sup>C&#8209;docetaxel has been
conducted in three cancer patients. Docetaxel was eliminated in both the urine
and faeces following cytochrome P450&#8209;mediated oxidative metabolism of the
tert&#8209;butyl ester group, within seven days, the urinary and faecal
excretion accounted for about 6% and 75% of the administered radioactivity,
respectively. About 80% of the radioactivity recovered in faeces is excreted
during the first 48&nbsp;hours as one major inactive metabolite and
3&nbsp;minor inactive metabolites and very low amounts of unchanged medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Special populations</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Age and gender</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>A population pharmacokinetic analysis has been
performed with docetaxel in 577&nbsp;patients. Pharmacokinetic parameters
estimated by the model were very close to those estimated from phase&nbsp;I
studies. The pharmacokinetics of docetaxel were not altered by the age or sex
of the patient. </span></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>In a small number of patients (n&nbsp;=&nbsp;23) with
clinical chemistry data suggestive of mild to moderate liver function
impairment (ALT, AST&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&sup3;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;1.5&nbsp;times the
ULN associated with alkaline phosphatase </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&sup3;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;2.5&nbsp;times the
ULN), total clearance was lowered by 27% on average (see section 4.2). </span></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Fluid retention</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>Docetaxel clearance was not modified in patients with
mild to moderate fluid retention and there are no data available in patients
with severe fluid retention.</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Combination therapy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Doxorubicin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>When used in
combination, docetaxel does not influence the clearance of doxorubicin and the
plasma levels of doxorubicinol (a doxorubicin metabolite). The pharmacokinetics
of docetaxel, doxorubicin and cyclophosphamide were not influenced by their
coadministration.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Capecitabine</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phase&nbsp;I study
evaluating the effect of capecitabine on the pharmacokinetics of docetaxel and
vice versa showed no effect by capecitabine on the pharmacokinetics of
docetaxel (C<sub>max</sub> and AUC) and no effect by docetaxel on the
pharmacokinetics of a relevant capecitabine metabolite 5&#8217;&#8209;DFUR.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Cisplatin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Clearance of
docetaxel in combination therapy with cisplatin was similar to that observed
following monotherapy. <span style='layout-grid-mode:line'>The pharmacokinetic
profile of cisplatin administered shortly after docetaxel infusion is similar
to that observed with cisplatin alone.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Cisplatin
and 5-fluorouracil</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The combined administration of docetaxel, cisplatin
and 5&#8209;fluorouracil in 12&nbsp;patients with solid tumours had no
influence on the pharmacokinetics of each individual medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone
and dexamethasone</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The effect of
prednisone on the pharmacokinetics of docetaxel administered with standard
dexamethasone premedication has been studied in 42&nbsp;patients. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Prednisone</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No effect of
prednisone on the pharmacokinetics of docetaxel was observed.</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.3&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The carcinogenic
potential of docetaxel has not been studied.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel has been
shown to be mutagenic in the <i>in vitro</i> micronucleus and chromosome
aberration test in CHO&#8209;K1 cells and in the <i>in vivo</i> micronucleus
test in the mouse. However, it did not induce mutagenicity in the Ames test or
the CHO/HGPRT gene mutation assay. These results are consistent with the
pharmacological activity of docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Undesirable
effects on the testis observed in rodent toxicity studies suggest that
docetaxel may impair male fertility.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoBodyText align=left style='text-align:left;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Concentrate vial: </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Polysorbate&nbsp;80</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Citric acid.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Solvent vial: </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Ethanol&nbsp;95% </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Water for injections.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>This medicinal
product must not be mixed with other medicinal products except those mentioned
in section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf-life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Premix solution: The
premix solution contains 10&nbsp;mg/ml docetaxel and should be used immediately
after preparation. However the chemical and physical stability of the premix
solution has been demonstrated for 8&nbsp;hours when stored either between
2&deg;C and 8&deg;C or at room temperature (below 25&deg;C).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Infusion solution: the
infusion solution should be used within 4&nbsp;hours at room temperature (below
25&deg;C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Do not store above
25&deg;C or below 2&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For storage
conditions of the diluted medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each blister pack
contains:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
concentrate and,</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
solvent.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>TAXOTERE 20 mg/0.5&nbsp;ml concentrate
for solution for infusion vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>7&nbsp;ml clear
glass Type&nbsp;I vial with a green flip&#8209;off cap.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>This vial contains
0.5&nbsp;ml of a 40&nbsp;mg/ml solution of docetaxel in polysorbate&nbsp;80
(fill volume: 24.4&nbsp;mg/0.61&nbsp;ml). This fill volume has been established
during the development of TAXOTERE to compensate for liquid loss during
preparation of the premix due to foaming, adhesion to the walls of the vial and
&quot;dead-volume&quot;. This overfill ensures that after dilution with the
entire contents of the accompanying solvent for TAXOTERE vial, there is a
minimal extractable premix volume of 2&nbsp;ml containing 10&nbsp;mg/ml
docetaxel which corresponds to the labelled amount of 20 mg/0.5&nbsp;ml per
vial.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Solvent vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>7&nbsp;ml clear
glass Type&nbsp;I vial with a transparent colourless flip&#8209;off cap.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Solvent vial
contains 1.5&nbsp;ml of a 13% w/w solution of ethanol 95% in water for
injections (fill volume: 1.98&nbsp;ml). The addition of the entire contents of
the solvent vial to the contents of the TAXOTERE 20 mg/0.5&nbsp;ml concentrate
for solution for infusion vial ensures a premix concentration of 10&nbsp;mg/ml
docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE is an
antineoplastic agent and, as with other potentially toxic compounds, caution
should be exercised when handling it and preparing TAXOTERE solutions. The use
of gloves is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
skin, wash immediately and thoroughly with soap and water. If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
mucous membranes, wash immediately and thoroughly with water.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Preparation for the intravenous
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preparation
of the TAXOTERE premix solution (10&nbsp;mg docetaxel/ml)</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If the vials are
stored under refrigeration, allow the required number of TAXOTERE boxes to
stand at room temperature (below 25&deg;C) for 5&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Using a syringe
fitted with a needle, aseptically withdraw the entire contents of the solvent
for TAXOTERE vial by partially inverting the vial. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the entire
contents of the syringe into the corresponding TAXOTERE vial.</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:-35.4pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Remove the syringe
and needle and mix manually by repeated inversions for at least
45&nbsp;seconds. Do not shake.</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:-35.4pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyTextIndent3 align=left style='margin:0in;margin-bottom:.0001pt;
text-align:left'><span style='font-size:11.0pt'>Allow the premix vial to stand
for 5&nbsp;minutes at room temperature (below 25&deg;C) and then check that the
solution is homogenous and clear (foaming is normal even after 5&nbsp;minutes
due to the presence of polysorbate&nbsp;80 in the formulation). </span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The premix solution contains
10&nbsp;mg/ml docetaxel and should be used immediately after preparation.
However the chemical and physical stability of the premix solution has been
demonstrated for 8&nbsp;hours when stored either between 2&deg;C and 8&deg;C or
at room temperature (below 25&deg;C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preparation
of the infusion solution</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>More than one premix
vial may be necessary to obtain the required dose for the patient. Based on the
required dose for the patient expressed in mg, aseptically withdraw the
corresponding premix volume containing 10&nbsp;mg/ml docetaxel from the
appropriate number of premix vials using graduated syringes fitted with a
needle. For example, a dose of 140&nbsp;mg docetaxel would require 14&nbsp;ml
docetaxel premix solution.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
required premix volume into a 250&nbsp;ml infusion bag or bottle containing
either 5% glucose solution or sodium chloride </span><span lang=EN-GB
style='font-size:11.0pt'>9&nbsp;mg/ml (0.9%) </span><span lang=EN-GB
style='font-size:11.0pt'>solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If a dose greater
than 200&nbsp;mg of docetaxel is required, use a larger volume of the infusion
vehicle so that a concentration of 0.74&nbsp;mg/ml docetaxel is not exceeded.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>Mix the infusion bag or bottle manually using a rocking motion.</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE
infusion solution should be used within 4&nbsp;hours and should be aseptically
administered as a 1&#8209;hour infusion under room temperature (below 25&deg;C)
and normal lighting conditions.</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>As with all parenteral products, TAXOTERE premix solution and infusion
solution should be visually inspected prior to use, solutions containing a
precipitate should be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left;
page-break-after:avoid;punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
style='font-size:11.0pt;font-style:normal'>7.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/001</span></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: </span><span lang=EN-GB
style='font-size:11.0pt'>27 November 1995</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of latest renewal: 27 November 2005</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <u>http://www.ema.europa.eu.</u> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE 80 mg/2&nbsp;ml
concentrate and solvent for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each single&#8209;dose
vial of TAXOTERE 80 mg/2&nbsp;ml concentrate contains docetaxel (as trihydrate)
corresponding to 80 mg of docetaxel (anhydrous). The viscous solution contains
40&nbsp;mg/ml docetaxel (anhydrous).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Excipient with
known effect: </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each single&#8209;dose
vial of solvent contains 13% (w/w) ethanol 95% v/v in water for injection </span><span
style='font-size:11.0pt'>(932 mg of ethanol 95% v/v)</span><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB>For the
full list of excipients, see section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Concentrate and
solvent for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The concentrate is
a clear viscous, yellow to brown-yellow solution.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;layout-grid-mode:both'>The solvent is a colourless solution.</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Breast cancer</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>TAXOTERE
in combination with doxorubicin and cyclophosphamide is indicated for the
adjuvant treatment of patients with:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;positive
breast cancer</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;negative
breast cancer</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients with
operable node</span><span lang=EN-GB style='font-size:11.0pt'>&#8209;negative
breast cancer, adjuvant treatment should be restricted to patients eligible to
receive chemotherapy according to internationally established criteria for
primary therapy of early breast cancer (see section 5.1).</span><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin is indicated for the treatment of patients with
locally advanced or metastatic breast cancer who have not previously received
cytotoxic therapy for this condition.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE
monotherapy is indicated for the treatment of patients with locally advanced or
metastatic breast cancer after failure of cytotoxic therapy. Previous
chemotherapy should have included an anthracycline or an alkylating agent.</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'> in combination with trastuzumab is indicated for the treatment
of patients with metastatic breast cancer whose tumours over express HER2 and
who previously have not received chemotherapy for metastatic disease.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>TAXOTERE in combination with
capecitabine is indicated for the treatment of patients with locally advanced
or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous
therapy should have included an anthracycline.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE is indicated for the treatment of patients
with locally advanced or metastatic non-small cell lung cancer after failure of
prior chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in combination
with cisplatin is indicated for the treatment of patients with unresectable,
locally advanced or metastatic non-small cell lung cancer, in patients who have
not previously received chemotherapy for this condition.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with prednisone or prednisolone is indicated
for the treatment of patients with&nbsp; metastatic castration-resistant
prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with androgen-deprivation therapy (ADT),
with or without prednisone or prednisolone, is indicated for the treatment of patients
with metastatic hormone-sensitive prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>TAXOTERE in
combination with cisplatin and 5&#8209;fluorouracil is indicated for the
treatment of patients with metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction, who have not received prior
chemotherapy for metastatic disease.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with cisplatin and 5&#8209;fluorouracil is
indicated for the induction treatment of patients with locally advanced
squamous cell carcinoma of the head and neck.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>The use of docetaxel should be confined to units
specialised in the administration of cytotoxic chemotherapy and it should only
be administered under the supervision of a physician qualified in the use of
anticancer chemotherapy (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For breast, non-small cell lung, gastric, and head and
neck cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can be used (see section 4.4).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For metastatic castration-resistant prostate cancer,
given the concurrent use of prednisone or prednisolone the recommended
premedication regimen is oral dexamethasone 8&nbsp;mg, 12&nbsp;hours,
3&nbsp;hours and 1&nbsp;hour before the docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>For metastatic hormone-sensitive prostate
cancer, irrespective of the concurrent use of prednisone or prednisolone, the
recommended premedication regimen is oral dexamethasone 8&nbsp;mg 12 hours, 3
hours, and 1 hour before docetaxel infusion (see section 4.4).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-variant:small-caps'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Prophylactic G&#8209;CSF may be used to mitigate the
risk of haematological toxicities.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is administered
as a one-hour infusion every three weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the adjuvant
treatment of operable node&#8209;positive and </span><span lang=EN-GB
style='font-size:11.0pt'>node&#8209;negative</span><span lang=EN-GB
style='font-size:11.0pt'> breast cancer, the recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour after doxorubicin
50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> every
3&nbsp;weeks for 6&nbsp;cycles (TAC regimen) (see also Dose adjustments during
treatment). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For the treatment
of patients with locally advanced or metastatic breast cancer, the recommended
dose of docetaxel is 100&nbsp;mg/m<sup>2</sup> in monotherapy. In first&#8209;line
treatment, docetaxel 75&nbsp;mg/m<sup>2 </sup>is given in combination therapy
with doxorubicin<sup> </sup>(50&nbsp;mg/m<sup>2</sup>).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with trastuzumab the recommended dose of docetaxel is 100&nbsp;mg/m<sup>2</sup>
every three weeks, with trastuzumab administered weekly. In the pivotal study
the initial docetaxel infusion was started the day following the first dose of
trastuzumab. The subsequent docetaxel doses were administered immediately after
completion of the trastuzumab infusion, if the preceding dose of trastuzumab
was well tolerated. For trastuzumab dose and administration, see trastuzumab
summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with capecitabine, the recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>
every three weeks, combined with capecitabine at 1250&nbsp;mg/m<sup>2</sup>
twice daily (within 30&nbsp;minutes after a meal) for 2&nbsp;weeks followed by
a 1&#8209;week rest period. For capecitabine dose calculation according to body
surface area, see capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In chemotherapy
na&iuml;ve patients treated for non-small cell lung cancer, the recommended
dose regimen is docetaxel 75&nbsp;mg/m<sup>2 </sup>immediately followed by
cisplatin 75&nbsp;mg/m<sup>2 </sup>over 30&#8209;60&nbsp;minutes. For treatment
after failure of prior platinum-based chemotherapy, the recommended dose is
75&nbsp;mg/m&sup2; as a single agent.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer</span></u></i></p>

<p class=Normal11pt><i><span style='color:black'>Metastatic
castration-resistant prostate cancer</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>. Prednisone or prednisolone
5&nbsp;mg orally twice daily is administered continuously </span><span
lang=EN-GB style='font-size:11.0pt'>(see section 5.1)</span><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic
hormone-sensitive prostate cancer</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>The recommended
dose of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel </span><span
style='font-size:11.0pt;color:black'>is 75&nbsp;mg/m<sup>2</sup> every 3 weeks
for 6 cycles. Prednisone or prednisolone 5&nbsp;mg orally twice daily may be
administered continuously.</span></p>

<p class=Heading41 style='text-align:justify;page-break-after:auto'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1&#8209;hour infusion,
followed by cisplatin 75&nbsp;mg/m<sup>2</sup>, as a 1&#8209; to 3&#8209;hour
infusion (both on day&nbsp;1 only), followed by 5&#8209;fluorouracil
750&nbsp;mg/m<sup>2</sup> per day given as a 24&#8209;hour continuous infusion
for 5&nbsp;days, starting at the end of the cisplatin infusion. Treatment is
repeated every three weeks. Patients must receive premedication with
antiemetics and appropriate hydration for cisplatin administration.
Prophylactic G&#8209;CSF should be used to mitigate the risk of haematological
toxicities (see also Dose adjustments during treatment).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients must
receive premedication with antiemetics and appropriate hydration (prior to and
after cisplatin administration). </span><span lang=EN-GB style='font-size:11.0pt'>Prophylactic
G&#8209;CSF may be used to mitigate the risk of haematological toxicities. </span><span
lang=EN-GB style='font-size:11.0pt'>All patients on the docetaxel-containing arm
of the TAX&nbsp;323 and TAX&nbsp;324 studies, received prophylactic
antibiotics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by radiotherapy (TAX&nbsp;323)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of inoperable locally advanced squamous
cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel
is 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion followed by cisplatin
75&nbsp;mg/m<sup>2</sup> over 1&nbsp;hour, on day one, followed by 5&#8209;fluorouracil
as a continuous infusion at 750&nbsp;mg/m<sup>2</sup> per day for five days.
This regimen is administered every 3&nbsp;weeks for 4&nbsp;cycles. Following
chemotherapy, patients should receive radiotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by chemoradiotherapy (TAX&nbsp;324)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of patients with locally advanced
(technically unresectable, low probability of surgical cure, and aiming at
organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1 hour
intravenous infusion on day&nbsp;1, followed by cisplatin 100&nbsp;mg/m<sup>2 </sup>administered
as a 30&#8209;minute to 3&#8209;hour infusion, followed by 5&#8209;fluorouracil
1000&nbsp;mg/m<sup>2</sup>/day as a continuous infusion from day&nbsp;1 to
day&nbsp;4. This regimen is administered every 3&nbsp;weeks for
3&nbsp;cycles.&nbsp; Following chemotherapy, patients should receive
chemoradiotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For cisplatin and
5&#8209;fluorouracil dose modifications, see the corresponding summary of
product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Dose adjustments during treatment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>General </span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel should
be administered when the neutrophil count is </span><span
lang=EN-GB style='font-size:11.0pt'>&sup3;</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;1,500&nbsp;cells/mm<sup>3</sup>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"(Utiliser une police de caract&egrave;",serif'>
</span><span lang=EN-GB style='font-size:11.0pt'>who experienced either febrile
neutropenia, neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for more
than one week, severe or cumulative cutaneous reactions or severe peripheral
neuropathy during docetaxel therapy, the dose of docetaxel should be reduced
from 100&nbsp;mg/m<sup>2</sup> to 75&nbsp;mg/m<sup>2</sup> and/or from 75 to
60&nbsp;mg/m&sup2;. If the patient continues to experience these reactions at
60&nbsp;mg/m&sup2;, the treatment should be discontinued. </span></p>

<h2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:
auto'><span class=BoldCharacter><span style='font-family:"Times New Roman",serif;
text-transform:none;font-weight:normal'>&nbsp;</span></span></h2>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Adjuvant therapy for breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Primary G&#8209;CSF
prophylaxis should be considered in patients who receive docetaxel, doxorubicin
and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who
experience febrile neutropenia and/or neutropenic infection should have their
docetaxel dose reduced to 60&nbsp;mg/m&sup2; in all subsequent cycles (see
sections 4.4 and 4.8). Patients who experience Grade&nbsp;3 or 4 stomatitis
should have their dose decreased to 60&nbsp;mg/m&sup2;.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with cisplatin</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients who
are dosed initially at docetaxel 75&nbsp;mg/m<sup>2</sup> in combination with
cisplatin and whose nadir of platelet count during the previous course of
therapy is &lt;&nbsp;25,000&nbsp;cells/mm<sup>3</sup>, or<sup> </sup>in
patients who experience febrile neutropenia, or in patients with serious non&#8209;haematologic
toxicities, the docetaxel dose in subsequent cycles should be reduced to
65&nbsp;mg/m<sup>2</sup>. For cisplatin dose adjustments, see the corresponding
summary of product characteristics.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with capecitabine</span></u></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For capecitabine dose modifications, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the first
appearance of Grade&nbsp;2 toxicity, which persists at the time of the next
docetaxel/capecitabine treatment, delay treatment until resolved to
Grade&nbsp;0&#8209;1, and resume at 100% of the original dose.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the second appearance
of Grade&nbsp;2 toxicity, or the first appearance of Grade&nbsp;3 toxicity, at
any time during the treatment cycle, delay treatment until resolved to
Grade&nbsp;0&#8209;1 and then resume treatment with docetaxel
55&nbsp;mg/m&sup2;.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For any subsequent appearances of
toxicities, or any Grade&nbsp;4 toxicities, discontinue the docetaxel dose.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>For
trastuzumab dose modifications, see trastuzumab summary of product
characteristics.</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>In combination with cisplatin and 5&#8209;fluorouracil</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If an episode of
febrile neutropenia, prolonged neutropenia or neutropenic infection occurs
despite G&#8209;CSF use, the docetaxel dose should be reduced from 75 to
60&nbsp;mg/m<sup>2</sup>. If subsequent episodes of complicated neutropenia
occur the docetaxel dose should be reduced from 60 to 45&nbsp;mg/m<sup>2</sup>.
In case of Grade&nbsp;4 thrombocytopenia the docetaxel dose should be reduced
from 75 to 60&nbsp;mg/m<sup>2</sup>. Patients should not be retreated with
subsequent cycles of docetaxel until neutrophils recover to a level
&gt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup> and platelets recover to a level
&gt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>. Discontinue treatment if these
toxicities persist see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Recommended dose
modifications for toxicities in patients treated with docetaxel in combination
with cisplatin and 5&#8209;fluorouracil (5&#8209;FU):</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Toxicity</span></b></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Dose adjustment</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce 5&#8209;FU dose by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: then reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce docetaxel and 5&#8209;FU doses
  by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis/mucositis grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>First episode: reduce 5&#8209;FU dose by 20%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Second episode: stop 5&#8209;FU only, at all
  subsequent cycles.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Third episode: reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis/mucositis
  grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>First episode:
  stop 5&#8209;FU only, at all subsequent cycles.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second episode:
  reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
</table>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=Questiontext align=left style='margin:0in;text-align:left;page-break-after:
auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;font-weight:
normal'>For cisplatin and 5&#8209;fluorouracil dose adjustments, see the
corresponding </span><span style='font-family:"Times New Roman",serif;
font-weight:normal'>summary of product characteristics</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the pivotal
SCCHN studies patients who experienced complicated neutropenia (including
prolonged neutropenia, febrile neutropenia, or infection), it was recommended to
use G&#8209;CSF to provide prophylactic coverage (eg, day&nbsp;6&#8209;15) in
all subsequent cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Special populations:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'>Patients with hepatic impairment</span></u></i></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Based on pharmacokinetic data with docetaxel at
100&nbsp;mg/m&sup2; as single agent, patients who have both elevations of transaminase
(ALT and/or AST) greater than 1.5&nbsp;times the upper limit of the normal
range (ULN) and alkaline phosphatase greater than 2.5&nbsp;times the ULN, the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> (see sections 4.4 and
5.2). For those patients with serum bilirubin &gt;&nbsp;ULN and/or ALT and
AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN associated with alkaline phosphatase
&gt;&nbsp;6&nbsp;times the ULN, no dose-reduction can be recommended and
docetaxel should not be used unless strictly indicated. </span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span></span><span lang=EN-GB style='font-size:11.0pt'> </span><span
class=BlueReplace><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span><span
lang=EN-GB style='font-size:11.0pt'>bilirubin &gt;&nbsp;1&nbsp;x&nbsp;ULN<span
class=BlueReplace><span style='color:windowtext'>; for these patients,</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>no dose-reductions can be recommended and docetaxel should not be used
unless strictly indicated.</span><span lang=EN-GB style='font-size:11.0pt'> No
data are available in patients with hepatic impairment treated by docetaxel in
combination </span><span lang=EN-GB style='font-size:11.0pt'>in the other
indications</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of TAXOTERE in nasopharyngeal carcinoma in children aged 1 month to
less than 18 years have not yet been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There is no
relevant use of TAXOTERE in the paediatric population in the indications breast
cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head
and neck cancer, not including type II and III less differentiated
nasopharyngeal carcinoma. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'>Older people</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Based on a
population pharmacokinetic analysis, there are no special instructions for use
in older people.</span></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>In combination with capecitabine, for patients
60&nbsp;years of age or more, a starting dose reduction of capecitabine to 75%
is recommended (see capecitabine summary of product characteristics).</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>For instructions on preparation and administration of
the product, see section</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;6.6.</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel must not
be used in patients with baseline neutrophil count of
&lt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel must not
be used in patients with severe liver impairment since there is no data available
(see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>Contraindications for other medicinal products also
apply, when combined with docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For breast and non&#8209;small
cell lung cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can reduce the incidence and severity of fluid retention as well as the
severity of hypersensitivity reactions. For prostate cancer, the premedication is
oral dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour
before the docetaxel infusion (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Haematology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenia is the
most frequent adverse reaction of docetaxel. Neutrophil nadirs occurred at a
median of 7&nbsp;days but this interval may be shorter in heavily pre&#8209;treated
patients. Frequent monitoring of complete blood counts should be conducted on
all patients receiving docetaxel. Patients should be retreated with docetaxel
when neutrophils recover to a level </span><span
lang=EN-GB style='font-size:11.0pt'>&sup3;</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;1,500&nbsp;cells/mm<sup>3</sup> (see section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In the case of
severe neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for seven days or
more) during a course of docetaxel therapy, a reduction in dose for subsequent
courses of therapy or the use of appropriate symptomatic measures are
recommended (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
(TCF), febrile neutropenia and neutropenic infection occurred at lower rates
when patients received prophylactic G&#8209;CSF. Patients treated with TCF
should receive prophylactic G&#8209;CSF to mitigate the risk of complicated
neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic
infection). Patients receiving TCF should be closely monitored (see sections
4.2 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with doxorubicin and cyclophosphamide
(TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates
when patients received primary G&#8209;CSF prophylaxis. Primary G&#8209;CSF
prophylaxis should be considered in patients who receive adjuvant therapy with
TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile </span><span
lang=EN-GB style='font-size:11.0pt'>neutropenia, prolonged neutropenia or
neutropenic infection). Patients receiving TAC should be closely monitored (see
sections 4.2 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Gastrointestinal reactions</span></u></p>

<p class=MsoNormal style='margin-left:15.85pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Caution is recommended for
patients with </span><span style='font-size:11.0pt'>neutropenia,</span><span
style='font-size:11.0pt'> particularly at risk for developing gastrointestinal
complications</span><span style='font-size:11.0pt'>. Although majority of cases
occurred during the first or second cycle of docetaxel containing regimen, e</span><span
lang=EN-GB style='font-size:11.0pt'>nterocolitis could develop at any time, and
could lead to death as early as on the first day of onset. Patients should be
closely monitored for early manifestations of serious gastrointestinal toxicity
(see sections 4.2, 4.4 Haematology, and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Hypersensitivity reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients should be
observed closely for hypersensitivity reactions especially during the first and
second infusions. Hypersensitivity reactions may occur within a few minutes following
the initiation of the</span><span lang=EN-GB style='font-size:11.0pt'> infusion
of docetaxel, thus facilities for the treatment of hypotension and bronchospasm
should be available. If hypersensitivity reactions occur, minor symptoms such as
flushing or localised cutaneous reactions do not require interruption of
therapy. However, severe reactions, such as severe hypotension, bronchospasm or
generalised rash/erythema require immediate discontinuation of docetaxel and
appropriate therapy. Patients who have developed severe hypersensitivity
reactions should not be re-challenged with docetaxel. </span><span lang=EN-GB
style='font-size:11.0pt'>Patients who have previously experienced a
hypersensitivity reaction to paclitaxel may be at risk to develop
hypersensitivity reaction to docetaxel, including more severe hypersensitivity
reaction. These patients should be closely monitored during initiation of
docetaxel therapy</span><span style='font-size:11.0pt'>.</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Cutaneous reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Localised skin erythema of the extremities (palms of
the hands and soles of the feet) with oedema followed by desquamation has been
observed. Severe symptoms such as eruptions followed by desquamation which lead
to interruption or discontinuation of docetaxel treatment were reported (see
section 4.2).</span></p>

<p class=00-Paragraph><span lang=EN-GB>Severe Cutaneous Adverse Reactions
(SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis</span><sup><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial Narrow",sans-serif'> </span></sup><span
lang=EN-GB>(TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have
been reported with docetaxel treatment. Patients should be informed about the
signs and symptoms of serious skin manifestations and closely monitored</span><strong><span
lang=EN-GB style='font-family:"Segoe UI",sans-serif;color:#444444;font-weight:
normal'>. </span></strong><span lang=EN-GB>If signs and symptoms suggestive of
these reactions appear discontinuation of docetaxel should be considered.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Fluid retention</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Patients with severe fluid retention such as pleural
effusion, pericardial effusion and ascites should be monitored closely.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Respiratory
disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung
disease, pulmonary fibrosis and respiratory failure have been reported and </span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>may be associated </span></span><span
lang=EN-GB style='font-size:11.0pt'>with fatal outcome. </span><span
class=BlueReplace><span lang=EN-GB style='color:windowtext'>Cases of radiation
pneumonitis have been reported in patients receiving concomitant radiotherapy.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If new or
worsening pulmonary symptoms develop, patients should be closely monitored,
promptly investigated, and appropriately treated. Interruption of docetaxel
therapy is recommended</span><span style='font-size:11.0pt'> until diagnosis is
available</span><span lang=EN-GB style='font-size:11.0pt'>. Early use of supportive
care measures may help improve the condition. The benefit of resuming docetaxel
treatment must be carefully evaluated.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Patients with liver impairment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel at 100&nbsp;mg/m<sup>2</sup> as single agent who have
serum transaminase levels (ALT and/or AST) greater than 1.5&nbsp;times the ULN
concurrent with serum alkaline phosphatase levels greater than 2.5&nbsp;times
the ULN, there is a higher risk of developing severe adverse reactions such as toxic
deaths including sepsis and gastrointestinal haemorrhage which can be fatal,
febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Therefore, the recommended dose of docetaxel in those patients with elevated
liver function test (LFTs) is 75&nbsp;mg/m<sup>2</sup> and LFTs should be
measured at baseline and before each cycle (see section 4.2).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>For patients with serum bilirubin levels &gt;&nbsp;ULN
and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN concurrent with serum
alkaline phosphatase levels &gt;&nbsp;6&nbsp;times the ULN, no dose-reduction
can be recommended and docetaxel should not be used unless strictly indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In combination
with cisplatin and 5&#8209;fluorouracil for the treatment of patients</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>with gastric adenocarcinoma, the pivotal clinical study excluded
patients with <span class=BlueReplace><span style='color:windowtext'>ALT and/or</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span class=BlueReplace><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span><span
lang=EN-GB style='font-size:11.0pt'>bilirubin &gt;&nbsp;1&nbsp;x&nbsp;ULN<span
class=BlueReplace><span style='color:windowtext'>; for these patients,</span></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>no dose-reductions can be recommended and docetaxel should not be used
unless strictly indicated.</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>No data are available in patients with
hepatic impairment treated by docetaxel in combination </span><span lang=EN-GB
style='font-size:11.0pt'>in the other indications</span><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Patients with renal impairment</span></u></p>

<p class=TblTextCenter align=left style='margin:0in;text-align:left;page-break-after:
avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There are no data
available in patients with severely impaired renal function treated with
docetaxel. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Nervous system</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The development of
severe peripheral neurotoxicity requires a reduction of dose (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Cardiac toxicity</span></u></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Heart failure has
been observed in patients receiving docetaxel in combination with trastuzumab,
particularly following anthracycline (doxorubicin or epirubicin)&#8209;containing
chemotherapy. This may be moderate to severe and has been associated with death
(see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>When patients are
candidates for treatment with docetaxel in combination with trastuzumab, they
should undergo baseline cardiac assessment. Cardiac function should be further
monitored during treatment (e.g. every three months) to help identify patients
who may develop cardiac dysfunction. For more details see summary of product
characteristics of trastuzumab.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Ventricular
arrhythmia including ventricular tachycardia (sometimes fatal) has been reported
in patients treated with docetaxel in combination regimens including doxorubicin,
5-fluorouracil and/ or cyclophosphamide (see section 4.8)</span><span
lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Baseline cardiac
assessment is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Eye</span></u><u><span
lang=EN-GB style='font-size:11.0pt'> disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cystoid macular
oedema (CMO) has been reported in patients treated with docetaxel. Patients
with impaired vision should undergo a prompt and complete ophthalmologic
examination. In case CMO is diagnosed, docetaxel treatment should be
discontinued and appropriate treatment initiated (see section </span><span
lang=EN-GB style='font-size:11.0pt'>4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies have been reported when docetaxel was given in combination with
anticancer treatments known to be associated with second primary malignancies. Second
primary malignancies (including acute myeloid leukaemia, myelodysplastic
syndrome and non-Hodgkin lymphoma) may occur several months or years after
docetaxel-containing therapy. Patients should be monitored for second primary
malignancies (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Tumour Lysis
Syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tumour lysis
syndrome has been reported with docetaxel after the first or the second cycle
(see section 4.8). Patients at risk of tumour lysis syndrome (e.g. with renal
impairment, hyperuricemia, bulky tumour, rapid progression) should be closely
monitored. Correction of dehydration and treatment of high uric acid levels are
recommended prior to initiation of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Others</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Contraceptive measures must be
taken by both men and women during treatment and for men at least&nbsp;
6&nbsp;months after cessation of therapy (see section 4.6).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The concomitant use of docetaxel with
strong CYP3A4 inhibitors </span><span style='font-family:"Times New Roman",serif;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole)
should be avoided (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Additional cautions for use in adjuvant
treatment of breast cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Complicated neutropenia</span></u></i></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For patients who experience complicated neutropenia
(prolonged neutropenia, febrile neutropenia or infection), G&#8209;CSF and dose
reduction should be considered (see section 4.2).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastrointestinal reactions</span></u></i></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Symptoms such as early abdominal pain and tenderness,
fever, diarrhoea, with or without neutropenia, may be early manifestations of
serious gastrointestinal toxicity and should be evaluated and treated promptly.</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Congestive heart failure (CHF)</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients should be monitored for
symptoms of congestive heart failure during therapy and during the follow up
period. In patients treated with the TAC regimen for node positive breast
cancer, the risk of CHF has been shown to be higher during the first year after
treatment (see sections 4.8 and 5.1).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Patients with 4+ nodes</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>As the benefit observed in patient
with 4+ nodes was not statistically significant on disease&#8209;free survival
(DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in
patients with 4+ nodes was not fully demonstrated at the final analysis (see
section 5.1).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Elderly</span></u></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in adjuvant treatment
of breast cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There are limited data available in
patients &gt;&nbsp;70&nbsp;years of age on docetaxel use in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><i><u>Cautions
for use in castration-resistant prostate cancer</u></i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Of the 333&nbsp;patients treated
with docetaxel every three weeks in a prostate cancer study (TAX 327),
209&nbsp;patients were 65&nbsp;years of age or greater and 68&nbsp;patients
were older than 75&nbsp;years. In patients treated with docetaxel every three
weeks, the incidence of related nail changes occurred at a rate </span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;10% higher in patients who
were 65&nbsp;years of age or greater compared to younger patients. The
incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred
at rates </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;10% higher in
patients who were 75&nbsp;years of age or greater versus less than 65&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Cautions for use in hormone-sensitive
prostate cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>Of the
</span><span style='font-size:11.0pt;color:black'>545 </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>patients treated with docetaxel every 3
weeks</span><span style='font-size:11.0pt;color:black'> in a hormone-sensitive
prostate cancer study (STAMPEDE)</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>, </span><span style='font-size:11.0pt;color:black'>296 patients
were 65 years of age or older, and 48 patients were 75 years of age or older</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>More patients aged &#8805;65 years in the
docetaxel arm reported hypersensitivity reaction, neutropenia, anaemia, fluid
retention, dyspnea, and nail changes when compared to the patients aged less
than 65 years. None of these increases in frequency reached 10% difference with
the control arm.</span><span style='font-size:11.0pt'> </span><span lang=EN-GB
style='font-size:11.0pt'>In patients who were 75&nbsp;years of age or older,
when compared to younger patients,</span><span style='font-size:11.0pt'>
neutropenia, anaemia, diarrhea, dyspnea and upper respiratory tract infection
were reported</span><span style='font-size:11.0pt'> </span><span
style='font-size:11.0pt'>with a greater incidence (at least 10% higher)</span><span
lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in gastric
adenocarcinoma cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Among the 300 (221&nbsp;patients in
the phase&nbsp;III part of the study and 79&nbsp;patients in the phase&nbsp;II
part) patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
in the gastric cancer study, 74 were 65&nbsp;years of age or older and
4&nbsp;patients were 75&nbsp;years of age or older. </span><span
style='font-family:"Times New Roman",serif'>The incidence of serious adverse
events was higher in older people compared to younger patients. The incidence
of the following adverse events (all grades): lethargy, stomatitis, neutropenic
infection occurred at rates </span><span style='font-family:Symbol'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;10% higher in patients who
were 65&nbsp;years of age or older compared to younger patients. </span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'>Older people
treated with TCF should be closely monitored.</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>13 % (w/w) ethanol 95% v/v (alcohol), i.e.
up to 932&nbsp;mg ethanol 95% v/v per solvent vial, equivalent to 23&nbsp;ml of
beer or 9.5&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, in children and in high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>Consideration
should be given to possible effects on the central nervous system.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'> studies have shown that the metabolism of docetaxel may be modified by
the concomitant administration of compounds which induce, inhibit or are
metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450&#8209;3A
such as ciclosporine, ketoconazole and erythromycin. As a result, caution
should be exercised when treating patients with these medicinal products as
concomitant therapy since there is a potential for a significant interaction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In case of
combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse
reactions may increase, as a result of reduced metabolism. If the concomitant
use of a strong CYP3A4 inhibitor </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) </span><span
lang=EN-GB style='font-size:11.0pt'>cannot be avoided, a close clinical
surveillance is warranted and a dose-adjustment of docetaxel may be suitable
during the treatment with the strong CYP3A4 inhibitor (see section 4.4). </span><span
lang=EN-GB style='font-size:11.0pt'>In a pharmacokinetic study with 7 patients,
the co-administration of docetaxel with the strong CYP3A4 inhibitor
ketoconazole leads to a&nbsp;significant decrease in docetaxel clearance by
49%.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Docetaxel pharmacokinetics in the
presence of prednisone was studied in patients with metastatic prostate cancer.
Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4. No
statistically significant effect of prednisone on the pharmacokinetics of
docetaxel was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
highly protein bound (&gt;&nbsp;95%). Although the possible <i>in vivo</i>
interaction of docetaxel with concomitantly administered medicinal product has
not been investigated formally, <i>in vitro</i> interactions with tightly
protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did
not affect protein binding of docetaxel. In addition, dexamethasone did not
affect protein binding of docetaxel. Docetaxel did not influence the binding of
digitoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not
influenced by their co&#8209;administration. Limited data from a single
uncontrolled study were suggestive of an interaction between docetaxel and
carboplatin. When combined to docetaxel, the clearance of carboplatin was about
50% higher than values previously reported for carboplatin monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and
lactation</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>There is no information on the use of docetaxel in
pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic
in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic
medicinal products, docetaxel may cause foetal harm when administered to
pregnant women. Therefore, docetaxel must not be used during pregnancy unless
clearly indicated.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Women of childbearing age receiving docetaxel should be
advised to avoid becoming pregnant, and to inform the treating physician
immediately should this occur.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is a
lipophilic substance but it is not known whether it is excreted in human milk.
Consequently, because of the potential for adverse reactions in nursing
infants, breast feeding must be discontinued for the duration of docetaxel
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Contraception
in males and females</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>An effective
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In non clinical
studies, docetaxel has genotoxic effects and may alter male fertility (see
section 5.3). Therefore, men being treated with docetaxel are advised not to father
a child during and up to 6&nbsp;months after treatment and to seek advice on
conservation of sperm prior to treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No studies on the
effects on the ability to drive and use machines have been performed. The
amount of alcohol in this </span><span lang=EN-GB style='font-size:11.0pt'>medicinal
product </span><span style='font-size:11.0pt'>and the side effects</span><span
lang=EN-GB style='font-size:11.0pt'> of the product may impair the ability to
drive or use machines (see sections 4.4</span><span style='font-size:11.0pt'>
and 4.8</span><span lang=EN-GB style='font-size:11.0pt'>). Therefore, patients
should be warned of the potential impact of the amount of alcohol and the side
effects of this medicinal product on the ability to drive or use machines, and
be advised not to drive or use machines if they experience these side effects
during treatment.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Summary of the safety profile for all
indications</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The adverse
reactions considered to be possibly or probably related to the administration
of docetaxel have been obtained in: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1312 and
     121&nbsp;patients who received 100&nbsp;mg/m&sup2;<sup> </sup>and
     75&nbsp;mg/m&sup2; of docetaxel as a single agent respectively.</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>258&nbsp;patients
     who received docetaxel in combination with doxorubicin. </span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>406&nbsp;patients
     who received docetaxel in combination with cisplatin. </span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>92&nbsp;patients
treated with </span><span style='font-family:"(Utiliser une police de caract&egrave;",serif'>docetaxel</span><span
style='font-family:"Times New Roman",serif;text-transform:uppercase'> </span><span
style='font-family:"Times New Roman",serif'>in combination with </span><span
style='font-family:"Times New Roman",serif'>trastuzumab. </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>255&nbsp;patients
     who received docetaxel in combination with capecitabine.</span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-family:"Times New Roman",serif'>332&nbsp;patients
(TAX327) who received docetaxel in combination with prednisone or prednisolone
(clinically important treatment related adverse events are presented).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1276&nbsp;patients
     (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received
     docetaxel in combination with doxorubicin and cyclophosphamide (clinically
     important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>300&nbsp;gastric
     adenocarcinoma patients (221&nbsp;patients in the phase&nbsp;III part of
     the study and 79&nbsp;patients in the phase&nbsp;II part) who received docetaxel
     in combination with cisplatin and 5&#8209;fluorouracil (clinically
     important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>174 and
     251&nbsp;head and neck cancer patients who received docetaxel in combination
     with cisplatin and 5&#8209;fluorouracil (clinically important treatment
     related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>545 patients
     (STAMPEDE study) who received docetaxel in combination with prednisone or
     prednisolone and ADT.</span></li>
</ul>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>These reactions were described using the NCI Common
Toxicity Criteria (grade&nbsp;3&nbsp;=&nbsp;G3; grade&nbsp;3&#8209;4&nbsp;=&nbsp;G3/4;
grade&nbsp;4&nbsp;=&nbsp;G4), the COSTART and the MedDRA terms. Frequencies are
defined as: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to
&lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from available data).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>The most commonly reported adverse reactions of
docetaxel alone are: neutropenia (which was reversible and not cumulative; the
median day to nadir was 7&nbsp;days and the median duration of severe
neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) was 7&nbsp;days),
anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The
severity of adverse events of docetaxel may be increased when docetaxel is
given in combination with other chemotherapeutic agents.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with </span><span lang=EN-GB style='font-size:11.0pt'>trastuzumab, </span><span
lang=EN-GB style='font-size:11.0pt'>adverse events (all grades) reported in
&#8805;&nbsp;10% are displayed. There was an increased incidence of SAEs (40%
vs. 31%) and Grade&nbsp;4 AEs (34% vs. 23%) in the trastuzumab combination arm
compared to docetaxel monotherapy.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For combination with capecitabine,
the most frequent treatment-related undesirable effects (&#8805;&nbsp;5%)
reported in a phase&nbsp;III study in breast cancer patients failing
anthracycline treatment are presented (see capecitabine summary of product characteristics).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring
over the 6 cycles of treatment with docetaxel and having at least 2% higher
incidence in the docetaxel treatment arm by comparison to the control arm, are
presented, using the CTCAE grading scale.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The following
adverse reactions are frequently observed with docetaxel:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Immune system disorders</span></u></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity reactions have
generally occurred within a few minutes following the start of the infusion of
docetaxel and were usually mild to moderate. The most frequently reported
symptoms were flushing, rash with or without pruritus, chest tightness, back
pain, dyspnoea and fever or chills.&nbsp; Severe reactions were characterised
by hypotension and/or bronchospasm or generalized rash/erythema (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></u></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The development of severe
peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and
4.4). Mild to moderate neuro-sensory signs are characterised by paresthesia,
dysesthesia or pain including burning. Neuro-motor events are mainly
characterised by weakness.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Reversible
cutaneous reactions have been observed and were generally considered as mild to
moderate. Reactions were characterised by a rash including localised eruptions
mainly on the feet and hands (including severe hand and foot syndrome), but
also on the arms, face or thorax, and frequently associated with pruritus.
Eruptions generally occurred within one week after the docetaxel infusion. Less
frequently, severe symptoms such as eruptions followed by desquamation which
rarely lead to interruption or discontinuation of docetaxel treatment were
reported (see sections 4.2 and 4.4). Severe nail disorders are characterised by
hypo- or hyperpigmentation and sometimes pain and onycholysis. &nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
reactions were generally mild and consisted of hyper pigmentation,
inflammation, redness or dryness of the skin, phlebitis or extravasation and
swelling of the vein.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Fluid retention includes events
such as peripheral oedema and less frequently pleural effusion, pericardial
effusion, ascites and weight gain. The peripheral oedema usually starts at the
lower extremities and may become generalised with a weight gain of 3&nbsp;kg or
more. Fluid retention is cumulative in incidence and severity (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 100&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA
   system organ classes</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Very common
   adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections
  (G3/4: 5.7%; including sepsis and pneumonia, fatal in 1.7%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection
  associated with G4 neutropenia (G3/4: 4.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  76.4%); <br>
  Anaemia (G3/4: 8.9%); <br>
  Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Thrombocytopenia
  (G4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (G3/4: 5.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3: 4.1%); <br>
  Peripheral motor neuropathy (G3/4: 4%); <br>
  Dysgeusia (severe: 0.07%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension;
  Hypertension;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Haemorrhage</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dyspnoea
  (severe: 2.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 5.3%); </span></p>
  <p class=MsoDate><span lang=EN-GB>Diarrhoea (G3/4: 4%); <br>
  Nausea (G3/4: 4%); <br>
  Vomiting (G3/4: 3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (severe: 0.2%); <br>
  Abdominal pain (severe: 1%); <br>
  Gastrointestinal haemorrhage (severe: 0.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oesophagitis
  (severe: 0.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  <br>
  Skin reaction (G3/4: 5.9%); <br>
  Nail </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders
  (severe: 2.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (severe:
  1.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arthralgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General disorders
  and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (severe: 6.5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 11.2%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
  reaction; </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Non-cardiac
  chest pain (severe: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  alkaline phosphatase increased (&lt;&nbsp;4%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 AST
  increased (&lt;&nbsp;3%);<br>
  G3/4 ALT increased (&lt;&nbsp;2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for TAXOTERE 100 mg/m<sup>2</sup>
single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare: bleeding episodes
associated with grade&nbsp;3/4 thrombocytopenia.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>Reversibility data are available among 35.3% of
patients who developed neurotoxicity following docetaxel treatment at
100&nbsp;mg/m&sup2; as single agent. The events were spontaneously reversible
within 3&nbsp;months.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Very rare: one
case of alopecia non-reversible at the end of the study. 73% of the cutaneous
reactions were reversible within 21&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The</span><span
lang=EN-GB style='font-size:11.0pt'> median cumulative dose to treatment
discontinuation was more than 1,000&nbsp;mg/m<sup>2 </sup>and the median time
to fluid retention reversibility was 16.4&nbsp;weeks (range 0 to
42&nbsp;weeks). The onset of moderate and severe retention is delayed (median
cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in patients with premedication
compared with patients without premedication (median cumulative dose:
489.7&nbsp;mg/m<sup>2</sup>); however, it has been reported in some patients
during the early courses of therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Tabulated list of adverse reactions in non-small
cell lung cancer for </span></u><u><span lang=EN-GB style='font-weight:normal'>TAXOTERE
75&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA
   system organ classes</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections
  (G3/4: 5%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  54.2%); </span></p>
  <p class=MsoDate><span lang=IT>Anaemia (G3/4: 10.8%); Thrombocytopenia (G4:
  1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Febrile
  neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (no severe)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 2.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia (no
  severe) </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  3.3%); <br>
  Stomatitis (G3/4: 1.7%); <br>
  Vomiting (G3/4: 0.8%); <br>
  Diarrhoea (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  <br>
  Skin reaction (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nail disorders
  (severe: 0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 12.4%); <br>
  Fluid retention (severe: 0.8%);<br>
  Pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;2%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Tabulated list of adverse reactions in breast cancer
for </span></u><u><span lang=EN-GB style='font-weight:normal'>TAXOTERE
75&nbsp;mg/m&sup2; in combination with doxorubicin</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA
   system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection (G3/4:
  7.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G4:
  91.7%);<br>
  Anaemia (G3/4: 9.4%); <br>
  Febrile neutropenia;<br>
  Thrombocytopenia (G4: 0.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cardiac failure;
  </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia (no
  severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  5%); Stomatitis (G3/4: 7.8%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  6.2%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  5%); Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  disorders (severe: 0.4%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
  reaction (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia
  (severe: 8.1%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (severe: 1.2%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infusion site
  reaction</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  bilirubin increased (&lt;&nbsp;2.5%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 Blood
  alkaline phosphatase increased (&lt;&nbsp;2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 AST
  increased (&lt;&nbsp;1%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>G3/4 ALT
  increased (&lt;&nbsp;1%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in non-small
cell lung cancer for </span></u><u><span lang=EN-GB style='font-weight:normal'>TAXOTERE
75&nbsp;mg/m&sup2; in combination with cisplatin</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 5.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Neutropenia (G4: 51.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Anaemia (G3/4: 6.9%); Thrombocytopenia (G4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>N</span><span lang=EN-GB style='font-size:11.0pt'>ervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3: 3.7%); Peripheral
  motor neuropathy (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypotension (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 9.6%); Vomiting (G3/4: 7.6%); <br>
  Diarrhoea (G3/4: 6.4%); <br>
  Stomatitis (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Skin and subcutaneous tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia; </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  (severe: 0.7%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin reaction
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia (severe: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia (severe: 9.9%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fluid retention (severe: 0.7%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fever (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infusion site reaction; Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood bilirubin increased (2.1%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 ALT increased (1.3%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 AST increased (0.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood alkaline phosphatase increased (0.3%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
breast cancer for </span></u><u><span lang=EN-GB style='font-weight:normal'>TAXOTERE
100&nbsp;mg/m&sup2; in combination with trastuzumab</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Neutropenia (G3/4: 32%); Febrile
  neutropenia (includes neutropenia associated with fever and antibiotic use)
  or neutropenic sepsis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Psychiatric disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Insomnia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Paresthesia; Headache; Dysgeusia; Hypoaesthesia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased; Conjunctivitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vascular disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lymphoedema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Epistaxis; Pharyngolaryngeal pain; Nasopharyngitis;
  Dyspnoea; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cough; Rhinorrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea; Diarrhoea; Vomiting; Constipation;
  Stomatitis; Dyspepsia; Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia;
  Erythema; Rash; Nail disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia; Arthralgia; Pain in extremity; Bone pain;
  Back pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia; Oedema peripheral; Pyrexia; Fatigue;
  Mucosal inflammation; Pain; Influenza like illness; Chest pain; Chills</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lethargy</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Weight increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for Taxotere 100 mg/m<sup>2</sup>
in combination with trastuzumab</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Symptomatic
cardiac failure was reported in 2.2% of the patients who received docetaxel
plus trastuzumab compared to 0% of patients given docetaxel alone. In the
docetaxel plus trastuzumab arm, 64% had received a prior anthracycline as
adjuvant therapy compared with 55% in the docetaxel arm alone.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>Very common: Haematological toxicity was increased
in patients receiving trastuzumab and docetaxel, compared with docetaxel alone
(32% grade&nbsp;3/4 neutropenia versus 22%, using NCI-CTC criteria). Note that
this is likely to be an underestimate since docetaxel alone at a dose of
100&nbsp;mg/m<sup>2</sup> is known to result in neutropenia in 97% of patients,
76% grade&nbsp;4, based on nadir blood counts. The incidence of febrile
neutropenia/neutropenic sepsis was also increased in patients treated with
Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel
alone).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in breast
cancer for </span></u><u><span lang=EN-GB style='font-weight:normal'>TAXOTERE
75&nbsp;mg/m&sup2; in combination with capecitabine</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Oral candidiasis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neutropenia (G3/4: 63%); Anaemia (G3/4: 10%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Thrombocytopenia (G3/4: 3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Anorexia (G3/4: 1%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Decreased appetite </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dehydration (G3/4: 2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dysgeusia (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pareaesthesia (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dizziness; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Headache (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neuropathy peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pharyngolaryngeal pain (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspnoea (G3/4:
  1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cough (G3/4:
  &lt;&nbsp;1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Epistaxis (G3/4:
  &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis (G3/4: 18%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea (G3/4: 14%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vomiting (G3/4: 4%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Constipation (G3/4: 1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Abdominal pain (G3/4: 2%); Dyspepsia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal pain
  upper; </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Hand-foot syndrome (G3/4: 24%);</span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Alopecia (G3/4: 6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nail disorders (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dermatitis;
  </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rash
  erythematous (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  discolouration; </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Onycholysis
  (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Myalgia (G3/4: 2%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Arthralgia (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pain in extremity (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Back pain (G3/4:
  1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia (G3/4: 3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pyrexia (G3/4: 1%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fatigue/weakness (G3/4: 5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Oedema peripheral (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lethargy;<br>
  Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Weight decreased;<br>
  G3/4 Blood bilirubin increased (9%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in </span></u><u><span
lang=EN-GB style='font-weight:normal'>metastatic castration-resistant</span><span
lang=EN-GB> </span></u><u><span lang=EN-GB style='font-weight:normal'>prostate cancer
for</span></u><u><span lang=EN-GB style='font-weight:normal'> </span></u><u><span
lang=EN-GB style='font-weight:normal'>TAXOTERE 75&nbsp;mg/m&sup2; in
combination with prednisone or prednisolone</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA system organ classes</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 3.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); </span></p>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Anaemia
  (G3/4: 4.9%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Thrombocytopenia (G3/4: 0.6%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia (G3/4: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3/4: 1.2%);</span></p>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral motor neuropathy (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac left ventricular function decrease (G3/4:
  0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Epistaxis (G3/4:
  0%);</span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspnoea (G3/4:
  0.6%); </span></p>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 2.4%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea (G3/4: 1.2%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Stomatitis/Pharyngitis (G3/4: 0.9%);&nbsp; </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vomiting (G3/4: 1.2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia; </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail </span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>disorders</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> (no
  severe)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Exfoliative rash (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Musculoskeletal and connective bone disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arthralgia (G3/4: 0.3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Myalgia (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fatigue (G3/4: 3.9%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Fluid retention (severe: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in high-risk locally advanced or metastatic
hormone-sensitive prostate cancer for TAXOTERE 75 mg/m&sup2; in combination
with prednisone or prednisolone and ADT (STAMPEDE sutdy) </span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:458.65pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:35.4pt'>
   <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA system organ
   classes</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Very common adverse reactions</span></b></p>
   </td>
   <td width=211 valign=top style='width:158.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Common adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:37.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Neutropenia (G3-4: 12 %)
  Anaemia </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Febrile
  neutropenia </span><span style='font-size:11.0pt'>(G3-4: 15%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Immune
  system disorders</span><span lang=EN-GB style='font-size:11.0pt;line-height:
  115%;color:black'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Hypersensitivity (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.2pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><s><span style='font-size:11.0pt'><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diabetes (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.8pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Anorexia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt' style='page-break-inside:
  avoid !msorm;height:20.45pt !msorm'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Psychiatric
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Insomnia (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Nervous
  system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Peripheral sensory
  neuropathy (&#8805;G3: 2%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Headache<br>
  <br>
  </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.5pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Eye
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Blurred vision</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.1pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Cardiac
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension </span><span
  style='font-size:11.0pt'>(G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:43.05pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Respiratory,
  thoracic and mediastinal disorders</span><span style='font-size:11.0pt;
  line-height:115%'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dyspnea (G3: 1%)<br>
  Coughing (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Upper respiratory tract
  infection (G3: 1%) </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Pharyngitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'><br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:64.3pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%'>Gastrointestinal
  disorders </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diarrhea (G3: 3%)<br>
  Stomatitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Constipation (G3: 0%)<br>
  Nausea (G3: 1%)<br>
  Dyspepsia<br>
  Abdominal pain (G3: 0%)<br>
  Flatulence</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Vomiting (G3: 1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.7pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Alopecia (G3: 3%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Nail changes (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  lang=FR style='font-size:11.0pt;line-height:115%'>Rash</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Myalgia </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Lethargy (G3-4: 2%)<br>
  Flu-like symptoms (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Asthenia (G3: 0%)<br>
  Fluid retention</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Fever (G3: 1%)<br>
  Oral candidiasis </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypocalcaemia (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypophosphataemia (G3-4:
  1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypokalaemia (G3: 0%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><sup><span
style='font-size:9.0pt;line-height:115%;font-family:"Arial Narrow",sans-serif'>a</span></sup><span
style='font-size:9.0pt;line-height:115%;font-family:"Arial Narrow",sans-serif'>
</span><span style='font-size:9.0pt;line-height:115%;color:black'>From the
GETUG AFU15 study</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span></u><u><span lang=EN-GB>adjuvant
therapy with TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin and
cyclophosphamide<b> </b>in patients with node&#8209;positive </span><span
lang=EN-GB>(TAX 316) </span></u><u><span lang=EN-GB>and node&#8209;negative </span><span
lang=EN-GB>(GEICAM 9805) </span></u><u><span lang=EN-GB>breast cancer<b> </b></span><span
lang=EN-GB>- pooled data</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA System Organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 2.4%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neutropenic infection </span><span lang=NL
  style='font-size:11.0pt'>(G3/4: 2.</span><span style='font-size:11.0pt'>6</span><span
  lang=NL style='font-size:11.0pt'>%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Anaemia (G3/4: 3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Neutropenia (G3/4: 59.2%); Thrombocytopenia (G3/4:
  1.6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Febrile neutropenia (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  1.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dysgeusia (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 0%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Syncope (G3/4:
  0%); Neurotoxicity (G3/4: 0%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Somnolence
  (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Conjunctivitis (G3/4:
  &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
  increased (G3/4: &lt;0.1%) </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.2%) </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hot flush (G3/4:
  0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phlebitis (G3/4:
  0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lymphoedema
  (G3/4: 0%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  5.0%); Stomatitis (G3/4: 6.0%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  4.2%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  3.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (G3/4: 0.5%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Abdominal pain
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia
  (persisting: &lt;3%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
  disorder (G3/4: 0.6%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  disorders (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.7%); Arthralgia (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Reproductive system and breast disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Amenorrhoea </span><span lang=NL style='font-size:
  11.0pt'>(G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia (G3/4:
  10.0%);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Pyrexia (G3/4: NA);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Oedema peripheral
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight increased
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight decreased
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions for adjuvant therapy with Taxotere 75 mg/m<sup>2</sup>
in combination with doxorubicin and cyclophosphamide in patients with
node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>peripheral sensory neuropathy </span><span style='font-size:11.0pt'>started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 84&nbsp;patients (11.3%) in TAC arm and 15
patients (2&nbsp;%) in FAC arm. At the end of the follow-up period (median
follow-up time of 8 years), p</span><span style='font-size:11.0pt'>eripheral
sensory neuropathy</span><span lang=EN-GB style='font-size:11.0pt'> was
observed to be ongoing in 10 patients (1.3</span><span style='font-size:11.0pt'>%)
in TAC arm, and in 2</span><span lang=EN-GB style='font-size:11.0pt'> patients
(0.3%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In GEICAM 9805 study peripheral sensory neuropathy that
started during the treatment period persisted into the follow-up period in
10&nbsp;patients (1.9%) in TAC arm and 4 patients (0.8&nbsp;%) in FAC arm. At
the end of the follow-up period (median follow-up time of 10 years and 5
months), peripheral sensory neuropathy was observed to be ongoing in 3 patients
(0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext;layout-grid-mode:
both'>In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%)
in the FAC arm experienced congestive heart failure. All except one patient in
each arm were diagnosed with CHF more than 30 days after the treatment
period.&nbsp; Two patients in the TAC arm and 4 patients in the FAC arm died
because of cardiac failure.</span></p>

<p class=MsoHeader style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In GEICAM 9805
study, 3</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
patients (0.6&nbsp;%) in TAC arm and 3 </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>patients </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(0.6&nbsp;%)
in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>FAC
arm developed congestive heart failure during the follow-up period. At the end
of the follow-up period (actual median follow-up time of 10 years and 5
months), no patients&nbsp; had CHF in TAC arm and 1 patient in TAC arm died
because of dilated cardiomyopathy, and CHF was observed to be ongoing in
1&nbsp;patient (0.2%) in FAC arm.</span></p>

<p class=MsoHeader style='text-align:justify'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In study
TAX316 alopecia persisting into the follow-up period after the end of
chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC
patients (87.6%).<br>
At the end of the follow-up period (actual median follow-up time of</span><span
lang=EN-GB style='font-size:14.0pt;font-family:"Cambria",serif;color:#00B0F0'> </span><span
lang=EN-GB style='font-size:11.0pt'>8 years), alopecia was observed to be
ongoing in 29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In
GEICAM 9805 study alopecia </span><span style='font-size:11.0pt'>that started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period was observed to be ongoing in 49&nbsp;patients
(9.2&nbsp;%) in TAC arm and 35 patients (6.7&nbsp;%) in FAC arm. Alopecia
related to study drug started or worsened during the follow-up period in
42&nbsp;patients (7.9&nbsp;%) in TAC arm and 30 patients (5.8&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm,
and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp; </span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Reproductive system and breast disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In TAX316 </span>amenorrhoea <span lang=EN-GB>that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%)
and 125 of 736 FAC patients (17.0%). Amenorrhea </span>was observed to be
ongoing <span lang=EN-GB>at the end of the </span>follow-up <span lang=EN-GB>period
(median follow-up time of 8 years) </span>in 121&nbsp;<span lang=EN-GB>of 744
TAC </span>patients <span lang=EN-GB>(16.3%) and 86 FAC patients (11.7%)</span>.</p>

<p class=Text style='margin-top:0in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>In GEICAM 9805 study</span><span lang=EN-GB
style='font-size:11.0pt'> amenorrhoea </span><span style='font-size:11.0pt'>that
started during the treatment period and </span><span lang=EN-GB
style='font-size:11.0pt'>persisted into the follow-up period was observed to be
ongoing in 18&nbsp;patients (3.4&nbsp;%) in TAC arm and 5 patients (1.0&nbsp;%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), amenorrhoea was observed to be ongoing in 7 patients
(1.3%) in TAC arm, and in 4 patients (0.8%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
peripheral oedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was observed in 119 of
744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), peripheral oedema was
ongoing in19&nbsp;TAC<u> </u>patients (2.6%) and 4 FAC<u> </u>patients (0.5%). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
lymphoedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was reported in 11 of
744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), lymphoedema was
observed to be ongoing in 6&nbsp;TAC patients (0.8%) and 1 FAC patient (0.1%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In study TAX316 asthenia that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%)
and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual
median follow-up time of 8 years), asthenia was observed to be ongoing in
29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study GEICAM
9805 peripheral oedema </span><span style='font-size:11.0pt'>that started
during the treatment period </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it
was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema </span><span
style='font-size:11.0pt'>that started during the treatment period </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period in
5&nbsp;patients (0.9%) in TAC arm and 2 patients (0.4&nbsp;%) in FAC arm. At
the end of the follow-up period, lymphoedema was observed to be ongoing in 4
patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia </span><span
style='font-size:11.0pt'>that started during the treatment period and </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period was
observed to be ongoing in 12&nbsp;patients (2.3&nbsp;%) in TAC arm and 4
patients (0.8&nbsp;%) in FAC arm. At the end of the follow-up period, asthenia
was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients
(0.4%) in FAC arm.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Acute leukaemia
/ Myelodysplastic syndrome.</span></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After 10 years of follow up in study
TAX316, acute leukaemia was reported in 3 of 744 TAC patients </span><span
style='font-weight:normal'>(0.4%)</span><span lang=EN-GB style='font-weight:
normal'> and in 1 of 736 FAC patients </span><span style='font-weight:normal'>(0.1%).</span><span
style='font-weight:normal'> </span><span style='font-weight:normal'>One TAC
patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up
period (median follow-up time of 8 years)</span><span lang=EN-GB
style='font-weight:normal'>. Myelodysplastic syndrome was reported in 2 of 744
TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-weight:normal'>10 years of follow-up </span><span
lang=EN-GB style='font-weight:normal'>in GEICAM 9805 study</span><span
lang=EN-GB style='font-weight:normal'>,</span><span lang=EN-GB
style='font-weight:normal'> acute leukaemia occurred in 1</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>of 532 (0.2%)</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>patients </span><span
lang=EN-GB style='font-weight:normal'>in TAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No cases were reported in patients</span><span
lang=EN-GB style='font-weight:normal'> in FAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No patient was diagnosed with myelodysplastic
syndrome in either treatment groups.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
complications</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Table below shows
that the incidence of Grade&nbsp;4 neutropenia, febrile neutropenia and
neutropenic infection was decreased in patients who received primary G&#8209;CSF
prophylaxis after it was made mandatory in the TAC arm. &#8211; GEICAM study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal'>Neutropenic complications in
patients receiving TAC with or without primary G&#8209;CSF prophylaxis (GEICAM
9805)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Without
  primary</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF
  prophylaxis (n&nbsp;=&nbsp;111)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n&nbsp;(%)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>With primary </span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF </span><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>prophylaxis</span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(n&nbsp;=&nbsp;421)
  </span></p>
  <p class=TableHeadCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>n&nbsp;(%)</span></p>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenia&nbsp;(Grade&nbsp;4)
  </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>104
  (93.7)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>135 (32.1)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Febrile
  neutropenia </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>28
  (25.2)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>23 (5.5)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>14
  (12.6)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>21 (5.0)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection (Grade&nbsp;3-4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2
  (1.8)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>5
  (1.2)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
gastric adenocarcinoma cancer for </span></u><u><span lang=EN-GB
style='font-weight:normal'>TAXOTERE 75&nbsp;mg/m&sup2; in combination with
cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Authors style='margin-top:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
   infestations</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Neutropenic infection;</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Infection
   (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
   style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Anaemia (G3/4:
   20.9%);</span></p>
   <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G3/4:
   83.2%); </span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=IT>Thrombocytopenia (G3/4: 8.8%);</span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Febrile neutropenia </span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt'>Immune system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid;
   punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity
   (G3/4: 1.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Anorexia (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:40.75pt'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
   disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
   sensory neuropathy (G3/4: 8.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>Dizziness (G3/4: 2.3%); </span></p>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'>Peripheral <span lang=EN-GB>motor </span>neuropathy<span
   lang=EN-GB> (G3/4: 1.3%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:
   "Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
   increased (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ear and
   labyrinth disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:
   "Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Hearing impaired (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
   style='font-size:11.0pt'>Cardiac disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
   (G3/4: 1.0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
   disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea
   (G3/4: 19.7%); </span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nausea
   (G3/4: 16%); </span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Stomatitis
   (G3/4: 23.7%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vomiting
   (G3/4: 14.3%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Constipation
   (G3/4: 1.0%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
   pain (G3/4: 1.0%);</span></p>
   <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Oesophagitis/dysphagia/odynophagia
   (G3/4: 0.7%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
   subcutaneous tissue disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
   4.0%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rash pruritus
   (G3/4: 0.7%); </span></p>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nail disorders
   (G3/4: 0.7%); </span></p>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
   exfoliation (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
   disorders and administration site conditions</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=xCover2Answ style='margin-top:0in;punctuation-wrap:hanging;
   text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
   11.0pt;font-family:"Times New Roman",serif'>Lethargy (G3/4: 19.0%);</span></p>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fever </span><span
   lang=EN-GB style='font-size:11.0pt'>(G3/4: 2.3%);<br>
   Fluid retention (severe</span><span lang=EN-GB style='font-size:11.0pt'>/life&#8209;threatening</span><span
   lang=EN-GB style='font-size:11.0pt'>: 1%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Description of selected adverse reactions in gastric
adenocarcinoma cancer for TAXOTERE 75&nbsp;mg/m<sup>2</sup> in combination with
cisplatin and 5-fluorouracil</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Febrile neutropenia and neutropenic infection occurred
in 17.2% and 13.5% of patients respectively, regardless of G&#8209;CSF
use.&nbsp; G&#8209;CSF was used for secondary prophylaxis in 19.3% of patients
(10.7% of the cycles). Febrile neutropenia and neutropenic infection occurred
respectively in 12.1% and 3.4% of patients when patients received prophylactic
G&#8209;CSF, in 15.6% and 12.9% of patients without prophylactic G&#8209;CSF
(see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Tabulated list of adverse reactions in
head and neck cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with
cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
radiotherapy (TAX 323)</span></p>

<p class=Authors style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA <span style='color:black'>system organ
   classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>Infection (G3/4: 6.3%);</p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
  infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neoplasms
  benign, malignant and unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cancer pain
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Neutropenia (G3/4: 76.3%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Anaemia (G3/4: 9.2%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Thrombocytopenia (G3/4: 5.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.75pt'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Dysgeusia/Parosmia;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Peripheral sensory
  neuropathy (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dizziness</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
  increased;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Conjunctivitis </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ear and
  labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hearing impaired</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myocardial
  ischemia (G3/4:1.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Venous disorder
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  2.9%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Constipation;</span></p>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Esophagitis/dysphagia/
  odynophagia (G3/4: 0.6%);</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  pain;</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspepsia;</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
  haemorrhage (G3/4: 0.6%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
  10.9%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>Rash pruritic;</p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=FR>Dry skin; </span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=FR>Skin exfoliative (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lethargy (G3/4:
  3.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pyrexia (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oedema</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
chemoradiotherapy (TAX 324)</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
   lang=EN-GB>MedDRA system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Very common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
   lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
   lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;page-break-after:avoid;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'>Infection (G3/4: 3.6%)</p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Neoplasms
  benign, malignant and unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Cancer
  pain (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Blood
  and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Neutropenia (G3/4: 83.5%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Anaemia (G3/4: 12.4%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Thrombocytopenia (G3/4:&nbsp;4.0%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  12.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Dysgeusia/Parosmia
  (G3/4:&nbsp;0.4%);</span></p>
  <p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
  line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
  baseline'><span lang=IT>Peripheral sensory neuropathy (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dizziness (G3/4:
  2.0%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Peripheral
  </span><span lang=EN-GB>motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Conjunctivitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Ear
  and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hearing impaired
  (G3/4:&nbsp;1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Arrhythmia
  (G3/4: 2.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Ischemia
  myocardial</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Venous
  disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  13.9%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Stomatitis
  (G3/4: 20.7%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  8.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  6.8%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Esophagitis/dysphagia/
  odynophagia (G3/4: 12.0%);</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Constipation (G3/4:
  0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dyspepsia
  (G3/4: 0.8%);</span></p>
  <p class=Header1><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.2%);</span></p>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Gastrointestinal
  haemorrhage (G3/4: 0.4%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Skin
  and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alopecia (G3/4:
  4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rash pruritic</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dry
  skin&nbsp;;</span></p>
  <p class=MsoHeader><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Desquamation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Musculoskeletal,
  connective tissue bone disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Myalgia
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lethargy (G3/4:
  4.0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pyrexia (G3/4:
  3.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fluid retention
  (G3/4: 1.2%);</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Oedema
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Weight
  decreased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><u><span lang=EN-GB
style='font-weight:normal'>Post-marketing experience</span></u></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Neoplasms benign, malignant and unspecified (incl
cysts and polyps)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S</span><span
style='font-size:11.0pt'>econd primary malignancies (</span><span lang=EN
style='font-size:11.0pt'>frequency not known)</span><span style='font-size:
11.0pt'>, including non-Hodgkin lymphoma have been reported in association with
docetaxel when used in combination with other anticancer treatments known to be
associated with second primary malignancies</span><span lang=EN-GB
style='font-size:11.0pt'>. </span><span style='font-size:11.0pt'>Acute myeloid
leukaemia and myelodysplastic syndrome have been reported (frequency uncommon)
in pivotal clinical studies in breast cancer with TAC regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Blood and lymphatic system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Bone marrow
suppression and other haematologic adverse reactions have been reported.
Disseminated intravascular coagulation (DIC), often in association with sepsis
or multiorgan failure, has been reported.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Immune system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Some cases of
anaphylactic shock, sometimes fatal, have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
reactions (frequency not known) have been reported with docetaxel in patients
who previously experienced hypersensitivity reactions to paclitaxel.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Rare
cases of convulsion or transient loss of consciousness have been observed with
docetaxel administration. These reactions sometimes appear during the infusion
of the medicinal product.</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Eye disorders</span></i></p>

<p class=MsoNormalIndent style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:
11.0pt;layout-grid-mode:line'>Very rare cases of transient visual disturbances
(flashes, flashing lights, scotomata) typically occurring during infusion of
the medicinal product and in association with hypersensitivity reactions have been
reported. These were reversible upon discontinuation of the infusion. </span><span
lang=EN-GB style='font-size:11.0pt'>Cases of lacrimation with or without
conjunctivitis, as cases of lacrimal duct obstruction resulting in excessive
tearing have been rarely reported</span><span lang=EN-GB style='font-size:11.0pt'>.&nbsp;Cases
of cystoid macular oedema (CMO) have been reported in patients treated with
docetaxel.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Ear and labyrinth disorders</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>Rare cases of ototoxicity,
hearing impaired and/or hearing loss have been reported.</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Rare cases of myocardial infarction have been
reported.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Ventricular
arrhythmia including ventricular tachycardia (frequency not known), sometimes
fatal, has been reported in patients treated with docetaxel in combination
regimens including doxorubicin, 5-fluorouracil and/ or cyclophosphamide.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Vascular disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>Venous thromboembolic
events have rarely been reported.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Respiratory, thoracic and mediastinal disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome and cases of<b><i> </i></b>interstitial pneumonia</span><span
class=msoins0><b><span lang=EN-GB style='font-size:11.0pt'>/ </span></b></span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>pneumonitis<b>,</b></span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span class=msoins0><span
lang=EN-GB style='font-size:11.0pt'>interstitial lung</span></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span class=msoins0><span
lang=EN-GB style='font-size:11.0pt'>disease, </span></span><span lang=EN-GB
style='font-size:11.0pt'>pulmonary fibrosis <span class=msoins0>and </span></span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>respiratory failure</span></span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'> </span></span><span
lang=EN-GB style='font-size:11.0pt'>sometimes fatal have rarely been reported. </span><span
style='font-size:11.0pt'>Rare cases of radiation pneumonitis have been reported
in patients receiving concomitant radiotherapy.</span><span lang=EN-GB
style='font-size:11.0pt'> </span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Gastrointestinal disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rare cases of e</span><span
style='font-size:11.0pt'>nterocolitis, including colitis, ischemic colitis, and
neutropenic enterocolitis, have been reported with a potential fatal outcome
(frequency not known).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rare occurrences
of dehydration have been reported as a consequence of gastrointestinal events
including enterocolitis and gastrointestinal perforation. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Rare cases of ileus
and intestinal obstruction have been reported.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Hepatobiliary disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Very rare cases of
hepatitis, sometimes fatal primarily in patients with pre&#8209;existing liver
disorders, have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Skin and subcutaneous tissue disorders&nbsp; </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cases of cutaneous
lupus erythematosus</span><span lang=EN-GB>, </span><span lang=EN-GB
style='font-size:11.0pt'>bullous eruptions such as erythema multiforme and </span><span
lang=EN-GB>severe cutaneous adverse reactions such as </span><span lang=EN-GB
style='font-size:11.0pt'>Stevens&#8209;Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
(TEN) and </span><span lang=EN-GB style='font-size:11.0pt'>Acute Generalized Exanthematous
Pustulosis (AGEP)</span><span lang=EN-GB style='font-size:11.0pt'> have been
reported with docetaxel. Scleroderma&#8209;like changes usually preceded by
peripheral lymphoedema have been reported with docetaxel. Cases of </span><span
lang=EN-GB style='font-size:11.0pt'>permanent</span><span lang=EN-GB
style='font-size:11.0pt'> alopecia (frequency not known) have been reported.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Renal and urinary disorders</span></i></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Renal insufficiency and renal failure have been reported. In
about 20% of these cases there were no risk factors for acute renal failure
such as concomitant nephrotoxic medicinal products and gastro-intestinal
disorders.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Radiation recall phenomena have rarely been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Injection site
recall reaction (recurrence of skin reaction at a site of previous
extravasation following administration of docetaxel at a different site) has
been observed at the site of previous extravasation (frequency not known).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Fluid retention has not been accompanied by acute
episodes of oliguria or hypotension. Dehydration and pulmonary oedema have
rarely been reported.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><i>Metabolism and nutrition disorders</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span style='color:windowtext'>Cases of electrolyte imbalance have been
reported. </span>Cases of hyponatraemia have been reported, mostly associated
with dehydration, vomiting and pneumonia. <span style='color:windowtext'>Hypokalaemia,
hypomagnesaemia, and hypocalcaemia were observed, usually in association with
gastrointestinal disorders and in particular with diarrhoea.</span><span
style='color:windowtext'> </span><span lang=EN-GB>Tumour lysis syndrome, potentially
fatal, has been reported (frequency not known).</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin-left:0in;text-indent:0in'><i>Musculoskeletal
disorder</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Myositis has been reported with docetaxel <span lang=EN-GB>(frequency not
known)</span>.</p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:#BFBFBF'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>There were a
few reports of overdose. There is no known antidote for docetaxel overdose. In
case of overdose, the patient should be kept in a specialised unit and vital
functions closely monitored. </span><span lang=EN-GB style='font-size:11.0pt'>In
cases of overdose, exacerbation of adverse events may be expected. </span><span
lang=EN-GB style='font-size:11.0pt'>The primary anticipated complications of
overdose would consist of bone marrow suppression, peripheral neurotoxicity and
mucositis. Patients should receive therapeutic G&#8209;CSF as soon as possible
after discovery of overdose. Other appropriate symptomatic measures should be
taken, as needed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pharmacotherapeutic
group: Taxanes, ATC Code: L01CD&nbsp;02</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Mechanism of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is an
antineoplastic agent which acts by promoting the assembly of tubulin into
stable microtubules and inhibits their disassembly which leads to a marked
decrease of free tubulin. The binding of docetaxel to microtubules does not
alter the number of protofilaments.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel has been
shown <i>in vitro</i> to disrupt the microtubular network in cells which is
essential for vital mitotic and interphase cellular functions. </span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel was
found to be cytotoxic <i>in vitro</i> against various murine and human tumour
cell lines and against freshly excised human tumour cells in clonogenic assays.
Docetaxel achieves high intracellular concentrations with a long cell residence
time. In addition, docetaxel was found to be active on some but not all cell
lines over expressing the p&#8209;glycoprotein which is encoded by the
multidrug resistance gene. <i>In vivo</i>, docetaxel is schedule independent
and has a broad spectrum of experimental anti-tumour activity against advanced
murine and human grafted tumours.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Breast cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with doxorubicin and cyclophosphamide: adjuvant therapy</span></i></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><u><span lang=EN-GB>Patients
with operable node&#8209;positive breast cancer </span></u><span lang=EN-GB>(TAX
316)</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Data
from a multi-centre open label randomised study support the use of docetaxel
for the adjuvant treatment of patients with operable node-positive breast
cancer and KPS&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;80%, between 18 and 70&nbsp;years of age. After stratification
according to the number of positive lymph nodes (1&#8209;3, 4+), 1491&nbsp;patients
were randomised to receive either docetaxel 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (TAC arm), or doxorubicin
50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (FAC arm). Both regimens were
administered once every 3&nbsp;weeks for 6&nbsp;cycles. Docetaxel was
administered as a 1&#8209;hour infusion, all other medicinal products were
given as intravenous bolus on day one. G&#8209;CSF was administered as secondary
prophylaxis to patients who experienced complicated neutropenia (febrile
neutropenia, prolonged neutropenia, or infection). Patients on the TAC arm
received antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice
daily for 10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. In
both arms, after the last cycle of chemotherapy, patients with positive eostrogen
and/or progesterone receptors received tamoxifen 20&nbsp;mg daily for up to
5&nbsp;years. Adjuvant radiation therapy was prescribed according to guidelines
in place at participating institutions and was given to 69% of patients who
received TAC and 72% of patients who received FAC.</span><span lang=EN-GB> </span><span
lang=EN-GB>Two interim analyses and one final analysis were performed. The
first interim analysis was planned 3 years after the date when half of study
enrolment was done. The second interim analysis was done after 400 DFS events
had been recorded overall, which led to a median follow-up of 55 months. The
final analysis was performed when all patients had reached their 10-year
follow-up visit (unless they had a DFS event or were lost to follow-up before).
Disease-free survival (DFS) was the primary efficacy endpoint and Overall
survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>A final
analysis was performed with an actual median follow up of 96&nbsp;months.
Significantly longer disease-free survival for the TAC arm compared to the FAC
arm was demonstrated. Incidence of relapses at 10 years was reduced in patients
receiving TAC compared to those who received FAC (39% versus 45%, respectively)
i.e. an absolute risk reduction by 6% (p&nbsp;=&nbsp;0.0043). Overall survival
at 10&nbsp;years was also significantly increased with TAC compared to FAC (76%
versus 69%, respectively) i.e. an absolute reduction of the risk of death by 7%
(p&nbsp;=&nbsp;0.002). </span><span lang=EN-GB>As the benefit observed in
patients with 4+ nodes was not statistically significant on DFS and OS, the
positive benefit/risk ratio for TAC in patients with 4+ nodes was not fully
demonstrated at the final analysis.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Overall,
the study results demonstrate a positive benefit risk ratio for TAC compared to
FAC. </span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>TAC-treated
patient subsets according to prospectively defined major prognostic factors
were analysed:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='width:104.4%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.92%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Disease free survival</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.6%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Overall survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>Patient subset</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Number of patients</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>p&nbsp;=</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.5pt'>p&nbsp;=</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.5pt'>No of positive nodes</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>Overall</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>745</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.80</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.68-0.93</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0043</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.74</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.61-0.90</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0020</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>1-3</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>467</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.72</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.58-0.91</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0047</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.62</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.46-0.82</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.0008</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.5pt'>4+</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>278</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.87</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.70-1.09</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.2290</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.67-1.12</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.5pt'>0.2746</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>*a hazard ratio of less than 1 indicates that TAC is associated with
a longer disease&#8209;free survival and overall survival compared to FAC</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Patients with operable node</span><span lang=EN-GB>&#8209;</span></u><u><span
lang=EN-GB style='font-size:11.0pt'>negative breast cancer eligible to receive
chemotherapy (</span></u><span lang=EN-GB style='font-size:11.0pt'>GEICAM 9805)<u>
</u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Data from a multi-centre open label randomised trial
support the use of TAXOTERE for the adjuvant treatment of patients with
operable node&#8209;negative breast cancer eligible to receive chemotherapy<u> </u>.
1060&nbsp;patients were randomised to receive either TAXOTERE 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (539 patients in TAC arm), or
doxorubicin 50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup>
and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (521 patients in FAC arm), as
adjuvant treatment of operable node-negative breast cancer patients with high
risk of relapse according to 1998 St. Gallen criteria (tumour size
&gt;2&nbsp;cm and/or negative ER and PR and/or high histological/nuclear grade
(grade 2 to 3) and /or age &lt;35&nbsp;years). Both regimens were administered
once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1&#8209;hour
infusion, all other medicinal products were given as intraveinously on day 1
every three weeks. Primary prophylactic G&#8209;CSF was made mandatory in TAC
arm after 230&nbsp;patients were randomised. The incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in patients
who received primary G&#8209;CSF prophylaxis (see section 4.8). In both arms,
after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours
received tamoxifen 20&nbsp;mg once a day for up to 5 years. Adjuvant radiation
therapy was administered according to guidelines in place at participating
institutions and was given to 57.3% of patients who received TAC and 51.2% of patients
who received FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>One
primary analysis and one updated analysis were performed. The primary analysis
was done when all patients had a follow-up of greater than 5 years (median
follow-up time of 77 months). The updated analysis was performed when all
patients had reached their 10-year (</span><span lang=EN-GB>median follow up
time of 10 years and 5&nbsp;months) </span><span lang=EN-GB>follow-up visit
(unless they had a DFS event or were lost to follow-up previously).
Disease-free survival (DFS) was the primary efficacy endpoint and Overall
survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, significantly longer disease-free survival for the
TAC arm compared to the FAC arm was demonstrated. TAC&#8209;treated patients
had a 32% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.68, 95% CI (0.49-0.93), p&nbsp;=&nbsp;0.01). At the
median follow up time of 10 years and 5&nbsp;months, TAC&#8209;treated patients
had a 16,5% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.84, 95% CI (0.65-1.08)</span><span
style='font-size:11.0pt'>, p=0.1646). DFS data were not statistically
significant but were still associated with a positive trend in favour of TAC</span><span
lang=EN-GB style='font-size:11.0pt'>.&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;At the
median follow-up time of 77 months, overall survival (OS) was longer in the TAC
arm with TAC-treated patients having a 24% reduction in the risk of death
compared to FAC (hazard ratio&nbsp;=&nbsp;0.76, 95% CI (0.46-1.26,
p&nbsp;=&nbsp;0.29). However, the distribution of OS was not significantly
different between the 2 groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow up time of 10 years and 5&nbsp;months, TAC-treated patients had a 9%
reduction in the risk of death compared to FAC-treated patients (hazard
ratio&nbsp;=&nbsp;0.91, 95% CI (0.63-1.32)). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The survival rate
was 93.7% in the TAC arm and 91.4&nbsp;% in the FAC arm, at the 8-year
follow-up time point, and 91.3&nbsp;% in the TAC arm and 89&nbsp;% in the FAC
arm, at the 10-year follow-up time point.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The positive benefit risk ratio for TAC compared to
FAC remained unchanged<b>. </b>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAC&#8209;treated
patient subsets according to prospectively defined major prognostic factors
were analysed in the primary analysis (at the median follow-up time of 77
months) (see table below):</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Subset
Analyses-Adjuvant Therapy in Patients with Node&#8209;negative Breast Cancer
Study </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>(Intent&#8209;to&#8209;Treat Analysis)</span></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=558
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=258 colspan=2 valign=top style='width:193.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Disease Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  subset</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of patients in TAC group</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio*</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Overall</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>539</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.49-0.93</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 1</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>260</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>279</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 2</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>42</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.31</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.11-0.89</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>497</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.52-1.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Hormonal receptor</span></b><span
  lang=EN-GB> <b>status</b></span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.6pt'>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt><span lang=EN-GB>Negative</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>195</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.7</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Positive</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>344</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.4-0.97</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Tumour size </span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB style='font-family:Symbol'>&pound;</span><span
  lang=EN-GB>2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.69</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&gt;2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Histological grade</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade1 (includes grade not assessed)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>64</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.79</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.24-2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 2</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>216</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.77</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.46-1.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 3</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>259</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.59</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.39-0.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Menopausal status</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Pre-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.64</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.40-1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Post-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.47-1.12</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*a hazard ratio
(TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease
free survival compared to FAC.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Exploratory subgroup analyses for&nbsp; disease-free
survival for&nbsp; patients who meet the 2009 St. Gallen chemotherapy criteria
&#8211; (ITT population) were performed and presented here below:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>TAC</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>FAC</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(TAC/FAC)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Subgroups</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=539)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=521)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Meeting
  relative indication for chemotherapy </span><sup><span lang=EN-GB
  style='font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>No</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18/214</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(8.4%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26/227</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(11.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.796 (0.434 - 1.459)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4593</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48/325</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.8%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>69/294</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(23.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.606 (0.42 - 0.877)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0072</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>TAC = docetaxel, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>FAC = 5-fluorouracil, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>CI = confidence interval</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>ER = eostrogen receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>PR = progesterone receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:10.0pt;font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> ER/PR-negative or Grade 3 or tumour size
&gt;5&nbsp;cm</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The estimated
hazard ratio was using Cox proportional hazard model with treatment group as
the factor.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
as single agent</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'>Two randomised phase&nbsp;III comparative studies,
involving a total of 326&nbsp;alkylating or 392&nbsp;anthracycline failure metastatic
breast cancer patients, have been performed with docetaxel at the recommended
dose and regimen of 100&nbsp;mg/m&sup2; every 3&nbsp;weeks.</p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In
alkylating-failure patients, docetaxel was compared to doxorubicin
(75&nbsp;mg/m&sup2; every 3&nbsp;weeks). Without affecting overall survival
time (docetaxel 15&nbsp;months vs. doxorubicin 14&nbsp;months,
p&nbsp;=&nbsp;0.38) or time to progression (docetaxel 27&nbsp;weeks vs.
doxorubicin 23&nbsp;weeks, p&nbsp;=&nbsp;0.54), docetaxel increased response
rate (52% vs. 37%, p&nbsp;=&nbsp;0.01) and shortened time to response
(12&nbsp;weeks vs. 23&nbsp;weeks, p&nbsp;=&nbsp;0.007). Three docetaxel
patients (2%) discontinued the treatment due to fluid retention, whereas
15&nbsp;doxorubicin patients (9%) discontinued due to cardiac toxicity (three
cases of fatal congestive heart failure).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In
anthracycline-failure patients, docetaxel was compared to the combination of
mitomycin&nbsp;C and vinblastine (12&nbsp;mg/m&sup2; every 6&nbsp;weeks and
6&nbsp;mg/m&sup2; every 3&nbsp;weeks). Docetaxel increased response rate (33%
vs. 12%, p&nbsp;&lt;&nbsp;0.0001), prolonged time to progression (19&nbsp;weeks
vs. 11&nbsp;weeks, p&nbsp;=&nbsp;0.0004) and prolonged overall survival
(11&nbsp;months vs. 9&nbsp;months, p&nbsp;=&nbsp;0.01).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>During these two
phase&nbsp;III studies, the safety profile of docetaxel was consistent with the
safety profile observed in phase&nbsp;II studies (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB>An open-label, multi-centre, randomised
phase&nbsp;III study was conducted to compare docetaxel monotherapy and
paclitaxel in the treatment of advanced breast cancer in patients whose
previous therapy should have included an anthracycline. A total of
449&nbsp;patients were randomised to receive either docetaxel monotherapy
100&nbsp;mg/m&sup2; as a 1&nbsp;hour infusion or paclitaxel 175&nbsp;mg/m&sup2;
as a 3&nbsp;hour infusion. Both regimens were administered every 3&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Without affecting
the primary endpoint, overall response rate (32% vs 25%, p&nbsp;=&nbsp;0.10),
docetaxel prolonged median time to progression (24.6&nbsp;weeks vs
15.6&nbsp;weeks; p&nbsp;&lt;&nbsp;0.01) and median survival (15.3&nbsp;months
vs 12.7&nbsp;months; p&nbsp;=&nbsp;0.03).</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext;
layout-grid-mode:both'>More grade&nbsp;3/4 adverse events were observed for
docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with doxorubicin</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><b><i><s><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></s></i></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>One large randomised phase&nbsp;III study, involving
429 previously untreated patients with metastatic disease, has been performed
with doxorubicin (50&nbsp;mg/m&sup2;) in combination with docetaxel
(75&nbsp;mg/m&sup2;) (AT arm) versus doxorubicin (60&nbsp;mg/m&sup2;) in combination
with cyclophosphamide (600&nbsp;mg/m&sup2;) (AC arm). Both regimens were
administered on day&nbsp;1 every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Time to progression
(TTP) was significantly longer in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.0138. The median TTP was 37.3&nbsp;weeks (95%&nbsp;CI:
33.4&nbsp;&#8209;&nbsp;42.1) in AT arm and 31.9&nbsp;weeks (95%&nbsp;CI:
27.4&nbsp;&#8209;&nbsp;36.0) in AC arm.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Overall response rate
(ORR) was significantly higher in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.009. The ORR was 59.3% (95%&nbsp;CI: 52.8&nbsp;&#8209;&nbsp;65.9)
in AT arm versus 46.5% (95%&nbsp;CI: 39.8&nbsp;&#8209;&nbsp;53.2) in AC arm.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><s><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>In this study, AT arm showed a higher incidence of
severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%),
infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus
2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed
a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in
addition, a higher incidence of severe cardiac toxicity: congestive heart
failure (3.8% versus 2.8%), absolute LVEF decrease </span><span
style='font-family:"Times New Roman",serif'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;20% (13.1% versus 6.1%),
absolute LVEF decrease </span><span
style='font-family:"Times New Roman",serif'>&sup3;</span><span
style='font-family:"Times New Roman",serif'>&nbsp;30% (6.2% versus 1.1%). Toxic
deaths occurred in 1&nbsp;patient in the AT arm (congestive heart failure) and
in 4&nbsp;patients in the AC arm (1 due to septic shock and 3 due to congestive
heart failure).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In both arms,
quality of life measured by the EORTC questionnaire was comparable and stable
during treatment and follow&#8209;up.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with trastuzumab</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'>Docetaxel in combination
with trastuzumab was studied for the treatment of patients with metastatic
breast cancer whose tumours over express HER2, and who previously had not
received chemotherapy for metastatic disease. One hundred eighty six patients
were randomised to receive docetaxel (100&nbsp;mg/m<sup>2</sup>) with or
without trastuzumab; 60% of patients received prior anthracycline-based
adjuvant chemotherapy. Docetaxel plus trastuzumab was efficacious in patients
whether or not they had received prior adjuvant anthracyclines. The main test
method used to determine HER2 positivity in this pivotal study was
immunohistochemistry (IHC). A minority of patients were tested using
fluorescence in&#8209;situ hybridization (FISH). In this study, 87% of patients
had disease that was IHC 3+, and 95% of patients entered had disease that was
IHC 3+ and/or FISH positive. Efficacy results are summarized in the following
table:</p>

<p class=MDSnormalsectionstyle style='margin-left:0in'>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Parameter</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'>Docetaxel <span lang=EN-GB>plus
  trastuzumab<sup>1</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>n&nbsp;=&nbsp;92</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'>Docetaxel<sup><span lang=EN-GB>1</span></sup></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=FR>n&nbsp;=&nbsp;94</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=FR>Response rate </span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=FR>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>61%</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(50-71)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>34%</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(25-45)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median duration of response (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>11.4</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(9.2-15.0)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>5.1</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(4.4-6.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median TTP (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>10.6</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(7.6-12.9)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>5.7</span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(5.0-6.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>Median survival (months)</span></p>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><span
  lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>30.5<sup>2</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(26.8-ne)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>22.1<sup>2</sup></span></p>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>(17.6-28.9)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify;
page-break-after:avoid'><span lang=EN-GB>TTP&nbsp;=&nbsp;time to progression;
&#8220;ne&#8221; indicates that it could not be estimated or it was not yet
reached.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify;
page-break-after:avoid'><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>Full
analysis set (intent-to-treat)</span></p>

<p class=MDSnormalsectionstyle style='margin-left:12.0pt;text-align:justify'><sup><span
lang=EN-GB>2 </span></sup><span lang=EN-GB>Estimated median survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with capecitabine</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Data
from one multi-centre, randomised, controlled phase&nbsp;III clinical study
support the use of docetaxel in combination with capecitabine for treatment of patients
with locally advanced or metastatic breast cancer after failure of cytotoxic
chemotherapy, including an anthracycline. In this study, 255&nbsp;patients were
randomised to treatment with docetaxel (75&nbsp;mg/m<sup>2</sup> as a
1&nbsp;hour intravenous infusion every 3&nbsp;weeks) and capecitabine
(1250&nbsp;mg/m<sup>2</sup> twice daily for 2&nbsp;weeks followed by 1&#8209;week
rest period). 256&nbsp;patients were randomised to treatment with docetaxel
alone (100&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour intravenous infusion every
3&nbsp;weeks). Survival was superior in the docetaxel&nbsp;+ capecitabine
combination arm (p&nbsp;=&nbsp;0.0126). Median survival was 442&nbsp;days
(docetaxel&nbsp;+ capecitabine) vs. 352&nbsp;days (docetaxel alone). The overall
objective response rates in the all&#8209;randomised population (investigator
assessment) were 41.6% (docetaxel&nbsp;+ capecitabine) vs. 29.7% (docetaxel
alone); p&nbsp;=&nbsp;0.0058. Time to progressive disease was superior in the
docetaxel&nbsp;+ capecitabine combination arm (p&nbsp;&lt;&nbsp;0.0001). The
median time to progression was 186&nbsp;days (docetaxel&nbsp;+ capecitabine)
vs. 128&nbsp;days (docetaxel alone).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Non-small cell lung cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Patients
previously treated with chemotherapy with or without radiotherapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In a
phase&nbsp;III study, in previously treated patients, time to progression
(12.3&nbsp;weeks versus 7&nbsp;weeks) and overall survival were significantly
longer for docetaxel at 75&nbsp;mg/m&sup2; compared to Best Supportive Care.
The 1&#8209;year survival rate was also significantly longer in docetaxel (40%)
versus BSC (16%).</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>There was less use of
morphinic analgesic (p&nbsp;&lt;&nbsp;0.01), non&#8209;morphinic analgesics
(p&nbsp;&lt;&nbsp;0.01), other disease-related medications (p&nbsp;=&nbsp;0.06)
and radiotherapy (p&nbsp;&lt;&nbsp;0.01) in patients treated with docetaxel at
75&nbsp;mg/m&sup2; compared to those with BSC.</p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The overall
response rate was 6.8% in the evaluable patients, and the median duration of
response was 26.1&nbsp;weeks.</span></p>

<p class=MsoHeading7 style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
page-break-after:auto'><b><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with platinum agents in chemotherapy-na&iuml;ve patients</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In a
phase&nbsp;III study, 1218&nbsp;patients with unresectable stage&nbsp;IIIB or
IV NSCLC, with KPS of 70% or greater, and who did not receive previous
chemotherapy for this condition, were randomised to either docetaxel&nbsp;(T)
75&nbsp;mg/m<sup>2 </sup>as a 1&nbsp;hour infusion immediately followed by
cisplatin&nbsp;(Cis) 75&nbsp;mg/m<sup>2 </sup>over </span><span lang=EN-GB
style='font-size:11.0pt'>30&#8209;60&nbsp;minutes every 3&nbsp;weeks (TCis),
docetaxel 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion in combination
with</span><span lang=EN-GB style='font-size:11.0pt'> carboplatin (AUC
6&nbsp;mg/ml.min) over 30&#8209;60&nbsp;minutes every 3&nbsp;weeks, or
vinorelbine&nbsp;(V) 25&nbsp;mg/m<sup>2</sup> administered over 6&#8209;10&nbsp;minutes
on days&nbsp;1, 8, 15, 22 followed by cisplatin 100&nbsp;mg/m<sup>2</sup>
administered on </span><span lang=EN-GB style='font-size:11.0pt'>day&nbsp;1 of
cycles repeated every 4&nbsp;weeks (VCis).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Survival data, median time to progression and response
rates for two arms of the study are illustrated in the following table:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=584
 style='margin-left:17.5pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>TCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;408</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>VCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;404</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Statistical analysis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Overall
  survival </span></p>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(Primary
  end-point):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>10.1</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hazard
  ratio: 1.122</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[97.2% CI: 0.937; 1.342]*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>1-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>41</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 5.4%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: -1.1; 12.0]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>2-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>21</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 6.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.2; 12.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
  none;vertical-align:baseline'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Median
  time to progression</span></p>
  <p class=Authors align=right style='margin-top:0in;text-align:right;
  punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(weeks):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.0</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>23.0</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Hazard ratio: 1.032</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.876; 1.216]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (%):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.6</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.5</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Treatment difference: 7.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[95% CI: 0.7; 13.5]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>*: Corrected for multiple comparisons and adjusted for
stratification factors (stage of disease and region of treatment), based on
evaluable patient population.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Secondary end&#8209;points
included change of pain, global rating of quality of life by EuroQoL-5D, Lung
Cancer Symptom Scale, and changes in Karnosfky performance status. Results on
these end-points were supportive of the primary end-points results.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For
docetaxel/carboplatin combination, neither equivalent nor non-inferior efficacy
could be proven compared to the reference treatment combination VCis.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Prostate cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Metastatic castration-resistant prostate cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left;
page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left;
page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
font-style:normal'>The safety and efficacy of docetaxel in combination with
prednisone or prednisolone</span><span style='font-size:11.0pt'> </span><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>in patients with
metastatic castration-resistant prostate cancer were evaluated in a randomised
multi-centre phase&nbsp;III study (TAX 327). A total of 1006&nbsp;patients with
KPS&nbsp;</span><span style='font-size:11.0pt;font-family:Symbol;font-weight:
normal;font-style:normal'>&sup3;</span><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;60 were randomised to the following
treatment groups:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 75&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 30&nbsp;mg/m<sup>2</sup>
administered weekly for the first 5&nbsp;weeks in a 6&nbsp;week cycle for
5&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mitoxantrone
12&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>All
3&nbsp;regimens were administered in combination with </span><span lang=EN-GB
style='font-size:11.0pt'>prednisone or prednisolone 5&nbsp;mg twice daily, continuously.</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;font-weight:normal;font-style:normal'>Patients who
received docetaxel every three weeks demonstrated significantly longer overall
survival compared to those treated with mitoxantrone. The increase in survival
seen in the docetaxel weekly arm was not statistically significant compared to
the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus
the control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=587
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Endpoint</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Docetaxel every 3 weeks </span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Docetaxel every week</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Mitoxantrone </span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>every 3 weeks</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Number of
  patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Median survival
  (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>Hazard
  ratio</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value<sup>&#8224;</sup>*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>335</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>18.9</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(17.0-21.2)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.761</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(0.619-0.936)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0094</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>334</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>17.4</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(15.7-19.0)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.912</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(0.747-1.113)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.3624</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>337</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>16.5</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(14.4-18.6)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Number of patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>PSA** response rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span lang=FR style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>291</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>45.4</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(39.5-51.3)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0005</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>282</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>47.9</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(41.9-53.9)<br>
  &lt;0.0001</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-weight:
  normal;font-style:normal'>300</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>31.7</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(26.4-37.3)<br>
  --</span></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Number of patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>Pain response rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:14.45pt;margin-bottom:.0001pt;text-indent:-14.45pt;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>153</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>34.6</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(27.1-42.7)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0107</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>154</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>31.2</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(24.0-39.1)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.0798</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>157</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>21.7</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(15.5-28.9)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.7pt'>
  <td width=199 valign=top style='width:149.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Number of
  patients</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>Tumour response
  rate (%)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>95% CI</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-weight:normal;font-style:normal'>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>141</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>12.1</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(7.2-18.6)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.1112</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>134</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>8.2</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(4.2-14.2)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>0.5853</span></p>
  </td>
  <td width=164 valign=top style='width:122.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>137</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>6.6</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>(3.0-12.1)</span></p>
  <p class=MsoBodyText3 align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span style='font-size:11.0pt;font-weight:normal;
  font-style:normal'>--</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoBodyText3 align=left style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:12.25pt;margin-bottom:.0001pt;text-align:left;
page-break-after:avoid'><sup><span style='font-size:11.0pt;font-weight:normal;
font-style:normal'>&#8224;</span></sup><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Stratified log-rank test<br>
*Threshold for statistical significance&nbsp;=&nbsp;0.0175</span></p>

<p class=MsoNormal style='margin-left:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>**PSA: Prostate-Specific Antigen<br>
<br>
</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Given the fact
that docetaxel every week presented a slightly better safety profile than
docetaxel every 3&nbsp;weeks, it is possible that certain patients may benefit
from docetaxel every week.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No statistical
differences were observed between treatment groups for Global Quality of Life.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Metastatic
hormone-sensitive prostate cancer</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>STAMPEDE </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered concomitantly with standard of care (ADT)<b> </b>in
patients with high-risk locally advanced or metastatic hormone-sensitive
prostate cancer were evaluated in a <span style='color:black'>randomised multi-centre,
multi-arm multi-stage (MAMS) study </span></span><span style='color:black'>with
a seamless phase II/III design</span><span style='font-size:11.0pt'> (STAMPEDE
&#8211; MRC PR08). A total of 1776 male patients were allocated to the
treatment arms of interest: </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>+ docetaxel
75 mg/m&sup2;, administered every 3 weeks for 6 cycles&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>alone<span
style='background:silver'> </span></span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Docetaxel regimen was
administered in combination with prednisone or prednisolone 5 mg twice daily
continuously. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Among the 1776 randomised
patients 1086 (61%) had metastatic disease, 362 were randomised to docetaxel in
combination with standard of care, 724 received standard of care<b> </b>alone. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In these metastatic prostate
cancer patients, the median overall survival was significantly longer in
docetaxel treatment groups than in the standard of care<b> </b>alone group,
with a median overall survival 19 months longer with the addition of docetaxel
to standard of care<b> </b>(HR =&nbsp; 0.76, 95% </span><span lang=EN-GB
style='font-size:11.0pt'>CI = 0.62-0.92,</span><span style='font-size:11.0pt'>
p=0.005). </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Efficacy results in
metastatic prostate cancer patients for </span><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span><span style='font-size:11.0pt'> arm
versus control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in combination with prednisone
or prednisolone and standard of care in the treatment of patients with
metastatic hormone-sensitive prostate cancer </span><span style='font-size:
11.0pt'>(STAMPEDE)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:maroon'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:11.0pt;
  color:black'>Endpoint</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span><span
  style='font-size:11.0pt;color:black'>+</span><span style='font-size:11.0pt;
  color:black'> standard of care</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Standard of care </span><span
  style='font-size:11.0pt;color:black'>alone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:54.3pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of metastatic prostate cancer
  patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months) </span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>362</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>51-73</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>724</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>43</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>40-48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>(0.62&#8209;0.92)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.005</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Failure-Free survival<i><span style='position:relative;
  top:-3.0pt'>b</span></i>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.8-25.2</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>9.6-12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.57&#8209;0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&lt; 0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.3pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>a </span></sup></i><span
  style='font-size:11.0pt;color:black'>p-value calculated from the likelihood
  ratio test and adjusted for all stratification factors (except center and
  planned hormone therapy) and stratified by trial period</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>b</span></sup></i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>
  Failure-free survival: time from randomization to first evidence of at least
  one of: biochemical failure (defined as a rise in PSA of 50% above the
  within-24-week nadir and above 4 ng/mL and confirmed by retest or treatment);
  progression either locally, in lymph nodes, or in distant metastases;
  skeletal-related event; or death from prostate cancer.</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:115%'><u><span style='font-size:11.0pt;
line-height:115%'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>CHAARTED </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered at the beginning of androgen-deprivation therapy (ADT) in
patients with metastatic hormone-sensitive prostate cancer were evaluated in a randomised
Phase III study (CHAARTED). A total of 790 male patients were allocated to the
2 treatment groups. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT + docetaxel
75 mg/m&sup2; given at the beginning of ADT, administered every 3 weeks for 6
cycles</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT alone<sup> </sup>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'><br>
The median overall survival was significantly longer in docetaxel treatment
group than in the ADT alone group, with a median overall survival 13.6
months&nbsp; longer with the addition of docetaxel to ADT (hazard ratio (HR) =
0.61, 95% </span><span lang=EN-GB style='font-size:11.0pt'>confidence interval
(CI)&nbsp;= 0.47-0.80, </span><span style='font-size:11.0pt'>p=0.0003). <br>
<br>
Efficacy results or the </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> arm versus the control arm are summarized in the
following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Efficacy
of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> and ADT in the treatment of patients with metastatic
hormone-sensitive prostate cancer (CHAARTED)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>Endpoint</span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=178 valign=top style='width:133.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span></b><b><span
   style='font-size:11.0pt;color:black'>+ADT </span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=112 valign=top style='width:83.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>ADT alone</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months)</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>All patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><i><span
  lang=IT style='font-size:11.0pt;color:black'>95% CI</span></i></b><span
  style='color:black'>Adjusted </span><span style='font-size:11.0pt;color:black'>hazard
  ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>397</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>57.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>49.1-72.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>393</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>44.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>34.4-49.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.47&#8209;0.80)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.0003</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Progression Free Survival</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value*</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.7-22.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.60</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.51-0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>P&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.6</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>10.8-14.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 6 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>127 (32.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>77 (19.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 12 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>110 (27.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>66 (16.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to castration-resistant prostate cancer<i><span
  style='position:relative;top:-3.0pt'>b</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months) </span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.2&#8209;23.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(10.8-14.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.51&#8209;0.72)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to clinical progression</span><i><span style='font-size:
  11.0pt;color:black;position:relative;top:-3.0pt'>c</span></i><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)<i><span style='position:relative;top:-3.0pt'> </span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>33.0</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(27.3-41.2)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.9-22.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.50-0.75)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.3pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>a</span></i><span style='font-size:11.0pt;color:black'>&nbsp;</span><span
  style='font-size:11.0pt;color:black'>Time to event variables: Stratified
  log-rank test. <br>
  &nbsp; Response rate variables: Fisher's Exact test</span><i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> </span></i></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>* p-value for
  descriptive purpose.</span></p>
  <p class=MsoCommentText><span style='font-size:11.0pt;color:black'>** </span><span
  lang=EN-GB style='color:black'>PSA r</span><span style='font-size:11.0pt;
  color:black'>esponse</span><span lang=EN-GB style='font-size:11.0pt;
  color:black'>: Prostate-Specific Antigen response: </span><span
  style='font-size:11.0pt;color:black'>PSA level &lt;0.2 ng/mL measured for two
  consecutive measurements at least 4 weeks apart.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>b </span></i><span style='font-size:11.0pt;color:black'>Time
  to castration-resistant prostate cancer = time from randomization to PSA
  progression </span><span lang=EN-GB style='color:black'>or clinical
  progression (i.e., increasing symptomatic bone metastases, progression per </span><span
  style='font-size:11.0pt;color:black'>Response Evaluation Criteria in Solid
  Tumours (</span><span lang=EN-GB style='color:black'>RECIST) criteria, or
  clinical deterioration due to cancer per the Investigator&#8217;s opinion),
  whichever occurred first.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>c</span></i><span style='font-size:11.0pt;color:black'>&nbsp;The
  time to clinical progression = the time from randomization until clinical
  progression (i.e., increased symptoms of bone metastases; progression
  according to RECIST; or clinical deterioration due to cancer according to the
  investigator&#8217;s opinion).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Gastric adenocarcinoma</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>A multi-centre,
open-label, randomised study was conducted to evaluate the safety and efficacy
of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma,
including adenocarcinoma of the gastroesophageal junction, who had not received
prior chemotherapy for metastatic disease. A total of 445&nbsp;patients with
KPS&nbsp;&gt;&nbsp;70 were treated with either docetaxel&nbsp;(T) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) in combination with cisplatin&nbsp;(C) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) and 5&#8209;fluorouracil&nbsp;(F) (750&nbsp;mg/m<sup>2</sup> per
day for 5&nbsp;days) or cisplatin (100&nbsp;mg/m<sup>2</sup> on day&nbsp;1) and
5&#8209;fluorouracil (1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days). The
length of a treatment cycle was 3&nbsp;weeks for the TCF arm and 4&nbsp;weeks
for the CF arm. The median number of cycles administered per patient was 6
(with a range of 1&#8209;16) for the TCF arm compared to 4 (with a range of 1&#8209;12)
for the CF arm. Time to progression (TTP) was the primary endpoint. The risk
reduction of progression was 32.1% and was associated with a significantly
longer TTP (p&nbsp;=&nbsp;0.0004) in favour of the TCF arm. Overall survival
was also significantly longer (p&nbsp;=&nbsp;0.0201) in favour of the TCF arm
with a risk reduction of mortality of 22.7%. Efficacy results are summarized in
the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Efficacy of docetaxel in the treatment of
patients with gastric adenocarcinoma </span></u></p>

<p align=center style='margin:0in;text-align:center;page-break-after:avoid'><b><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=477
 style='width:357.55pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>TCF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;221</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;224</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median TTP (months)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>5.6</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>3.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(4.86-5.91)</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(3.45-4.47)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>1.473</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.189-1.825)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.2</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(8.38-10.58)</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(7.16-9.46)</span></p>
  </td>
 </tr>
 <tr>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>2-year estimate (%)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18.4</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.293</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.041-1.606)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0201</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (CR+PR) (%)</span></p>
  </td>
  <td width=103 valign=top style='width:77.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36.7</span></p>
  </td>
  <td width=110 valign=top style='width:82.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>p-value</span></p>
  </td>
  <td width=214 colspan=2 valign=top style='width:160.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0106</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=263 valign=top style='width:197.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progressive disease as best overall Response (%)</span></p>
  </td>
  <td width=103 style='width:77.55pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.7</span></p>
  </td>
  <td width=110 style='width:82.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.9</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>*Unstratified
logrank test</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext;layout-grid-mode:both'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext;
layout-grid-mode:both'>Subgroup analyses across age, gender and race
consistently favoured the TCF arm compared to the CF arm.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>A survival update
analysis conducted with a median follow-up time of 41.6&nbsp;months no longer
showed a statistically significant difference although always in favour of the
TCF regimen and showed that the benefit of TCF over CF is clearly observed
between 18 and 30&nbsp;months of follow up.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Overall, quality
of life (QoL) and clinical benefit results consistently indicated improvement
in favour of the TCF arm. Patients treated with TCF had a longer time to 5%
definitive<b> </b>deterioration of global health status on the QLQ&#8209;C30
questionnaire (p&nbsp;=&nbsp;0.0121) and a longer time to definitive worsening<b>
</b>of Karnofsky performance status (p&nbsp;=&nbsp;0.0088) compared to patients
treated with CF.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>Head and neck cancer</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction</span><span lang=EN-GB
style='font-size:11.0pt'> chemotherapy followed by radiotherapy (TAX323)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of docetaxel in the induction treatment of patients with squamous cell
carcinoma of the head and neck (SCCHN) was evaluated in a phase&nbsp;III,
multicenter, open-label, randomised study (TAX323). In this study,
358&nbsp;patients with inoperable locally advanced SCCHN, and WHO performance
status&nbsp;0 or 1, were randomised to one of two treatment arms.&nbsp;
Patients on the docetaxel arm received docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2</sup>
followed by cisplatin&nbsp;(P) 75&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
750&nbsp;mg/m<sup>2</sup> per day as a continuous infusion for 5&nbsp;days.
This regimen was administered every three weeks for 4&nbsp;cycles in case at
least a minor response (&#8805;&nbsp;25% reduction in bidimensionally measured
tumour size) was observed after 2&nbsp;cycles. At the end of chemotherapy, with
a minimal interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks,
patients whose disease did not progress received radiotherapy (RT) according to
institutional guidelines for 7&nbsp;weeks (TPF/RT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days. This regimen was
administered every three weeks for 4&nbsp;cycles in case at least a minor
response (&#8805;&nbsp;25% reduction in bidimensionally measured tumour size)
was observed after 2&nbsp;cycles. At the end of chemotherapy, with a minimal
interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks, patients whose
disease did not progress received radiotherapy&nbsp;(RT) according to
institutional guidelines for 7&nbsp;weeks (PF/RT). Locoregional therapy with
radiation was delivered either with a conventional fraction (1.8&nbsp;Gy&nbsp;&#8209;&nbsp;2.0&nbsp;Gy
once a day, 5&nbsp;days per week for a total dose of 66 to 70&nbsp;Gy), or accelerated/hyperfractionated
regimens of radiation therapy (twice a day, with a minimum interfraction
interval of 6&nbsp;hours, 5&nbsp;days per week). A total of 70&nbsp;Gy was
recommended for accelerated regimens and 74&nbsp;Gy for hyperfractionated schemes.
Surgical resection was allowed following chemotherapy, before or after
radiotherapy. Patients on the TPF arm received antibiotic prophylaxis with
ciprofloxacin 500&nbsp;mg orally twice daily for 10&nbsp;days starting on
day&nbsp;5 of each cycle, or equivalent. The primary endpoint in this study,
progression-free survival (PFS), was significantly longer in the TPF arm
compared to the PF arm, p&nbsp;=&nbsp;0.0042 (median PFS: 11.4 vs.
8.3&nbsp;months respectively) with an overall median follow up time of
33.7&nbsp;months. Median overall survival was also significantly longer in favour
of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5&nbsp;months
respectively) with a 28% risk reduction of mortality, p&nbsp;=&nbsp;0.0128.
Efficacy results are presented in the table below:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in the induction treatment of
patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 style='margin-top:0in'><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
  text-transform:none'>Endpoint</span></h1>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;177</span></b></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;181</span></b></p>
  </td>
 </tr>
 <tr style='height:22.0pt'>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median progression free survival (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>11.4</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>(10.1-14.0)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>8.3</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt'>(7.4-9.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.70</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.55-0.89)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0042</span></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>18.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(15.7-24.0)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>14.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(11.6-18.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.56-0.93)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0128</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Best overall response to chemotherapy (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>67.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(60.4-74.6)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>53.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(46.0-61.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Best overall response to study treatment
  [chemotherapy +/- radiotherapy] (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>72.3</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.1-78.8)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(51.0-65.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=304 valign=top style='width:227.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median duration of response to chemotherapy&nbsp;</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&plusmn;</span><span
  lang=EN-GB style='font-size:11.0pt'> radiotherapy (months)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;128</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>15.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>(13.4-24.6)</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt'>n&nbsp;=&nbsp;106</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(10.2-17.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value</span></p>
  </td>
  <td width=232 colspan=2 valign=top style='width:173.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.52-0.99)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0457</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>A hazard ratio of less than&nbsp;1 favours
docetaxel&nbsp;+ cisplatin&nbsp;+ 5&#8209;FU</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>*Cox model (adjustment for Primary tumour site, T and
N clinical stages and PSWHO)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>**Logrank test</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>*** Chi-square
test</span></p>

<p class=MsoNormal style='margin-left:.5in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Quality
of life parameters</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Patients treated with TPF experienced significantly
less deterioration of their Global health score compared to those treated with
PF (p&nbsp;=&nbsp;0.01, using the EORTC QLQ&#8209;C30 scale). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span style='font-family:"Times New Roman",serif'>Clinical
benefit parameters</span></i></p>

<p class=Authors style='margin-top:0in;line-height:12.0pt;page-break-after:
auto;text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
performance status scale, for head and neck (PSS&#8209;HN) subscales designed
to measure understandability of speech, ability to eat in public, and normalcy
of diet, was significantly in favour of TPF as compared to PF.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Median time to
first deterioration of WHO performance status was significantly longer in the
TPF arm compared to PF.</span><span lang=EN-GB style='font-size:11.0pt;
layout-grid-mode:line'> Pain intensity score improved during treatment in both
groups indicating adequate pain management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:
line'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Induction
</span><span lang=EN-GB style='font-size:11.0pt'>chemotherapy</span><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'> followed by
chemoradiotherapy (TAX324)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The safety and efficacy of docetaxel in the induction
treatment of patients with locally advanced squamous cell carcinoma of the head
and neck (SCCHN) was evaluated in a randomised, multi-centre open-label,
phase&nbsp;III study (TAX324). In this study, 501&nbsp;patients, with locally
advanced SCCHN, and a WHO performance status of 0 or 1, were randomised to one
of two arms. The study population comprised patients with technically
unresectable disease, patients with low probability of surgical cure and
patients aiming at organ preservation. The efficacy and safety evaluation
solely addressed survival endpoints and the success of organ preservation was
not formally addressed. Patients on the docetaxel arm received
docetaxel&nbsp;(T) 75&nbsp;mg/m&sup2; by intravenous infusion on day 1 followed
by cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; administered as a 30&#8209;minute to
three&#8209;hour intravenous infusion, followed by the continuous intravenous
infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day from
day&nbsp;1 to day&nbsp;4. The cycles were repeated every 3 weeks for 3 cycles.
All patients who did not have progressive disease were to receive
chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; as a 30&#8209;minute to
three&#8209;hour intravenous infusion on day&nbsp;1 followed by the continuous
intravenous infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day
from day&nbsp;1 to day&nbsp;5. The cycles were repeated every 3&nbsp;weeks for
3&nbsp;cycles. All patients who did not have progressive disease were to
receive CRT as per protocol (PF/CRT).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Patients in both
treatment arms were to receive 7&nbsp;weeks of CRT following induction
chemotherapy with a minimum interval of 3&nbsp;weeks and no later than
8&nbsp;weeks after start of the last cycle (day&nbsp;22 to day&nbsp;56 of last
cycle). During radiotherapy, carboplatin (AUC&nbsp;1.5) was given weekly as a
one&#8209;hour intravenous infusion for a maximum of 7&nbsp;doses. Radiation
was delivered with megavoltage equipment using once daily fractionation
(2&nbsp;Gy per day, 5&nbsp;days per week for 7&nbsp;weeks, for a total dose of
70&#8209;72&nbsp;Gy). Surgery on the primary site of disease and/or neck could
be considered at any time following completion of CRT. </span><span lang=EN-GB
style='font-size:11.0pt'>All patients on the docetaxel-containing arm of the
study received prophylactic antibiotics. </span><span lang=EN-GB
style='font-size:11.0pt'>The primary efficacy endpoint in this study, overall
survival (OS) was significantly longer (log-rank test, p&nbsp;=&nbsp;0.0058)
with the docetaxel&#8209;containing regimen compared to PF (median OS: 70.6
versus 30.1&nbsp;months respectively), with a 30% risk reduction in mortality
compared to PF (hazard ratio (HR)&nbsp;=&nbsp;0.70, 95% confidence interval
(CI)&nbsp;=&nbsp;0.54&#8209;0.90) with an overall median follow up time of
41.9&nbsp;months. The secondary endpoint, PFS, demonstrated a 29% risk
reduction of progression or death and a 22&nbsp;month improvement in median PFS
(35.5&nbsp;months for TPF and 13.1 for PF). This was also statistically significant
with an HR of 0.71; 95% CI 0.56-0.90; log-rank test p&nbsp;=&nbsp;0.004.
Efficacy results are presented in the table below:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in the induction treatment of
patients with locally advanced SCCHN (Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=162 colspan=2 valign=bottom style='width:121.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+
  Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  255</span></b></p>
  </td>
  <td width=153 valign=bottom style='width:114.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+
  5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  246</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median overall survival (months) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=162 colspan=2 valign=top style='width:121.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>70.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(49.0-NA)</span></p>
  </td>
  <td width=153 valign=top style='width:114.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>30.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(20.9-51.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 style='width:187.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value </span></p>
  </td>
  <td width=316 colspan=3 valign=top style='width:236.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.70</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.54-0.90)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0058</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 style='width:187.4pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median PFS (months) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=162 colspan=2 valign=top style='width:121.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>35.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(19.3-NA)</span></p>
  </td>
  <td width=153 valign=top style='width:114.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>13.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(10.6 - 20.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Hazard ratio:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>**p-value </span></p>
  </td>
  <td width=316 colspan=3 valign=bottom style='width:236.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.71</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(0.56 - 0.90)</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Best overall response (CR + PR) to
  chemotherapy (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95% CI)</span></p>
  </td>
  <td width=158 valign=top style='width:118.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>71.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.8-77.2)</span></p>
  </td>
  <td width=158 colspan=2 valign=top style='width:118.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>64.2</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(57.9-70.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=316 colspan=3 style='width:236.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.070</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Best overall response (CR + PR) to study
  treatment [chemotherapy +/- chemoradiotherapy] (%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%CI)</span></p>
  </td>
  <td width=158 valign=top style='width:118.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>76.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(70.8-81.5)</span></p>
  </td>
  <td width=158 colspan=2 valign=top style='width:118.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>71.5</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(65.5-77.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=250 valign=top style='width:187.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>***p-value</span></p>
  </td>
  <td width=316 colspan=3 style='width:236.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>0.209</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=250 style='border:none'></td>
  <td width=158 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=153 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:2.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>A hazard ratio of less than 1 favours
docetaxel&nbsp;+ cisplatin&nbsp;+ fluorouracil</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>*un-adjusted log-rank test</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>**un-adjusted log-rank test, not adjusted for multiple
comparisons</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>***Chi square test, not adjusted for multiple
comparisons</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>NA-not applicable</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></p>

<p class=MsoNormal style='margin-left:26.3pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The European
Medicines Agency has waived the obligation to submit the results of studies
with TAXOTERE in all subsets of the paediatric population in breast cancer,
non-small cell lung cancer, prostate cancer, gastric carcinoma and head and
neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel have been evaluated in cancer patients after
administration of 20&#8209;115&nbsp;mg/m<sup>2</sup> in phase&nbsp;I studies.
The kinetic profile of docetaxel is dose independent and consistent with a
three-compartment pharmacokinetic model with half-lives for the </span><span lang=EN-GB style='font-size:11.0pt'>a</span><span lang=EN-GB style='font-size:
11.0pt'>, </span><span
lang=EN-GB style='font-size:11.0pt'>b</span><span lang=EN-GB style='font-size:
11.0pt'> and </span><span
lang=EN-GB style='font-size:11.0pt'>g</span><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;phases of 4&nbsp;min, 36&nbsp;min and 11.1&nbsp;h, respectively.
The late phase is due, in part, to a relatively slow efflux of docetaxel from
the peripheral compartment. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Following the
administration of a 100&nbsp;mg/m<sup>2</sup> dose given as a one&#8209;hour
infusion a mean peak plasma level of 3.7&nbsp;&micro;g/ml was obtained with a
corresponding AUC of 4.6&nbsp;h.&micro;g/ml. Mean values for total body
clearance and steady-state volume of distribution were 21&nbsp;l/h/m<sup>2</sup>
and 113&nbsp;l, respectively. Inter individual variation in total body
clearance was approximately 50%. Docetaxel is more than 95% bound to plasma
proteins.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>A study of <sup>14</sup>C&#8209;docetaxel
has been conducted in three cancer patients. Docetaxel was eliminated in both
the urine and faeces following cytochrome P450&#8209;mediated oxidative
metabolism of the tert&#8209;butyl ester group, within seven days, the urinary
and faecal excretion accounted for about 6% and 75% of the administered
radioactivity, respectively. About 80% of the radioactivity recovered in faeces
is excreted during the first 48&nbsp;hours as one major inactive metabolite and
3&nbsp;minor inactive metabolites and very low amounts of unchanged medicinal
product.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Special populations</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Age and gender</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>A population pharmacokinetic analysis has been
performed with docetaxel in 577&nbsp;patients. Pharmacokinetic parameters
estimated by the model were very close to those estimated from phase&nbsp;I
studies. The pharmacokinetics of docetaxel were not altered by the age or sex
of the patient. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>In a small number of patients (n&nbsp;=&nbsp;23) with
clinical chemistry data suggestive of mild to moderate liver function
impairment (ALT, AST&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&sup3;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;1.5&nbsp;times the
ULN associated with alkaline phosphatase </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&sup3;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;2.5&nbsp;times the
ULN), total clearance was lowered by 27% on average (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Fluid retention</span></i></p>

<p class=MsoBodyText2 style='margin-top:0in'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>Docetaxel clearance was not modified in patients with
mild to moderate fluid retention and there are no data available in patients
with severe fluid retention.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Combination therapy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Doxorubicin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>When used in
combination, docetaxel does not influence the clearance of doxorubicin and the
plasma levels of doxorubicinol (a doxorubicin metabolite). The pharmacokinetics
of docetaxel, doxorubicin and cyclophosphamide were not influenced by their
coadministration.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Capecitabine</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phase&nbsp;I study
evaluating the effect of capecitabine on the pharmacokinetics of docetaxel and
vice versa showed no effect by capecitabine on the pharmacokinetics of
docetaxel (C<sub>max</sub> and AUC) and no effect by docetaxel on the
pharmacokinetics of a relevant capecitabine metabolite 5&#8217;&#8209;DFUR.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cisplatin</span></i><span lang=EN-GB
style='font-size:11.0pt'>Clearance of docetaxel in combination therapy with
cisplatin was similar to that observed following monotherapy. <span
style='layout-grid-mode:line'>The pharmacokinetic profile of cisplatin
administered shortly after docetaxel infusion is similar to that observed with
cisplatin alone.</span></span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Cisplatin
and 5-fluorouracil</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The combined administration of docetaxel, cisplatin
and 5&#8209;fluorouracil in 12&nbsp;patients with solid tumours had no
influence on the pharmacokinetics of each individual medicinal product.</span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone
and dexamethasone</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The effect of
prednisone on the pharmacokinetics of docetaxel administered with standard
dexamethasone premedication has been studied in 42&nbsp;patients. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Prednisone</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No effect of
prednisone on the pharmacokinetics of docetaxel was observed.</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>5.3&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The carcinogenic
potential of docetaxel has not been studied.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel has been
shown to be mutagenic in the <i>in vitro</i> micronucleus and chromosome
aberration test in CHO&#8209;K1 cells and in the <i>in vivo</i> micronucleus
test in the mouse. However, it did not induce mutagenicity in the Ames test or
the CHO/HGPRT gene mutation assay. These results are consistent with the
pharmacological activity of docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Undesirable
effects on the testis observed in rodent toxicity studies suggest that
docetaxel may impair male fertility.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoBodyText align=left style='text-align:left;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid;punctuation-wrap:
hanging;text-autospace:ideograph-numeric ideograph-other'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Concentrate vial: </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Polysorbate&nbsp;80</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Citric acid.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Solvent vial: </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Ethanol&nbsp;95% </span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>Water for injections.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>This medicinal
product must not be mixed with other medicinal products except those mentioned
in section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf-life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3&nbsp;years.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Premix solution: The
premix solution contains 10&nbsp;mg/ml docetaxel and should be used immediately
after preparation. However the chemical and physical stability of the premix
solution has been demonstrated for 8&nbsp;hours when stored either between
2&deg;C and 8&deg;C or at room temperature (below 25&deg;C).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Infusion solution: the
infusion solution should be used within 4&nbsp;hours at room temperature (below
25&deg;C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Do not store above
25&deg;C or below 2&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For storage
conditions of the diluted medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt;font-style:normal'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each blister pack
contains:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
concentrate and,</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
solvent.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>TAXOTERE 80 mg/2&nbsp;ml concentrate for
solution for infusion vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>15&nbsp;ml clear
glass Type&nbsp;I vial with a red flip&#8209;off cap.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>This vial contains
2&nbsp;ml of a 40&nbsp;mg/ml solution of docetaxel in polysorbate&nbsp;80 (fill
volume: 94.4&nbsp;mg/2.36&nbsp;ml). This fill volume has been established
during the development of TAXOTERE to compensate for liquid loss during
preparation of the premix due to foaming, adhesion to the walls of the vial and
&quot;dead-volume&quot;. This overfill ensures that after dilution with the
entire contents of the accompanying solvent for TAXOTERE vial, there is a minimal
extractable premix volume of 8&nbsp;ml containing 10&nbsp;mg/ml docetaxel which
corresponds to the labelled amount of 80 mg/2&nbsp;ml per vial.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Solvent vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>15&nbsp;ml clear
glass Type&nbsp;I vial with a transparent colourless flip&#8209;off cap.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Solvent vial
contains 6&nbsp;ml of a 13% w/w solution of ethanol 95% in water for injections
(fill volume: 7.33&nbsp;ml). The addition of the entire contents of the solvent
vial to the contents of the TAXOTERE 80&nbsp;mg/2&nbsp;ml concentrate for
solution for infusion vial ensures a premix concentration of 10&nbsp;mg/ml docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='page-break-after:avoid;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE is an
antineoplastic agent and, as with other potentially toxic compounds, caution
should be exercised when handling it and preparing TAXOTERE solutions. The use
of gloves is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
skin, wash immediately and thoroughly with soap and water. If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
mucous membranes, wash immediately and thoroughly with water.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><u><span
lang=EN-GB style='font-weight:normal'>Preparation for the intravenous
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preparation
of the TAXOTERE premix solution (10&nbsp;mg docetaxel/ml)</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If the vials are
stored under refrigeration, allow the required number of TAXOTERE boxes to
stand at room temperature (below 25&deg;C) for 5&nbsp;minutes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Using a syringe
fitted with a needle, aseptically withdraw the entire contents of the solvent
for TAXOTERE vial by partially inverting the vial. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the entire
contents of the syringe into the corresponding TAXOTERE vial.</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:-35.4pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Remove the syringe
and needle and mix manually by repeated inversions for at least
45&nbsp;seconds. Do not shake.</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:-35.4pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyTextIndent3 align=left style='margin:0in;margin-bottom:.0001pt;
text-align:left'><span style='font-size:11.0pt'>Allow the premix vial to stand
for 5&nbsp;minutes at room temperature (below 25&deg;C) and then check that the
solution is homogenous and clear (foaming is normal even after 5&nbsp;minutes
due to the presence of polysorbate&nbsp;80 in the formulation). </span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The premix solution contains
10&nbsp;mg/ml docetaxel and should be used immediately after preparation.
However the chemical and physical stability of the premix solution has been
demonstrated for 8&nbsp;hours when stored either between 2&deg;C and 8&deg;C or
at room temperature (below 25&deg;C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><u><span
lang=EN-GB style='font-weight:normal'>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preparation
of the infusion solution</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>More than one
premix vial may be necessary to obtain the required dose for the patient. Based
on the required dose for the patient expressed in mg, aseptically withdraw the
corresponding premix volume containing 10&nbsp;mg/ml docetaxel from the
appropriate number of premix vials using graduated syringes fitted with a
needle. For example, a dose of 140&nbsp;mg docetaxel would require 14&nbsp;ml
docetaxel premix solution.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
required premix volume into a 250&nbsp;ml infusion bag or bottle containing
either 5% glucose solution or sodium chloride </span><span lang=EN-GB
style='font-size:11.0pt'>9&nbsp;mg/ml (0.9%) </span><span lang=EN-GB
style='font-size:11.0pt'>solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If a dose greater
than 200&nbsp;mg of docetaxel is required, use a larger volume of the infusion
vehicle so that a concentration of 0.74&nbsp;mg/ml docetaxel is not exceeded.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>Mix the infusion bag or bottle manually using a rocking motion.</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE
infusion solution should be used within 4&nbsp;hours and should be aseptically
administered as a 1&#8209;hour infusion under room temperature (below 25&deg;C)
and normal lighting conditions.</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>As with all parenteral products, TAXOTERE premix solution and infusion
solution should be visually inspected prior to use, solutions containing a
precipitate should be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 style='margin-top:0in'><span style='font-size:11.0pt;
font-weight:normal'>&nbsp;</span></p>

<p class=MsoBodyText3 align=left style='margin-top:0in;text-align:left;
page-break-after:avoid;punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
style='font-size:11.0pt;font-style:normal'>7.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54 rue
La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/002</span></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: </span><span lang=EN-GB
style='font-size:11.0pt'>27 November 1995</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of latest renewal: 27 November 2005</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <u>http://www.ema.europa.eu.</u> </span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 20&nbsp;mg/1&nbsp;ml concentrate
for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Each ml of concentrate contains 20&nbsp;mg
docetaxel (as trihydrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One&nbsp;vial of 1&nbsp;ml of concentrate
contains 20&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Excipient with known effect:</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Each vial of concentrate contains
0.5&nbsp;ml of ethanol anhydrous (395&nbsp;mg). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is a pale yellow to
brownish&#8209;yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Breast cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin and cyclophosphamide is indicated for the adjuvant
treatment of patients with:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;positive
breast cancer</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;negative
breast cancer .</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients with
operable node</span><span lang=EN-GB style='font-size:11.0pt'>&#8209;negative
breast cancer, adjuvant treatment should be restricted to patients eligible to
receive chemotherapy according to internationally established criteria for
primary therapy of early breast cancer (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in combination
with doxorubicin is indicated for the treatment of patients with locally
advanced or metastatic breast cancer who have not previously received cytotoxic
therapy for this condition.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE monotherapy
is indicated for the treatment of patients with locally advanced or metastatic
breast cancer after failure of cytotoxic therapy. Previous chemotherapy should
have included an anthracycline or an alkylating agent.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with trastuzumab is indicated for the treatment of patients with
metastatic breast cancer whose tumours over express HER2 and who previously
have not received chemotherapy for metastatic disease.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>TAXOTERE in combination with capecitabine is indicated for the treatment
of patients with locally advanced or metastatic breast cancer after failure of
cytotoxic chemotherapy. Previous therapy should have included an anthracycline.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>TAXOTERE is
indicated for the treatment of patients with locally advanced or metastatic
non-small cell lung cancer after failure of prior chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with cisplatin is indicated for the treatment of patients with
unresectable, locally advanced or metastatic non-small cell lung cancer, in patients
who have not previously received chemotherapy for this condition.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Prostate
cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE in combination with prednisone or
prednisolone is indicated for the treatment of patients with&nbsp; metastatic</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt'>castration-resistant</span><span
lang=EN-GB style='font-size:11.0pt'> prostate cancer.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE in combination with androgen-deprivation
therapy (ADT), with or without prednisone or prednisolone, is indicated for the
treatment of patients with metastatic hormone-sensitive prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the treatment of patients with metastatic
gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal
junction, who have not received prior chemotherapy for metastatic disease.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Head and neck cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the induction treatment of patients with
locally advanced squamous cell carcinoma of the head and neck.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The use of docetaxel should be confined to
units specialised in the administration of cytotoxic chemotherapy and it should
only be administered under the supervision of a physician qualified in the use
of anticancer chemotherapy (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Posology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast, non-small cell lung, gastric,
and head and neck cancers, premedication consisting of an oral corticosteroid,
such as dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for
3&nbsp;days starting 1&nbsp;day prior to docetaxel administration, unless
contraindicated, can be used (see section 4.4).<br>
For metastatic castration-resistant prostate cancer, given the concurrent use
of prednisone or prednisolone the recommended premedication regimen is oral
dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour before the
docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>For metastatic hormone-sensitive prostate
cancer, irrespective of the concurrent use of prednisone or prednisolone, the
recommended premedication regimen is oral dexamethasone 8&nbsp;mg 12 hours, 3
hours, and 1 hour before docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Prophylactic G&#8209;CSF may be used to
mitigate the risk of haematological toxicities.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is administered as a one-hour
infusion every three weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>In the adjuvant treatment of operable
node-positive and node&#8209;negative breast cancer, the recommended dose of
docetaxel is 75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour after doxorubicin
50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> every
3&nbsp;weeks for 6&nbsp;cycles (TAC regimen) (see also Dose adjustments during
treatment). </span></p>

<p class=Normal11pt><span lang=EN-GB>For the treatment of patients with locally
advanced or metastatic breast cancer, the recommended dose of docetaxel is
100&nbsp;mg/m<sup>2</sup> in monotherapy. In first-line treatment, docetaxel
75&nbsp;mg/m<sup>2 </sup>is given in combination therapy with doxorubicin<sup> </sup>(50&nbsp;mg/m<sup>2</sup>).
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with trastuzumab the
recommended dose of docetaxel is 100&nbsp;mg/m<sup>2</sup> every three weeks,
with trastuzumab administered weekly. In the pivotal study the initial
docetaxel infusion was started the day following the first dose of trastuzumab.
The subsequent docetaxel doses were administered immediately after completion
of the trastuzumab infusion, if the preceding dose of trastuzumab was well
tolerated. For trastuzumab dose and administration, see trastuzumab summary of
product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> every three weeks,
combined with capecitabine at 1250&nbsp;mg/m<sup>2</sup> twice daily (within
30&nbsp;minutes after a meal) for 2&nbsp;weeks followed by a 1&#8209;week rest
period. For capecitabine dose calculation according to body surface area, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>In chemotherapy
na&iuml;ve patients treated for non-small cell lung cancer, the recommended
dose regimen is docetaxel 75&nbsp;mg/m<sup>2 </sup>immediately followed by
cisplatin 75&nbsp;mg/m<sup>2 </sup>over 30-60&nbsp;minutes. For treatment after
failure of prior platinum-based chemotherapy, the recommended dose is
75&nbsp;mg/m&sup2; as a single agent.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer</span></u></i></p>

<p class=Normal11pt><i><span style='color:black'>Metastatic
castration-resistant prostate cancer</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup>. Prednisone or prednisolone 5&nbsp;mg orally twice
daily is administered continuously (see section 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic hormone-sensitive
prostate cancer</span></i></p>

<p class=Normal11pt><span style='color:black'>The recommended dose of </span><span
lang=EN-GB>docetaxel </span><span style='color:black'>is 75&nbsp;mg/m<sup>2</sup>
every 3 weeks for 6 cycles. Prednisone or prednisolone 5&nbsp;mg orally twice
daily may be administered continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>
as a 1-hour infusion, followed by cisplatin 75&nbsp;mg/m<sup>2</sup>, as a 1-
to 3-hour infusion (both on day&nbsp;1 only), followed by 5&#8209;fluorouracil
750&nbsp;mg/m<sup>2</sup> per day given as a 24&#8209;hour continuous infusion
for 5&nbsp;days, starting at the end of the cisplatin infusion. Treatment is
repeated every three weeks. Patients must receive premedication with
antiemetics and appropriate hydration for cisplatin administration.
Prophylactic G&#8209;CSF should be used to mitigate the risk of haematological
toxicities (see also Dose adjustments during treatment).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients must receive premedication with
antiemetics and appropriate hydration (prior to and after cisplatin
administration). Prophylactic G&#8209;CSF may be used to mitigate the risk of haematological
toxicities. All patients on the docetaxel-containing arm of the TAX&nbsp;323
and TAX&nbsp;324 studies, received prophylactic antibiotics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by radiotherapy (TAX&nbsp;323)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of inoperable locally advanced squamous cell
carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion followed by cisplatin
75&nbsp;mg/m<sup>2</sup> over 1 hour, on day one, followed by 5&#8209;fluorouracil
as a continuous infusion at 750&nbsp;mg/m<sup>2</sup> per day for five days. This
regimen is administered every 3&nbsp;weeks for 4&nbsp;cycles. Following
chemotherapy, patients should receive radiotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by chemoradiotherapy (TAX&nbsp;324)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of patients with locally advanced (technically
unresectable, low probability of surgical cure, and aiming at organ
preservation) squamous cell carcinoma of the head and neck (SCCHN), the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1 hour
intravenous infusion on day&nbsp;1, followed by cisplatin 100&nbsp;mg/m<sup>2 </sup>administered
as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000&nbsp;mg/m<sup>2</sup>/day
as a continuous infusion from day&nbsp;1 to day&nbsp;4. This regimen is
administered every 3&nbsp;weeks for 3&nbsp;cycles. Following chemotherapy,
patients should receive chemoradiotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose modifications, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Dose adjustments during treatment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>General </span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel should be administered when the
neutrophil count is </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.
</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients who experienced either febrile
neutropenia, neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for more
than one week, severe or cumulative cutaneous reactions or severe peripheral
neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from
100&nbsp;mg/m<sup>2</sup> to 75&nbsp;mg/m<sup>2</sup> and/or from 75 to
60&nbsp;mg/m&sup2;. If the patient continues to experience these reactions at
60&nbsp;mg/m&sup2;, the treatment should be discontinued. </span></p>

<p class=Normal11pt><span class=BoldCharacter><span style='text-transform:uppercase'>&nbsp;</span></span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Adjuvant
therapy for breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Primary G&#8209;CSF
prophylaxis should be considered in patients who receive docetaxel, doxorubicin
and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who
experience febrile neutropenia and/or neutropenic infection should have their
docetaxel dose reduced to 60&nbsp;mg/m&sup2; in all subsequent cycles (see sections
4.4 and 4.8). Patients who experience Grade&nbsp;3 or 4 stomatitis should have
their dose decreased to 60&nbsp;mg/m&sup2;.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who are dosed initially at
docetaxel 75&nbsp;mg/m<sup>2</sup> in combination with cisplatin and whose
nadir of platelet count during the previous course of therapy is
&lt;&nbsp;25,000&nbsp;cells/mm<sup>3</sup>, or<sup> </sup>in patients who
experience febrile neutropenia, or in patients with serious non-haematologic
toxicities, the docetaxel dose in subsequent cycles should be reduced to
65&nbsp;mg/m<sup>2</sup>. For cisplatin dose adjustments, see the corresponding
summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with capecitabine</span></u></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For capecitabine dose modifications, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the first
appearance of Grade&nbsp;2 toxicity, which persists at the time of the next
docetaxel/capecitabine treatment, delay treatment until resolved to
Grade&nbsp;0&#8209;1, and resume at 100% of the original dose. </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the second appearance
of Grade&nbsp;2 toxicity, or the first appearance of Grade&nbsp;3 toxicity, at
any time during the treatment cycle, delay treatment until resolved to
Grade&nbsp;0&#8209;1 and then resume treatment with docetaxel 55&nbsp;mg/m&sup2;.
</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For any subsequent appearances of
toxicities, or any Grade&nbsp;4 toxicities, discontinue the docetaxel dose.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For trastuzumab dose modifications, see
trastuzumab summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If an episode of febrile neutropenia,
prolonged neutropenia or neutropenic infection occurs despite G&#8209;CSF use,
the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>. If
subsequent episodes of complicated neutropenia occur the docetaxel dose should
be reduced from 60 to 45&nbsp;mg/m<sup>2</sup>. In case of Grade&nbsp;4
thrombocytopenia the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>.
Patients should not be retreated with subsequent cycles of docetaxel until
neutrophils recover to a level &gt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup> and
platelets recover to a level &gt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>.
Discontinue treatment if these toxicities persist (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>Recommended dose modifications for
toxicities in patients treated with docetaxel in combination with cisplatin and
5&#8209;fluorouracil (5&#8209;FU):</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Toxicity</span></b></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Dose adjustment</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: then reduce docetaxel
  dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce docetaxel and 5&#8209;FU
  doses by 20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: stop 5&#8209;FU only, at
  all subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Third episode: reduce docetaxel dose by
  20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: stop 5&#8209;FU only, at
  all subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: reduce docetaxel dose by
  20%.</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose adjustments, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the pivotal SCCHN studies patients who
experienced complicated neutropenia (including prolonged neutropenia, febrile
neutropenia, or infection), it was recommended to use G&#8209;CSF to provide
prophylactic coverage (eg, day&nbsp;6&#8209;15) in all subsequent cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Patients
with hepatic impairment</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Based on
pharmacokinetic data with docetaxel at 100&nbsp;mg/m&sup2; as single agent,
patients who have both elevations of transaminase (ALT and/or AST) greater than
1.5&nbsp;times the upper limit of the normal range (ULN) and alkaline
phosphatase greater than 2.5&nbsp;times the ULN, the recommended dose of
docetaxel is 75&nbsp;mg/m<sup>2</sup> (see sections 4.4 and 5.2). For those
patients with serum bilirubin &gt;&nbsp;ULN and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times
the ULN associated with alkaline phosphatase &gt;&nbsp;6&nbsp;times the ULN, no
dose-reduction can be recommended and docetaxel should not be used unless
strictly indicated. </span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available
in patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of TAXOTERE in nasopharyngeal carcinoma in children aged 1 month to
less than 18 years have not yet been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There is no
relevant use of TAXOTERE in the paediatric population in the indications breast
cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head
and neck cancer, not including type II and III less differentiated
nasopharyngeal carcinoma. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Older people</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Based on a population pharmacokinetic
analysis, there are no special instructions for use in the older people.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, for
patients 60&nbsp;years of age or more, a starting dose reduction of
capecitabine to 75% is recommended (see capecitabine summary of product
characteristics).</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>For instructions on preparation and administration of
the product, see section</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;6.6.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity to the active substance
or to any of the excipients listed in section 6.1. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with baseline neutrophil count of
&lt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe liver impairment (see
sections 4.2 and 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Contraindications for other medicinal
products also apply, when combined with docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast and non-small cell lung
cancers, premedication consisting of an oral corticosteroid, such as dexamethasone
16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days starting
1&nbsp;day prior to docetaxel administration, unless contraindicated, can
reduce the incidence and severity of fluid retention as well as the severity of
hypersensitivity reactions. For prostate cancer, the premedication is oral
dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour before the
docetaxel infusion (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Haematology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Neutropenia is the most frequent adverse
reaction of docetaxel. Neutrophil nadirs occurred at a median of 7&nbsp;days but
this interval may be shorter in heavily pre&#8209;treated patients. Frequent
monitoring of complete blood counts should be conducted on all patients
receiving docetaxel. Patients should be retreated with docetaxel when
neutrophils recover to a level </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm3 (see
section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the case of severe neutropenia
(&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for seven days or more) during a
course of docetaxel therapy, a reduction in dose for subsequent courses of
therapy or the use of appropriate symptomatic measures are recommended (see
section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel in
combination with cisplatin and 5&#8209;fluorouracil (TCF), febrile neutropenia
and neutropenic infection occurred at lower rates when patients received
prophylactic G&#8209;CSF. Patients treated with TCF should receive prophylactic
G&#8209;CSF to mitigate the risk of complicated neutropenia (febrile
neutropenia, prolonged neutropenia or neutropenic infection). Patients receiving
TCF should be closely monitored (see sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with doxorubicin and cyclophosphamide
(TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates
when patients received primary G&#8209;CSF prophylaxis. Primary G&#8209;CSF
prophylaxis should be considered in patients who receive adjuvant therapy with
TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile </span><span
lang=EN-GB style='font-size:11.0pt'>neutropenia, prolonged neutropenia or
neutropenic infection). Patients receiving TAC should be closely monitored (see
sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Gastrointestinal reactions</span></u></p>

<p class=MsoNormal style='margin-left:15.85pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Caution is recommended for
patients with </span><span style='font-size:11.0pt'>neutropenia,</span><span
style='font-size:11.0pt'> particularly at risk for developing gastrointestinal
complications</span><span style='font-size:11.0pt'>. Although majority of cases
occurred during the first or second cycle of docetaxel containing regimen, e</span><span
lang=EN-GB style='font-size:11.0pt'>nterocolitis could develop at any time, and
could lead to death as early as on the first day of onset. Patients should be
closely monitored for early manifestations of serious gastrointestinal toxicity
(see sections 4.2, 4.4 Haematology, and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Hypersensitivity reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients should be observed closely for
hypersensitivity reactions especially during the first and second infusions.
Hypersensitivity reactions may occur within a few minutes following the
initiation of the infusion of docetaxel, thus facilities for the treatment of
hypotension and bronchospasm should be available. If hypersensitivity reactions
occur, minor symptoms such as flushing or localised cutaneous reactions do not
require interruption of therapy. However, severe reactions, such as severe
hypotension, bronchospasm or generalised rash/erythema require immediate
discontinuation of docetaxel and appropriate therapy. Patients who have
developed severe hypersensitivity reactions should not be re-challenged with docetaxel.
</span><span lang=EN-GB>Patients who have previously experienced a
hypersensitivity reaction to paclitaxel may be at risk to develop
hypersensitivity reaction to docetaxel, including more severe hypersensitivity
reaction. These patients should be closely monitored during initiation of
docetaxel therapy</span>.</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Cutaneous reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Localised skin erythema of the extremities
(palms of the hands and soles of the feet) with oedema followed by desquamation
has been observed. Severe symptoms such as eruptions followed by desquamation
which lead to interruption or discontinuation of docetaxel treatment were
reported (see section 4.2). </span></p>

<p class=00-Paragraph><span lang=EN-GB>Severe Cutaneous Adverse Reactions
(SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis</span><sup><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial Narrow",sans-serif'> </span></sup><span
lang=EN-GB>(TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have been
reported with docetaxel treatment. Patients should be informed about the signs
and symptoms of serious skin manifestations and closely monitored</span><strong><span
lang=EN-GB style='font-family:"Segoe UI",sans-serif;color:#444444;font-weight:
normal'>. </span></strong><span lang=EN-GB>If signs and symptoms suggestive of
these reactions appear discontinuation of docetaxel should be considered.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Fluid retention</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe fluid retention such
as pleural effusion, pericardial effusion and ascites should be monitored
closely.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Respiratory
disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung
disease, pulmonary fibrosis and respiratory failure have been reported and </span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>may be associated </span></span><span
lang=EN-GB style='font-size:11.0pt'>with fatal outcome. </span><span
class=BlueReplace><span lang=EN-GB style='color:windowtext'>Cases of radiation
pneumonitis have been reported in patients receiving concomitant radiotherapy.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If new or worsening
pulmonary symptoms develop, patients should be closely monitored, promptly
investigated, and appropriately treated. Interruption of docetaxel therapy is
recommended</span><span style='font-size:11.0pt'> until diagnosis is available</span><span
lang=EN-GB style='font-size:11.0pt'>. Early use of supportive care measures may
help improve the condition. The benefit of resuming docetaxel treatment must be
carefully evaluated.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Patients with liver impairment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel at
100&nbsp;mg/m<sup>2</sup> as single agent who have serum transaminase levels
(ALT and/or AST) greater than 1.5&nbsp;times the ULN concurrent with serum
alkaline phosphatase levels greater than 2.5&nbsp;times the ULN, there is a
higher risk of developing severe adverse reactions such as toxic deaths
including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia,
infections, thrombocytopenia, stomatitis and asthenia. Therefore, the
recommended dose of docetaxel in those patients with elevated liver function
test (LFTs) is 75&nbsp;mg/m<sup>2</sup> and LFTs should be measured at baseline
and before each cycle (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>For patients with serum bilirubin levels
&gt;&nbsp;ULN and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN
concurrent with serum alkaline phosphatase levels &gt;&nbsp;6&nbsp;times the
ULN, no dose-reduction can be recommended and docetaxel should not be used
unless strictly indicated.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available
in patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with renal impairment</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>There are
no data available in patients with severely impaired renal function treated
with docetaxel. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
development of severe peripheral neurotoxicity requires a reduction of dose
(see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
toxicity</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Heart failure
has been observed in patients receiving docetaxel in combination with
trastuzumab, particularly following anthracycline (doxorubicin or
epirubicin)-containing chemotherapy. This may be moderate to severe and has
been associated with death (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>When patients are candidates for treatment
with docetaxel in combination with trastuzumab, they should undergo baseline
cardiac assessment. Cardiac function should be further monitored during
treatment (e.g. every three months) to help identify patients who may develop
cardiac dysfunction. For more details see summary of product characteristics of
trastuzumab.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Ventricular arrhythmia
including ventricular tachycardia (sometimes fatal) has been reported in
patients treated with docetaxel in combination regimens including doxorubicin,
5-fluorouracil and/ or cyclophosphamide (see section 4.8)</span><span
lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Baseline cardiac
assessment is recommended</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Eye</span></u><u><span
lang=EN-GB style='font-size:11.0pt'> disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Cystoid macular oedema (CMO) has been
reported in patients treated with docetaxel. Patients with impaired vision should
undergo a prompt and complete ophthalmologic examination. In case CMO is
diagnosed, docetaxel treatment should be discontinued and appropriate treatment
initiated (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies have been reported when docetaxel was given in combination with
anticancer treatments known to be associated with second primary malignancies. Second
primary malignancies (including acute myeloid leukaemia, myelodysplastic
syndrome and non-Hodgkin lymphoma) may occur several months or years after
docetaxel-containing therapy. Patients should be monitored for second primary
malignancies (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Tumour Lysis
Syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tumour lysis
syndrome has been reported with docetaxel after the first or the second cycle (see
section 4.8). Patients at risk of tumour lysis syndrome (e.g. with renal
impairment, hyperuricemia, bulky tumour, rapid progression) should be closely
monitored. Correction of dehydration and treatment of high uric acid levels are
recommended prior to initiation of treatment.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Others</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Contraceptive measures must be
taken by both men and women during treatment and for men at least&nbsp;
6&nbsp;months after cessation of therapy (see section 4.6).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The concomitant use of docetaxel
with strong CYP3A4 inhibitors </span><span style='font-family:"Times New Roman",serif;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole)
should be avoided (see section 4.5).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Additional cautions for use in adjuvant
treatment of breast cancer</span></u></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Complicated neutropenia</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who experience complicated
neutropenia (prolonged neutropenia, febrile neutropenia or infection), G&#8209;CSF
and dose reduction should be considered (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Gastrointestinal
reactions</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Symptoms
such as early abdominal pain and tenderness, fever, diarrhoea, with or without
neutropenia, may be early manifestations of serious gastrointestinal toxicity and
should be evaluated and treated promptly.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Congestive
heart failure (CHF)</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Patients
should be monitored for symptoms of congestive heart failure during therapy and
during the follow up period. </span><span lang=EN-GB>In patients treated with
the TAC regimen for node positive breast cancer, the risk of CHF has been shown
to be higher during the first year after treatment (see sections 4.8 and 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Patients with 4+ nodes</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>As the benefit observed in patient with 4+
nodes was not statistically significant on disease&#8209;free survival (DFS)
and overall survival (OS), the positive benefit/risk ratio for TAC in patients
with 4+ nodes was not fully demonstrated at the final analysis (see section
5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Elderly</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in adjuvant
treatment of breast cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There are limited data available in
patients &gt;&nbsp;70&nbsp;years of age on docetaxel use in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in castration-resistant
prostate cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Of the 333&nbsp;patients treated with
docetaxel every three weeks in a prostate cancer study</span><span lang=EN-GB>(TAX
327)</span><span lang=EN-GB>, 209&nbsp;patients were 65&nbsp;years of age or
greater and 68&nbsp;patients were older than 75&nbsp;years. In patients treated
with docetaxel every three weeks, the incidence of related nail changes
occurred at a rate </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;10% higher in patients who were 65&nbsp;years of age or
greater compared to younger patients. The incidence of related fever,
diarrhoea, anorexia, and peripheral oedema occurred at rates </span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10%
higher in patients who were 75&nbsp;years of age or greater versus less than
65&nbsp;years.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Cautions for use in hormone-sensitive
prostate cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>Of the
</span><span style='font-size:11.0pt;color:black'>545 </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>patients treated with docetaxel every 3
weeks</span><span style='font-size:11.0pt;color:black'> in a hormone-sensitive
prostate cancer study (STAMPEDE)</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>, </span><span style='font-size:11.0pt;color:black'>296 patients
were 65 years of age or older, and 48 patients were 75 years of age or older</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>More patients aged &#8805;65 years in the
docetaxel arm reported hypersensitivity reaction, neutropenia, anaemia, fluid
retention, dyspnea, and nail changes when compared to the patients aged less
than 65 years. None of these increases in frequency reached 10% difference with
the control arm.</span><span style='font-size:11.0pt'> </span><span lang=EN-GB
style='font-size:11.0pt'>In patients who were 75&nbsp;years of age or older,
when compared to younger patients,</span><span style='font-size:11.0pt'>
neutropenia, anaemia, diarrhea, dyspnea and upper respiratory tract infection
were reported</span><span style='font-size:11.0pt'> </span><span
style='font-size:11.0pt'>with a greater incidence (at least 10% higher)</span><span
lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in gastric
adenocarcinoma cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Among the 300 (221&nbsp;patients in the
phase&nbsp;III part of the study and 79&nbsp;patients in the phase&nbsp;II
part) patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
in the gastric cancer study, 74 were 65&nbsp;years of age or older and
4&nbsp;patients were 75&nbsp;years of age or older. The incidence of serious
adverse events was higher in older people compared to younger patients. The
incidence of the following adverse events (all grades): lethargy, stomatitis,
neutropenic infection occurred at rates </span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10% higher in
patients who were 65&nbsp;years of age or older compared to younger patients. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Older people
treated with TCF should be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 395&nbsp;mg ethanol anhydrous per vial, equivalent to 10&nbsp;ml of
beer or 4&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, children and high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>Consideration
should be given to possible effects on the central nervous system.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'> studies have shown that the metabolism of docetaxel may be modified by
the concomitant administration of compounds which induce, inhibit or are
metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450&#8209;3A
such as ciclosporine, ketoconazole and erythromycin. As a result, caution
should be exercised when treating patients with these medicinal products as
concomitant therapy since there is a potential for a significant interaction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In case of combination
with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong
CYP3A4 inhibitor </span><span lang=EN-GB style='font-size:11.0pt;color:black'>(e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir,
ritonavir, saquinavir, telithromycin and voriconazole) </span><span lang=EN-GB
style='font-size:11.0pt'>cannot be avoided, a close clinical surveillance is
warranted and a dose-adjustment of docetaxel may be suitable during the
treatment with the strong CYP3A4 inhibitor (see section 4.4). </span><span
lang=EN-GB style='font-size:11.0pt'>In a pharmacokinetic study with 7 patients,
the co-administration of docetaxel with the strong CYP3A4 inhibitor
ketoconazole leads to a&nbsp;significant decrease in docetaxel clearance by
49%.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Docetaxel pharmacokinetics in the
presence of prednisone was studied in patients with metastatic prostate cancer.
Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4. No
statistically significant effect of prednisone on the pharmacokinetics of docetaxel
was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
highly protein bound (&gt;&nbsp;95%). Although the possible <i>in vivo</i>
interaction of docetaxel with concomitantly administered medicinal product has
not been investigated formally, <i>in vitro</i> interactions with tightly
protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect
protein binding of docetaxel. In addition, dexamethasone did not affect protein
binding of docetaxel. Docetaxel did not influence the binding of digitoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The pharmacokinetics
of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co&#8209;administration.
Limited data from a single uncontrolled study were suggestive of an interaction
between docetaxel and carboplatin. When combined to docetaxel, the clearance of
carboplatin was about 50% higher than values previously reported for
carboplatin monotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>There is no information on the use of docetaxel in
pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic
in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic
medicinal products, docetaxel may cause foetal harm when administered to
pregnant women. Therefore, docetaxel must not be used during pregnancy unless
clearly indicated.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Women of childbearing age receiving docetaxel should
be advised to avoid becoming pregnant, and to inform the treating physician
immediately should this occur.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is a
lipophilic substance but it is not known whether it is excreted in human milk.
Consequently, because of the potential for adverse reactions in nursing
infants, breast feeding must be discontinued for the duration of docetaxel
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Contraception
in males and females</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>An effective
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>In non clinical studies, docetaxel has genotoxic
effects and may alter male fertility (see section 5.3). Therefore, men being
treated with docetaxel are advised not to father a child during and up to 6&nbsp;months
after treatment and to seek advice on conservation of sperm prior to treatment.
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No studies on the
effects on the ability to drive and use machines have been performed. The
amount of alcohol in this </span><span lang=EN-GB style='font-size:11.0pt'>medicinal
product </span><span style='font-size:11.0pt'>and the side effects</span><span
lang=EN-GB style='font-size:11.0pt'> of the product may impair the ability to
drive or use machines (see sections 4.4</span><span style='font-size:11.0pt'>
and 4.8</span><span lang=EN-GB style='font-size:11.0pt'>). Therefore, patients
should be warned of the potential impact of the amount of alcohol and the side
effects of this medicinal product on the ability to drive or use machines, and
be advised not to drive or use machines if they experience these side effects
during treatment.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile for all indications</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The adverse
reactions considered to be possibly or probably related to the administration
of docetaxel have been obtained in: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1312 and
     121&nbsp;patients who received 100&nbsp;mg/m&sup2;<sup> </sup>and
     75&nbsp;mg/m&sup2; of docetaxel as a single agent respectively.</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>258&nbsp;patients
     who received docetaxel in combination with doxorubicin. </span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>406&nbsp;patients
     who received docetaxel in combination with cisplatin. </span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>92&nbsp;patients
treated with docetaxel in combination with trastuzumab. </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>255&nbsp;patients
     who received docetaxel in combination with capecitabine.</span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>332&nbsp;patients
</span><span style='font-family:"Times New Roman",serif'>(TAX327)</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> who received docetaxel
in combination with prednisone or prednisolone (clinically important treatment
related adverse events are presented).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1276&nbsp;patients
     (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received
     docetaxel in combination with doxorubicin and cyclophosphamide (clinically
     important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>300&nbsp;gastric
     adenocarcinoma patients (221&nbsp;patients in the phase&nbsp;III part of
     the study and 79&nbsp;patients in the phase&nbsp;II part) who received
     docetaxel in combination with cisplatin and 5&#8209;fluorouracil
     (clinically important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>174 and
     251&nbsp;head and neck cancer patients who received docetaxel in
     combination with cisplatin and 5&#8209;fluorouracil (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>545 patients
     (STAMPEDE study) who received docetaxel in combination with prednisone or
     prednisolone and ADT.</span></li>
</ul>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>These reactions were described using the NCI Common
Toxicity Criteria (grade&nbsp;3&nbsp;=&nbsp;G3; grade&nbsp;3&#8209;4&nbsp;=&nbsp;G3/4;
grade&nbsp;4&nbsp;=&nbsp;G4), the COSTART and the MedDRA terms. Frequencies are
defined as: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to
&lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from available data).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse
reactions of docetaxel alone are: neutropenia (which was reversible and not
cumulative; the median day to nadir was 7&nbsp;days and the median duration of
severe neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) was 7&nbsp;days), anaemia,
alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The severity of
adverse events of docetaxel may be increased when docetaxel is given in
combination with other chemotherapeutic agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with trastuzumab, adverse
events (all grades) reported in &#8805;&nbsp;10% are displayed. There was an
increased incidence of SAEs (40% vs. 31%) and Grade&nbsp;4 AEs (34% vs. 23%) in
the trastuzumab combination arm compared to docetaxel monotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with capecitabine, the
most frequent treatment-related undesirable effects (&#8805;&nbsp;5%) reported
in a phase&nbsp;III study in breast cancer patients failing anthracycline
treatment are presented (see capecitabine summary of product characteristics).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring
occurring over the 6 cycles of treatment with docetaxel and having at least 2%
higher incidence in the docetaxel treatment arm by comparison to the control
arm, are presented, using the CTCAE grading scale.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
following adverse reactions are frequently observed with docetaxel:</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
reactions have generally occurred within a few minutes following the start of
the infusion of docetaxel and were usually mild to moderate. The most
frequently reported symptoms were flushing, rash with or without pruritus,
chest tightness, back pain, dyspnoea and fever or chills. Severe reactions were
characterised by hypotension and/or bronchospasm or generalized rash/erythema
(see section 4.4).</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
development of severe peripheral neurotoxicity requires a reduction of dose
(see sections 4.2 and 4.4). Mild to moderate neuro-sensory signs are
characterised by paresthesia, dysesthesia or pain including burning.
Neuro-motor events are mainly characterised by weakness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Reversible cutaneous reactions have been
observed and were generally considered as mild to moderate. Reactions were
characterised by a rash including localised eruptions mainly on the feet and
hands (including severe hand and foot syndrome), but also on the arms, face or
thorax, and frequently associated with pruritus. Eruptions generally occurred
within one week after the docetaxel infusion. Less frequently, severe symptoms
such as eruptions followed by desquamation which rarely lead to interruption or
discontinuation of docetaxel treatment were reported (see sections 4.2 and
4.4). Severe nail disorders are characterised by hypo- or hyperpigmentation and
sometimes pain and onycholysis. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>General disorders and administration
site conditions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Infusion site reactions were generally
mild and consisted of hyper pigmentation, inflammation, redness or dryness of
the skin, phlebitis or extravasation and swelling of the vein.</span></p>

<p class=Normal11pt><span lang=EN-GB>Fluid retention includes events such as
peripheral oedema and less frequently pleural effusion, pericardial effusion,
ascites and weight gain. The peripheral oedema usually starts at the lower
extremities and may become generalised with a weight gain of 3&nbsp;kg or more.
Fluid retention is cumulative in incidence and severity (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for<b> </b></span><span lang=EN-GB>TAXOTERE 100&nbsp;mg/m&sup2;
single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections (G3/4: 5.7%; including sepsis
  and pneumonia, fatal in 1.7%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection associated with G4 neutropenia
  (G3/4: 4.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 76.4%); <br>
  Anaemia (G3/4: 8.9%); <br>
  Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Thrombocytopenia (G4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 5.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3:
  4.1%); <br>
  Peripheral motor neuropathy (G3/4: 4%); <br>
  Dysgeusia (severe: 0.07%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension; <br>
  Hypertension;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Haemorrhage</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspnoea (severe: 2.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 5.3%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 4%); <br>
  Nausea (G3/4: 4%); <br>
  Vomiting (G3/4: 3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation (severe: 0.2%); <br>
  Abdominal pain (severe: 1%); <br>
  Gastrointestinal haemorrhage (severe: 0.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Oesophagitis (severe: 0.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Skin reaction (G3/4: 5.9%); <br>
  Nail disorders (severe: 2.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (severe: 1.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arthralgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (severe: 6.5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 11.2%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Non-cardiac chest pain (severe: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased
  (&lt;&nbsp;5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood alkaline phosphatase
  increased (&lt;&nbsp;4%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 AST increased (&lt;&nbsp;3%);<br>
  G3/4 ALT increased (&lt;&nbsp;2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for Taxotere 100 mg/m<sup>2</sup>
single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare: bleeding episodes associated with
grade&nbsp;3/4 thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Reversibility data are available among
35.3% of patients who developed neurotoxicity following docetaxel treatment at
100&nbsp;mg/m&sup2; as single agent. The events were spontaneously reversible
within 3&nbsp;months.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare: one case of alopecia
non-reversible at the end of the study. 73% of the cutaneous reactions were
reversible within 21&nbsp;days.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>General disorders and administration
site conditions</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The median cumulative dose to treatment
discontinuation was more than 1,000&nbsp;mg/m<sup>2 </sup>and the median time
to fluid retention reversibility was 16.4&nbsp;weeks (range 0 to
42&nbsp;weeks). The onset of moderate and severe retention is delayed (median
cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in patients with premedication
compared with patients without premedication (median cumulative dose:
489.7&nbsp;mg/m<sup>2</sup>); however, it has been reported in some patients
during the early courses of therapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in non-small cell lung cancer for </span><span
lang=EN-GB>TAXOTERE 75&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections (G3/4: 5%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 54.2%); </span></p>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 10.8%); Thrombocytopenia
  (G4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (no severe)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3/4:
  0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 2.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (no severe) </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 3.3%); <br>
  Stomatitis (G3/4: 1.7%); <br>
  Vomiting (G3/4: 0.8%); <br>
  Diarrhoea (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Skin reaction (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nail disorders (severe: 0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 12.4%); <br>
  Fluid retention (severe: 0.8%);<br>
  Pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased
  (&lt;&nbsp;2%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for </span><span lang=EN-GB>TAXOTERE 75&nbsp;mg/m&sup2; in
combination with doxorubicin</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 7.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 91.7%);<br>
  Anaemia (G3/4: 9.4%); <br>
  Febrile neutropenia;<br>
  Thrombocytopenia (G4: 0.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 5%); <br>
  Stomatitis (G3/4: 7.8%); <br>
  Diarrhoea (G3/4: 6.2%); <br>
  Vomiting (G3/4: 5%); <br>
  Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Nail disorders (severe: 0.4%); <br>
  Skin reaction (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 8.1%); <br>
  Fluid retention (severe: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased
  (&lt;&nbsp;2.5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood alkaline phosphatase
  increased (&lt;&nbsp;2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 AST increased (&lt;&nbsp;1%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 ALT increased (&lt;&nbsp;1%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in non-small
cell lung cancer for </span><span lang=EN-GB>TAXOTERE 75&nbsp;mg/m&sup2; in
combination with cisplatin</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 5.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 51.5%); <br>
  Anaemia (G3/4: 6.9%); <br>
  Thrombocytopenia (G4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3: 3.7%); <br>
  Peripheral motor neuropathy (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 9.6%); <br>
  Vomiting (G3/4: 7.6%); <br>
  Diarrhoea (G3/4: 6.4%); <br>
  Stomatitis (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (severe: 0.7%); <br>
  Skin reaction (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (severe: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (severe: 9.9%);<br>
  Fluid retention (severe: 0.7%);<br>
  Fever (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infusion
  site reaction; <br>
  Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (2.1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4 ALT
  increased (1.3%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 AST increased (0.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood alkaline phosphatase increased (0.3%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
100&nbsp;mg/m&sup2; in combination with trastuzumab</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); <br>
  Febrile neutropenia (includes neutropenia associated with fever and
  antibiotic use) or neutropenic sepsis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Paresthesia;
  Headache; Dysgeusia; Hypoaesthesia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased; Conjunctivitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lymphoedema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Epistaxis;
  Pharyngolaryngeal pain; Nasopharyngitis; Dyspnoea; <br>
  Cough; Rhinorrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea;
  Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia; Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Alopecia;
  Erythema; Rash; Nail disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia;
  Arthralgia; Pain in extremity; Bone pain; Back pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia;
  Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza
  like illness; Chest pain; Chills</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for Taxotere 100 mg/m<sup>2</sup>
in combination with trastuzumab</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very common: Haematological toxicity was
increased in patients receiving trastuzumab and docetaxel, compared with
docetaxel alone (32% grade&nbsp;3/4 neutropenia versus 22%, using NCI-CTC
criteria). Note that this is likely to be an underestimate since docetaxel
alone at a dose of 100&nbsp;mg/m<sup>2</sup> is known to result in neutropenia
in 97% of patients, 76% grade&nbsp;4, based on nadir blood counts. The
incidence of febrile neutropenia/neutropenic sepsis was also increased in
patients treated with Herceptin plus docetaxel (23% versus 17% for patients
treated with docetaxel alone).</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Symptomatic
cardiac failure was reported in 2.2% of the patients who received docetaxel
plus trastuzumab compared to 0% of patients given docetaxel alone. In the
docetaxel plus trastuzumab arm, 64% had received a prior anthracycline as
adjuvant therapy compared with 55% in the docetaxel arm alone.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
75&nbsp;mg/m&sup2; in combination with capecitabine</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oral
  candidiasis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 63%); Anaemia (G3/4: 10%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Thrombocytopenia
  (G3/4: 3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 1%); <br>
  Decreased appetite </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dehydration
  (G3/4: 2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: &lt;&nbsp;1%);<br>
  Pareaesthesia (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dizziness;
  <br>
  Headache (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neuropathy
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pharyngolaryngeal
  pain (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dyspnoea
  (G3/4: 1%); <br>
  Cough (G3/4: &lt;&nbsp;1%); <br>
  Epistaxis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Stomatitis
  (G3/4: 18%); <br>
  Diarrhoea (G3/4: 14%); <br>
  Nausea (G3/4: 6%); <br>
  Vomiting (G3/4: 4%); <br>
  Constipation (G3/4: 1%); <br>
  Abdominal pain (G3/4: 2%); <br>
  Dyspepsia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Abdominal
  pain upper; <br>
  Dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hand-foot
  syndrome (G3/4: 24%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia
  (G3/4: 6%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nail
  disorders (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Dermatitis; <br>
  Rash erythematous (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Nail
  discolouration; <br>
  Onycholysis (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (G3/4: 2%); <br>
  Arthralgia (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain in
  extremity (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Back pain
  (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (G3/4: 3%); <br>
  Pyrexia (G3/4: 1%); <br>
  Fatigue/weakness (G3/4: 5%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oedema
  peripheral (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy;<br>
  Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  decreased;<br>
  G3/4 Blood bilirubin increased (9%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in </span><span lang=EN-GB>metastatic
castration-resistant prostate cancer for TAXOTERE 75&nbsp;mg/m&sup2; in
combination with prednisone or prednisolone</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 3.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); <br>
  Anaemia (G3/4: 4.9%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Thrombocytopenia
  (G3/4: 0.6%);<br>
  Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: 1.2%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  left ventricular function decrease (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Epistaxis
  (G3/4: 0%);<br>
  Dyspnoea (G3/4: 0.6%); <br>
  Cough (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 2.4%); <br>
  Diarrhoea (G3/4: 1.2%); <br>
  Stomatitis/Pharyngitis (G3/4: 0.9%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vomiting
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (no severe)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Exfoliative
  rash (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective bone disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arthralgia
  (G3/4: 0.3%); <br>
  Myalgia (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fatigue
  (G3/4: 3.9%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
  retention (severe: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in high-risk locally advanced or metastatic
hormone-sensitive prostate cancer for TAXOTERE 75 mg/m&sup2; in combination
with prednisone or prednisolone and ADT (STAMPEDE study) </span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:458.65pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:35.4pt'>
   <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA system organ
   classes</span></b></p>
   <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
   115%;page-break-after:avoid'><b><span style='font-size:11.0pt;line-height:
   115%'>&nbsp;</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Very common adverse reactions</span></b></p>
   </td>
   <td width=211 valign=top style='width:158.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Common adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:37.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Neutropenia (G3-4: 12 %)
  Anaemia </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Febrile
  neutropenia </span><span style='font-size:11.0pt'>(G3-4: 15%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Immune
  system disorders</span><span lang=EN-GB style='font-size:11.0pt;line-height:
  115%;color:black'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Hypersensitivity (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.2pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><s><span style='font-size:11.0pt'><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diabetes (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.8pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Anorexia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt' style='page-break-inside:
  avoid !msorm;height:20.45pt !msorm'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Psychiatric
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Insomnia (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Nervous
  system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Peripheral sensory
  neuropathy (&#8805;G3: 2%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Headache<br>
  <br>
  </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.5pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Eye
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Blurred vision</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.1pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Cardiac
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension </span><span
  style='font-size:11.0pt'>(G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:43.05pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Respiratory,
  thoracic and mediastinal disorders</span><span style='font-size:11.0pt;
  line-height:115%'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dyspnea (G3: 1%)<br>
  Coughing (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Upper respiratory tract
  infection (G3: 1%) </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Pharyngitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'><br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:64.3pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%'>Gastrointestinal
  disorders </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diarrhea (G3: 3%)<br>
  Stomatitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Constipation (G3: 0%)<br>
  Nausea (G3: 1%)<br>
  Dyspepsia<br>
  Abdominal pain (G3: 0%)<br>
  Flatulence</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Vomiting (G3: 1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.7pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Alopecia (G3: 3%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Nail changes (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  lang=FR style='font-size:11.0pt;line-height:115%'>Rash</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Myalgia </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Lethargy (G3-4: 2%)<br>
  Flu-like symptoms (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Asthenia (G3: 0%)<br>
  Fluid retention</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Fever (G3: 1%)<br>
  Oral candidiasis </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypocalcaemia (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypophosphataemia (G3-4:
  1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypokalaemia (G3: 0%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt style='page-break-after:avoid'><sup><span style='font-size:
9.0pt;font-family:"Arial Narrow",sans-serif'>a</span></sup><span
style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'> </span><span
style='font-size:9.0pt;color:black'>From the GETUG AFU15 study</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span></u><u><span lang=EN-GB>adjuvant
therapy with TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin and
cyclophosphamide<b> </b>in patients with node&#8209;positive </span><span
lang=EN-GB>(TAX 316) </span></u><u><span lang=EN-GB>and node&#8209;negative </span><span
lang=EN-GB>(GEICAM 9805) </span></u><u><span lang=EN-GB>breast cancer<b> </b></span><span
lang=EN-GB>- pooled data</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><b><span lang=EN-GB>MedDRA System Organ classes</span></b></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Very common adverse reactions</span></b></p>
  <p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Common adverse reactions</span></b></p>
  <p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Uncommon adverse reactions</span></b></p>
  <p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 2.4%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection (G3/4: 2.6%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 3%); </span></p>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 59.2%); Thrombocytopenia
  (G3/4: 1.6%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 1.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0.6%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 0%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Syncope
  (G3/4: 0%); Neurotoxicity (G3/4: 0%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Somnolence
  (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Conjunctivitis
  (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased (G3/4: &lt;0.1%) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (G3/4: 0.2%) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hot flush
  (G3/4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension
  (G3/4: 0%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Phlebitis
  (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lymphoedema
  (G3/4: 0%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cough
  (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 5.0%); Stomatitis (G3/4: 6.0%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vomiting
  (G3/4: 4.2%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Diarrhoea
  (G3/4: 3.4%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Constipation
  (G3/4: 0.5%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Abdominal
  pain (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia (persisting:
  &lt;3%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin
  disorder (G3/4: 0.6%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nail
  disorders (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (G3/4: 0.7%); Arthralgia (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Amenorrhoea (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General disorders
  and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (G3/4: 10.0%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pyrexia
  (G3/4: NA);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oedema
  peripheral (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  increased (G3/4: 0%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  decreased (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions for </span><span lang=EN-GB>adjuvant therapy with
TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin and
cyclophosphamide<b> </b>in patients with node&#8209;positive </span><span
lang=EN-GB>(TAX 316) and node&#8209;negative (GEICAM 9805) breast cancer</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>peripheral sensory neuropathy </span><span style='font-size:11.0pt'>started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 84&nbsp;patients (11.3%) in TAC arm and 15
patients (2&nbsp;%) in FAC arm. At the end of the follow-up period (median
follow-up time of 8 years), p</span><span style='font-size:11.0pt'>eripheral
sensory neuropathy</span><span lang=EN-GB style='font-size:11.0pt'> was
observed to be ongoing in 10 patients (1.3</span><span style='font-size:11.0pt'>%)
in TAC arm, and in 2</span><span lang=EN-GB style='font-size:11.0pt'> patients
(0.3%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In GEICAM 9805 study peripheral sensory neuropathy
that started during the treatment period persisted into the follow-up period in
10&nbsp;patients (1.9%) in TAC arm and 4 patients (0.8&nbsp;%) in FAC arm. At
the end of the follow-up period (median follow-up time of 10 years and 5
months), peripheral sensory neuropathy was observed to be ongoing in 3 patients
(0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext;layout-grid-mode:
both'>In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%)
in the FAC arm experienced congestive heart failure. All except one patient in
each arm were diagnosed with CHF more than 30 days after the treatment period.
Two patients in the TAC arm and 4 patients in the FAC arm died because of
cardiac failure.</span></p>

<p class=MsoHeader style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In GEICAM 9805
study, 3</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
patients (0.6&nbsp;%) in TAC arm and 3 </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>patients </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(0.6&nbsp;%)
in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>FAC
arm developed congestive heart failure during the follow-up period. At the end
of the follow-up period (actual median follow-up time of 10 years and 5
months), no patients&nbsp; had CHF in TAC arm and 1 patient in TAC arm died
because of dilated cardiomyopathy, and CHF was observed to be ongoing in
1&nbsp;patient (0.2%) in FAC arm.</span></p>

<p class=MsoHeader style='text-align:justify'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
alopecia persisting into the follow-up period after the end of chemotherapy was
reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%).<br>
At the end of the follow-up period (actual median follow-up time of</span><span
lang=EN-GB style='font-size:14.0pt;font-family:"Cambria",serif;color:#00B0F0'> </span><span
lang=EN-GB style='font-size:11.0pt'>8 years), alopecia was observed to be
ongoing in 29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In
GEICAM 9805 study alopecia </span><span style='font-size:11.0pt'>that started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period was observed to be ongoing in 49&nbsp;patients
(9.2&nbsp;%) in TAC arm and 35 patients (6.7&nbsp;%) in FAC arm. Alopecia
related to study drug started or worsened during the follow-up period in
42&nbsp;patients (7.9&nbsp;%) in TAC arm and 30 patients (5.8&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm,
and in 1 patient (0.2%) in FAC arm.</span><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Reproductive system and breast disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In TAX316 </span>amenorrhoea <span lang=EN-GB>that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%)
and 125 of 736 FAC patients (17.0%). Amenorrhea </span>was observed to be
ongoing <span lang=EN-GB>at the end of the </span>follow-up <span lang=EN-GB>period
(median follow-up time of 8 years) </span>in 121&nbsp;<span lang=EN-GB>of 744
TAC </span>patients <span lang=EN-GB>(16.3%) and 86 FAC patients (11.7%)</span>.</p>

<p class=Text style='margin-top:0in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>In GEICAM 9805 study</span><span lang=EN-GB
style='font-size:11.0pt'> amenorrhoea </span><span style='font-size:11.0pt'>that
started during the treatment period and </span><span lang=EN-GB
style='font-size:11.0pt'>persisted into the follow-up period was observed to be
ongoing in 18&nbsp;patients (3.4&nbsp;%) in TAC arm and 5 patients (1.0&nbsp;%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), amenorrhoea was observed to be ongoing in 7 patients
(1.3%) in TAC arm, and in 4 patients (0.8%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
peripheral oedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was observed in 119 of
744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), peripheral oedema was
ongoing in19&nbsp;TAC<u> </u>patients (2.6%) and 4 FAC<u> </u>patients (0.5%). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
lymphoedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was reported in 11 of
744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), lymphoedema was
observed to be ongoing in 6&nbsp;TAC patients (0.8%) and 1 FAC patient (0.1%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In study TAX316 asthenia that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%)
and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual
median follow-up time of 8 years), asthenia was observed to be ongoing in
29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study GEICAM
9805 peripheral oedema </span><span style='font-size:11.0pt'>that started
during the treatment period </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it
was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema </span><span
style='font-size:11.0pt'>that started during the treatment period </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period in
5&nbsp;patients (0.9%) in TAC arm and 2 patients (0.4&nbsp;%) in FAC arm. At
the end of the follow-up period, lymphoedema was observed to be ongoing in 4
patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia </span><span
style='font-size:11.0pt'>that started during the treatment period and </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period was
observed to be ongoing in 12&nbsp;patients (2.3&nbsp;%) in TAC arm and 4
patients (0.8&nbsp;%) in FAC arm. At the end of the follow-up period, asthenia
was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients
(0.4%) in FAC arm.</span></p>

<p class=MsoNormal><b><i><u><span style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Acute leukaemia
/ Myelodysplastic syndrome.</span></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After 10 years of follow up in study
TAX316, acute leukaemia was reported in 3 of 744 TAC patients </span><span
style='font-weight:normal'>(0.4%)</span><span lang=EN-GB style='font-weight:
normal'> and in 1 of 736 FAC patients </span><span style='font-weight:normal'>(0.1%).</span><span
style='font-weight:normal'> </span><span style='font-weight:normal'>One TAC
patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up
period (median follow-up time of 8 years)</span><span lang=EN-GB
style='font-weight:normal'>. Myelodysplastic syndrome was reported in 2 of 744
TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-weight:normal'>10 years of follow-up </span><span
lang=EN-GB style='font-weight:normal'>in GEICAM 9805 study</span><span
lang=EN-GB style='font-weight:normal'>,</span><span lang=EN-GB
style='font-weight:normal'> acute leukaemia occurred in 1</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>of 532 (0.2%)</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>patients</span><span
lang=EN-GB style='font-weight:normal'> in TAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No cases were reported in patients </span><span
style='font-weight:normal'>in FAC arm</span><span lang=EN-GB style='font-weight:
normal'>. No patient was diagnosed with myelodysplastic syndrome in either
treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
complications</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Table below shows
that the incidence of Grade&nbsp;4 neutropenia, febrile neutropenia and
neutropenic infection was decreased in patients who received primary G&#8209;CSF
prophylaxis after it was made mandatory in the TAC arm &#8211; GEICAM study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal'>Neutropenic complications in
patients receiving TAC with or without primary G&#8209;CSF prophylaxis (GEICAM
9805)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Without
  primary</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF
  prophylaxis (n&nbsp;=&nbsp;111)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n&nbsp;(%)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>With primary </span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF </span><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>prophylaxis</span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(n&nbsp;=&nbsp;421)
  </span></p>
  <p class=TableHeadCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>n&nbsp;(%)</span></p>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenia&nbsp;(Grade&nbsp;4)
  </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>104
  (93.7)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>135 (32.1)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=IT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Febrile
  neutropenia </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>28 (25.2)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>23 (5.5)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenic infection </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>14 (12.6)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>21 (5.0)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection (Grade&nbsp;3-4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (1.8)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5 (1.2)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in gastric adenocarcinoma cancer for TAXOTERE
75&nbsp;mg/m&sup2; in combination with cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenic
  infection;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 11.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 20.9%);</span></p>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.2%); </span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4: 8.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 11.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:40.75pt'>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3/4:
  8.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.3%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Peripheral </span><span lang=EN-GB>motor
  neuropathy (G3/4: 1.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 1.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 19.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 16%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 23.7%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 14.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 1.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oesophagitis/dysphagia/odynophagia
  (G3/4: 0.7%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritus (G3/4: 0.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Nail disorders (G3/4: 0.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Skin exfoliation (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 19.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fever (G3/4: 2.3%);<br>
  Fluid retention (severe/life-threatening: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75
mg/m<sup>2</sup> in combination with cisplatin and 5-fluorouracil</span></u></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Blood
and lymphatic system disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Febrile
neutropenia and neutropenic infection occurred in 17.2% and 13.5% of patients
respectively, regardless of G&#8209;CSF use. G&#8209;CSF was used for secondary
prophylaxis in 19.3% of patients (10.7% of the cycles). Febrile neutropenia and
neutropenic infection occurred respectively in 12.1% and 3.4% of patients when
patients received prophylactic G&#8209;CSF, in 15.6% and 12.9% of patients
without prophylactic G&#8209;CSF (see section 4.2).</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in head and neck cancer for TAXOTERE
75&nbsp;mg/m&sup2; in combination with cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
radiotherapy (TAX 323)</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 6.3%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenic
  infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neoplasms
  benign, malignant and unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cancer
  pain (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Neutropenia
  (G3/4: 76.3%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Anaemia
  (G3/4: 9.2%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Thrombocytopenia
  (G3/4: 5.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.75pt'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Dysgeusia/Parosmia;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Peripheral
  sensory neuropathy (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Conjunctivitis
  </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Ear and
  labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hearing
  impaired</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myocardial
  ischemia (G3/4:1.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Venous
  disorder (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 0.6%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Stomatitis
  (G3/4: 4.0%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Diarrhoea
  (G3/4: 2.9%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vomiting
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Constipation;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Esophagitis/dysphagia/
  odynophagia (G3/4: 0.6%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Abdominal
  pain;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dyspepsia;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  haemorrhage (G3/4: 0.6%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia
  (G3/4: 10.9%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Rash
  pruritic;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dry skin;
  </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin
  exfoliative (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy
  (G3/4: 3.4%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pyrexia
  (G3/4: 0.6%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
  retention;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oedema</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
chemoradiotherapy (TAX 324)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 3.6%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neoplasms benign, malignant and
  unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cancer pain</span><span lang=EN-GB>
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.5%);</span></p>
  <p class=Normal11pt><span lang=IT>Anaemia</span><span lang=IT> (G3/4: 12.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4:&nbsp;4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 12.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Dysgeusia/Parosmia (G3/4:&nbsp;0.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Peripheral sensory neuropathy (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Conjunctivitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4:&nbsp;1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia</span><span lang=EN-GB>
  (G3/4: 2.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ischemia myocardial</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Venous disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 13.9%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 20.7%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 8.4%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 6.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Esophagitis/dysphagia/ odynophagia
  (G3/4: 12.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspepsia (G3/4: 0.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal haemorrhage (G3/4:
  0.4%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritic</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dry skin&nbsp;;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Desquamation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal, connective tissue bone
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pyrexia (G3/4: 3.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oedema (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight decreased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight increased</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Post-marketing
experience</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Neoplasms
benign, malignant and unspecified (incl cysts and polyps)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S</span><span
style='font-size:11.0pt'>econd primary malignancies (</span><span lang=EN
style='font-size:11.0pt'>frequency not known)</span><span style='font-size:
11.0pt'>, including non-Hodgkin lymphoma have been reported in association with
docetaxel when used in combination with other anticancer treatments known to be
associated with second primary malignancies</span><span lang=EN-GB
style='font-size:11.0pt'>. </span><span style='font-size:11.0pt'>Acute myeloid
leukaemia and myelodysplastic syndrome have been reported (frequency uncommon)
in pivotal clinical studies in breast cancer with TAC regimen.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Bone marrow suppression and other
haematologic adverse reactions have been reported. Disseminated intravascular
coagulation (DIC), often in association with sepsis or multiorgan failure, has
been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Immune system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Some cases of anaphylactic shock,
sometimes fatal, have been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity reactions (frequency not
known) have been reported with docetaxel in patients who previously experienced
hypersensitivity reactions to paclitaxel.</span></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of convulsion or transient loss
of consciousness have been observed with docetaxel administration. These
reactions sometimes appear during the infusion of the medicinal product.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt><i><span lang=EN-GB>Eye disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>Very rare
cases of transient visual disturbances (flashes, flashing lights, scotomata)
typically occurring during infusion of the medicinal product and in association
with hypersensitivity reactions have been reported. These were reversible upon
discontinuation of the infusion. </span><span lang=EN-GB>Cases of lacrimation
with or without conjunctivitis, as cases of lacrimal duct obstruction resulting
in excessive tearing have been rarely reported.&nbsp;Cases of cystoid macular
oedema (CMO) have been reported in patients treated with docetaxel.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Ear and labyrinth disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>Rare cases
of ototoxicity, hearing impaired and/or hearing loss have been reported.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Rare cases
of myocardial infarction have been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including
ventricular tachycardia (frequency not known), sometimes fatal, has been
reported in patients treated with docetaxel in combination regimens including
doxorubicin, 5-fluorouracil and/ or cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Vascular disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Venous thromboembolic events have rarely
been reported.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Respiratory, thoracic and mediastinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome and cases of<b><i> </i></b>interstitial pneumonia</span><b><span
lang=EN-GB style='font-size:11.0pt'>/ </span></b><span lang=EN-GB
style='font-size:11.0pt'>pneumonitis<b>,</b></span><span lang=EN-GB
style='font-size:11.0pt'> interstitial lung disease, </span><span lang=EN-GB
style='font-size:11.0pt'>pulmonary fibrosis <span class=msoins0>and respiratory
failure </span>sometimes fatal have rarely been reported. Rare cases of
radiation pneumonitis have been reported in patients receiving concomitant
radiotherapy. </span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Gastrointestinal disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare cases of enterocolitis, including
colitis, ischemic colitis, and neutropenic enterocolitis, have been reported
with a potential fatal outcome (frequency not known).</span></p>

<p class=Normal11pt><span lang=EN-GB>Rare occurrences of dehydration have been
reported as a consequence of gastrointestinal events including enterocolitis
and gastrointestinal perforation. </span></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of ileus and intestinal
obstruction have been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatobiliary disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare cases of hepatitis, sometimes
fatal primarily in patients with pre&#8209;existing liver disorders, have been
reported.</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cases of cutaneous
lupus erythematosus</span><span lang=EN-GB>, </span><span lang=EN-GB
style='font-size:11.0pt'>bullous eruptions such as erythema multiforme and </span><span
lang=EN-GB>severe cutaneous adverse reactions such as </span><span lang=EN-GB
style='font-size:11.0pt'>Stevens&#8209;Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
(TEN) and </span><span lang=EN-GB style='font-size:11.0pt'>Acute Generalized Exanthematous
Pustulosis (AGEP)</span><span lang=EN-GB style='font-size:11.0pt'> have been
reported with docetaxel. Scleroderma&#8209;like changes usually preceded by
peripheral lymphoedema have been reported with docetaxel. Cases of </span><span
lang=EN-GB style='font-size:11.0pt'>permanent</span><span lang=EN-GB
style='font-size:11.0pt'> alopecia (frequency not known) have been reported.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Renal and urinary disorders</span></i></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Renal insufficiency and renal failure have been reported. In
about 20% of these cases there were no risk factors for acute renal failure
such as concomitant nephrotoxic medicinal products and gastro-intestinal
disorders.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>General
disorders and administration site conditions</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Radiation
recall phenomena have rarely been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Injection site
recall reaction (recurrence of skin reaction at a site of previous
extravasation following administration of docetaxel at a different site) has
been observed at the site of previous extravasation (frequency not known).</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
retention has not been accompanied by acute episodes of oliguria or
hypotension. Dehydration and pulmonary oedema have rarely been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><i>Metabolism and nutrition disorders</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB style='color:windowtext'>Cases of electrolyte imbalance
have been reported. </span><span lang=EN-GB>Cases of hyponatraemia have been
reported, mostly associated with dehydration, vomiting and pneumonia. </span><span
lang=EN-GB style='color:windowtext'>Hypokalaemia, hypomagnesaemia, and
hypocalcaemia were observed, usually in association with gastrointestinal disorders
and in particular with diarrhoea. </span><span lang=EN-GB>Tumour lysis
syndrome, potentially fatal, has been reported (frequency not known).</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin-left:0in;text-indent:0in'><i>Musculoskeletal
disorder</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Myositis has been reported with docetaxel <span lang=EN-GB>(frequency not
known)</span>.</p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='color:black;background:#BFBFBF'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>There were a few reports of overdose.
There is no known antidote for docetaxel overdose. In case of overdose, the patient
should be kept in a specialised unit and vital functions closely monitored. In
cases of overdose, exacerbation of adverse events may be expected. The primary
anticipated complications of overdose would consist of bone marrow suppression,
peripheral neurotoxicity and mucositis. Patients should receive therapeutic G&#8209;CSF
as soon as possible after discovery of overdose. Other appropriate symptomatic
measures should be taken, as needed.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Pharmacotherapeutic group: Taxanes, ATC
Code: L01CD02</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is an antineoplastic agent which
acts by promoting the assembly of tubulin into stable microtubules and inhibits
their disassembly which leads to a marked decrease of free tubulin. The binding
of docetaxel to microtubules does not alter the number of protofilaments.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown <i>in vitro</i>
to disrupt the microtubular network in cells which is essential for vital
mitotic and interphase cellular functions. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel was found to be cytotoxic <i>in
vitro</i> against various murine and human tumour cell lines and against
freshly excised human tumour cells in clonogenic assays. Docetaxel achieves
high intracellular concentrations with a long cell residence time. In addition,
docetaxel was found to be active on some but not all cell lines over expressing
the p&#8209;glycoprotein which is encoded by the multidrug resistance gene. <i>In
vivo</i>, docetaxel is schedule independent and has a broad spectrum of
experimental anti-tumour activity against advanced murine and human grafted
tumours.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
doxorubicin and cyclophosphamide: adjuvant therapy</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><u><span
lang=EN-GB>Patients with operable node&#8209;positive breast cancer </span></u><span
lang=EN-GB>(TAX 316)</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Data from a
multi-centre open label randomised study support the use of docetaxel for the
adjuvant treatment of patients with operable node-positive breast cancer and KPS&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;80%,
between 18 and 70&nbsp;years of age. After stratification according to the number
of positive lymph nodes (1&#8209;3, 4+), 1491&nbsp;patients were randomised to
receive either docetaxel 75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour
after doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup>
(TAC arm), or doxorubicin 50&nbsp;mg/m<sup>2</sup> followed by fluorouracil
500&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (FAC
arm). Both regimens were administered once every 3&nbsp;weeks for
6&nbsp;cycles. Docetaxel was administered as a 1&#8209;hour infusion, all other
medicinal products were given as intravenous bolus on day one. G&#8209;CSF was
administered as secondary prophylaxis to patients who experienced complicated
neutropenia (febrile neutropenia, prolonged neutropenia, or infection).
Patients on the TAC arm received antibiotic prophylaxis with ciprofloxacin
500&nbsp;mg orally twice daily for 10&nbsp;days starting on day&nbsp;5 of each
cycle, or equivalent. In both arms, after the last cycle of chemotherapy,
patients with positive eostrogen and/or progesterone receptors received
tamoxifen 20&nbsp;mg daily for up to 5&nbsp;years. Adjuvant radiation therapy
was prescribed according to guidelines in place at participating institutions
and was given to 69% of patients who received TAC and 72% of patients who
received FAC. Two interim analyses and one final analysis were performed. The
first interim analysis was planned 3 years after the date when half of study
enrolment was done. The second interim analysis was done after 400 DFS events
had been recorded overall, which led to a median follow-up of 55 months. The
final analysis was performed when all patients had reached their 10-year follow-up
visit (unless they had a DFS event or were lost to follow-up before).
Disease-free survival (DFS) was the primary efficacy endpoint and Overall
survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>A final analysis was performed with an
actual median follow up of 96&nbsp;months. Significantly longer disease-free
survival for the TAC arm compared to the FAC arm was demonstrated. Incidence of
relapses at 10&nbsp;years was reduced in patients receiving TAC compared to
those who received FAC (39% versus 45%, respectively) i.e. an absolute risk
reduction by 6% (p&nbsp;=&nbsp;0.0043). Overall survival at 10&nbsp;years was
also significantly increased with TAC compared to FAC (76% versus 69%,
respectively) i.e. an absolute reduction of the risk of death by 7%
(p&nbsp;=&nbsp;0.002). As the benefit observed in patients with 4+ nodes was not
statistically significant on DFS and OS, the positive benefit/risk ratio for
TAC in patients with 4+ nodes was not fully demonstrated at the final analysis.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=Normal11pt><span lang=EN-GB>Overall, the study results demonstrate a
positive benefit risk ratio for TAC compared to FAC.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAC-treated patient subsets according to
prospectively defined major prognostic factors were analysed:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.22%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="20%" valign=top style='width:20.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" colspan=3 valign=top style='width:33.58%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Disease free survival</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.98%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Overall survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.46%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>Patient subset</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Number of patients</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="8%" valign=top style='width:8.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>No of positive nodes</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.52%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.34%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="8%" valign=top style='width:8.74%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.72%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.78%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Overall</span></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>745</span></p>
  </td>
  <td width="11%" valign=top style='width:11.52%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.80</span></p>
  </td>
  <td width="13%" valign=top style='width:13.34%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>68</span><span lang=EN-GB>-0.</span><span lang=EN-GB>93</span></p>
  </td>
  <td width="8%" valign=top style='width:8.74%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0043</span></p>
  </td>
  <td width="11%" valign=top style='width:11.72%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.74</span></p>
  </td>
  <td width="12%" valign=top style='width:12.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>61</span><span lang=EN-GB>-0.</span><span lang=EN-GB>90</span></p>
  </td>
  <td width="10%" valign=top style='width:10.78%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0020</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>1-3</span></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>467</span></p>
  </td>
  <td width="11%" valign=top style='width:11.52%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width="13%" valign=top style='width:13.34%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>58</span><span lang=EN-GB>-0.</span><span lang=EN-GB>91</span></p>
  </td>
  <td width="8%" valign=top style='width:8.74%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0047</span></p>
  </td>
  <td width="11%" valign=top style='width:11.72%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width="12%" valign=top style='width:12.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>46</span><span lang=EN-GB>-0.</span><span lang=EN-GB>82</span></p>
  </td>
  <td width="10%" valign=top style='width:10.78%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0008</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.46%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>4+</span></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>278</span></p>
  </td>
  <td width="11%" valign=top style='width:11.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="13%" valign=top style='width:13.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>70</span><span lang=EN-GB>-1.</span><span lang=EN-GB>09</span></p>
  </td>
  <td width="8%" valign=top style='width:8.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2290</span></p>
  </td>
  <td width="11%" valign=top style='width:11.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.67-1.12</span></p>
  </td>
  <td width="10%" valign=top style='width:10.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2746</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>*a hazard ratio of less than 1 indicates
that TAC is associated with a longer disease-free survival and overall survival
compared to FAC</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Patients with
operable node</span><span lang=EN-GB>&#8209;</span></u><u><span lang=EN-GB
style='font-size:11.0pt'>negative breast cancer eligible to receive
chemotherapy (</span></u><span lang=EN-GB style='font-size:11.0pt'>GEICAM 9805)<u>
</u></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Data</span><span
lang=EN-GB style='font-size:11.0pt'> from a multi-centre open label randomised
trial support the use of TAXOTERE for the adjuvant treatment of patients with
operable node&#8209;negative breast cancer eligible to receive chemotherapy<u> </u>.
1060&nbsp;patients were randomised to receive either TAXOTERE 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide
500&nbsp;mg/m<sup>2</sup> (539 patients in TAC arm), or doxorubicin
50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (521 patients in FAC arm), as
adjuvant treatment of operable node-negative breast cancer patients with high
risk of relapse according to 1998 St. Gallen criteria (tumour size
&gt;2&nbsp;cm and/or negative ER and PR and/or high histological/nuclear grade
(grade 2 to 3) and /or age &lt;35&nbsp;years).). Both regimens were
administered once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1&#8209;hour
infusion, all other medicinal products were given intraveinously on day 1 every
three weeks. Primary prophylactic G&#8209;CSF was made mandatory in TAC arm
after 230&nbsp;patients were randomised. The incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in patients
who received primary G&#8209;CSF prophylaxis (see section 4.8). In both arms,
after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours
received tamoxifen 20&nbsp;mg once a day for up to 5 years. Adjuvant radiation
therapy was administered according to guidelines in place at participating
institutions and was given to 57.3% of patients who received TAC and 51.2% of patients
who received FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>One
primary analysis and one updated analysis were performed. The primary analysis
was done when all patients had a follow-up of greater than 5 years (median
follow-up time of 77 months). The updated analysis was performed when all
patients had reached their 10-year (</span><span lang=EN-GB>median follow up
time of 10 years and 5&nbsp;months) </span><span lang=EN-GB>follow-up visit
(unless they had a DFS event or were lost to follow-up previously).
Disease-free survival (DFS) was the primary efficacy endpoint and Overall
survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, significantly longer disease-free survival for the
TAC arm compared to the FAC arm was demonstrated. TAC&#8209;treated patients
had a 32% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.68, 95% CI (0.49-0.93), p&nbsp;=&nbsp;0.01). At the
median follow up time of 10 years and 5&nbsp;months, TAC&#8209;treated patients
had a 16,5% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.84, 95% CI (0.65-1.08)</span><span
style='font-size:11.0pt'>, p=0.1646). DFS data were not statistically
significant but were still associated with a positive trend in favour of TAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;At the
median follow-up time of 77 months, overall survival (OS) was longer in the TAC
arm with TAC-treated patients having a 24% reduction in the risk of death
compared to FAC (hazard ratio&nbsp;=&nbsp;0.76, 95% CI (0.46-1.26,
p&nbsp;=&nbsp;0.29). However, the distribution of OS was not significantly
different between the 2 groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow up time of 10 years and 5&nbsp;months, TAC-treated patients had a 9%
reduction in the risk of death compared to FAC-treated patients (hazard
ratio&nbsp;=&nbsp;0.91, 95% CI (0.63-1.32)). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The survival rate
was 93.7% in the TAC arm and 91.4&nbsp;% in the FAC arm, at the 8-year
follow-up time point, and 91.3&nbsp;% in the TAC arm and 89&nbsp;% in the FAC
arm, at the 10-year follow-up time point.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The positive benefit risk ratio for TAC compared to
FAC remained unchanged<b>. </b>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAC&#8209;treated
patient subsets according to prospectively defined major prognostic factors
were analysed in the primary analysis (at the median follow-up time of 77
months) (see table below):</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Subset Analyses-Adjuvant Therapy in Patients with Node&#8209;negative
Breast Cancer Study </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>(Intent&#8209;to&#8209;Treat Analysis)</span></u></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=558
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=258 colspan=2 valign=top style='width:193.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Disease Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  subset</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of patients in TAC group</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio*</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Overall</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>539</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.49-0.93</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 1</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>260</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>279</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 2</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>42</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.31</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.11-0.89</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>497</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.52-1.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Hormonal receptor</span></b><span
  lang=EN-GB> <b>status</b></span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.6pt'>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt><span lang=EN-GB>Negative</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>195</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.7</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Positive</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>344</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.4-0.97</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Tumour size </span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB style='font-family:Symbol'>&pound;</span><span
  lang=EN-GB>2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.69</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&gt;2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Histological grade</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade1 (includes grade not assessed)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>64</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.79</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.24-2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 2</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>216</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.77</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.46-1.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 3</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>259</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.59</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.39-0.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Menopausal status</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Pre-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.64</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.40-1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Post-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.47-1.12</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*a hazard ratio
(TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease
free survival compared to FAC.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Exploratory subgroup analyses for disease-free
survival for patients who meet the 2009 St. Gallen chemotherapy criteria
&#8211; (ITT population) were performed and presented here below:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>TAC</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>FAC</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(TAC/FAC)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Subgroups</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=539)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=521)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Meeting
  relative indication for chemotherapy </span><sup><span lang=EN-GB
  style='font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>No</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18/214</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(8.4%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26/227</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(11.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.796 (0.434 - 1.459)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4593</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48/325</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.8%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>69/294</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(23.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.606 (0.42 - 0.877)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0072</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>TAC = docetaxel, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>FAC = 5-fluorouracil, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>CI = confidence interval; ER = eostrogen receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>PR = progesterone receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:10.0pt;font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> ER/PR-negative or Grade 3 or tumour size
&gt;5&nbsp;cm</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The estimated
hazard ratio was using Cox proportional hazard model with treatment group as
the factor.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE as single agent</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Two randomised phase&nbsp;III comparative
studies, involving a total of 326&nbsp;alkylating or 392&nbsp;anthracycline
failure metastatic breast cancer patients, have been performed with docetaxel
at the recommended dose and regimen of 100&nbsp;mg/m&sup2; every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In alkylating-failure patients, docetaxel
was compared to doxorubicin (75&nbsp;mg/m&sup2; every 3&nbsp;weeks). Without
affecting overall survival time (docetaxel 15&nbsp;months vs. doxorubicin
14&nbsp;months, p&nbsp;=&nbsp;0.38) or time to progression (docetaxel
27&nbsp;weeks vs. doxorubicin 23&nbsp;weeks, p&nbsp;=&nbsp;0.54), docetaxel
increased response rate (52% vs. 37%, p&nbsp;=&nbsp;0.01) and shortened time to
response (12&nbsp;weeks vs. 23&nbsp;weeks, p&nbsp;=&nbsp;0.007). Three
docetaxel patients (2%) discontinued the treatment due to fluid retention,
whereas 15&nbsp;doxorubicin patients (9%) discontinued due to cardiac toxicity
(three cases of fatal congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In anthracycline-failure patients,
docetaxel was compared to the combination of mitomycin&nbsp;C and vinblastine
(12&nbsp;mg/m&sup2; every 6&nbsp;weeks and 6&nbsp;mg/m&sup2; every
3&nbsp;weeks). Docetaxel increased response rate (33% vs. 12%,
p&nbsp;&lt;&nbsp;0.0001), prolonged time to progression (19&nbsp;weeks vs.
11&nbsp;weeks, p&nbsp;=&nbsp;0.0004) and prolonged overall survival
(11&nbsp;months vs. 9&nbsp;months, p&nbsp;=&nbsp;0.01).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During these two phase&nbsp;III studies,
the safety profile of docetaxel was consistent with the safety profile observed
in phase&nbsp;II studies (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>An open-label, multi-centre, randomised
phase&nbsp;III study was conducted to compare docetaxel monotherapy and
paclitaxel in the treatment of advanced breast cancer in patients whose
previous therapy should have included an anthracycline. A total of 449&nbsp;patients
were randomised to receive either docetaxel monotherapy 100&nbsp;mg/m&sup2; as
a 1&nbsp;hour infusion or paclitaxel 175&nbsp;mg/m&sup2; as a 3&nbsp;hour
infusion. Both regimens were administered every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>Without affecting the primary endpoint,
overall response rate (32% vs 25%, p&nbsp;=&nbsp;0.10), docetaxel prolonged
median time to progression (24.6&nbsp;weeks vs 15.6&nbsp;weeks;
p&nbsp;&lt;&nbsp;0.01) and median survival (15.3&nbsp;months vs
12.7&nbsp;months; p&nbsp;=&nbsp;0.03).</span></p>

<p class=Normal11pt><span lang=EN-GB>More grade&nbsp;3/4 adverse events were
observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%). </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
doxorubicin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One large randomised phase&nbsp;III study,
involving 429 previously untreated patients with metastatic disease, has been
performed with doxorubicin (50&nbsp;mg/m&sup2;) in combination with docetaxel
(75&nbsp;mg/m&sup2;) (AT arm) versus doxorubicin (60&nbsp;mg/m&sup2;) in
combination with cyclophosphamide (600&nbsp;mg/m&sup2;) (AC&nbsp;arm). Both
regimens were administered on day&nbsp;1 every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Time to progression
(TTP) was significantly longer in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.0138. The median TTP was 37.3&nbsp;weeks (95%&nbsp;CI: 33.4&nbsp;&#8209;&nbsp;42.1)
in AT arm and 31.9&nbsp;weeks (95%&nbsp;CI: 27.4&nbsp;&#8209;&nbsp;36.0) in AC
arm.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Overall response rate
(ORR) was significantly higher in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.009. The ORR was 59.3% (95%&nbsp;CI: 52.8&nbsp;&#8209;&nbsp;65.9)
in AT arm versus 46.5% (95%&nbsp;CI: 39.8&nbsp;&#8209;&nbsp;53.2) in AC arm.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In this study, AT arm showed a higher
incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3%
versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia
(8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand,
AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT
arm, and, in addition, a higher incidence of severe cardiac toxicity:
congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;20% (13.1% versus 6.1%), absolute
LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;30%
(6.2% versus 1.1%). Toxic deaths occurred in 1&nbsp;patient in the AT arm
(congestive heart failure) and in 4&nbsp;patients in the AC arm (1&nbsp;due to
septic shock and 3 due to congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>In both arms, quality of life measured by
the EORTC questionnaire was comparable and stable during treatment and follow&#8209;up.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
trastuzumab</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel in combination with trastuzumab
was studied for the treatment of patients with metastatic breast cancer whose
tumours overexpress HER2, and who previously had not received chemotherapy for
metastatic disease. One hundred eighty six patients were randomised to receive
docetaxel (100&nbsp;mg/m<sup>2</sup>) with or without trastuzumab; 60% of
patients received prior anthracycline-based adjuvant chemotherapy. Docetaxel
plus trastuzumab was efficacious in patients whether or not they had received
prior adjuvant anthracyclines. The main test method used to determine HER2
positivity in this pivotal study was immunohistochemistry (IHC). A minority of
patients were tested using fluorescence in&#8209;situ hybridization (FISH). In
this study, 87% of patients had disease that was IHC 3+, and 95% of patients
entered had disease that was IHC 3+ and/or FISH positive. Efficacy results are
summarized in the following table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Parameter</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel
  plus trastuzumab<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;92</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;94</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Response rate </span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>61%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(50-71)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>34%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(25-45)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(9.2-15.0)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.1</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(4.4-6.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median TTP (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>10.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.6-12.9)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(5.0-6.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>30.5<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(26.8-ne)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>22.1<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(17.6-28.9)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0><span lang=EN-GB>TTP&nbsp;=&nbsp;time to
progression; &#8220;ne&#8221; indicates that it could not be estimated or it
was not yet reached.</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB>Full analysis set (intent-to-treat)</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>2 </span></sup><span
lang=EN-GB>Estimated median survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with capecitabine</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Data from
one multi-centre, randomised, controlled phase&nbsp;III clinical study support
the use of docetaxel in combination with capecitabine for treatment of patients
with locally advanced or metastatic breast cancer after failure of cytotoxic
chemotherapy, including an anthracycline. In this study, 255&nbsp;patients were
randomised to treatment with docetaxel (75&nbsp;mg/m<sup>2</sup> as a
1&nbsp;hour intravenous infusion every 3&nbsp;weeks) and capecitabine
(1250&nbsp;mg/m<sup>2</sup> twice daily for 2&nbsp;weeks followed by 1&#8209;week
rest period). 256&nbsp;patients were randomised to treatment with docetaxel
alone (100&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour intravenous infusion every
3&nbsp;weeks). Survival was superior in the docetaxel&nbsp;+ capecitabine
combination arm (p&nbsp;=&nbsp;0.0126). Median survival was 442&nbsp;days
(docetaxel&nbsp;+ capecitabine) vs. 352&nbsp;days (docetaxel alone). The
overall objective response rates in the all&#8209;randomised population
(investigator assessment) were 41.6% (docetaxel&nbsp;+ capecitabine) vs. 29.7%
(docetaxel alone); p&nbsp;=&nbsp;0.0058. Time to progressive disease was
superior in the docetaxel&nbsp;+ capecitabine combination arm
(p&nbsp;&lt;&nbsp;0.0001). The median time to progression was 186&nbsp;days
(docetaxel&nbsp;+ capecitabine) vs. 128&nbsp;days (docetaxel alone).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Non-small cell lung cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Patients previously treated with
chemotherapy with or without radiotherapy</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In a phase&nbsp;III study, in previously
treated patients, time to progression (12.3&nbsp;weeks versus 7&nbsp;weeks) and
overall survival were significantly longer for docetaxel at 75&nbsp;mg/m&sup2;
compared to Best Supportive Care. The 1&#8209;year survival rate was also
significantly longer in docetaxel (40%) versus BSC (16%).</span></p>

<p class=Normal11pt><span lang=EN-GB>There was less use of morphinic analgesic
(p&nbsp;&lt;&nbsp;0.01), non&#8209;morphinic analgesics
(p&nbsp;&lt;&nbsp;0.01), other disease-related medicinal products
(p&nbsp;=&nbsp;0.06) and radiotherapy (p&nbsp;&lt;&nbsp;0.01) in patients
treated with docetaxel at 75&nbsp;mg/m&sup2; compared to those with BSC.</span></p>

<p class=Normal11pt><span lang=EN-GB>The overall response rate was 6.8% in the
evaluable patients, and the median duration of response was 26.1&nbsp;weeks.</span></p>

<p class=Normal11pt><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with platinum
agents in chemotherapy-na&iuml;ve patients</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In a phase&nbsp;III study,
1218&nbsp;patients with unresectable stage&nbsp;IIIB or IV NSCLC, with KPS of
70% or greater, and who did not receive previous chemotherapy for this
condition, were randomised to either docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2 </sup>as
a 1&nbsp;hour infusion immediately followed by cisplatin&nbsp;(Cis)
75&nbsp;mg/m<sup>2 </sup>over 30&#8209;60&nbsp;minutes every 3&nbsp;weeks
(TCis), docetaxel 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion in
combination with carboplatin (AUC 6&nbsp;mg/ml.min) over 30&#8209;60&nbsp;minutes
every 3&nbsp;weeks, or vinorelbine&nbsp;(V) 25&nbsp;mg/m<sup>2</sup>
administered over 6&#8209;10&nbsp;minutes on days&nbsp;1, 8, 15, 22 followed by
cisplatin 100&nbsp;mg/m<sup>2</sup> administered on day&nbsp;1 of cycles
repeated every 4&nbsp;weeks (VCis).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Survival
data, median time to progression and response rates for two arms of the study
are illustrated in the following table:</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=584
 style='margin-left:17.5pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>TCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;408</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>VCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;404</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Statistical analysis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  survival </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(Primary
  end-point):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>Median survival (months)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>10.1</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.122</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[97.2% CI: 0.937; 1.342]*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>1-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>41</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 5.4%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: -1.1; 12.0]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>2-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>21</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 6.2%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.2; 12.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  time to progression</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(weeks):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.0</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>23.0</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.032</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.876; 1.216]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  response rate (%):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.6</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.5</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 7.1%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.7; 13.5]</span></p>
  </td>
 </tr>
</table>

<p class=Normal11ptGauche0 style='page-break-after:avoid'><span lang=EN-GB>*:
Corrected for multiple comparisons and adjusted for stratification factors
(stage of disease and region of treatment), based on evaluable patient
population.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Secondary end&#8209;points included change
of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom
Scale, and changes in Karnosfky performance status. Results on these end-points
were supportive of the primary end-points results. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For docetaxel/carboplatin combination,
neither equivalent nor non-inferior efficacy could be proven compared to the
reference treatment combination VCis.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer</span></u></i></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Metastatic castration-resistant prostate cancer</span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in combination
with prednisone or prednisolone in patients with&nbsp; metastatic castration-resistant
prostate cancer were evaluated in a randomised multi-centre phase&nbsp;III study
(TAX 327). A total of 1006&nbsp;patients with KPS&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;60 were randomised
to the following treatment groups:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 75&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 30&nbsp;mg/m<sup>2</sup>
administered weekly for the first 5&nbsp;weeks in a 6&nbsp;week cycle for
5&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mitoxantrone
12&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>All 3&nbsp;regimens were administered in
combination with prednisone or prednisolone 5&nbsp;mg twice daily,
continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients who received docetaxel every
three weeks demonstrated significantly longer overall survival compared to
those treated with mitoxantrone. The increase in survival seen in the docetaxel
weekly arm was not statistically significant compared to the mitoxantrone
control arm. Efficacy endpoints for the docetaxel arms versus the control arm
are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=608
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Endpoint</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks </span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every week</span></p>
  </td>
  <td width=141 valign=top style='width:105.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Mitoxantrone </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  survival (months)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Hazard ratio</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>p-value<sup>&#8224;</sup>*</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>335</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(17.0-21.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.761</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.619-0.936)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0094</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>334</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>17.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.7-19.0)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.912</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.747-1.113)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.3624</span></p>
  </td>
  <td width=141 valign=top style='width:105.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>337</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.4-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>PSA** response
  rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>291</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>45.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(39.5-51.3)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0005</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>282</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>47.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(41.9-53.9)<br>
  &lt;0.0001</span></p>
  </td>
  <td width=141 valign=top style='width:105.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>300</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(26.4-37.3)<br>
  --</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>153</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(27.1-42.7)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0107</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>154</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(24.0-39.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0798</span></p>
  </td>
  <td width=141 valign=top style='width:105.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>157</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.5-28.9)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.7pt'>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Tumour
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>141</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(7.2-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.1112</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>134</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(4.2-14.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.5853</span></p>
  </td>
  <td width=141 valign=top style='width:105.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>137</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.0-12.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><sup><span lang=EN-GB>&#8224;</span></sup><span
lang=EN-GB>Stratified log-rank test<br>
*Threshold for statistical significance&nbsp;=&nbsp;0.0175</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**PSA:
Prostate-Specific Antigen<br>
<br>
</span></p>

<p class=Normal11pt><span lang=EN-GB>Given the fact that docetaxel every week
presented a slightly better safety profile than docetaxel every 3&nbsp;weeks,
it is possible that certain patients may benefit from docetaxel every week.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>No statistical differences were observed
between treatment groups for Global Quality of Life.</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Metastatic
hormone-sensitive prostate cancer</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>STAMPEDE </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered concomitantly with standard of care (ADT)<b> </b>in
patients with high-risk locally advanced or metastatic hormone-sensitive
prostate cancer were evaluated in a <span style='color:black'>randomised multi-centre,
multi-arm multi-stage (MAMS) study </span></span><span style='color:black'>with
a seamless phase II/III design</span><span style='font-size:11.0pt'> (STAMPEDE
&#8211; MRC PR08). A total of 1776 male patients were allocated to the
treatment arms of interest: </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>+ docetaxel 75
mg/m&sup2;, administered every 3 weeks for 6 cycles&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>alone<span
style='background:silver'> </span></span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Docetaxel regimen was
administered in combination with prednisone or prednisolone 5 mg &nbsp;twice daily
continuously. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Among the 1776 randomised
patients 1086 (61%) had metastatic disease, 362 were randomised to docetaxel in
combination with standard of care, 724 received standard of care<b> </b>alone. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In these metastatic prostate
cancer patients, the median overall survival was significantly longer in
docetaxel treatment groups than in the standard of care<b> </b>alone group,
with a median overall survival 19 months longer with the addition of docetaxel
to standard of care<b> </b>(HR =&nbsp; 0.76, 95% </span><span lang=EN-GB
style='font-size:11.0pt'>CI = 0.62-0.92,</span><span style='font-size:11.0pt'>
p=0.005). </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Efficacy results in
metastatic prostate cancer patients for </span><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span><span style='font-size:11.0pt'> arm
versus control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in combination with prednisone
or prednisolone and standard of care in the treatment of patients with
metastatic hormone-sensitive prostate cancer </span><span style='font-size:
11.0pt'>(STAMPEDE)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:maroon'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:11.0pt;
  color:black'>Endpoint</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span><span
  style='font-size:11.0pt;color:black'>+</span><span style='font-size:11.0pt;
  color:black'> standard of care</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Standard of care </span><span
  style='font-size:11.0pt;color:black'>alone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:59.05pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.05pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of metastatic prostate cancer
  patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months) </span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>362</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>51-73</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:59.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>724</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>43</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>40-48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>(0.62&#8209;0.92)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.005</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Failure-Free survival<i><span style='position:relative;
  top:-3.0pt'>b</span></i>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.8-25.2</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>9.6-12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:41.15pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:41.15pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:41.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.57&#8209;0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&lt; 0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.3pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>a </span></sup></i><span
  style='font-size:11.0pt;color:black'>p-value calculated from the likelihood
  ratio test and adjusted for all stratification factors (except center and
  planned hormone therapy) and stratified by trial period</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>b</span></sup></i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>
  Failure-free survival: time from randomization to first evidence of at least
  one of: biochemical failure (defined as a rise in PSA of 50% above the
  within-24-week nadir and above 4 ng/mL and confirmed by retest or treatment);
  progression either locally, in lymph nodes, or in distant metastases;
  skeletal-related event; or death from prostate cancer.</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:115%'><u><span style='font-size:11.0pt;
line-height:115%'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>CHAARTED </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered at the beginning of androgen-deprivation therapy (ADT) in
patients with metastatic hormone-sensitive prostate cancer were evaluated in a randomised
Phase III multi-centre study (CHAARTED). A total of 790 male patients were
allocated to the 2 treatment groups. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT + docetaxel
75 mg/m&sup2; given at the beginning of ADT, administered every 3 weeks for 6
cycles</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT alone<sup> </sup>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'><br>
The median overall survival was significantly longer in docetaxel treatment
group than in the ADT alone group, with a median overall survival 13.6
months&nbsp; longer with the addition of docetaxel to ADT (hazard ratio (HR) =
0.61, 95% </span><span lang=EN-GB style='font-size:11.0pt'>confidence interval
(CI)&nbsp;= 0.47-0.80, </span><span style='font-size:11.0pt'>p=0.0003). <br>
<br>
Efficacy results or the </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> arm versus the control arm are summarized in the
following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Efficacy
of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> and ADT in the treatment of patients with metastatic
hormone-sensitive prostate cancer (CHAARTED)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>Endpoint</span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=178 valign=top style='width:133.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span></b><b><span
   style='font-size:11.0pt;color:black'>+ADT </span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=112 valign=top style='width:83.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>ADT alone</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months)</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>All patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><i><span
  lang=IT style='font-size:11.0pt;color:black'>95% CI</span></i></b><span
  style='color:black'>Adjusted </span><span style='font-size:11.0pt;color:black'>hazard
  ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>397</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>57.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>49.1-72.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>393</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>44.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>34.4-49.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.47&#8209;0.80)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.0003</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Progression Free Survival</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value*</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.7-22.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.60</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.51-0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>P&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.6</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>10.8-14.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 6 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>127 (32.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>77 (19.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 12 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>110 (27.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>66 (16.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to castration-resistant prostate cancer<i><span
  style='position:relative;top:-3.0pt'>b</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months) </span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.2&#8209;23.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(10.8-14.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.51&#8209;0.72)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to clinical progression</span><i><span style='font-size:
  11.0pt;color:black;position:relative;top:-3.0pt'>c</span></i><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)<i><span style='position:relative;top:-3.0pt'> </span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>33.0</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(27.3-41.2)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.9-22.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.50-0.75)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.3pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>a</span></i><span style='font-size:11.0pt;color:black'>&nbsp;</span><span
  style='font-size:11.0pt;color:black'>Time to event variables: Stratified
  log-rank test. <br>
  &nbsp; Response rate variables: Fisher's Exact test</span><i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> </span></i></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>* p-value for
  descriptive purpose.</span></p>
  <p class=MsoCommentText><span style='font-size:11.0pt;color:black'>** </span><span
  lang=EN-GB style='color:black'>PSA r</span><span style='font-size:11.0pt;
  color:black'>esponse</span><span lang=EN-GB style='font-size:11.0pt;
  color:black'>: Prostate-Specific Antigen response: </span><span
  style='font-size:11.0pt;color:black'>PSA level &lt;0.2 ng/mL measured for two
  consecutive measurements at least 4 weeks apart.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>b </span></i><span style='font-size:11.0pt;color:black'>Time
  to castration-resistant prostate cancer = time from randomization to PSA progression
  </span><span lang=EN-GB style='color:black'>or clinical progression (i.e.,
  increasing symptomatic bone metastases, progression per </span><span
  style='font-size:11.0pt;color:black'>Response Evaluation Criteria in Solid
  Tumours (</span><span lang=EN-GB style='color:black'>RECIST) criteria, or
  clinical deterioration due to cancer per the Investigator&#8217;s opinion),
  whichever occurred first.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>c</span></i><span style='font-size:11.0pt;color:black'>&nbsp;The
  time to clinical progression = the time from randomization until clinical
  progression (i.e., increased symptoms of bone metastases; progression
  according to RECIST; or clinical deterioration due to cancer according to the
  investigator&#8217;s opinion).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A multi-centre, open-label, randomised
study was conducted to evaluate the safety and efficacy of docetaxel for the
treatment of patients with metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy
for metastatic disease. A total of 445&nbsp;patients with KPS&nbsp;&gt;&nbsp;70
were treated with either docetaxel&nbsp;(T) (75&nbsp;mg/m<sup>2</sup> on
day&nbsp;1) in combination with cisplatin&nbsp;(C) (75&nbsp;mg/m<sup>2</sup> on
day&nbsp;1) and 5&#8209;fluorouracil&nbsp;(F) (750&nbsp;mg/m<sup>2</sup> per
day for 5&nbsp;days) or cisplatin (100&nbsp;mg/m<sup>2</sup> on day&nbsp;1) and
5&#8209;fluorouracil (1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days). The
length of a treatment cycle was 3&nbsp;weeks for the TCF arm and 4&nbsp;weeks
for the CF arm. The median number of cycles administered per patient was 6 (with
a range of 1&#8209;16) for the TCF arm compared to 4 (with a range of 1&#8209;12)
for the CF arm. Time to progression (TTP) was the primary endpoint. The risk
reduction of progression was 32.1% and was associated with a significantly
longer TTP (p&nbsp;=&nbsp;0.0004) in favour of the TCF arm. Overall survival
was also significantly longer (p&nbsp;=&nbsp;0.0201) in favour of the TCF arm
with a risk reduction of mortality of 22.7%. Efficacy results are summarized in
the following table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the treatment of patients with gastric adenocarcinoma</span></u></p>

<p align=center style='margin:0in;text-align:center;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>TCF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;221</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;224</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median TTP (months)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>5.6</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>3.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(4.86-5.91)</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(3.45-4.47)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.473</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.189-1.825)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.2</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(8.38-10.58)</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(7.16-9.46)</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>2-year estimate (%)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18.4</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.293</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.041-1.606)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0201</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (CR+PR) (%)</span></p>
  </td>
  <td width=126 valign=top style='width:94.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36.7</span></p>
  </td>
  <td width=140 valign=top style='width:104.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0106</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progressive disease as best overall response (%)</span></p>
  </td>
  <td width=126 style='width:94.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.7</span></p>
  </td>
  <td width=140 style='width:104.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.9</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Unstratified
logrank test</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Subgroup analyses across age, gender and
race consistently favoured the TCF arm compared to the CF arm.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>A survival update analysis conducted with
a median follow-up time of 41.6&nbsp;months no longer showed a statistically
significant difference although always in favour of the TCF regimen and showed
that the benefit of TCF over CF is clearly observed between 18 and
30&nbsp;months of follow up.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Overall, quality of life (QoL) and
clinical benefit results consistently indicated improvement in favour of the
TCF arm. Patients treated with TCF had a longer time to 5% definitive<b> </b>deterioration
of global health status on the QLQ&#8209;C30 questionnaire
(p&nbsp;=&nbsp;0.0121) and a longer time to definitive worsening<b> </b>of
Karnofsky performance status (p&nbsp;=&nbsp;0.0088) compared to patients
treated with CF.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction</span><span lang=EN-GB
style='font-size:11.0pt'> chemotherapy followed by radiotherapy (TAX323)</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in
the induction treatment of patients with squamous cell carcinoma of the head
and neck (SCCHN) was evaluated in a phase&nbsp;III, multi-centre, open-label, randomised
study (TAX323). In this study, 358&nbsp;patients with inoperable locally
advanced SCCHN, and WHO performance status&nbsp;0 or 1, were randomised to one
of two treatment arms. Patients on the docetaxel arm received
docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2</sup> followed by cisplatin&nbsp;(P)
75&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
750&nbsp;mg/m<sup>2</sup> per day as a continuous infusion for 5&nbsp;days.
This regimen was administered every three weeks for 4&nbsp;cycles in case at
least a minor response (&#8805;&nbsp;25% reduction in bidimensionally measured
tumour size) was observed after 2&nbsp;cycles. At the end of chemotherapy, with
a minimal interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks,
patients whose disease did not progress received radiotherapy (RT) according to
institutional guidelines for 7&nbsp;weeks (TPF/RT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days. This regimen was administered
every three weeks for 4&nbsp;cycles in case at least a minor response
(&#8805;&nbsp;25% reduction in bidimensionally measured tumour size) was
observed after 2&nbsp;cycles. At the end of chemotherapy, with a minimal
interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks, patients whose
disease did not progress received radiotherapy&nbsp;(RT) according to
institutional guidelines for 7&nbsp;weeks (PF/RT). Locoregional therapy with
radiation was delivered either with a conventional fraction (1.8&nbsp;Gy&nbsp;&#8209;&nbsp;2.0&nbsp;Gy
once a day, 5&nbsp;days per week for a total dose of 66 to 70&nbsp;Gy), or
accelerated/hyperfractionated regimens of radiation therapy (twice a day, with
a minimum interfraction interval of 6&nbsp;hours, 5&nbsp;days per week). A
total of 70&nbsp;Gy was recommended for accelerated regimens and 74&nbsp;Gy for
hyperfractionated schemes. Surgical resection was allowed following
chemotherapy, before or after radiotherapy. Patients on the TPF arm received
antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice daily for
10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. The primary
endpoint in this study, progression-free survival (PFS), was significantly
longer in the TPF arm compared to the PF arm, p&nbsp;=&nbsp;0.0042 (median PFS:
11.4 vs. 8.3&nbsp;months respectively) with an overall median follow up time of
33.7&nbsp;months. Median overall survival was also significantly longer in favour
of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5&nbsp;months
respectively) with a 28% risk reduction of mortality, p&nbsp;=&nbsp;0.0128.
Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Efficacy of docetaxel in the induction
treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat
Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 style='margin-top:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;text-transform:none'>Endpoint</span></h1>
  </td>
  <td width=144 valign=top style='width:107.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;177</span></b></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;181</span></b></p>
  </td>
 </tr>
 <tr style='height:22.0pt'>
  <td width=318 valign=top style='width:238.15pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt><span lang=EN-GB>Median progression free survival
  (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.1-14.0)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>8.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.4-9.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Adjusted hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>*p-value</span></p>
  </td>
  <td width=288 colspan=2 valign=top style='width:215.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.55-0.89)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0042</span></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=318 valign=top style='width:238.15pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>18.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(15.7-24.0)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>14.5</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(11.6-18.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=288 colspan=2 valign=top style='width:215.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.56-0.93)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0128</span></p>
  </td>
 </tr>
 <tr>
  <td width=318 valign=top style='width:238.15pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to chemotherapy
  (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>67.8</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(60.4-74.6)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>53.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(46.0-61.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=288 colspan=2 valign=top style='width:215.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=318 valign=top style='width:238.15pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to study treatment
  [chemotherapy +/- radiotherapy] (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>72.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(65.1-78.8)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>58.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(51.0-65.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=288 colspan=2 valign=top style='width:215.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=318 valign=top style='width:238.15pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response to
  chemotherapy&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&plusmn;</span><span
  lang=EN-GB> radiotherapy (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;128</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>15.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(13.4-24.6)</span></p>
  </td>
  <td width=144 valign=top style='width:107.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;106</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.2-17.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=288 colspan=2 valign=top style='width:215.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.52-0.99)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0457</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>A hazard
ratio of less than&nbsp;1 favours docetaxel&nbsp;+ cisplatin&nbsp;+ 5&#8209;FU</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Cox model
(adjustment for Primary tumour site, T and N clinical stages and PSWHO)</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**Logrank
test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>***
Chi-square test</span></p>

<p class=MsoNormal style='margin-left:.5in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Quality of life parameters</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients treated with TPF experienced
significantly less deterioration of their Global health score compared to those
treated with PF (p&nbsp;=&nbsp;0.01, using the EORTC QLQ&#8209;C30 scale). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Clinical benefit parameters</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The performance status scale, for head and
neck (PSS&#8209;HN) subscales designed to measure understandability of speech,
ability to eat in public, and normalcy of diet, was significantly in favour of
TPF as compared to PF.</span></p>

<p class=Normal11pt><span lang=EN-GB>Median time to first deterioration of WHO
performance status was significantly longer in the TPF arm compared to PF.</span><span
lang=EN-GB style='layout-grid-mode:line'> Pain intensity score improved during
treatment in both groups indicating adequate pain management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:
line'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Induction
</span><span lang=EN-GB style='font-size:11.0pt'>chemotherapy</span><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'> followed by chemoradiotherapy
(TAX324)</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of docetaxel in the induction treatment of patients with locally
advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in
a randomised, multi-centre open-label, phase&nbsp;III study (TAX324). In this
study, 501&nbsp;patients, with locally advanced SCCHN, and a WHO performance
status of 0 or 1, were randomised to one of two arms. The study population
comprised patients with technically unresectable disease, patients with low
probability of surgical cure and patients aiming at organ preservation. The
efficacy and safety evaluation solely addressed survival endpoints and the
success of organ preservation was not formally addressed. Patients on the
docetaxel arm received docetaxel&nbsp;(T) 75&nbsp;mg/m&sup2; by intravenous
infusion on day 1 followed by cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2;
administered as a 30&#8209;minute to three-hour intravenous infusion, followed
by the continuous intravenous infusion of 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m&sup2;/day from day&nbsp;1 to day&nbsp;4. The cycles were
repeated every 3 weeks for 3 cycles. All patients who did not have progressive
disease were to receive chemoradiotherapy (CRT) as per protocol (TPF/CRT).
Patients on the comparator arm received cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2;
as a 30&#8209;minute to three&#8209;hour intravenous infusion on day&nbsp;1
followed by the continuous intravenous infusion of 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m&sup2;/day from day&nbsp;1 to day&nbsp;5. The cycles were
repeated every 3&nbsp;weeks for 3&nbsp;cycles. All patients who did not have
progressive disease were to receive CRT as per protocol (PF/CRT). </span></p>

<p class=Normal11pt><span lang=EN-GB>Patients in both treatment arms were to
receive 7&nbsp;weeks of CRT following induction chemotherapy with a minimum
interval of 3&nbsp;weeks and no later than 8&nbsp;weeks after start of the last
cycle (day&nbsp;22 to day&nbsp;56 of last cycle). During radiotherapy, carboplatin
(AUC&nbsp;1.5) was given weekly as a one&#8209;hour intravenous infusion for a
maximum of 7&nbsp;doses. Radiation was delivered with megavoltage equipment
using once daily fractionation (2&nbsp;Gy per day, 5&nbsp;days per week for
7&nbsp;weeks, for a total dose of 70&#8209;72&nbsp;Gy). Surgery on the primary
site of disease and/or neck could be considered at any time following
completion of CRT. All patients on the docetaxel-containing arm of the study
received prophylactic antibiotics. The primary efficacy endpoint in this study,
overall survival (OS) was significantly longer (log-rank test,
p&nbsp;=&nbsp;0.0058) with the docetaxel-containing regimen compared to PF
(median OS: 70.6 versus 30.1&nbsp;months respectively), with a 30% risk
reduction in mortality compared to PF (hazard ratio (HR)&nbsp;=&nbsp;0.70, 95%
confidence interval (CI)&nbsp;=&nbsp;0.54&#8209;0.90) with an overall median
follow up time of 41.9&nbsp;months. The secondary endpoint, PFS, demonstrated a
29% risk reduction of progression or death and a 22&nbsp;month improvement in
median PFS (35.5&nbsp;months for TPF and 13.1 for PF). This was also
statistically significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test
p&nbsp;=&nbsp;0.004. Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the induction treatment of patients with locally advanced SCCHN
(Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=258 valign=top style='width:193.2pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=169 valign=bottom style='width:126.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+
  Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  255</span></b></p>
  </td>
  <td width=169 valign=bottom style='width:126.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+
  5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  246</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  overall survival (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>70.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(49.0-NA)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>30.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(20.9-51.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 style='width:193.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>*p-value </span></p>
  </td>
  <td width=339 colspan=2 valign=top style='width:253.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.54-0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0058</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 style='width:193.2pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  PFS (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>35.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(19.3-NA)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(10.6 - 20.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>**p-value
  </span></p>
  </td>
  <td width=339 colspan=2 valign=bottom style='width:253.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.71</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.56 - 0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to chemotherapy (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.8</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.8-77.2)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(57.9-70.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=339 colspan=2 style='width:253.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.070</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to study treatment [chemotherapy +/-
  chemoradiotherapy] (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95%CI)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>76.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(70.8-81.5)</span></p>
  </td>
  <td width=169 valign=top style='width:126.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.5-77.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=258 valign=top style='width:193.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=339 colspan=2 style='width:253.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.209</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>A hazard ratio of less than 1 favours docetaxel&nbsp;+
cisplatin&nbsp;+ fluorouracil</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>*un-adjusted log-rank test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>**un-adjusted log-rank test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>***Chi square test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>NA-not applicable</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The European
Medicines Agency has waived the obligation to submit the results of studies
with TAXOTERE in all subsets of the paediatric population in breast cancer,
non-small cell lung cancer, prostate cancer, gastric carcinoma and head and
neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Absorption</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The pharmacokinetics of docetaxel have
been evaluated in cancer patients after administration of 20&#8209;115&nbsp;mg/m<sup>2</sup>
in phase&nbsp;I studies. The kinetic profile of docetaxel is dose independent
and consistent with a three-compartment pharmacokinetic model with half-lives
for the </span><span lang=EN-GB>a</span><span lang=EN-GB>, </span><span lang=EN-GB>b</span><span lang=EN-GB> and </span><span
lang=EN-GB>g</span><span lang=EN-GB>&nbsp;phases of 4&nbsp;min, 36&nbsp;min and
11.1&nbsp;h, respectively. The late phase is due, in part, to a relatively slow
efflux of docetaxel from the peripheral compartment. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Distribution</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Following the administration of a
100&nbsp;mg/m<sup>2</sup> dose given as a one&#8209;hour infusion a mean peak
plasma level of 3.7&nbsp;&micro;g/ml was obtained with a corresponding AUC of
4.6&nbsp;h.&micro;g/ml. Mean values for total body clearance and steady-state
volume of distribution were 21&nbsp;l/h/m<sup>2</sup> and 113&nbsp;l,
respectively. Inter individual variation in total body clearance was
approximately 50%. Docetaxel is more than 95% bound to plasma proteins.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A study of <sup>14</sup>C&#8209;docetaxel
has been conducted in three cancer patients. Docetaxel was eliminated in both
the urine and faeces following cytochrome P450&#8209;mediated oxidative
metabolism of the tert-butyl ester group, within seven days, the urinary and
faecal excretion accounted for about 6% and 75% of the administered
radioactivity, respectively. About 80% of the radioactivity recovered in faeces
is excreted during the first 48&nbsp;hours as one major inactive metabolite and
3&nbsp;minor inactive metabolites and very low amounts of unchanged medicinal
product.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Special populations</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Age and gender</span></i></p>

<p class=Normal11pt><span lang=EN-GB>A population pharmacokinetic analysis has
been performed with docetaxel in 577&nbsp;patients. Pharmacokinetic parameters
estimated by the model were very close to those estimated from phase&nbsp;I
studies. The pharmacokinetics of docetaxel were not altered by the age or sex
of the patient. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=Normal11pt><span lang=EN-GB>In a small number of patients
(n&nbsp;=&nbsp;23) with clinical chemistry data suggestive of mild to moderate
liver function impairment (ALT, AST&nbsp;</span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1.5&nbsp;times the ULN
associated with alkaline phosphatase </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;2.5&nbsp;times the ULN), total
clearance was lowered by 27% on average (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Fluid retention</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel clearance was not modified in
patients with mild to moderate fluid retention and there are no data available
in patients with severe fluid retention.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Combination therapy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Doxorubicin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>When used in combination, docetaxel does
not influence the clearance of doxorubicin and the plasma levels of
doxorubicinol (a doxorubicin metabolite). The pharmacokinetics of docetaxel,
doxorubicin and cyclophosphamide were not influenced by their co&#8209;administration.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Capecitabine</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Phase&nbsp;I study evaluating the effect
of capecitabine on the pharmacokinetics of docetaxel and vice versa showed no
effect by capecitabine on the pharmacokinetics of docetaxel (Cmax and AUC) and
no effect by docetaxel on the pharmacokinetics of a relevant capecitabine
metabolite 5&#8217;&#8209;DFUR.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Cisplatin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Clearance of docetaxel in combination
therapy with cisplatin was similar to that observed following monotherapy. <span
style='layout-grid-mode:line'>The pharmacokinetic profile of cisplatin
administered shortly after docetaxel infusion is similar to that observed with
cisplatin alone.</span></span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Cisplatin
and 5-fluorouracil</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The combined administration of docetaxel,
cisplatin and 5&#8209;fluorouracil in 12&nbsp;patients with solid tumours had
no influence on the pharmacokinetics of each individual medicinal product.</span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone
and dexamethasone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The effect of prednisone on the
pharmacokinetics of docetaxel administered with standard dexamethasone
premedication has been studied in 42&nbsp;patients. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Prednisone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>No effect of prednisone on the
pharmacokinetics of docetaxel was observed.</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.3&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The carcinogenic potential of docetaxel
has not been studied.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown to be mutagenic
in the <i>in vitro</i> micronucleus and chromosome aberration test in CHO&#8209;K1
cells and in the <i>in vivo</i> micronucleus test in the mouse. However, it did
not induce mutagenicity in the Ames test or the CHO/HGPRT gene mutation assay.
These results are consistent with the pharmacological activity of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Undesirable effects on the testis observed
in rodent toxicity studies suggest that docetaxel may impair male fertility.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=Normal11pt><span lang=EN-GB>Ethanol anhydrous</span></p>

<p class=Normal11pt><span lang=EN-GB>Citric acid</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>This medicinal product must not be mixed
with other medicinal products except those mentioned in section 6.6.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp; Shelf-life</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Unopened vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>2&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>After opening
of the vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is for
single use and should be used immediately after opening. If not used
immediately, in&#8209;use storage times and conditions are the responsibility
of the user. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TblTextLeft style='margin:0in;page-break-after:avoid'><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Once added to the </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>infusion </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>bag</span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>From a
microbiological point of view,</span><span lang=EN-GB style='font-size:11.0pt'>
reconstitution/dilution must take place in controlled and aseptic conditions</span><span
lang=EN-GB style='font-size:11.0pt'> and the medicinal product should be used
immediately. If not used immediately, in&#8209;use storage times and conditions
are the responsibility of the user</span><span lang=EN-GB style='font-size:
11.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Once added as
recommended into the infusion bag, the docetaxel infusion solution, if stored
below 25&deg;C, is stable for 6 hours. It should be used within 6 hours
(including the one hour infusion intravenous administration). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In addition,
physical and chemical in-use stability of the infusion solution prepared as
recommended has been demonstrated in non-PVC bags up to 48 hours when stored
between 2 to 8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel infusion
solution is supersaturated, therefore may crystallize over time. If crystals
appear, the solution must no longer be used and shall be discarded. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 25&deg;C. </span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Store in
the original package in order to protect from light.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>For storage
conditions of the diluted medicinal product, see section 6.3.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>7&nbsp;ml
clear glass (type&nbsp;I) vial with a green aluminium seal<i> </i>and a green
plastic flip&#8209;off cap containing 1&nbsp;ml of concentrate.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each box contains
one vial.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it and preparing TAXOTERE solutions. The use of gloves is recommended.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion
solution should come into contact with skin, wash immediately and thoroughly
with soap and water. If TAXOTERE concentrate or infusion solution should come
into contact with mucous membranes, wash immediately and thoroughly with water.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation for the intravenous
administration</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2&nbsp;vials (concentrate and
solvent) with this medicinal product (TAXOTERE 20&nbsp;mg/1&nbsp;ml concentrate
for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE
20&nbsp;mg/1&nbsp;ml </span></b><b><span lang=EN-GB style='font-size:11.0pt'>concentrate
for solution for infusion </span></b><b><span lang=EN-GB style='font-size:11.0pt'>requires
NO prior dilution with a solvent and is ready to add to the infusion solution.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is of
single use and should be used immediately.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If the vials are stored under
refrigeration, allow the required number of boxes of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> to
stand below 25&deg;C for 5&nbsp;minutes before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>More than one vial of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> may be
necessary to obtain the required dose for the patient. Aseptically withdraw the
required amount of TAXOTERE concentrate for solution for infusion using a
calibrated syringe fitted with a 21G needle.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 20&nbsp;mg /1&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=Normal11pt><span lang=EN-GB>The required volume of TAXOTERE concentrate
</span><span lang=EN-GB>for solution for infusion</span><span lang=EN-GB> must
be injected via a single injection (one shot) into a 250&nbsp;ml infusion bag
or bottle containing either 5% glucose solution or sodium chloride 9&nbsp;mg/ml
(0.9%) solution for infusion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If a dose greater than 190&nbsp;mg of
docetaxel is required, use a larger volume of the infusion vehicle so that a
concentration of 0.74&nbsp;mg/ml docetaxel is not exceeded. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Mix the infusion bag or bottle manually
using a rocking motion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The infusion bag solution should be used
within 6&nbsp;hours below 25&deg;C including the one hour infusion to the
patient.</span></p>

<p class=Normal11pt><span lang=EN-GB>As with all parenteral products, TAXOTERE
infusion solution should be visually inspected prior to use, solutions
containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/003</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: </span><span lang=EN-GB
style='font-size:11.0pt'>27 November 1995</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of latest renewal: 27 November 2005</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <u>http://www.ema.europa.eu</u> </span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 80&nbsp;mg/4&nbsp;ml concentrate
for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Each ml of concentrate contains 20&nbsp;mg
docetaxel (as trihydrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One&nbsp;vial of 4&nbsp;ml of concentrate
contains 80&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Excipient with known effect:</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Each vial of concentrate contains
2&nbsp;ml of ethanol anhydrous (1.58&nbsp;g). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is a pale yellow to
brownish-yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.1&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Breast cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin and cyclophosphamide is indicated for the adjuvant
treatment of patients with:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node- positive
breast cancer</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;negative
breast cancer .</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients with
operable node</span><span lang=EN-GB style='font-size:11.0pt'>&#8209;negative
breast cancer, adjuvant treatment should be restricted to patients eligible to
receive chemotherapy according to internationally established criteria for
primary therapy of early breast cancer (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin is indicated for the treatment of patients with
locally advanced or metastatic breast cancer who have not previously received
cytotoxic therapy for this condition.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE
monotherapy is indicated for the treatment of patients with locally advanced or
metastatic breast cancer after failure of cytotoxic therapy. Previous
chemotherapy should have included an anthracycline or an alkylating agent.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with trastuzumab is indicated for the treatment of patients with
metastatic breast cancer whose tumours over express HER2 and who previously
have not received chemotherapy for metastatic disease.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>TAXOTERE in combination with capecitabine is indicated for the
treatment of patients with locally advanced or metastatic breast cancer after
failure of cytotoxic chemotherapy. Previous therapy should have included an
anthracycline.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>TAXOTERE is
indicated for the treatment of patients with locally advanced or metastatic
non-small cell lung cancer after failure of prior chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with cisplatin is indicated for the treatment of patients with
unresectable, locally advanced or metastatic non-small cell lung cancer, in
patients who have not previously received chemotherapy for this condition.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Prostate
cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE in combination with prednisone or prednisolone
is indicated for the treatment of patients with&nbsp; metastatic </span><span
lang=EN-GB style='font-size:11.0pt'>castration-resistant</span><span
lang=EN-GB style='font-size:11.0pt'> prostate cancer.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in combination with androgen-deprivation therapy (ADT),
with or without prednisone or prednisolone, is</span><span lang=EN-GB>
indicated for the treatment of patients with metastatic hormone-sensitive
prostate cancer.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the treatment of patients with metastatic
gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal
junction, who have not received prior chemotherapy for metastatic disease.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Head and neck cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the induction treatment of patients with
locally advanced squamous cell carcinoma of the head and neck.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The use of docetaxel should be confined to
units specialised in the administration of cytotoxic chemotherapy and it should
only be administered under the supervision of a physician qualified in the use
of anticancer chemotherapy (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Posology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast, non-small cell lung, gastric,
and head and neck cancers, premedication consisting of an oral corticosteroid,
such as dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for
3&nbsp;days starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can be used (see section 4.4). <br>
For metastatic castration-resistant prostate cancer, given the concurrent use
of prednisone or prednisolone the recommended premedication regimen is oral
dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour before the
docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>For metastatic hormone-sensitive prostate
cancer, irrespective of the concurrent use of prednisone or prednisolone, the
recommended premedication regimen is oral dexamethasone 8&nbsp;mg 12 hours, 3
hours, and 1 hour before docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB style='font-variant:small-caps'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Prophylactic G&#8209;CSF may be used to
mitigate the risk of haematological toxicities.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is administered as a one-hour
infusion every three weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>In the adjuvant treatment of operable
node-positive and node&#8209;negative breast cancer, the recommended dose of
docetaxel is 75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour after
doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 6&nbsp;cycles (TAC regimen) (see also Dose adjustments
during treatment). </span></p>

<p class=Normal11pt><span lang=EN-GB>For the treatment of patients with locally
advanced or metastatic breast cancer, the recommended dose of docetaxel is
100&nbsp;mg/m<sup>2</sup> in monotherapy. In first-line treatment, docetaxel
75&nbsp;mg/m<sup>2 </sup>is given in combination therapy with doxorubicin<sup> </sup>(50&nbsp;mg/m<sup>2</sup>).
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with trastuzumab the
recommended dose of docetaxel is 100&nbsp;mg/m<sup>2</sup> every three weeks,
with trastuzumab administered weekly. In the pivotal study the initial
docetaxel infusion was started the day following the first dose of trastuzumab.
The subsequent docetaxel doses were administered immediately after completion
of the trastuzumab infusion, if the preceding dose of trastuzumab was well
tolerated. For trastuzumab dose and administration, see trastuzumab summary of
product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> every three weeks,
combined with capecitabine at 1250&nbsp;mg/m<sup>2</sup> twice daily (within
30&nbsp;minutes after a meal) for 2&nbsp;weeks followed by a 1&#8209;week rest
period. For capecitabine dose calculation according to body surface area, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>In
chemotherapy na&iuml;ve patients treated for non-small cell lung cancer, the
recommended dose regimen is docetaxel 75&nbsp;mg/m<sup>2 </sup>immediately followed
by cisplatin 75&nbsp;mg/m<sup>2 </sup>over 30-60&nbsp;minutes. For treatment
after failure of prior platinum-based chemotherapy, the recommended dose is
75&nbsp;mg/m&sup2; as a single agent.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer </span></u></i></p>

<p class=Normal11pt><i><span style='color:black'>Metastatic castration-resistant
prostate cancer</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>.
Prednisone or prednisolone 5&nbsp;mg orally twice daily is administered
continuously (see section 5.1).</span></p>

<p class=MsoNormal><i><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic
hormone-sensitive prostate cancer</span></i></p>

<p class=Normal11pt><span style='color:black'>The recommended dose of </span><span
lang=EN-GB>docetaxel </span><span style='color:black'>is 75&nbsp;mg/m<sup>2</sup>
every 3 weeks for 6 cycles. Prednisone or prednisolone 5&nbsp;mg orally twice
daily may be administered continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> as a 1-hour infusion, followed by cisplatin
75&nbsp;mg/m<sup>2</sup>, as a 1- to 3-hour infusion (both on day&nbsp;1 only),
followed by 5&#8209;fluorouracil 750&nbsp;mg/m<sup>2</sup> per day given as a
24&#8209;hour continuous infusion for 5&nbsp;days, starting at the end of the
cisplatin infusion. Treatment is repeated every three weeks. Patients must
receive premedication with antiemetics and appropriate hydration for cisplatin
administration. Prophylactic G&#8209;CSF should be used to mitigate the risk of
haematological toxicities (see also Dose adjustments during treatment).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients must receive premedication with
antiemetics and appropriate hydration (prior to and after cisplatin
administration). Prophylactic G&#8209;CSF may be used to mitigate the risk of
haematological toxicities. All patients on the docetaxel-containing arm of the
TAX&nbsp;323 and TAX&nbsp;324 studies, received prophylactic antibiotics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed
by radiotherapy (TAX&nbsp;323)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of inoperable locally advanced squamous
cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel
is 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion followed by cisplatin
75&nbsp;mg/m<sup>2</sup> over 1 hour, on day one, followed by 5&#8209;fluorouracil
as a continuous infusion at 750&nbsp;mg/m<sup>2</sup> per day for five days.
This regimen is administered every 3&nbsp;weeks for 4&nbsp;cycles. Following
chemotherapy, patients should receive radiotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by chemoradiotherapy (TAX&nbsp;324)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of patients with locally advanced
(technically unresectable, low probability of surgical cure, and aiming at
organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1 hour
intravenous infusion on day&nbsp;1, followed by cisplatin 100&nbsp;mg/m<sup>2 </sup>administered
as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000&nbsp;mg/m<sup>2</sup>/day
as a continuous infusion from day&nbsp;1 to day&nbsp;4. This regimen is
administered every 3&nbsp;weeks for 3&nbsp;cycles. Following chemotherapy,
patients should receive chemoradiotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose modifications, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Dose adjustments during treatment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>General </span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel should be administered when the
neutrophil count is </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.
</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients who experienced either febrile
neutropenia, neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for more
than one week, severe or cumulative cutaneous reactions or severe peripheral
neuropathy during docetaxel therapy, the dose of docetaxel should be reduced
from 100&nbsp;mg/m<sup>2</sup> to 75&nbsp;mg/m<sup>2</sup> and/or from 75 to
60&nbsp;mg/m&sup2;. If the patient continues to experience these reactions at
60&nbsp;mg/m&sup2;, the treatment should be discontinued. </span></p>

<p class=Normal11pt><span class=BoldCharacter><span style='text-transform:uppercase'>&nbsp;</span></span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Adjuvant
therapy for breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Primary G&#8209;CSF
prophylaxis should be considered in patients who receive docetaxel, doxorubicin
and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who
experience febrile neutropenia and/or neutropenic infection should have their
docetaxel dose reduced to 60&nbsp;mg/m&sup2; in all subsequent cycles (see
sections 4.4 and 4.8). Patients who experience Grade&nbsp;3 or 4 stomatitis
should have their dose decreased to 60&nbsp;mg/m&sup2;.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who are dosed initially at
docetaxel 75&nbsp;mg/m<sup>2</sup> in combination with cisplatin and whose
nadir of platelet count during the previous course of therapy is
&lt;&nbsp;25,000&nbsp;cells/mm<sup>3</sup>, or<sup> </sup>in patients who
experience febrile neutropenia, or in patients with serious non-haematologic
toxicities, the docetaxel dose in subsequent cycles should be reduced to
65&nbsp;mg/m<sup>2</sup>. For cisplatin dose adjustments, see the corresponding
summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with capecitabine</span></u></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For capecitabine dose modifications, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the first
appearance of Grade&nbsp;2 toxicity, which persists at the time of the next docetaxel/capecitabine
treatment, delay treatment until resolved to Grade&nbsp;0&#8209;1, and resume
at 100% of the original dose. </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the second
appearance of Grade&nbsp;2 toxicity, or the first appearance of Grade&nbsp;3
toxicity, at any time during the treatment cycle, delay treatment until
resolved to Grade&nbsp;0&#8209;1 and then resume treatment with docetaxel
55&nbsp;mg/m&sup2;. </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For any subsequent appearances of
toxicities, or any Grade&nbsp;4 toxicities, discontinue the docetaxel dose.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For trastuzumab dose modifications, see
trastuzumab summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If an episode of febrile neutropenia,
prolonged neutropenia or neutropenic infection occurs despite G&#8209;CSF use,
the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>. If
subsequent episodes of complicated neutropenia occur the docetaxel dose should
be reduced from 60 to 45&nbsp;mg/m<sup>2</sup>. In case of Grade&nbsp;4
thrombocytopenia the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>.
Patients should not be retreated with subsequent cycles of docetaxel until
neutrophils recover to a level &gt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup> and
platelets recover to a level &gt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>.
Discontinue treatment if these toxicities persist (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>Recommended dose modifications for
toxicities in patients treated with docetaxel in combination with cisplatin and
5&#8209;fluorouracil (5&#8209;FU):</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Toxicity</span></b></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Dose adjustment</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: then reduce docetaxel
  dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce docetaxel and 5&#8209;FU
  doses by 20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: stop 5&#8209;FU only, at
  all subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Third episode: reduce docetaxel dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: stop 5&#8209;FU only, at
  all subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: reduce docetaxel dose by
  20%.</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose adjustments, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the pivotal SCCHN studies patients who
experienced complicated neutropenia (including prolonged neutropenia, febrile
neutropenia, or infection), it was recommended to use G&#8209;CSF to provide
prophylactic coverage (eg, day&nbsp;6&#8209;15) in all subsequent cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Patients
with hepatic impairment</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Based on pharmacokinetic
data with docetaxel at 100&nbsp;mg/m&sup2; as single agent, patients who have
both elevations of transaminase (ALT and/or AST) greater than 1.5&nbsp;times
the upper limit of the normal range (ULN) and alkaline phosphatase greater than
2.5&nbsp;times the ULN, the recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup>
(see sections 4.4 and 5.2). For those patients with serum bilirubin
&gt;&nbsp;ULN and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN
associated with alkaline phosphatase &gt;&nbsp;6&nbsp;times the ULN, no
dose-reduction can be recommended and docetaxel should not be used unless
strictly indicated. </span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available in
patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of TAXOTERE in nasopharyngeal carcinoma in children aged 1 month to
less than 18 years have not yet been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There is no
relevant use of TAXOTERE in the paediatric population in the indications breast
cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head
and neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Older people</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Based on a population pharmacokinetic analysis,
there are no special instructions for use in the older people.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, for
patients 60&nbsp;years of age or more, a starting dose reduction of
capecitabine to 75% is recommended (see capecitabine summary of product
characteristics).</span></p>

<p class=Normal2 align=left style='text-align:left;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>For instructions on preparation and administration of
the product, see section</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;6.6.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity to the active substance
or to any of the excipients listed in section 6.1. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with baseline neutrophil count of
&lt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe liver impairment (see
sections 4.2 and 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Contraindications for other medicinal
products also apply, when combined with docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast and non-small cell lung
cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can reduce the incidence and severity of fluid retention as well as the
severity of hypersensitivity reactions. For prostate cancer, the premedication
is oral dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour
before the docetaxel infusion (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Haematology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Neutropenia is the most frequent adverse
reaction of docetaxel. Neutrophil nadirs occurred at a median of 7&nbsp;days
but this interval may be shorter in heavily pre&#8209;treated patients.
Frequent monitoring of complete blood counts should be conducted on all
patients receiving docetaxel. Patients should be retreated with docetaxel when
neutrophils recover to a level </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm3 (see
section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the case of severe neutropenia
(&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for seven days or more) during a course
of docetaxel therapy, a reduction in dose for subsequent courses of therapy or
the use of appropriate symptomatic measures are recommended (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel in
combination with cisplatin and 5&#8209;fluorouracil (TCF), febrile neutropenia
and neutropenic infection occurred at lower rates when patients received
prophylactic G&#8209;CSF. Patients treated with TCF should receive prophylactic
G&#8209;CSF to mitigate the risk of complicated neutropenia (febrile
neutropenia, prolonged neutropenia or neutropenic infection). Patients
receiving TCF should be closely monitored (see sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with doxorubicin and cyclophosphamide
(TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates
when patients received primary G&#8209;CSF prophylaxis. Primary G&#8209;CSF
prophylaxis should be considered in patients who receive adjuvant therapy with
TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile
neutropenia, prolonged neutropenia or neutropenic infection). Patients
receiving TAC should be </span><span lang=EN-GB style='font-size:11.0pt'>closely
monitored (see sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Gastrointestinal reactions</span></u></p>

<p class=MsoNormal style='margin-left:15.85pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Caution is recommended for
patients with </span><span style='font-size:11.0pt'>neutropenia,</span><span
style='font-size:11.0pt'> particularly at risk for developing gastrointestinal
complications</span><span style='font-size:11.0pt'>. Although majority of cases
occurred during the first or second cycle of docetaxel containing regimen, e</span><span
lang=EN-GB style='font-size:11.0pt'>nterocolitis could develop at any time, and
could lead to death as early as on the first day of onset. Patients should be
closely monitored for early manifestations of serious gastrointestinal toxicity
(see sections 4.2, 4.4 Haematology, and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Hypersensitivity reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients should be observed closely for
hypersensitivity reactions especially during the first and second infusions. Hypersensitivity
reactions may occur within a few minutes following the initiation of the
infusion of docetaxel, thus facilities for the treatment of hypotension and
bronchospasm should be available. If hypersensitivity reactions occur, minor
symptoms such as flushing or localised cutaneous reactions do not require
interruption of therapy. However, severe reactions, such as severe hypotension,
bronchospasm or generalised rash/erythema require immediate discontinuation of
docetaxel and appropriate therapy. Patients who have developed severe
hypersensitivity reactions should not be re-challenged with docetaxel. </span><span
lang=EN-GB>Patients who have previously experienced a hypersensitivity reaction
to paclitaxel may be at risk to develop hypersensitivity reaction to docetaxel,
including more severe hypersensitivity reaction. These patients should be
closely monitored during initiation of docetaxel therapy</span>.</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Cutaneous reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Localised skin erythema of the extremities
(palms of the hands and soles of the feet) with oedema followed by desquamation
has been observed. Severe symptoms such as eruptions followed by desquamation
which lead to interruption or discontinuation of docetaxel treatment were
reported (see section 4.2). </span></p>

<p class=00-Paragraph><span lang=EN-GB>Severe Cutaneous Adverse Reactions
(SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis</span><sup><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial Narrow",sans-serif'> </span></sup><span
lang=EN-GB>(TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have
been reported with docetaxel treatment. Patients should be informed about the
signs and symptoms of serious skin manifestations and closely monitored</span><strong><span
lang=EN-GB style='font-family:"Segoe UI",sans-serif;color:#444444;font-weight:
normal'>. </span></strong><span lang=EN-GB>If signs and symptoms suggestive of
these reactions appear discontinuation of docetaxel should be considered.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Fluid retention</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe fluid retention such
as pleural effusion, pericardial effusion and ascites should be monitored closely.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Respiratory
disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung
disease, pulmonary fibrosis and respiratory failure have been reported and </span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>may be associated </span></span><span
lang=EN-GB style='font-size:11.0pt'>with fatal outcome. </span><span
class=BlueReplace><span lang=EN-GB style='color:windowtext'>Cases of radiation pneumonitis
have been reported in patients receiving concomitant radiotherapy.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If new or
worsening pulmonary symptoms develop, patients should be closely monitored,
promptly investigated, and appropriately treated. Interruption of docetaxel
therapy is recommended</span><span style='font-size:11.0pt'> until diagnosis is
available</span><span lang=EN-GB style='font-size:11.0pt'>. Early use of
supportive care measures may help improve the condition. The benefit of
resuming docetaxel treatment must be carefully evaluated.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Patients with liver impairment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel at 100&nbsp;mg/m<sup>2</sup>
as single agent who have serum transaminase levels (ALT and/or AST) greater
than 1.5&nbsp;times the ULN concurrent with serum alkaline phosphatase levels
greater than 2.5&nbsp;times the ULN, there is a higher risk of developing
severe adverse reactions such as toxic deaths including sepsis and
gastrointestinal haemorrhage which can be fatal, febrile neutropenia,
infections, thrombocytopenia, stomatitis and asthenia. Therefore, the recommended
dose of docetaxel in those patients with elevated liver function test (LFTs) is
75&nbsp;mg/m<sup>2</sup> and LFTs should be measured at baseline and before
each cycle (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>For patients with serum bilirubin levels
&gt;&nbsp;ULN and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN
concurrent with serum alkaline phosphatase levels &gt;&nbsp;6&nbsp;times the
ULN, no dose-reduction can be recommended and docetaxel should not be used
unless strictly indicated.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available
in patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Patients with renal impairment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>There are no data available in patients
with severely impaired renal function treated with docetaxel. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The development
of severe peripheral neurotoxicity requires a reduction of dose (see section
4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
toxicity</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Heart
failure has been observed in patients receiving docetaxel in combination with
trastuzumab, particularly following anthracycline (doxorubicin or epirubicin)-containing
chemotherapy. This may be moderate to severe and has been associated with death
(see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>When patients are candidates for treatment
with docetaxel in combination with trastuzumab, they should undergo baseline
cardiac assessment. Cardiac function should be further monitored during
treatment (e.g. every three months) to help identify patients who may develop
cardiac dysfunction. For more details see summary of product characteristics of
trastuzumab.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including ventricular
tachycardia (sometimes fatal) has been reported in patients treated with
docetaxel in combination regimens including doxorubicin, 5-fluorouracil and/ or
cyclophosphamide (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>Baseline cardiac assessment is recommended.
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><strong><u><span
lang=EN-GB style='font-size:11.0pt;font-weight:normal'>Eye disorders</span></u></strong></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Cystoid macular oedema (CMO) has been
reported in patients treated with docetaxel. Patients with impaired vision
should undergo a prompt and complete ophthalmologic examination. In case CMO is
diagnosed, docetaxel treatment should be discontinued and appropriate treatment
initiated (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies have been reported when docetaxel was given in combination with
anticancer treatments known to be associated with second primary malignancies. Second
primary malignancies (including acute myeloid leukaemia, myelodysplastic
syndrome and non-Hodgkin lymphoma) may occur several months or years after
docetaxel-containing therapy. Patients should be monitored for second primary
malignancies (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Tumour Lysis
Syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tumour lysis
syndrome has been reported with docetaxel after the first or the second cycle
(see section 4.8). Patients at risk of tumour lysis syndrome (e.g. with renal
impairment, hyperuricemia, bulky tumour, rapid progression) should be closely
monitored. Correction of dehydration and treatment of high uric acid levels are
recommended prior to initiation of </span><span lang=EN-GB style='font-size:
11.0pt'>treatment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Others</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Contraceptive measures must be
taken by both men and women during treatment and for men at least &nbsp;6&nbsp;months
after cessation of therapy (see section 4.6).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The concomitant use of docetaxel
with strong CYP3A4 inhibitors </span><span style='font-family:"Times New Roman",serif;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole)
should be avoided (see section 4.5).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Additional cautions for use in adjuvant
treatment of breast cancer</span></u></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Complicated neutropenia</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who experience complicated
neutropenia (prolonged neutropenia, febrile neutropenia or infection), G&#8209;CSF
and dose reduction should be considered (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Gastrointestinal
reactions</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Symptoms
such as early abdominal pain and tenderness, fever, diarrhoea, with or without
neutropenia, may be early manifestations of serious gastrointestinal toxicity
and should be evaluated and treated promptly.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Congestive
heart failure (CHF)</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Patients
should be monitored for symptoms of congestive heart failure during therapy and
during the follow up period.</span><span lang=EN-GB> In patients treated with
the TAC regimen for node positive breast cancer, the risk of CHF has been shown
to be higher during the first year after treatment (see sections 4.8 and 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Patients with 4+ nodes</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>As the benefit observed in patient with 4+
nodes was not statistically significant on disease&#8209;free survival (DFS) and
overall survival (OS), the positive benefit/risk ratio for TAC in patients with
4+&nbsp;nodes was not fully demonstrated at the final analysis (see section
5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Elderly</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in adjuvant
treatment of breast cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There are limited data available in
patients &gt;&nbsp;70&nbsp;years of age on docetaxel use in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in castration-resistant
prostate cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Of the 333&nbsp;patients treated with docetaxel
every three weeks in a prostate cancer study </span><span lang=EN-GB>(TAX 327)</span><span
lang=EN-GB>, 209&nbsp;patients were 65&nbsp;years of age or greater and
68&nbsp;patients were older than 75&nbsp;years. In patients treated with
docetaxel every three weeks, the incidence of related nail changes occurred at
a rate </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;10% higher in patients who were 65&nbsp;years of age or
greater compared to younger patients. The incidence of related fever,
diarrhoea, anorexia, and peripheral oedema occurred at rates </span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10%
higher in patients who were 75&nbsp;years of age or greater versus less than
65&nbsp;years.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Cautions for use in hormone-sensitive
prostate cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>Of the
</span><span style='font-size:11.0pt;color:black'>545 </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>patients treated with docetaxel every 3 weeks</span><span
style='font-size:11.0pt;color:black'> in a hormone-sensitive prostate cancer
study (STAMPEDE)</span><span lang=EN-GB style='font-size:11.0pt;color:black'>, </span><span
style='font-size:11.0pt;color:black'>296 patients were 65 years of age or
older, and 48 patients were 75 years of age or older</span><span lang=EN-GB
style='font-size:11.0pt;color:black'>. </span><span style='font-size:11.0pt;
color:black'>More patients aged &#8805;65 years in the docetaxel arm reported
hypersensitivity reaction, neutropenia, anaemia, fluid retention, dyspnea, and
nail changes when compared to the patients aged less than 65 years. None of
these increases in frequency reached 10% difference with the control arm.</span><span
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>In
patients who were 75&nbsp;years of age or older, when compared to younger
patients,</span><span style='font-size:11.0pt'> neutropenia, anaemia, diarrhea,
dyspnea and upper respiratory tract infection were reported</span><span
style='font-size:11.0pt'> </span><span style='font-size:11.0pt'>with a greater
incidence (at least 10% higher)</span><span lang=EN-GB style='font-size:11.0pt'>.
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in gastric
adenocarcinoma cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Among the 300 (221&nbsp;patients in the
phase&nbsp;III part of the study and 79&nbsp;patients in the phase&nbsp;II
part) patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
in the gastric cancer study, 74 were 65&nbsp;years of age or older and
4&nbsp;patients were 75&nbsp;years of age or older. The incidence of serious
adverse events was higher in older people compared to younger patients. The
incidence of the following adverse events (all grades): lethargy, stomatitis,
neutropenic infection occurred at rates </span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10% higher in
patients who were 65&nbsp;years of age or older compared to younger patients. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Older people
treated with TCF should be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 1.58&nbsp;g ethanol anhydrous per vial, equivalent to 40&nbsp;ml of
beer or 17&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, children and high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>Consideration
should be given to possible effects on the central nervous system.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'> studies have shown that the metabolism of docetaxel may be modified by
the concomitant administration of compounds which induce, inhibit or are
metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450&#8209;3A
such as ciclosporine, ketoconazole and erythromycin. As a result, caution should
be exercised when treating patients with these medicinal products as
concomitant therapy since there is a potential for a significant interaction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In case of
combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse
reactions may increase, as a result of reduced metabolism. If the concomitant
use of a strong CYP3A4 inhibitor </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) </span><span
lang=EN-GB style='font-size:11.0pt'>cannot be avoided, a close clinical
surveillance is warranted and a dose-adjustment of docetaxel may be suitable
during the treatment with the strong CYP3A4 inhibitor (see section 4.4). </span><span
lang=EN-GB style='font-size:11.0pt'>In a pharmacokinetic study with 7 patients,
the co-administration of docetaxel with the strong CYP3A4 inhibitor
ketoconazole leads to a&nbsp;significant decrease in docetaxel clearance by
49%.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Docetaxel pharmacokinetics in the
presence of prednisone was studied in patients with metastatic prostate cancer.
Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4. No
statistically significant effect of prednisone on the pharmacokinetics of
docetaxel was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
highly protein bound (&gt;&nbsp;95%). Although the possible <i>in vivo</i>
interaction of docetaxel with concomitantly administered medicinal product has
not been investigated formally, <i>in vitro</i> interactions with tightly
protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did
not affect protein binding of docetaxel. In addition, dexamethasone did not
affect protein binding of docetaxel. Docetaxel did not influence the binding of
digitoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not
influenced by their co&#8209;administration. Limited data from a single
uncontrolled study were suggestive of an interaction between docetaxel and
carboplatin. When combined to docetaxel, the clearance of carboplatin was about
50% higher than values previously reported for carboplatin monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>There is no information on the use of docetaxel in
pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic
in rabbits and rats, and to reduce fertility in rats. As with other cytotoxic
medicinal products, docetaxel may cause foetal harm when administered to
pregnant women. Therefore, docetaxel must not be used during pregnancy unless
clearly indicated.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Women of childbearing age receiving docetaxel should
be advised to avoid becoming pregnant, and to inform the treating physician
immediately should this occur.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is a lipophilic
substance but it is not known whether it is excreted in human milk.
Consequently, because of the potential for adverse reactions in nursing
infants, breast feeding must be discontinued for the duration of docetaxel
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Contraception
in males and females</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>An effective
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>In non clinical studies, docetaxel has genotoxic
effects and may alter male fertility (see section 5.3). Therefore, men being
treated with docetaxel are advised not to father a child during and up to
6&nbsp;months after treatment and to seek advice on conservation of sperm prior
to treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use
machines</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No studies on the
effects on the ability to drive and use machines have been performed. The
amount of alcohol in this </span><span lang=EN-GB style='font-size:11.0pt'>medicinal
product </span><span style='font-size:11.0pt'>and the side effects</span><span
lang=EN-GB style='font-size:11.0pt'> of the product may impair the ability to
drive or use machines (see sections 4.4</span><span style='font-size:11.0pt'>
and 4.8</span><span lang=EN-GB style='font-size:11.0pt'>). Therefore, patients
should be warned of the potential impact of the amount of alcohol and the side
effects of this medicinal product on the ability to drive or use machines, and
be advised not to drive or use machines if they experience these side effects
during treatment.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile for all indications</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The adverse
reactions considered to be possibly or probably related to the administration
of docetaxel have been obtained in: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
     style='font-size:11.0pt'>1312 and 121&nbsp;patients who received
     100&nbsp;mg/m&sup2;<sup> </sup>and 75&nbsp;mg/m&sup2; of docetaxel as a
     single agent respectively.</span></li>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
     style='font-size:11.0pt'>258&nbsp;patients who received docetaxel in
     combination with doxorubicin. </span></li>
 <li class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
     style='font-size:11.0pt'>406&nbsp;patients who received docetaxel in
     combination with cisplatin. </span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>92&nbsp;patients
treated with docetaxel in combination with trastuzumab. </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>255&nbsp;patients
     who received docetaxel in combination with capecitabine.</span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>332&nbsp;patients
</span><span style='font-family:"Times New Roman",serif'>(TAX327) </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>who received docetaxel
in combination with prednisone or prednisolone (clinically important treatment
related adverse events are presented).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1276&nbsp;patients
     (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel
     in combination with doxorubicin and cyclophosphamide (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>300&nbsp;gastric
     adenocarcinoma patients (221&nbsp;patients in the phase&nbsp;III part of
     the study and 79&nbsp;patients in the phase&nbsp;II part) who received
     docetaxel in combination with cisplatin and 5&#8209;fluorouracil
     (clinically important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>174 and
     251&nbsp;head and neck cancer patients who received docetaxel in
     combination with cisplatin and 5&#8209;fluorouracil (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>545 patients
     (STAMPEDE study) who received docetaxel in combination with prednisone or prednisolone
     and ADT.</span></li>
</ul>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>These reactions were described using the NCI Common
Toxicity Criteria (grade&nbsp;3&nbsp;=&nbsp;G3; grade&nbsp;3&#8209;4&nbsp;=&nbsp;G3/4;
grade&nbsp;4&nbsp;=&nbsp;G4), the COSTART and the MedDRA terms. Frequencies are
defined as: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to
&lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from available data).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse
reactions of docetaxel alone are: neutropenia (which was reversible and not
cumulative; the median day to nadir was 7&nbsp;days and the median duration of
severe neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) was 7&nbsp;days), anaemia,
alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The severity of
adverse events of docetaxel may be increased when docetaxel is given in
combination with other chemotherapeutic agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with trastuzumab, adverse
events (all grades) reported in &#8805;&nbsp;10% are displayed. There was an
increased incidence of SAEs (40% vs. 31%) and Grade&nbsp;4 AEs (34% vs. 23%) in
the trastuzumab combination arm compared to docetaxel monotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with capecitabine, the
most frequent treatment-related undesirable effects (&#8805;&nbsp;5%) reported
in a phase&nbsp;III study in breast cancer patients failing anthracycline
treatment are presented (see capecitabine summary of product characteristics).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring
over the 6 cycles of treatment with docetaxel and having at least 2% higher
incidence in the docetaxel treatment arm by comparison to the control arm, are
presented, using the CTCAE grading scale.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following adverse reactions are
frequently observed with docetaxel:</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Immune
system disorders</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
reactions have generally occurred within a few minutes following the start of
the infusion of docetaxel and were usually mild to moderate. The most
frequently reported symptoms were flushing, rash with or without pruritus,
chest tightness, back pain, dyspnoea and fever or chills. Severe reactions were
characterised by hypotension and/or bronchospasm or generalized rash/erythema
(see section 4.4).</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
development of severe peripheral neurotoxicity requires a reduction of dose
(see sections 4.2 and 4.4). Mild to moderate neuro-sensory signs are characterised
by paresthesia, dysesthesia or pain including burning. Neuro-motor events are
mainly characterised by weakness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Reversible cutaneous reactions have been
observed and were generally considered as mild to moderate. Reactions were
characterised by a rash including localised eruptions mainly on the feet and
hands (including severe hand and foot syndrome), but also on the arms, face or
thorax, and frequently associated with pruritus. Eruptions generally occurred
within one week after the docetaxel infusion. Less frequently, severe symptoms
such as eruptions followed by desquamation which rarely lead to interruption or
discontinuation of docetaxel treatment were reported (see sections 4.2 and
4.4). Severe nail disorders are characterised by hypo- or hyperpigmentation and
sometimes pain and onycholysis. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>General disorders and administration
site conditions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Infusion site reactions were generally
mild and consisted of hyper pigmentation, inflammation, redness or dryness of
the skin, phlebitis or extravasation and swelling of the vein.</span></p>

<p class=Normal11pt><span lang=EN-GB>Fluid retention includes events such as
peripheral oedema and less frequently pleural effusion, pericardial effusion,
ascites and weight gain. The peripheral oedema usually starts at the lower
extremities and may become generalised with a weight gain of 3&nbsp;kg or more.
Fluid retention is cumulative in incidence and severity (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for </span><span lang=EN-GB>TAXOTERE 100&nbsp;mg/m&sup2; single
agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDR<span style='color:black'>A system organ classes</span></span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections (G3/4: 5.7%; including sepsis
  and pneumonia, fatal in 1.7%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection associated with G4 neutropenia
  (G3/4: 4.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 76.4%); <br>
  Anaemia (G3/4: 8.9%); <br>
  Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Thrombocytopenia (G4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 5.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3:
  4.1%); <br>
  Peripheral motor neuropathy (G3/4: 4%); <br>
  Dysgeusia (severe: 0.07%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension; <br>
  Hypertension;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Haemorrhage</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspnoea (severe: 2.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 5.3%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 4%); <br>
  Nausea (G3/4: 4%); <br>
  Vomiting (G3/4: 3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation (severe: 0.2%); <br>
  Abdominal pain (severe: 1%); <br>
  Gastrointestinal haemorrhage (severe: 0.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Oesophagitis (severe: 0.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Skin reaction (G3/4: 5.9%); <br>
  Nail disorders (severe: 2.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (severe: 1.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arthralgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (severe: 6.5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 11.2%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Non-cardiac chest pain (severe: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased
  (&lt;&nbsp;5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood alkaline phosphatase
  increased (&lt;&nbsp;4%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 AST increased (&lt;&nbsp;3%);<br>
  G3/4 ALT increased (&lt;&nbsp;2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
100&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare: bleeding episodes associated with
grade&nbsp;3/4 thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Reversibility data are available among
35.3% of patients who developed neurotoxicity following docetaxel treatment at
100&nbsp;mg/m&sup2; as single agent. The events were spontaneously reversible
within 3&nbsp;months.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare: one case of alopecia
non-reversible at the end of the study. 73% of the cutaneous reactions were
reversible within 21&nbsp;days.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>General
disorders and administration site conditions</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The median
cumulative dose to treatment discontinuation was more than 1,000&nbsp;mg/m<sup>2
</sup>and the median time to fluid retention reversibility was 16.4&nbsp;weeks
(range 0 to 42&nbsp;weeks). The onset of moderate and severe retention is
delayed (median cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in patients with
premedication compared with patients without premedication (median cumulative
dose: 489.7&nbsp;mg/m<sup>2</sup>); however, it has been reported in some
patients during the early courses of therapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in non-small cell lung cancer for </span><span
lang=EN-GB>TAXOTERE 75&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  (G3/4: 5%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Neutropenia
  (G4: 54.2%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Anaemia
  (G3/4: 10.8%); Thrombocytopenia (G4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (no severe)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 2.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (no severe) </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 3.3%); <br>
  Stomatitis (G3/4: 1.7%); <br>
  Vomiting (G3/4: 0.8%); <br>
  Diarrhoea (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Constipation</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Skin reaction (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nail
  disorders (severe: 0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (severe: 12.4%); <br>
  Fluid retention (severe: 0.8%);<br>
  Pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (&lt;&nbsp;2%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
75&nbsp;mg/m&sup2; in combination with doxorubicin</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Uncommon adverse
   reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 7.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Neutropenia
  (G4: 91.7%);<br>
  Anaemia (G3/4: 9.4%); <br>
  Febrile neutropenia;<br>
  Thrombocytopenia (G4: 0.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  failure; </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 5%); <br>
  Stomatitis (G3/4: 7.8%); <br>
  Diarrhoea (G3/4: 6.2%); <br>
  Vomiting (G3/4: 5%); <br>
  Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (severe: 0.4%); <br>
  Skin reaction (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (severe: 8.1%); <br>
  Fluid retention (severe: 1.2%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infusion
  site reaction</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (&lt;&nbsp;2.5%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood alkaline phosphatase increased (&lt;&nbsp;2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4 AST
  increased (&lt;&nbsp;1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4 ALT
  increased (&lt;&nbsp;1%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in non-small cell lung cancer for </span><span
lang=EN-GB>TAXOTERE 75&nbsp;mg/m&sup2; in combination with cisplatin</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 5.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Neutropenia
  (G4: 51.5%); <br>
  Anaemia (G3/4: 6.9%); <br>
  Thrombocytopenia (G4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (G3/4: 2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3: 3.7%); <br>
  Peripheral motor neuropathy (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension
  (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 9.6%); <br>
  Vomiting (G3/4: 7.6%); <br>
  Diarrhoea (G3/4: 6.4%); <br>
  Stomatitis (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (severe: 0.7%); <br>
  Skin reaction (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (severe: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (severe: 9.9%);<br>
  Fluid retention (severe: 0.7%);<br>
  Fever (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infusion
  site reaction; <br>
  Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (2.1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4 ALT
  increased (1.3%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 AST increased (0.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood alkaline phosphatase increased (0.3%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
100&nbsp;mg/m&sup2; in combination with trastuzumab</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); <br>
  Febrile neutropenia (includes neutropenia associated with fever and
  antibiotic use) or neutropenic sepsis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Paresthesia;
  Headache; Dysgeusia; Hypoaesthesia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased; Conjunctivitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lymphoedema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Epistaxis;
  Pharyngolaryngeal pain; Nasopharyngitis; Dyspnoea; <br>
  Cough; Rhinorrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea;
  Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia; Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Alopecia;
  Erythema; Rash; Nail disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia;
  Arthralgia; Pain in extremity; Bone pain; Back pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia;
  Oedema peripheral; Pyrexia; Fatigue; Mucosal inflammation; Pain; Influenza
  like illness; Chest pain; Chills</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
100&nbsp;mg/m&sup2; in combination with trastuzumab</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very common: Haematological toxicity was
increased in patients receiving trastuzumab and docetaxel, compared with
docetaxel alone (32% grade&nbsp;3/4 neutropenia versus 22%, using NCI-CTC
criteria). Note that this is likely to be an underestimate since docetaxel
alone at a dose of 100&nbsp;mg/m<sup>2</sup> is known to result in neutropenia
in 97% of patients, 76% grade&nbsp;4, based on nadir blood counts. The incidence
of febrile neutropenia/neutropenic sepsis was also increased in patients
treated with Herceptin plus docetaxel (23% versus 17% for patients treated with
docetaxel alone).</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Cardiac disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Symptomatic cardiac failure was reported
in 2.2% of the patients who received docetaxel plus trastuzumab compared to 0%
of patients given docetaxel alone. In the docetaxel plus trastuzumab arm, 64%
had received a prior anthracycline as adjuvant therapy compared with 55% in the
docetaxel arm alone.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span><span lang=EN-GB>TAXOTERE
75&nbsp;mg/m&sup2; in combination with capecitabine</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oral
  candidiasis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 63%); Anaemia (G3/4: 10%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Thrombocytopenia
  (G3/4: 3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 1%); <br>
  Decreased appetite </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dehydration
  (G3/4: 2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: &lt;&nbsp;1%);<br>
  Pareaesthesia (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dizziness;
  <br>
  Headache (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neuropathy
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pharyngolaryngeal
  pain (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dyspnoea
  (G3/4: 1%); <br>
  Cough (G3/4: &lt;&nbsp;1%); <br>
  Epistaxis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Stomatitis
  (G3/4: 18%); <br>
  Diarrhoea (G3/4: 14%); <br>
  Nausea (G3/4: 6%); <br>
  Vomiting (G3/4: 4%); <br>
  Constipation (G3/4: 1%); <br>
  Abdominal pain (G3/4: 2%); <br>
  Dyspepsia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Abdominal
  pain upper; <br>
  Dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hand-foot
  syndrome (G3/4: 24%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia
  (G3/4: 6%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nail
  disorders (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Dermatitis; <br>
  Rash erythematous (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=FR>Nail
  discolouration; <br>
  Onycholysis (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (G3/4: 2%); <br>
  Arthralgia (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain in
  extremity (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Back pain
  (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (G3/4: 3%); <br>
  Pyrexia (G3/4: 1%); <br>
  Fatigue/weakness (G3/4: 5%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oedema
  peripheral (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy;<br>
  Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  decreased;<br>
  G3/4 Blood bilirubin increased (9%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in </span><span lang=EN-GB>metastatic
castration-resistant prostate cancer for TAXOTERE 75&nbsp;mg/m&sup2; in
combination with prednisone or prednisolone</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 3.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); <br>
  Anaemia (G3/4: 4.9%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Thrombocytopenia
  (G3/4: 0.6%);<br>
  Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: 1.2%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  left ventricular function decrease (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Epistaxis
  (G3/4: 0%);<br>
  Dyspnoea (G3/4: 0.6%); <br>
  Cough (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 2.4%); <br>
  Diarrhoea (G3/4: 1.2%); <br>
  Stomatitis/Pharyngitis (G3/4: 0.9%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vomiting
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (no severe)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Exfoliative
  rash (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective bone disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arthralgia
  (G3/4: 0.3%); <br>
  Myalgia (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fatigue
  (G3/4: 3.9%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
  retention (severe: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in high-risk locally advanced or metastatic
hormone-sensitive prostate cancer for TAXOTERE 75 mg/m&sup2; in combination
with prednisone or prednisolone and ADT (STAMPEDE study) </span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:458.65pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:35.4pt'>
   <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA system organ
   classes</span></b></p>
   <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
   115%;page-break-after:avoid'><b><span style='font-size:11.0pt;line-height:
   115%'>&nbsp;</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Very common adverse reactions</span></b></p>
   </td>
   <td width=211 valign=top style='width:158.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Common adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:37.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Neutropenia (G3-4: 12 %)
  Anaemia </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Febrile
  neutropenia </span><span style='font-size:11.0pt'>(G3-4: 15%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Immune
  system disorders</span><span lang=EN-GB style='font-size:11.0pt;line-height:
  115%;color:black'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Hypersensitivity (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.2pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><s><span style='font-size:11.0pt'><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diabetes (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.8pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Anorexia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt' style='page-break-inside:
  avoid !msorm;height:20.45pt !msorm'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Psychiatric
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Insomnia (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Nervous
  system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Peripheral sensory
  neuropathy (&#8805;G3: 2%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Headache<br>
  <br>
  </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.5pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Eye
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Blurred vision</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.1pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Cardiac
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension </span><span
  style='font-size:11.0pt'>(G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:43.05pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Respiratory,
  thoracic and mediastinal disorders</span><span style='font-size:11.0pt;
  line-height:115%'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dyspnea (G3: 1%)<br>
  Coughing (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Upper respiratory tract
  infection (G3: 1%) </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Pharyngitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'><br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:64.3pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%'>Gastrointestinal
  disorders </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diarrhea (G3: 3%)<br>
  Stomatitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Constipation (G3: 0%)<br>
  Nausea (G3: 1%)<br>
  Dyspepsia<br>
  Abdominal pain (G3: 0%)<br>
  Flatulence</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Vomiting (G3: 1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.7pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Alopecia (G3: 3%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Nail changes (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  lang=FR style='font-size:11.0pt;line-height:115%'>Rash</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Myalgia </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Lethargy (G3-4: 2%)<br>
  Flu-like symptoms (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Asthenia (G3: 0%)<br>
  Fluid retention</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Fever (G3: 1%)<br>
  Oral candidiasis </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypocalcaemia (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypophosphataemia (G3-4:
  1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypokalaemia (G3: 0%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><sup><span style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'>a</span></sup><span
style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'> </span><span
style='font-size:9.0pt;color:black'>From the GETUG AFU15 study</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for </span></u><u><span lang=EN-GB>adjuvant therapy with TAXOTERE
75&nbsp;mg/m&sup2; in combination with doxorubicin and cyclophosphamide<b> </b>in
patients with node&#8209;positive </span><span lang=EN-GB>(TAX 316) </span></u><u><span
lang=EN-GB>and node&#8209;negative </span><span lang=EN-GB>(GEICAM 9805) </span></u><u><span
lang=EN-GB>breast cancer<b> </b></span><span lang=EN-GB>- pooled data</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>MedDRA
   System Organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Very common
   adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Uncommon
   adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infections and
  infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Infection (G3/4:
  2.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neutropenic
  infection </span><span lang=NL style='font-size:11.0pt'>(G3/4: 2.</span><span
  style='font-size:11.0pt'>6</span><span lang=NL style='font-size:11.0pt'>%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Anaemia (G3/4: 3%);
  </span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Neutropenia (G3/4:
  59.2%); Thrombocytopenia (G3/4: 1.6%); </span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Febrile neutropenia
  (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Immune system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypersensitivity
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Metabolism and
  nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anorexia (G3/4:
  1.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nervous system
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dysgeusia (G3/4:
  0.6%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  sensory neuropathy (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Peripheral motor
  neuropathy (G3/4: 0%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Syncope (G3/4:
  0%); Neurotoxicity (G3/4: 0%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Somnolence
  (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Conjunctivitis
  (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lacrimation
  increased (G3/4: &lt;0.1%) </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Arrhythmia
  (G3/4: 0.2%) </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hot flush (G3/4:
  0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phlebitis (G3/4:
  0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lymphoedema
  (G3/4: 0%)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Nausea (G3/4:
  5.0%); Stomatitis (G3/4: 6.0%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vomiting (G3/4:
  4.2%); </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea (G3/4:
  3.4%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Constipation
  (G3/4: 0.5%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Abdominal pain
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia
  (persisting: &lt;3%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
  disorder (G3/4: 0.6%); </span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail
  disorders (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.7%); Arthralgia (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Reproductive
  system and breast disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Amenorrhoea </span><span
  lang=NL style='font-size:11.0pt'>(G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia (G3/4:
  10.0%);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Pyrexia (G3/4: NA);</span></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Oedema peripheral
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left'><span
  style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight increased
  (G3/4: 0%);</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Weight decreased
  (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Description of selected adverse reactions for </span><span
lang=EN-GB>adjuvant therapy with TAXOTERE 75&nbsp;mg/m&sup2; in combination
with doxorubicin and cyclophosphamide<b> </b>in patients with node&#8209;positive
</span><span lang=EN-GB>(TAX 316) and node&#8209;negative (GEICAM 9805) breast
cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>peripheral sensory neuropathy </span><span style='font-size:11.0pt'>started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 84&nbsp;patients (11.3%) in TAC arm and 15
patients (2&nbsp;%) in FAC arm. At the end of the follow-up period (median
follow-up time of 8 years), p</span><span style='font-size:11.0pt'>eripheral
sensory neuropathy</span><span lang=EN-GB style='font-size:11.0pt'> was observed
to be ongoing in 10 patients (1.3</span><span style='font-size:11.0pt'>%) in
TAC arm, and in 2</span><span lang=EN-GB style='font-size:11.0pt'> patients
(0.3%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In GEICAM 9805 study peripheral sensory neuropathy
that started during the treatment period persisted into the follow-up period in
10&nbsp;patients (1.9%) in TAC arm and 4 patients (0.8&nbsp;%) in FAC arm. At
the end of the follow-up period (median follow-up time of 10 years and 5
months), peripheral sensory neuropathy was observed to be ongoing in 3 patients
(0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext;layout-grid-mode:
both'>In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%)
in the FAC arm experienced congestive heart failure. All except one patient in
each arm were diagnosed with CHF more than 30 days after the treatment period.
Two patients in the TAC arm and 4 patients in the FAC arm died because of
cardiac failure.</span></p>

<p class=MsoHeader style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In GEICAM 9805
study, 3</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
patients (0.6&nbsp;%) in TAC arm and 3 </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>patients </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(0.6&nbsp;%)
in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>FAC
arm developed congestive heart failure during the follow-up period. At the end
of the follow-up period (actual median follow-up time of 10 years and 5
months), no patients&nbsp; had CHF in TAC arm and 1 patient in TAC arm died
because of dilated cardiomyopathy, and CHF was observed to be ongoing in
1&nbsp;patient (0.2%) in FAC arm.</span></p>

<p class=MsoHeader style='text-align:justify'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In study
TAX316 alopecia persisting into the follow-up period after the end of
chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC
patients (87.6%).<br>
At the end of the follow-up period (actual median follow-up time of</span><span
lang=EN-GB style='font-size:14.0pt;font-family:"Cambria",serif;color:#00B0F0'> </span><span
lang=EN-GB style='font-size:11.0pt'>8 years), alopecia was observed to be
ongoing in 29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In
GEICAM 9805 study alopecia </span><span style='font-size:11.0pt'>that started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period was observed to be ongoing in 49&nbsp;patients
(9.2&nbsp;%) in TAC arm and 35 patients (6.7&nbsp;%) in FAC arm. Alopecia
related to study drug started or worsened during the follow-up period in
42&nbsp;patients (7.9&nbsp;%) in TAC arm and 30 patients (5.8&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm,
and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Reproductive system and breast disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In TAX316 </span>amenorrhoea <span lang=EN-GB>that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%)
and 125 of 736 FAC patients (17.0%). Amenorrhea </span>was observed to be
ongoing <span lang=EN-GB>at the end of the </span>follow-up <span lang=EN-GB>period
(median follow-up time of 8 years) </span>in 121&nbsp;<span lang=EN-GB>of 744
TAC </span>patients <span lang=EN-GB>(16.3%) and 86 FAC patients (11.7%)</span>.</p>

<p class=Text style='margin-top:0in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>In GEICAM 9805 study</span><span lang=EN-GB
style='font-size:11.0pt'> amenorrhoea </span><span style='font-size:11.0pt'>that
started during the treatment period and </span><span lang=EN-GB
style='font-size:11.0pt'>persisted into the follow-up period was observed to be
ongoing in 18&nbsp;patients (3.4&nbsp;%) in TAC arm and 5 patients (1.0&nbsp;%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), amenorrhoea was observed to be ongoing in 7 patients
(1.3%) in TAC arm, and in 4 patients (0.8%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'>&nbsp;</p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
peripheral oedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was observed in 119 of
744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), peripheral oedema was
ongoing in19&nbsp;TAC<u> </u>patients (2.6%) and 4 FAC<u> </u>patients (0.5%). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
lymphoedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was reported in 11 of
744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), lymphoedema was
observed to be ongoing in 6&nbsp;TAC patients (0.8%) and 1 FAC patient (0.1%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In study TAX316 asthenia that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%)
and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual
median follow-up time of 8 years), asthenia was observed to be ongoing in
29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study GEICAM
9805 peripheral oedema </span><span style='font-size:11.0pt'>that started
during the treatment period </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%)
in FAC arm. At the end of the follow-up period (median follow-up time of 10
years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it
was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema </span><span
style='font-size:11.0pt'>that started during the treatment period </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period in
5&nbsp;patients (0.9%) in TAC arm and 2 patients (0.4&nbsp;%) in FAC arm. At
the end of the follow-up period, lymphoedema was observed to be ongoing in 4
patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia </span><span
style='font-size:11.0pt'>that started during the treatment period and </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period was
observed to be ongoing in 12&nbsp;patients (2.3&nbsp;%) in TAC arm and 4
patients (0.8&nbsp;%) in FAC arm. At the end of the follow-up period, asthenia
was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients
(0.4%) in FAC arm.</span></p>

<p class=MsoNormal><b><i><u><span style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Acute leukaemia
/ Myelodysplastic syndrome.</span></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After 10 years of follow up in study
TAX316, acute leukaemia was reported in 3 of 744 TAC patients </span><span
style='font-weight:normal'>(0.4%)</span><span lang=EN-GB style='font-weight:
normal'> and in 1 of 736 FAC patients </span><span style='font-weight:normal'>(0.1%).</span><span
style='font-weight:normal'> </span><span style='font-weight:normal'>One TAC
patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up
period (median follow-up time of 8 years)</span><span lang=EN-GB
style='font-weight:normal'>. Myelodysplastic syndrome was reported in 2 of 744
TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-weight:normal'>10 years of follow-up </span><span
lang=EN-GB style='font-weight:normal'>in GEICAM 9805 study</span><span
lang=EN-GB style='font-weight:normal'>,</span><span lang=EN-GB
style='font-weight:normal'> acute leukaemia occurred in 1</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>of 532 (0.2%)</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>patients </span><span
lang=EN-GB style='font-weight:normal'>in TAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No cases were reported in patients</span><span
lang=EN-GB style='font-weight:normal'> in FAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No patient was diagnosed with myelodysplastic
syndrome in either treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Neutropenic complications</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;page-break-after:avoid;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'>Table below shows that the incidence of
Grade&nbsp;4 neutropenia, febrile neutropenia and neutropenic infection was
decreased in patients who received primary G&#8209;CSF prophylaxis after it was
made mandatory in the TAC arm &#8211; GEICAM study. </p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-weight:normal'>Neutropenic complications in
patients receiving TAC with or without primary G&#8209;CSF prophylaxis (GEICAM
9805)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Without
  primary</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF
  prophylaxis (n&nbsp;=&nbsp;111)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n&nbsp;(%)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>With primary </span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF </span><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>prophylaxis</span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(n&nbsp;=&nbsp;421)
  </span></p>
  <p class=TableHeadCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>n&nbsp;(%)</span></p>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenia&nbsp;(Grade&nbsp;4)
  </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>104
  (93.7)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>135 (32.1)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Febrile
  neutropenia </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>28
  (25.2)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>23 (5.5)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>14
  (12.6)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>21 (5.0)</span></p>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection (Grade&nbsp;3-4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2
  (1.8)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>5
  (1.2)</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
gastric adenocarcinoma center for TAXOTERE 75&nbsp;mg/m&sup2; in combination
with cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 11.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 20.9%);</span></p>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.2%); </span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4: 8.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 11.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:40.75pt'>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3/4:
  8.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.3%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Peripheral </span><span lang=EN-GB>motor
  neuropathy (G3/4: 1.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 1.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 19.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 16%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 23.7%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 14.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 1.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oesophagitis/dysphagia/odynophagia
  (G3/4: 0.7%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritus (G3/4: 0.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Nail disorders (G3/4: 0.7%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Skin exfoliation (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 19.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fever (G3/4: 2.3%);<br>
  Fluid retention (severe/life&#8209;threatening: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75
mg/m<sup>2</sup> in combination with cisplatin and 5-fluorouracil</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Febrile neutropenia and neutropenic
infection occurred in 17.2% and 13.5% of patients respectively, regardless of G&#8209;CSF
use. G&#8209;CSF was used for secondary prophylaxis in 19.3% of patients (10.7%
of the cycles). Febrile neutropenia and neutropenic infection occurred
respectively in 12.1% and 3.4% of patients when patients received prophylactic
G&#8209;CSF, in 15.6% and 12.9% of patients without prophylactic G&#8209;CSF
(see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
head and neck cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with
cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
radiotherapy (TAX 323)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 6.3%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Neoplasms benign, malignant and
  unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cancer pain (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 76.3%);</span></p>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 9.2%);</span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4: 5.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.75pt'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=IT>Dysgeusia/Parosmia;</span></p>
  <p class=Normal11pt><span lang=IT>Peripheral sensory neuropathy (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Conjunctivitis </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myocardial ischemia (G3/4:1.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Venous disorder (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 0.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 2.9%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=FR>Constipation;</span></p>
  <p class=Normal11pt><span lang=FR>Esophagitis/dysphagia/ odynophagia (G3/4:
  0.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Abdominal pain;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Dyspepsia;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal haemorrhage (G3/4:
  0.6%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 10.9%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritic;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Dry skin; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Skin exfoliative (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 3.4%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pyrexia (G3/4: 0.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oedema</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
chemoradiotherapy (TAX 324)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 3.6%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neoplasms benign, malignant and
  unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cancer pain</span><span lang=EN-GB>
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.5%);</span></p>
  <p class=Normal11pt><span lang=IT>Anaemia</span><span lang=IT> (G3/4: 12.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4:&nbsp;4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 12.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Dysgeusia/Parosmia (G3/4:&nbsp;0.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Peripheral sensory neuropathy (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Conjunctivitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4:&nbsp;1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia</span><span lang=EN-GB>
  (G3/4: 2.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ischemia myocardial</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Venous disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 13.9%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 20.7%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 8.4%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 6.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Esophagitis/dysphagia/ odynophagia
  (G3/4: 12.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspepsia (G3/4: 0.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal haemorrhage (G3/4:
  0.4%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritic</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dry skin&nbsp;;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Desquamation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal, connective tissue bone
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pyrexia (G3/4: 3.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oedema (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight decreased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight increased</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Post-marketing
experience</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Neoplasms
benign, malignant and unspecified (incl cysts and polyps)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S</span><span
style='font-size:11.0pt'>econd primary malignancies (</span><span lang=EN
style='font-size:11.0pt'>frequency not known)</span><span style='font-size:
11.0pt'>, including non-Hodgkin lymphoma have been reported in association with
docetaxel when used in combination with other anticancer treatments known to be
associated with second primary malignancies</span><span lang=EN-GB
style='font-size:11.0pt'>. </span><span style='font-size:11.0pt'>Acute myeloid
leukaemia and myelodysplastic syndrome have been reported (frequency uncommon)
in pivotal clinical studies in breast cancer with TAC regimen.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Bone marrow suppression and other
haematologic adverse reactions have been reported. Disseminated intravascular
coagulation (DIC), often in association with sepsis or multiorgan failure, has
been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Immune system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Some cases of anaphylactic shock,
sometimes fatal, have been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity reactions (frequency not
known) have been reported with docetaxel in patients who previously experienced
hypersensitivity reactions to paclitaxel.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of convulsion or transient loss
of consciousness have been observed with docetaxel administration. These
reactions sometimes appear during the infusion of the medicinal product.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt><i><span lang=EN-GB>Eye disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>Very rare
cases of transient visual disturbances (flashes, flashing lights, scotomata)
typically occurring during infusion of the medicinal product and in association
with hypersensitivity reactions have been reported. These were reversible upon
discontinuation of the infusion. </span><span lang=EN-GB>Cases of lacrimation
with or without conjunctivitis, as cases of lacrimal duct obstruction resulting
in excessive tearing have been rarely reported.&nbsp;Cases of cystoid macular
oedema (CMO) have been reported in patients treated with docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Ear and
labyrinth disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Rare cases of ototoxicity, hearing impaired
and/or hearing loss have been reported.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt><i><span lang=EN-GB>Cardiac disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of myocardial infarction have
been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including
ventricular tachycardia (frequency not known), sometimes fatal, has been
reported in patients treated with docetaxel in combination regimens including
doxorubicin, 5-fluorouracil and/ or cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Vascular disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Venous thromboembolic events have rarely
been reported.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Respiratory, thoracic and mediastinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome and cases of<b><i> </i></b>interstitial pneumonia/ </span><span
lang=EN-GB style='font-size:11.0pt'>pneumonitis<b>,</b></span><span lang=EN-GB
style='font-size:11.0pt'> interstitial lung disease, </span><span lang=EN-GB
style='font-size:11.0pt'>pulmonary fibrosis <span class=msoins0>and respiratory
failure </span>sometimes fatal have rarely been reported. Rare cases of
radiation pneumonitis have been reported in patients receiving concomitant
radiotherapy. </span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Gastrointestinal disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare cases of enterocolitis, including
colitis, ischemic colitis, and neutropenic enterocolitis, have been reported
with a potential fatal outcome (frequency not known).</span></p>

<p class=Normal11pt><span lang=EN-GB>Rare occurrences of dehydration have been
reported as a consequence of gastrointestinal events including enterocolitis
and gastrointestinal perforation. </span></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of ileus and intestinal
obstruction have been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatobiliary disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare cases of hepatitis, sometimes
fatal primarily in patients with pre&#8209;existing liver disorders, have been
reported.</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cases of cutaneous
lupus erythematosus</span><span lang=EN-GB>, </span><span lang=EN-GB
style='font-size:11.0pt'>bullous eruptions such as erythema multiforme and </span><span
lang=EN-GB>severe cutaneous adverse reactions such as </span><span lang=EN-GB
style='font-size:11.0pt'>Stevens&#8209;Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
(TEN) and </span><span lang=EN-GB style='font-size:11.0pt'>Acute Generalized Exanthematous
Pustulosis (AGEP)</span><span lang=EN-GB style='font-size:11.0pt'> have been
reported with docetaxel. Scleroderma&#8209;like changes usually preceded by
peripheral lymphoedema have been reported with docetaxel. Cases of </span><span
lang=EN-GB style='font-size:11.0pt'>permanent</span><span lang=EN-GB
style='font-size:11.0pt'> alopecia (frequency not known) have been reported.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Renal and urinary disorders</span></i></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Renal insufficiency and renal failure have been reported. In
about 20% of these cases there were no risk factors for acute renal failure
such as concomitant nephrotoxic medicinal products and gastro-intestinal
disorders.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>General
disorders and administration site conditions</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Radiation
recall phenomena have rarely been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Injection site
recall reaction (recurrence of skin reaction at a site of previous
extravasation following administration of docetaxel at a different site) has
been observed at the site of previous extravasation (frequency not known).</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
retention has not been accompanied by acute episodes of oliguria or
hypotension. Dehydration and pulmonary oedema have rarely been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><i><span style='color:windowtext'>Metabolism and nutrition disorders</span></i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Cases of electrolyte imbalance have been reported. Cases of hyponatraemia
have been reported, mostly associated with dehydration, vomiting and pneumonia.
Hypokalaemia, hypomagnesaemia, and hypocalcaemia were observed, usually in
association with gastrointestinal disorders and in particular with diarrhoea. <span
lang=EN-GB>Tumour lysis syndrome, potentially fatal, has been reported (frequency
not known).</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin-left:0in;text-indent:0in'><i>Musculoskeletal
disorder</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Myositis has been reported with docetaxel <span lang=EN-GB>(frequency not
known)</span>.</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='color:black;background:#BFBFBF'>the national reporting system listed in </span><span
style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>There were a few reports of overdose.
There is no known antidote for docetaxel overdose. In case of overdose, the
patient should be kept in a specialised unit and vital functions closely
monitored. In cases of overdose, exacerbation of adverse events may be
expected. The primary anticipated complications of overdose would consist of
bone marrow suppression, peripheral neurotoxicity and mucositis. Patients
should receive therapeutic G&#8209;CSF as soon as possible after discovery of
overdose. Other appropriate symptomatic measures should be taken, as needed.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Pharmacotherapeutic group: Taxanes, ATC
Code: L01CD02</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Docetaxel
is an antineoplastic agent which acts by promoting the assembly of tubulin into
stable microtubules and inhibits their disassembly which leads to a marked decrease
of free tubulin. The binding of docetaxel to microtubules does not alter the
number of protofilaments.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown <i>in vitro</i>
to disrupt the microtubular network in cells which is essential for vital
mitotic and interphase cellular functions. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel was found to be cytotoxic <i>in
vitro</i> against various murine and human tumour cell lines and against
freshly excised human tumour cells in clonogenic assays. Docetaxel achieves
high intracellular concentrations with a long cell residence time. In addition,
docetaxel was found to be active on some but not all cell lines over expressing
the p&#8209;glycoprotein which is encoded by the multidrug resistance gene. <i>In
vivo</i>, docetaxel is schedule independent and has a broad spectrum of
experimental anti-tumour activity against advanced murine and human grafted
tumours.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with doxorubicin
and cyclophosphamide: adjuvant therapy</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><u><span lang=EN-GB>Patients
with operable node&#8209;positive breast cancer </span></u><span lang=EN-GB>(TAX
316)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Data from a multi-centre open label randomised study
support the use of docetaxel for the adjuvant treatment of patients with
operable node-positive breast cancer and KPS&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&sup3;</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;80%, between 18 and 70&nbsp;years of age. After
stratification according to the number of positive lymph nodes (1&#8209;3, 4+),
1491&nbsp;patients were randomised to receive either docetaxel 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide
500&nbsp;mg/m<sup>2</sup> (TAC arm), or doxorubicin 50&nbsp;mg/m<sup>2</sup>
followed by fluorouracil 500&nbsp;mg/m<sup>2</sup> and cyclophosphamide
500&nbsp;mg/m<sup>2</sup> (FAC arm). Both regimens were administered once every
3&nbsp;weeks for 6&nbsp;cycles. Docetaxel was administered as a 1&#8209;hour
infusion, all other medicinal products were given as intravenous bolus on day
one. G&#8209;CSF was administered as secondary prophylaxis to patients who
experienced complicated neutropenia (febrile neutropenia, prolonged
neutropenia, or infection). Patients on the TAC arm received antibiotic
prophylaxis with ciprofloxacin 500&nbsp;mg orally twice daily for 10&nbsp;days
starting on day&nbsp;5 of each cycle, or equivalent. In both arms, after the
last cycle of chemotherapy, patients with positive eostrogen and/or
progesterone receptors received tamoxifen 20&nbsp;mg daily for up to
5&nbsp;years. Adjuvant radiation therapy was prescribed according to guidelines
in place at participating institutions and was given to 69% of patients who
received TAC and 72% of patients who received FAC. Two interim analyses and one
final analysis were performed. The first interim analysis was planned 3 years
after the date when half of study enrolment was done. The second interim
analysis was done after 400 DFS events had been recorded overall, which led to a
median follow-up of 55 months. The final analysis was performed when all
patients had reached their 10-year follow-up visit (unless they had a DFS event
or were lost to follow-up before). Disease-free survival (DFS) was the primary
efficacy endpoint and Overall survival (OS) was the secondary efficacy
endpoint.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A final analysis was performed with an
actual median follow up of 96&nbsp;months. Significantly longer disease-free
survival for the TAC arm compared to the FAC arm was demonstrated. Incidence of
relapses at 10 years was reduced in patients receiving TAC compared to those
who received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction
by 6% (p&nbsp;=&nbsp;0.0043). Overall survival at 10&nbsp;years was also
significantly increased with TAC compared to FAC (76%versus 69%, respectively)
i.e. an absolute reduction of the risk of death by 7% (p&nbsp;=&nbsp;0.002). As
the benefit observed in patients with 4+ nodes was not statistically
significant on DFS and OS, the positive benefit/risk ratio for TAC in patients
with 4+ nodes was not fully demonstrated at the final analysis.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Overall,
the study results demonstrate a positive benefit risk ratio for TAC compared to
FAC. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>TAC-treated
patient subsets according to prospectively defined major prognostic factors
were analysed:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='width:104.4%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.92%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Disease free survival</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.6%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Overall survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>Patient subset</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Number of patients</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>No of positive nodes</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>745</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.80</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>68</span><span lang=EN-GB>-0.</span><span lang=EN-GB>93</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0043</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.74</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>61</span><span lang=EN-GB>-0.</span><span lang=EN-GB>90</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0020</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>1-3</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>467</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>58</span><span lang=EN-GB>-0.</span><span lang=EN-GB>91</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0047</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>46</span><span lang=EN-GB>-0.</span><span lang=EN-GB>82</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0008</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>4+</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>278</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>70</span><span lang=EN-GB>-1.</span><span lang=EN-GB>09</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2290</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.</span><span
  lang=EN-GB>67</span><span lang=EN-GB>-1.</span><span lang=EN-GB>12</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2746</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>*a hazard
ratio of less than 1 indicates that TAC is associated with a longer disease-free
survival and overall survival compared to FAC</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Patients with
operable node</span><span lang=EN-GB>&#8209;</span></u><u><span lang=EN-GB
style='font-size:11.0pt'>negative breast cancer eligible to receive
chemotherapy (</span></u><span lang=EN-GB style='font-size:11.0pt'>GEICAM 9805)<u>
</u></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Data</span><span
lang=EN-GB style='font-size:11.0pt'> from a multi-centre open label randomised
trial support the use of TAXOTERE for the adjuvant treatment of patients with
operable node&#8209;negative breast cancer eligible to receive chemotherapy.
1060&nbsp;patients were randomised to receive either TAXOTERE 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (539 patients in TAC arm), or
doxorubicin 50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup>
and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (521 patients in FAC arm), as
adjuvant treatment of operable node-negative breast cancer patients with high
risk of relapse according to 1998 St. Gallen criteria (tumour size
&gt;2&nbsp;cm and/or negative ER and PR and/or high histological/nuclear grade
(grade 2 to 3) and /or age &lt;35&nbsp;years). Both regimens were administered
once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1&#8209;hour
infusion, all other medicinal products were given intraveinously on day 1 every
three weeks. Primary prophylactic G&#8209;CSF was made mandatory in TAC arm
after 230&nbsp;patients were randomised. The incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in
patients who received primary G&#8209;CSF prophylaxis (see section 4.8). In
both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+
tumours received tamoxifen 20&nbsp;mg once a day for up to 5 years. Adjuvant
radiation therapy was administered according to guidelines in place at
participating institutions and was given to 57.3% of patients who received TAC and
51.2% of patients who received FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>One
primary analysis and one updated analysis were performed. The primary analysis
was done when all patients had a follow-up of greater than 5 years (median
follow-up time of 77 months). The updated analysis was performed when all
patients had reached their 10-year (</span><span lang=EN-GB>median follow up
time of 10 years and 5&nbsp;months) </span><span lang=EN-GB>follow-up visit (unless
they had a DFS event or were lost to follow-up previously). Disease-free
survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was
the secondary efficacy endpoint.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, significantly longer disease-free survival for the
TAC arm compared to the FAC arm was demonstrated. TAC&#8209;treated patients
had a 32% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.68, 95% CI (0.49-0.93), p&nbsp;=&nbsp;0.01). At the
median follow up time of 10 years and 5&nbsp;months, TAC&#8209;treated patients
had a 16,5% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.84, 95% CI (0.65-1.08)</span><span
style='font-size:11.0pt'>, p=0.1646). DFS data were not statistically significant
but were still associated with a positive trend in favour of TAC.</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, overall survival (OS) was longer in the TAC arm
with TAC-treated patients having a 24% reduction in the risk of death compared
to FAC (hazard ratio&nbsp;=&nbsp;0.76, 95% CI (0.46-1.26, p&nbsp;=&nbsp;0.29).
However, the distribution of OS was not significantly different between the 2
groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow up time of 10 years and 5&nbsp;months, TAC-treated patients had a 9%
reduction in the risk of death compared to FAC-treated patients (hazard ratio&nbsp;=&nbsp;0.91,
95% CI (0.63-1.32)). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The survival rate
was 93.7% in the TAC arm and 91.4&nbsp;% in the FAC arm, at the 8-year
follow-up time point, and 91.3&nbsp;% in the TAC arm and 89&nbsp;% in the FAC
arm, at the 10-year follow-up time point.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The positive
benefit risk ratio for TAC compared to FAC remained unchanged<b>. </b>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAC&#8209;treated
patient subsets according to prospectively defined major prognostic factors
were analysed in the primary analysis (at the median follow-up time of 77 months)
(see table below):</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Subset Analyses-Adjuvant Therapy in Patients with Node&#8209;negative
Breast Cancer Study </span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>(Intent&#8209;to&#8209;Treat Analysis)</span></u></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=558
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=258 colspan=2 valign=top style='width:193.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Disease Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  subset</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of patients in TAC group</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio*</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Overall</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>539</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.49-0.93</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Age
  category 1</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&lt;50
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>260</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&#8805;50
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>279</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Age
  category 2</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&lt;35
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>42</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.31</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.11-0.89</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&#8805;35
  years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>497</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.52-1.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Hormonal
  receptor</span></b><span lang=EN-GB> <b>status</b></span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.6pt'>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Negative</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>195</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.7</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.45-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Positive</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>344</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4-0.97</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Tumour
  size </span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:Symbol'>&pound;</span><span lang=EN-GB>2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.69</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&gt;2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.45-1.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Histological
  grade</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade1
  (includes grade not assessed)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.79</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.24-2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade 2</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>216</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.77</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.46-1.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Grade 3</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>259</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.59</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.39-0.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Menopausal
  status</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pre-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.64</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.40-1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Post-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.47-1.12</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>*a hazard ratio (TAC/FAC) of less than 1 indicates
that TAC is associated with a longer disease free survival compared to FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Exploratory subgroup analyses for&nbsp; disease-free
survival for&nbsp; patients who meet the 2009 St. Gallen chemotherapy criteria
&#8211; (ITT population) were performed and presented here below:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>TAC</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>FAC</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(TAC/FAC)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Subgroups</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=539)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=521)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Meeting
  relative indication for chemotherapy </span><sup><span lang=EN-GB
  style='font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>No</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18/214</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(8.4%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26/227</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(11.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.796 (0.434 - 1.459)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4593</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48/325</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.8%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>69/294</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(23.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.606 (0.42 - 0.877)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0072</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>TAC = docetaxel, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>FAC = 5-fluorouracil, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>CI = confidence interval</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>ER = eostrogen receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>PR = progesterone receptor</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:10.0pt;font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> ER/PR-negative or Grade 3 or tumour size
&gt;5&nbsp;cm</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The estimated
hazard ratio was using Cox proportional hazard model with treatment group as
the factor.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
as single agent</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Two
randomised phase&nbsp;III comparative studies, involving a total of
326&nbsp;alkylating or 392&nbsp;anthracycline failure metastatic breast cancer
patients, have been performed with docetaxel at the recommended dose and
regimen of 100&nbsp;mg/m&sup2; every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In alkylating-failure patients, docetaxel
was compared to doxorubicin (75&nbsp;mg/m&sup2; every 3&nbsp;weeks). Without
affecting overall survival time (docetaxel 15&nbsp;months vs. doxorubicin
14&nbsp;months, p&nbsp;=&nbsp;0.38) or time to progression (docetaxel
27&nbsp;weeks vs. doxorubicin 23&nbsp;weeks, p&nbsp;=&nbsp;0.54), docetaxel
increased response rate (52% vs. 37%, p&nbsp;=&nbsp;0.01) and shortened time to
response (12&nbsp;weeks vs. 23&nbsp;weeks, p&nbsp;=&nbsp;0.007). Three
docetaxel patients (2%) discontinued the treatment due to fluid retention,
whereas 15&nbsp;doxorubicin patients (9%) discontinued due to cardiac toxicity
(three cases of fatal congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In anthracycline-failure patients,
docetaxel was compared to the combination of mitomycin&nbsp;C and vinblastine
(12&nbsp;mg/m&sup2; every 6&nbsp;weeks and 6&nbsp;mg/m&sup2; every
3&nbsp;weeks). Docetaxel increased response rate (33% vs. 12%,
p&nbsp;&lt;&nbsp;0.0001), prolonged time to progression (19&nbsp;weeks vs. 11&nbsp;weeks,
p&nbsp;=&nbsp;0.0004) and prolonged overall survival (11&nbsp;months vs.
9&nbsp;months, p&nbsp;=&nbsp;0.01).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During these two phase&nbsp;III studies,
the safety profile of docetaxel was consistent with the safety profile observed
in phase&nbsp;II studies (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>An open-label, multi-centre, randomised
phase&nbsp;III study was conducted to compare docetaxel monotherapy and
paclitaxel in the treatment of advanced breast cancer in patients whose
previous therapy should have included an anthracycline. A total of
449&nbsp;patients were randomised to receive either docetaxel monotherapy
100&nbsp;mg/m&sup2; as a 1&nbsp;hour infusion or paclitaxel 175&nbsp;mg/m&sup2;
as a 3&nbsp;hour infusion. Both regimens were administered every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>Without affecting the primary endpoint,
overall response rate (32% vs 25%, p&nbsp;=&nbsp;0.10), docetaxel prolonged
median time to progression (24.6&nbsp;weeks vs 15.6&nbsp;weeks;
p&nbsp;&lt;&nbsp;0.01) and median survival (15.3&nbsp;months vs
12.7&nbsp;months; p&nbsp;=&nbsp;0.03).</span></p>

<p class=Normal11pt><span lang=EN-GB>More grade&nbsp;3/4 adverse events were
observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%). </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
doxorubicin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One large randomised phase&nbsp;III study,
involving 429 previously untreated patients with metastatic disease, has been
performed with doxorubicin (50&nbsp;mg/m&sup2;) in combination with docetaxel
(75&nbsp;mg/m&sup2;) (AT arm) versus doxorubicin (60&nbsp;mg/m&sup2;) in
combination with cyclophosphamide (600&nbsp;mg/m&sup2;) (AC&nbsp;arm). Both
regimens were administered on day&nbsp;1 every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Time to progression
(TTP) was significantly longer in the AT arm versus AC arm, p&nbsp;=&nbsp;0.0138.
The median TTP was 37.3&nbsp;weeks (95%&nbsp;CI: 33.4&nbsp;&#8209;&nbsp;42.1)
in AT arm and 31.9&nbsp;weeks (95%&nbsp;CI: 27.4&nbsp;&#8209;&nbsp;36.0) in AC
arm.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Overall response rate
(ORR) was significantly higher in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.009. The ORR was 59.3% (95%&nbsp;CI: 52.8&nbsp;&#8209;&nbsp;65.9)
in AT arm versus 46.5% (95%&nbsp;CI: 39.8&nbsp;&#8209;&nbsp;53.2) in AC arm.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In this study, AT arm showed a higher
incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3%
versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia
(8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand,
AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT
arm, and, in addition, a higher incidence of severe cardiac toxicity:
congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;20% (13.1% versus 6.1%), absolute
LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;30%
(6.2% versus 1.1%). Toxic deaths occurred in 1&nbsp;patient in the AT arm
(congestive heart failure) and in 4&nbsp;patients in the AC arm (1&nbsp;due to
septic shock and 3 due to congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>In both arms, quality of life measured by
the EORTC questionnaire was comparable and stable during treatment and follow&#8209;up.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
trastuzumab</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel in combination with trastuzumab
was studied for the treatment of patients with metastatic breast cancer whose
tumours overexpress HER2, and who previously had not received chemotherapy for
metastatic disease. One hundred eighty six patients were randomised to receive
docetaxel (100&nbsp;mg/m<sup>2</sup>) with or without trastuzumab; 60% of
patients received prior anthracycline-based adjuvant chemotherapy. Docetaxel
plus trastuzumab was efficacious in patients whether or not they had received
prior adjuvant anthracyclines. The main test method used to determine HER2 positivity
in this pivotal study was immunohistochemistry (IHC). A minority of patients
were tested using fluorescence in&#8209;situ hybridization (FISH). In this
study, 87% of patients had disease that was IHC 3+, and 95% of patients entered
had disease that was IHC 3+ and/or FISH positive. Efficacy results are
summarized in the following table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Parameter</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel
  plus trastuzumab<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;92</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;94</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Response rate </span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>61%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(50-71)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>34%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(25-45)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(9.2-15.0)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.1</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(4.4-6.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median TTP (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>10.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.6-12.9)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(5.0-6.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>30.5<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(26.8-ne)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>22.1<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(17.6-28.9)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0><span lang=EN-GB>TTP&nbsp;=&nbsp;time to
progression; &#8220;ne&#8221; indicates that it could not be estimated or it
was not yet reached.</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB>Full analysis set (intent-to-treat)</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>2 </span></sup><span
lang=EN-GB>Estimated median survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with capecitabine</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Data from
one multi-centre, randomised, controlled phase&nbsp;III clinical study support
the use of docetaxel in combination with capecitabine for treatment of patients
with locally advanced or metastatic breast cancer after failure of cytotoxic
chemotherapy, including an anthracycline. In this study, 255&nbsp;patients were
randomised to treatment with docetaxel (75&nbsp;mg/m<sup>2</sup> as a
1&nbsp;hour intravenous infusion every 3&nbsp;weeks) and capecitabine
(1250&nbsp;mg/m<sup>2</sup> twice daily for 2&nbsp;weeks followed by 1&#8209;week
rest period). 256&nbsp;patients were randomised to treatment with docetaxel
alone (100&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour intravenous infusion every
3&nbsp;weeks). Survival was superior in the docetaxel&nbsp;+ capecitabine
combination arm (p&nbsp;=&nbsp;0.0126). Median survival was 442&nbsp;days
(docetaxel&nbsp;+ capecitabine) vs. 352&nbsp;days (docetaxel alone). The
overall objective response rates in the all&#8209;randomised population (investigator
assessment) were 41.6% (docetaxel&nbsp;+ capecitabine) vs. 29.7% (docetaxel
alone); p&nbsp;=&nbsp;0.0058. Time to progressive disease was superior in the
docetaxel&nbsp;+ capecitabine combination arm (p&nbsp;&lt;&nbsp;0.0001). The
median time to progression was 186&nbsp;days (docetaxel&nbsp;+ capecitabine)
vs. 128&nbsp;days (docetaxel alone).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Non-small cell lung cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Patients previously treated with
chemotherapy with or without radiotherapy</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In a phase&nbsp;III study, in previously
treated patients, time to progression (12.3&nbsp;weeks versus 7&nbsp;weeks) and
overall survival were significantly longer for docetaxel at 75&nbsp;mg/m&sup2;
compared to Best Supportive Care. The 1&#8209;year survival rate was also
significantly longer in docetaxel (40%) versus BSC (16%).</span></p>

<p class=Normal11pt><span lang=EN-GB>There was less use of morphinic analgesic
(p&nbsp;&lt;&nbsp;0.01), non&#8209;morphinic analgesics (p&nbsp;&lt;&nbsp;0.01),
other disease-related medicinal products (p&nbsp;=&nbsp;0.06) and radiotherapy
(p&nbsp;&lt;&nbsp;0.01) in patients treated with docetaxel at
75&nbsp;mg/m&sup2; compared to those with BSC.</span></p>

<p class=Normal11pt><span lang=EN-GB>The overall response rate was 6.8% in the
evaluable patients, and the median duration of response was 26.1&nbsp;weeks.</span></p>

<p class=Normal11pt><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
in combination with platinum agents in chemotherapy-na&iuml;ve patients</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>In a
phase&nbsp;III study, 1218&nbsp;patients with unresectable stage&nbsp;IIIB or
IV NSCLC, with KPS of 70% or greater, and who did not receive previous
chemotherapy for this condition, were randomised to either docetaxel&nbsp;(T)
75&nbsp;mg/m<sup>2 </sup>as a 1&nbsp;hour infusion immediately followed by
cisplatin&nbsp;(Cis) 75&nbsp;mg/m<sup>2 </sup>over 30&#8209;60&nbsp;minutes
every 3&nbsp;weeks (TCis), docetaxel 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour
infusion in combination with carboplatin (AUC 6&nbsp;mg/ml.min) over 30&#8209;60&nbsp;minutes
every 3&nbsp;weeks, or vinorelbine&nbsp;(V) 25&nbsp;mg/m<sup>2</sup>
administered over 6&#8209;10&nbsp;minutes on days&nbsp;1, 8, 15, 22 followed by
cisplatin 100&nbsp;mg/m<sup>2</sup> administered on day&nbsp;1 of cycles
repeated every 4&nbsp;weeks (VCis).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Survival
data, median time to progression and response rates for two arms of the study
are illustrated in the following table:</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=584
 style='margin-left:17.5pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>TCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;408</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>VCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;404</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Statistical analysis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  survival </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(Primary
  end-point):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>Median survival (months)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>10.1</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.122</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[97.2% CI: 0.937; 1.342]*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>1-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>41</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 5.4%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: -1.1; 12.0]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>2-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>21</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 6.2%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.2; 12.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  time to progression</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(weeks):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.0</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>23.0</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.032</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.876; 1.216]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  response rate (%):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.6</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.5</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 7.1%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.7; 13.5]</span></p>
  </td>
 </tr>
</table>

<p class=Normal11ptGauche0 style='page-break-after:avoid'><span lang=EN-GB>*:
Corrected for multiple comparisons and adjusted for stratification factors
(stage of disease and region of treatment), based on evaluable patient
population.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Secondary end&#8209;points included change
of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom
Scale, and changes in Karnosfky performance status. Results on these end-points
were supportive of the primary end-points results. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For docetaxel/carboplatin combination, neither
equivalent nor non-inferior efficacy could be proven compared to the reference
treatment combination VCis.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer</span></u></i></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Metastatic castration-resistant prostate cancer</span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in
combination with prednisone or prednisolone in patients with metastatic castration-resistant
prostate cancer were evaluated in a randomised multi-centre phase&nbsp;III study
(TAX 327). A total of 1006&nbsp;patients with KPS&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;60 were randomised
to the following treatment groups:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 75&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 30&nbsp;mg/m<sup>2</sup>
administered weekly for the first 5&nbsp;weeks in a 6&nbsp;week cycle for
5&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mitoxantrone
12&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>All 3&nbsp;regimens were administered in
combination with prednisone or prednisolone 5&nbsp;mg twice daily,
continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients who received docetaxel every
three weeks demonstrated significantly longer overall survival compared to
those treated with mitoxantrone. The increase in survival seen in the docetaxel
weekly arm was not statistically significant compared to the mitoxantrone
control arm. Efficacy endpoints for the docetaxel arms versus the control arm
are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=608
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Endpoint</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks </span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every week</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Mitoxantrone </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  survival (months)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Hazard ratio</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>p-value<sup>&#8224;</sup>*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>335</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(17.0-21.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.761</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.619-0.936)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0094</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>334</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>17.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.7-19.0)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.912</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.747-1.113)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.3624</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>337</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.4-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>PSA**
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>291</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>45.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(39.5-51.3)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0005</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>282</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>47.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(41.9-53.9)<br>
  &lt;0.0001</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>300</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(26.4-37.3)<br>
  --</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>153</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(27.1-42.7)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0107</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>154</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(24.0-39.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0798</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>157</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.5-28.9)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.7pt'>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Tumour
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>141</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(7.2-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.1112</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>134</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(4.2-14.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.5853</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>137</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.0-12.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><sup><span lang=EN-GB>&#8224;</span></sup><span
lang=EN-GB>Stratified log-rank test<br>
*Threshold for statistical significance&nbsp;=&nbsp;0.0175</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**PSA:
Prostate-Specific Antigen<br>
<br>
</span></p>

<p class=Normal11pt><span lang=EN-GB>Given the fact that docetaxel every week
presented a slightly better safety profile than docetaxel every 3&nbsp;weeks,
it is possible that certain patients may benefit from docetaxel every week.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>No statistical differences were observed
between treatment groups for Global Quality of Life.</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Metastatic hormone-sensitive
prostate cancer</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>STAMPEDE </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered concomitantly with standard of care (ADT)<b> </b>in
patients with high-risk locally advanced or metastatic hormone-sensitive
prostate cancer were evaluated in a <span style='color:black'>randomised multi-centre,
multi-arm multi-stage (MAMS) study </span></span><span style='color:black'>with
a seamless phase II/III design</span><span style='font-size:11.0pt'> (STAMPEDE
&#8211; MRC PR08). A total of 1776 male patients were allocated to the
treatment armss of interest: </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>+ docetaxel
75 mg/m&sup2;, administered every 3 weeks for 6 cycles&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>alone<span
style='background:silver'> </span></span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Docetaxel regimen was
administered in combination with prednisone or prednisolone 5 mg twice daily
continuously. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Among the 1776 randomised
patients 1086 (61%) had metastatic disease, 362 were randomised to docetaxel in
combination with standard of care, 724 received standard of care<b> </b>alone. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In these metastatic prostate
cancer patients, the median overall survival was significantly longer in
docetaxel treatment groups than in the standard of care<b> </b>alone group, with
a median overall survival 19 months longer with the addition of docetaxel to
standard of care<b> </b>(HR =&nbsp; 0.76, 95% </span><span lang=EN-GB
style='font-size:11.0pt'>CI = 0.62-0.92,</span><span style='font-size:11.0pt'>
p=0.005). </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Efficacy results in
metastatic prostate cancer patients for </span><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span><span style='font-size:11.0pt'> arm
versus control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in combination with prednisone
or prednisolone and standard of care in the treatment of patients with
metastatic hormone-sensitive prostate cancer </span><span style='font-size:
11.0pt'>(STAMPEDE)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:maroon'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:11.0pt;
  color:black'>Endpoint</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span><span
  style='font-size:11.0pt;color:black'>+</span><span style='font-size:11.0pt;
  color:black'> standard of care</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Standard of care </span><span
  style='font-size:11.0pt;color:black'>alone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:57.7pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.7pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of metastatic prostate cancer
  patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months) </span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.7pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>362</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>51-73</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.7pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>724</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>43</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>40-48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>(0.62&#8209;0.92)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.005</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Failure-Free survival<i><span style='position:relative;
  top:-3.0pt'>b</span></i>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.8-25.2</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>9.6-12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.57&#8209;0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&lt; 0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.3pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>a </span></sup></i><span
  style='font-size:11.0pt;color:black'>p-value calculated from the likelihood
  ratio test and adjusted for all stratification factors (except center and
  planned hormone therapy) and stratified by trial period</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>b</span></sup></i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> Failure-free
  survival: time from randomization to first evidence of at least one of:
  biochemical failure (defined as a rise in PSA of 50% above the within-24-week
  nadir and above 4 ng/mL and confirmed by retest or treatment); progression
  either locally, in lymph nodes, or in distant metastases; skeletal-related
  event; or death from prostate cancer.</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:115%'><u><span style='font-size:11.0pt;
line-height:115%'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>CHAARTED </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered at the beginning of androgen-deprivation therapy (ADT) in
patients with metastatic hormone-sensitive prostate cancer were evaluated in a randomised
Phase III multi-centre study (CHAARTED). A total of 790 male patients were
allocated to the 2 treatment groups. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT + docetaxel
75 mg/m&sup2; given at the beginning of ADT, administered every 3 weeks for 6
cycles</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT alone<sup> </sup>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'><br>
The median overall survival was significantly longer in docetaxel treatment
group than in the ADT alone group, with a median overall survival 13.6
months&nbsp; longer with the addition of docetaxel to ADT (hazard ratio (HR) =
0.61, 95% </span><span lang=EN-GB style='font-size:11.0pt'>confidence interval
(CI)&nbsp;= 0.47-0.80, </span><span style='font-size:11.0pt'>p=0.0003). <br>
<br>
Efficacy results or the </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> arm versus the control arm are summarized in the
following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Efficacy
of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> and ADT in the treatment of patients with metastatic
hormone-sensitive prostate cancer (CHAARTED)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>Endpoint</span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=178 valign=top style='width:133.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span></b><b><span
   style='font-size:11.0pt;color:black'>+ADT </span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=112 valign=top style='width:83.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>ADT alone</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months)</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>All patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><i><span
  lang=IT style='font-size:11.0pt;color:black'>95% CI</span></i></b><span
  style='color:black'>Adjusted </span><span style='font-size:11.0pt;color:black'>hazard
  ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>397</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>57.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>49.1-72.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>393</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>44.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>34.4-49.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.47&#8209;0.80)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.0003</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Progression Free Survival</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value*</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.7-22.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.60</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.51-0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>P&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.6</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>10.8-14.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 6 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>127 (32.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>77 (19.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 12 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>110 (27.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>66 (16.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to castration-resistant prostate cancer<i><span
  style='position:relative;top:-3.0pt'>b</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months) </span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.2&#8209;23.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(10.8-14.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.51&#8209;0.72)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to clinical progression</span><i><span style='font-size:
  11.0pt;color:black;position:relative;top:-3.0pt'>c</span></i><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)<i><span style='position:relative;top:-3.0pt'> </span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>33.0</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(27.3-41.2)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.9-22.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.50-0.75)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.3pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>a</span></i><span style='font-size:11.0pt;color:black'>&nbsp;</span><span
  style='font-size:11.0pt;color:black'>Time to event variables: Stratified
  log-rank test. <br>
  &nbsp; Response rate variables: Fisher's Exact test</span><i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> </span></i></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>* p-value for
  descriptive purpose.</span></p>
  <p class=MsoCommentText><span style='font-size:11.0pt;color:black'>** </span><span
  lang=EN-GB style='color:black'>PSA r</span><span style='font-size:11.0pt;
  color:black'>esponse</span><span lang=EN-GB style='font-size:11.0pt;
  color:black'>: Prostate-Specific Antigen response: </span><span
  style='font-size:11.0pt;color:black'>PSA level &lt;0.2 ng/mL measured for two
  consecutive measurements at least 4 weeks apart.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>b </span></i><span style='font-size:11.0pt;color:black'>Time
  to castration-resistant prostate cancer = time from randomization to PSA
  progression </span><span lang=EN-GB style='color:black'>or clinical progression
  (i.e., increasing symptomatic bone metastases, progression per </span><span
  style='font-size:11.0pt;color:black'>Response Evaluation Criteria in Solid
  Tumours (</span><span lang=EN-GB style='color:black'>RECIST) criteria, or
  clinical deterioration due to cancer per the Investigator&#8217;s opinion),
  whichever occurred first.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>c</span></i><span style='font-size:11.0pt;color:black'>&nbsp;The
  time to clinical progression = the time from randomization until clinical
  progression (i.e., increased symptoms of bone metastases; progression
  according to RECIST; or clinical deterioration due to cancer according to the
  investigator&#8217;s opinion).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A multi-centre, open-label, randomised
study was conducted to evaluate the safety and efficacy of docetaxel for the
treatment of patients with metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction, who had not received prior
chemotherapy for metastatic disease. A total of 445&nbsp;patients with
KPS&nbsp;&gt;&nbsp;70 were treated with either docetaxel&nbsp;(T) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) in combination with cisplatin&nbsp;(C) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) and 5&#8209;fluorouracil&nbsp;(F) (750&nbsp;mg/m<sup>2</sup> per
day for 5&nbsp;days) or cisplatin (100&nbsp;mg/m<sup>2</sup> on day&nbsp;1) and
5&#8209;fluorouracil (1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days). The
length of a treatment cycle was 3&nbsp;weeks for the TCF arm and 4&nbsp;weeks
for the CF arm. The median number of cycles administered per patient was 6
(with a range of 1&#8209;16) for the TCF arm compared to 4 (with a range of 1&#8209;12)
for the CF arm. Time to progression (TTP) was the primary endpoint. The risk
reduction of progression was 32.1% and was associated with a significantly
longer TTP (p&nbsp;=&nbsp;0.0004) in favour of the TCF arm. Overall survival
was also significantly longer (p&nbsp;=&nbsp;0.0201) in favour of the TCF arm
with a risk reduction of mortality of 22.7%. Efficacy results are summarized in
the following table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the treatment of patients with gastric adenocarcinoma</span></u></p>

<p align=center style='margin:0in;text-align:center;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>TCF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;221</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;224</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median TTP (months)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>5.6</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>3.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(4.86-5.91)</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(3.45-4.47)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.473</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.189-1.825)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.2</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(8.38-10.58)</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(7.16-9.46)</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>2-year estimate (%)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18.4</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.293</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.041-1.606)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0201</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (CR+PR) (%)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36.7</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0106</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progressive disease as best overall response (%)</span></p>
  </td>
  <td width=133 style='width:99.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.7</span></p>
  </td>
  <td width=133 style='width:99.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.9</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Unstratified
logrank test</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Subgroup analyses across age, gender and
race consistently favoured the TCF arm compared to the CF arm.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>A survival update analysis conducted with
a median follow-up time of 41.6&nbsp;months no longer showed a statistically
significant difference although always in favour of the TCF regimen and showed
that the benefit of TCF over CF is clearly observed between 18 and
30&nbsp;months of follow up.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Overall, quality of life (QoL) and
clinical benefit results consistently indicated improvement in favour of the
TCF arm. Patients treated with TCF had a longer time to 5% definitive<b> </b>deterioration
of global health status on the QLQ&#8209;C30 questionnaire
(p&nbsp;=&nbsp;0.0121) and a longer time to definitive worsening<b> </b>of
Karnofsky performance status (p&nbsp;=&nbsp;0.0088) compared to patients
treated with CF.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction</span><span lang=EN-GB
style='font-size:11.0pt'> chemotherapy followed by radiotherapy (TAX323)</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in
the induction treatment of patients with squamous cell carcinoma of the head
and neck (SCCHN) was evaluated in a phase&nbsp;III, multi-centre, open-label, randomised
study (TAX323). In this study, 358&nbsp;patients with inoperable locally
advanced SCCHN, and WHO performance status&nbsp;0 or 1, were randomised to one
of two treatment arms. Patients on the docetaxel arm received
docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2</sup> followed by cisplatin&nbsp;(P)
75&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
750&nbsp;mg/m<sup>2</sup> per day as a continuous infusion for 5&nbsp;days.
This regimen was administered every three weeks for 4&nbsp;cycles in case at
least a minor response (&#8805;&nbsp;25% reduction in bidimensionally measured
tumour size) was observed after 2&nbsp;cycles. At the end of chemotherapy, with
a minimal interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks,
patients whose disease did not progress received radiotherapy (RT) according to
institutional guidelines for 7&nbsp;weeks (TPF/RT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days. This regimen was
administered every three weeks for 4&nbsp;cycles in case at least a minor
response (&#8805;&nbsp;25% reduction in bidimensionally measured tumour size)
was observed after 2&nbsp;cycles. At the end of chemotherapy, with a minimal
interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks, patients whose
disease did not progress received radiotherapy&nbsp;(RT) according to
institutional guidelines for 7&nbsp;weeks (PF/RT). Locoregional therapy with
radiation was delivered either with a conventional fraction (1.8&nbsp;Gy&nbsp;&#8209;&nbsp;2.0&nbsp;Gy
once a day, 5&nbsp;days per week for a total dose of 66 to 70&nbsp;Gy), or
accelerated/hyperfractionated regimens of radiation therapy (twice a day, with
a minimum interfraction interval of 6&nbsp;hours, 5&nbsp;days per week). A
total of 70&nbsp;Gy was recommended for accelerated regimens and 74&nbsp;Gy for
hyperfractionated schemes. Surgical resection was allowed following
chemotherapy, before or after radiotherapy. Patients on the TPF arm received
antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice daily for
10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. The primary
endpoint in this study, progression-free survival (PFS), was significantly
longer in the TPF arm compared to the PF arm, p&nbsp;=&nbsp;0.0042 (median PFS:
11.4 vs. 8.3&nbsp;months respectively) with an overall median follow up time of
33.7&nbsp;months. Median overall survival was also significantly longer in favour
of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5&nbsp;months
respectively) with a 28% risk reduction of mortality, p&nbsp;=&nbsp;0.0128.
Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Efficacy of docetaxel in the induction
treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat
Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 style='margin-top:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;text-transform:none'>Endpoint</span></h1>
  </td>
  <td width=128 valign=top style='width:96.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;177</span></b></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;181</span></b></p>
  </td>
 </tr>
 <tr style='height:22.0pt'>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt><span lang=EN-GB>Median progression free survival
  (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.1-14.0)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>8.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.4-9.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Adjusted hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>*p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.55-0.89)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0042</span></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>18.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(15.7-24.0)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>14.5</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(11.6-18.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.56-0.93)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0128</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to chemotherapy
  (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>67.8</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(60.4-74.6)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>53.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(46.0-61.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to study treatment
  [chemotherapy +/- radiotherapy] (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>72.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(65.1-78.8)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>58.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(51.0-65.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response to
  chemotherapy&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&plusmn;</span><span
  lang=EN-GB> radiotherapy (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;128</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>15.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(13.4-24.6)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;106</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.2-17.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.52-0.99)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0457</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>A hazard
ratio of less than&nbsp;1 favours docetaxel&nbsp;+ cisplatin&nbsp;+ 5&#8209;FU</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Cox model
(adjustment for Primary tumour site, T and N clinical stages and PSWHO)</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**Logrank
test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>***
Chi-square test</span></p>

<p class=MsoNormal style='margin-left:.5in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Quality of life parameters</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients treated with TPF experienced
significantly less deterioration of their Global health score compared to those
treated with PF (p&nbsp;=&nbsp;0.01, using the EORTC QLQ&#8209;C30 scale). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Clinical benefit parameters</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The performance status scale, for head and
neck (PSS&#8209;HN) subscales designed to measure understandability of speech,
ability to eat in public, and normalcy of diet, was significantly in favour of
TPF as compared to PF.</span></p>

<p class=Normal11pt><span lang=EN-GB>Median time to first deterioration of WHO
performance status was significantly longer in the TPF arm compared to PF.</span><span
lang=EN-GB style='layout-grid-mode:line'> Pain intensity score improved during
treatment in both groups indicating adequate pain management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:
line'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Induction
</span><span lang=EN-GB style='font-size:11.0pt'>chemotherapy</span><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'> followed by chemoradiotherapy
(TAX324)</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of docetaxel in the induction treatment of patients with locally
advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in
a randomised, multi-centre open-label, phase&nbsp;III study (TAX324). In this
study, 501&nbsp;patients, with locally advanced SCCHN, and a WHO performance
status of 0 or 1, were randomised to one of two arms. The study population
comprised patients with technically unresectable disease, patients with low
probability of surgical cure and patients aiming at organ preservation. The
efficacy and safety evaluation solely addressed survival endpoints and the
success of organ preservation was not formally addressed. Patients on the
docetaxel arm received docetaxel&nbsp;(T) 75&nbsp;mg/m&sup2; by intravenous
infusion on day 1 followed by cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2;
administered as a 30&#8209;minute to three-hour intravenous infusion, followed
by the continuous intravenous infusion of 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m&sup2;/day from day&nbsp;1 to day&nbsp;4. The cycles were repeated
every 3 weeks for 3 cycles. All patients who did not have progressive disease
were to receive chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on
the comparator arm received cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; as a 30&#8209;minute
to three&#8209;hour intravenous infusion on day&nbsp;1 followed by the
continuous intravenous infusion of 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m&sup2;/day from day&nbsp;1 to day&nbsp;5. The cycles were
repeated every 3&nbsp;weeks for 3&nbsp;cycles. All patients who did not have
progressive disease were to receive CRT as per protocol (PF/CRT). </span></p>

<p class=Normal11pt><span lang=EN-GB>Patients in both treatment arms were to
receive 7&nbsp;weeks of CRT following induction chemotherapy with a minimum
interval of 3&nbsp;weeks and no later than 8&nbsp;weeks after start of the last
cycle (day&nbsp;22 to day&nbsp;56 of last cycle). During radiotherapy, carboplatin
(AUC&nbsp;1.5) was given weekly as a one&#8209;hour intravenous infusion for a
maximum of 7&nbsp;doses. Radiation was delivered with megavoltage equipment
using once daily fractionation (2&nbsp;Gy per day, 5&nbsp;days per week for
7&nbsp;weeks, for a total dose of 70&#8209;72&nbsp;Gy). Surgery on the primary
site of disease and/or neck could be considered at any time following
completion of CRT. All patients on the docetaxel-containing arm of the study
received prophylactic antibiotics. The primary efficacy endpoint in this study,
overall survival (OS) was significantly longer (log-rank test,
p&nbsp;=&nbsp;0.0058) with the docetaxel-containing regimen compared to PF
(median OS: 70.6 versus 30.1&nbsp;months respectively), with a 30% risk
reduction in mortality compared to PF (hazard ratio (HR)&nbsp;=&nbsp;0.70, 95%
confidence interval (CI)&nbsp;=&nbsp;0.54&#8209;0.90) with an overall median
follow up time of 41.9&nbsp;months. The secondary endpoint, PFS, demonstrated a
29% risk reduction of progression or death and a 22&nbsp;month improvement in
median PFS (35.5&nbsp;months for TPF and 13.1 for PF). This was also
statistically significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test
p&nbsp;=&nbsp;0.004. Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the induction treatment of patients with locally advanced SCCHN
(Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=166 valign=bottom style='width:124.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+
  Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  255</span></b></p>
  </td>
  <td width=166 valign=bottom style='width:124.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+
  5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  246</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  overall survival (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>70.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(49.0-NA)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>30.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(20.9-51.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 style='width:202.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>*p-value </span></p>
  </td>
  <td width=333 colspan=2 valign=top style='width:249.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.54-0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0058</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 style='width:202.2pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  PFS (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>35.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(19.3-NA)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(10.6 - 20.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>**p-value
  </span></p>
  </td>
  <td width=333 colspan=2 valign=bottom style='width:249.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.71</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.56 - 0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to chemotherapy (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.8</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.8-77.2)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(57.9-70.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=333 colspan=2 style='width:249.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.070</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to study treatment [chemotherapy +/-
  chemoradiotherapy] (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95%CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>76.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(70.8-81.5)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.5-77.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=333 colspan=2 style='width:249.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.209</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>A hazard ratio of less than 1 favours docetaxel&nbsp;+
cisplatin&nbsp;+ fluorouracil</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>*un-adjusted log-rank test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>**un-adjusted log-rank test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>***Chi square test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>NA-not applicable</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The European
Medicines Agency has waived the obligation to submit the results of studies
with TAXOTERE in all subsets of the paediatric population in breast cancer,
non-small cell lung cancer, prostate cancer, gastric carcinoma and head and
neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Absorption</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The pharmacokinetics of docetaxel have
been evaluated in cancer patients after administration of 20&#8209;115&nbsp;mg/m<sup>2</sup>
in phase&nbsp;I studies. The kinetic profile of docetaxel is dose independent
and consistent with a three-compartment pharmacokinetic model with half-lives
for the </span><span lang=EN-GB>a</span><span lang=EN-GB>, </span><span lang=EN-GB>b</span><span lang=EN-GB> and </span><span
lang=EN-GB>g</span><span lang=EN-GB>&nbsp;phases of 4&nbsp;min, 36&nbsp;min and
11.1&nbsp;h, respectively. The late phase is due, in part, to a relatively slow
efflux of docetaxel from the peripheral compartment. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Distribution</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Following the administration of a
100&nbsp;mg/m<sup>2</sup> dose given as a one&#8209;hour infusion a mean peak
plasma level of 3.7&nbsp;&micro;g/ml was obtained with a corresponding AUC of
4.6&nbsp;h.&micro;g/ml. Mean values for total body clearance and steady-state
volume of distribution were 21&nbsp;l/h/m<sup>2</sup> and 113&nbsp;l,
respectively. Inter individual variation in total body clearance was
approximately 50%. Docetaxel is more than 95% bound to plasma proteins.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>A study of <sup>14</sup>C&#8209;docetaxel
has been conducted in three cancer patients. Docetaxel was eliminated in both
the urine and faeces following cytochrome P450&#8209;mediated oxidative
metabolism of the tert-butyl ester group, within seven days, the urinary and
faecal excretion accounted for about 6% and 75% of the administered
radioactivity, respectively. About 80% of the radioactivity recovered in faeces
is excreted during the first 48&nbsp;hours as one major inactive metabolite and
3&nbsp;minor inactive metabolites and very low amounts of unchanged medicinal
product.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Special populations</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Age and gender</span></i></p>

<p class=Normal11pt><span lang=EN-GB>A population pharmacokinetic analysis has
been performed with docetaxel in 577&nbsp;patients. Pharmacokinetic parameters
estimated by the model were very close to those estimated from phase&nbsp;I
studies. The pharmacokinetics of docetaxel were not altered by the age or sex
of the patient. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=Normal11pt><span lang=EN-GB>In a small number of patients
(n&nbsp;=&nbsp;23) with clinical chemistry data suggestive of mild to moderate
liver function impairment (ALT, AST&nbsp;</span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1.5&nbsp;times the ULN
associated with alkaline phosphatase </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;2.5&nbsp;times the ULN), total
clearance was lowered by 27% on average (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Fluid retention</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel clearance was not modified in
patients with mild to moderate fluid retention and there are no data available
in patients with severe fluid retention.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Combination therapy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Doxorubicin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>When used in combination, docetaxel does
not influence the clearance of doxorubicin and the plasma levels of
doxorubicinol (a doxorubicin metabolite). The pharmacokinetics of docetaxel,
doxorubicin and cyclophosphamide were not influenced by their co&#8209;administration.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Capecitabine</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Phase&nbsp;I study evaluating the effect
of capecitabine on the pharmacokinetics of docetaxel and vice versa showed no
effect by capecitabine on the pharmacokinetics of docetaxel (Cmax and AUC) and
no effect by docetaxel on the pharmacokinetics of a relevant capecitabine
metabolite 5&#8217;&#8209;DFUR.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Cisplatin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Clearance of docetaxel in combination
therapy with cisplatin was similar to that observed following monotherapy. <span
style='layout-grid-mode:line'>The pharmacokinetic profile of cisplatin
administered shortly after docetaxel infusion is similar to that observed with
cisplatin alone.</span></span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Cisplatin
and 5-fluorouracil</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The combined administration of docetaxel,
cisplatin and 5&#8209;fluorouracil in 12&nbsp;patients with solid tumours had
no influence on the pharmacokinetics of each individual medicinal product.</span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone
and dexamethasone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The effect of prednisone on the
pharmacokinetics of docetaxel administered with standard dexamethasone
premedication has been studied in 42&nbsp;patients. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Prednisone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>No effect of prednisone on the
pharmacokinetics of docetaxel was observed.</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.3&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The carcinogenic potential of docetaxel
has not been studied.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown to be mutagenic
in the <i>in vitro</i> micronucleus and chromosome aberration test in CHO&#8209;K1
cells and in the <i>in vivo</i> micronucleus test in the mouse. However, it did
not induce mutagenicity in the Ames test or the CHO/HGPRT gene mutation assay.
These results are consistent with the pharmacological activity of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Undesirable effects on the testis observed
in rodent toxicity studies suggest that docetaxel may impair male fertility.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=Normal11pt><span lang=EN-GB>Ethanol anhydrous</span></p>

<p class=Normal11pt><span lang=EN-GB>Citric acid</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>This medicinal product must not be mixed
with other medicinal products except those mentioned in section 6.6.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp; Shelf-life</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Unopened vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>3&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>After opening
of the vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is for
single use and should be used immediately after opening. If not used
immediately, in&#8209;use storage times and conditions are the responsibility
of the user. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TblTextLeft style='margin:0in;page-break-after:avoid'><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Once added to the </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>infusion </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>bag</span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>From a
microbiological point of view,</span><span lang=EN-GB style='font-size:11.0pt'>
reconstitution/dilution must take place in controlled and aseptic conditions</span><span
lang=EN-GB style='font-size:11.0pt'> and the medicinal product should be used
immediately. If not used immediately, in&#8209;use storage times and conditions
are the responsibility of the user.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Once added as
recommended into the infusion bag, the docetaxel infusion solution, if stored
below 25&deg;C, is stable for 6 hours. It should be used within 6 hours
(including the one hour infusion intravenous administration). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In addition,
physical and chemical in-use stability of the infusion solution prepared as
recommended has been demonstrated in non-PVC bags up to 48 hours when stored
between 2 to 8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel infusion
solution is supersaturated, therefore may crystallize over time. If crystals
appear, the solution must no longer be used and shall be discarded. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 25&deg;C. </span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Store in
the original package in order to protect from light.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>For storage
conditions of the diluted medicinal product, see section 6.3.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp; Nature and
contents of container</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>7&nbsp;ml clear glass (type&nbsp;I) vial
with a magenta aluminium seal<i> </i>and a magenta plastic flip&#8209;off cap
containing 4&nbsp;ml of concentrate.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Each box contains one vial.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it and preparing TAXOTERE solutions. The use of gloves is recommended.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion
solution should come into contact with skin, wash immediately and thoroughly
with soap and water. If TAXOTERE concentrate or infusion solution should come
into contact with mucous membranes, wash immediately and thoroughly with water.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation for the intravenous
administration</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2 vials (concentrate and
solvent) with this medicinal product (TAXOTERE 80&nbsp;mg/4&nbsp;ml concentrate
for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE
80&nbsp;mg/4&nbsp;ml </span></b><b><span lang=EN-GB style='font-size:11.0pt'>concentrate
for solution for infusion </span></b><b><span lang=EN-GB style='font-size:11.0pt'>requires
NO prior dilution with a solvent and is ready to add to the infusion solution.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is of
single use and should be used immediately.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If the vials are stored under
refrigeration, allow the required number of boxes of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> to
stand below 25&deg;C for 5&nbsp;minutes before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>More than one vial of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> may be
necessary to obtain the required dose for the patient. Aseptically withdraw the
required amount of TAXOTERE concentrate for solution for infusion using a
calibrated syringe fitted with a 21G needle.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 80&nbsp;mg /4&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=Normal11pt><span lang=EN-GB>The required volume of TAXOTERE concentrate
</span><span lang=EN-GB>for solution for infusion</span><span lang=EN-GB> must
be injected via a single injection (one shot) into a 250&nbsp;ml infusion bag
or bottle containing either 5% glucose solution or sodium chloride 9&nbsp;mg/ml
(0.9%) solution for infusion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If a dose greater than 190&nbsp;mg of
docetaxel is required, use a larger volume of the infusion vehicle so that a
concentration of 0.74&nbsp;mg/ml docetaxel is not exceeded. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Mix the infusion bag or bottle manually
using a rocking motion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The infusion bag solution should be used
within 6&nbsp;hours below 25&deg;C including the one hour infusion to the
patient.</span></p>

<p class=Normal11pt><span lang=EN-GB>As with all parenteral products, TAXOTERE
infusion solution should be visually inspected prior to use, solutions
containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>8.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>EU/1/95/002/004</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>9.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: </span><span lang=EN-GB
style='font-size:11.0pt'>27 November 1995</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of latest renewal: 27 November 2005</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>10.&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <u>http://www.ema.europa.eu.</u> </span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 160&nbsp;mg/8&nbsp;ml concentrate
for solution for infusion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Each ml of concentrate contains 20&nbsp;mg
docetaxel (as trihydrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One&nbsp;vial of 8&nbsp;ml of concentrate
contains 160&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Excipient with known effect:</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Each vial of concentrate contains
4&nbsp;ml of ethanol anhydrous (3.16&nbsp;g). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is a pale yellow to
brownish-yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.1&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Breast cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin and cyclophosphamide is indicated for the adjuvant
treatment of patients with:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;positive
breast cancer</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>operable node&#8209;negative
breast cancer </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For patients with
operable node</span><span lang=EN-GB style='font-size:11.0pt'>&#8209;negative
breast cancer, adjuvant treatment should be restricted to patients eligible to
receive chemotherapy according to internationally established criteria for
primary therapy of early breast cancer (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with doxorubicin is indicated for the treatment of patients with
locally advanced or metastatic breast cancer who have not previously received cytotoxic
therapy for this condition.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE
monotherapy is indicated for the treatment of patients with locally advanced or
metastatic breast cancer after failure of cytotoxic therapy. Previous
chemotherapy should have included an anthracycline or an alkylating agent.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with trastuzumab is indicated for the treatment of patients with
metastatic breast cancer whose tumours over express HER2 and who previously have
not received chemotherapy for metastatic disease.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.05pt'><span lang=EN-GB style='font-size:
11.0pt'>TAXOTERE in combination with capecitabine is indicated for the
treatment of patients with locally advanced or metastatic breast cancer after
failure of cytotoxic chemotherapy. Previous therapy should have included an
anthracycline.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>TAXOTERE is
indicated for the treatment of patients with locally advanced or metastatic
non-small cell lung cancer after failure of prior chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE in
combination with cisplatin is indicated for the treatment of patients with
unresectable, locally advanced or metastatic non-small cell lung cancer, in
patients who have not previously received chemotherapy for this condition.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Prostate
cancer</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE in combination with prednisone or prednisolone
is indicated for the treatment of patients with&nbsp; metastatic </span><span
lang=EN-GB style='font-size:11.0pt'>castration-resistant</span><span
lang=EN-GB style='font-size:11.0pt'> prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>TAXOTERE in</span><span lang=EN-GB> combination with
androgen-deprivation therapy (ADT), with or without</span><span lang=EN-GB>
prednisone or prednisolone, is indicated for the treatment of patients with metastatic
hormone-sensitive prostate cancer.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in;text-align:justify'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the treatment of patients with metastatic
gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal
junction, who have not received prior chemotherapy for metastatic disease.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Head and neck cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE in combination with cisplatin and
5&#8209;fluorouracil is indicated for the induction treatment of patients with
locally advanced squamous cell carcinoma of the head and neck.</span></p>

<p class=MsoBodyText2 style='margin-top:0in;text-align:justify'><b><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The use of docetaxel should be confined to
units specialised in the administration of cytotoxic chemotherapy and it should
only be administered under the supervision of a physician qualified in the use
of anticancer chemotherapy (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Posology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast, non-small cell lung, gastric,
and head and neck cancers, premedication consisting of an oral corticosteroid,
such as dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for
3&nbsp;days starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can be used (see section 4.4). <br>
For metastatic castration-resistant prostate cancer, given the concurrent use
of prednisone or prednisolone the recommended premedication regimen is oral
dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour before the
docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>For metastatic hormone-sensitive prostate
cancer, irrespective of the concurrent use of prednisone or prednisolone, the
recommended premedication regimen is oral dexamethasone 8&nbsp;mg 12 hours, 3
hours, and 1 hour before docetaxel infusion (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Prophylactic G&#8209;CSF may be used to
mitigate the risk of haematological toxicities.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is administered as a one-hour
infusion every three weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>In the adjuvant treatment of operable node&#8209;positive
and node&#8209;negative breast cancer, the recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour after doxorubicin
50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> every
3&nbsp;weeks for 6&nbsp;cycles (TAC regimen) (see also Dose adjustments during treatment).
</span></p>

<p class=Normal11pt><span lang=EN-GB>For the treatment of patients with locally
advanced or metastatic breast cancer, the recommended dose of docetaxel is
100&nbsp;mg/m<sup>2</sup> in monotherapy. In first-line treatment, docetaxel
75&nbsp;mg/m<sup>2 </sup>is given in combination therapy with doxorubicin<sup> </sup>(50&nbsp;mg/m<sup>2</sup>).
</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with trastuzumab the
recommended dose of docetaxel is 100&nbsp;mg/m<sup>2</sup> every three weeks,
with trastuzumab administered weekly. In the pivotal study the initial
docetaxel infusion was started the day following the first dose of trastuzumab.
The subsequent docetaxel doses were administered immediately after completion
of the trastuzumab infusion, if the preceding dose of trastuzumab was well
tolerated. For trastuzumab dose and administration, see trastuzumab summary of
product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> every three weeks,
combined with capecitabine at 1250&nbsp;mg/m<sup>2</sup> twice daily (within
30&nbsp;minutes after a meal) for 2&nbsp;weeks followed by a 1&#8209;week rest
period. For capecitabine dose calculation according to body surface area, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Non-small
cell lung cancer</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>In
chemotherapy na&iuml;ve patients treated for non-small cell lung cancer, the recommended
dose regimen is docetaxel 75&nbsp;mg/m<sup>2 </sup>immediately followed by cisplatin
75&nbsp;mg/m<sup>2 </sup>over 30-60&nbsp;minutes. For treatment after failure
of prior platinum-based chemotherapy, the recommended dose is
75&nbsp;mg/m&sup2; as a single agent.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer </span></u></i></p>

<p class=Normal11pt><i><span style='color:black'>Metastatic
castration-resistant prostate cancer</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup>. Prednisone or prednisolone 5&nbsp;mg orally twice
daily is administered continuously (see section 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:11.0pt;color:black'>Metastatic
hormone-sensitive prostate cancer</span></i></p>

<p class=Normal11pt><span style='color:black'>The recommended dose of </span><span
lang=EN-GB>docetaxel </span><span style='color:black'>is 75&nbsp;mg/m<sup>2</sup>
every 3 weeks for 6 cycles. Prednisone or prednisolone 5&nbsp;mg orally twice
daily may be administered continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>The recommended dose of docetaxel is
75&nbsp;mg/m<sup>2</sup> as a 1-hour infusion, followed by cisplatin
75&nbsp;mg/m<sup>2</sup>, as a 1- to 3-hour infusion (both on day&nbsp;1 only),
followed by 5&#8209;fluorouracil 750&nbsp;mg/m<sup>2</sup> per day given as a
24&#8209;hour continuous infusion for 5&nbsp;days, starting at the end of the
cisplatin infusion. Treatment is repeated every three weeks. Patients must
receive premedication with antiemetics and appropriate hydration for cisplatin
administration. Prophylactic G&#8209;CSF should be used to mitigate the risk of
haematological toxicities (see also Dose adjustments during treatment).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients must receive premedication with
antiemetics and appropriate hydration (prior to and after cisplatin
administration). Prophylactic G&#8209;CSF may be used to mitigate the risk of
haematological toxicities. All patients on the docetaxel-containing arm of the
TAX&nbsp;323 and TAX&nbsp;324 studies, received prophylactic antibiotics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by radiotherapy (TAX&nbsp;323)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of inoperable locally advanced squamous
cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel
is 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour infusion followed by cisplatin 75&nbsp;mg/m<sup>2</sup>
over 1 hour, on day one, followed by 5&#8209;fluorouracil as a continuous
infusion at 750&nbsp;mg/m<sup>2</sup> per day for five days. This regimen is
administered every 3&nbsp;weeks for 4&nbsp;cycles. Following chemotherapy,
patients should receive radiotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy
followed by chemoradiotherapy (TAX&nbsp;324)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB style='font-size:
11.0pt'>For the induction treatment of patients with locally advanced
(technically unresectable, low probability of surgical cure, and aiming at
organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the
recommended dose of docetaxel is 75&nbsp;mg/m<sup>2</sup> as a 1 hour
intravenous infusion on day&nbsp;1, followed by cisplatin 100&nbsp;mg/m<sup>2 </sup>administered
as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000&nbsp;mg/m<sup>2</sup>/day
as a continuous infusion from day&nbsp;1 to day&nbsp;4. This regimen is
administered every 3&nbsp;weeks for 3&nbsp;cycles. Following chemotherapy,
patients should receive chemoradiotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose modifications, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Dose adjustments during treatment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>General </span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel should be administered when the
neutrophil count is </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.
</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients who experienced either febrile
neutropenia, neutrophil count &lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for more
than one week, severe or cumulative cutaneous reactions or severe peripheral
neuropathy during docetaxel therapy, the dose of docetaxel should be reduced
from 100&nbsp;mg/m<sup>2</sup> to 75&nbsp;mg/m<sup>2</sup> and/or from 75 to
60&nbsp;mg/m&sup2;. If the patient continues to experience these reactions at
60&nbsp;mg/m&sup2;, the treatment should be discontinued. </span></p>

<p class=Normal11pt><span class=BoldCharacter><span style='text-transform:uppercase'>&nbsp;</span></span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Adjuvant
therapy for breast cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Primary G&#8209;CSF
prophylaxis should be considered in patients who receive docetaxel, doxorubicin
and cyclophosphamide (TAC) adjuvant therapy for breast cancer. Patients who
experience febrile neutropenia and/or neutropenic infection should have their
docetaxel dose reduced to 60&nbsp;mg/m&sup2; in all subsequent cycles (see
sections 4.4 and 4.8). Patients who experience Grade&nbsp;3 or 4 stomatitis
should have their dose decreased to 60&nbsp;mg/m&sup2;.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who are dosed initially at
docetaxel 75&nbsp;mg/m<sup>2</sup> in combination with cisplatin and whose
nadir of platelet count during the previous course of therapy is &lt;&nbsp;25,000&nbsp;cells/mm<sup>3</sup>,
or<sup> </sup>in patients who experience febrile neutropenia, or in patients
with serious non-haematologic toxicities, the docetaxel dose in subsequent
cycles should be reduced to 65&nbsp;mg/m<sup>2</sup>. For cisplatin dose
adjustments, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with capecitabine</span></u></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For capecitabine dose modifications, see
capecitabine summary of product characteristics.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the first
appearance of Grade&nbsp;2 toxicity, which persists at the time of the next
docetaxel/capecitabine treatment, delay treatment until resolved to Grade&nbsp;0&#8209;1,
and resume at 100% of the original dose. </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For patients developing the second
appearance of Grade&nbsp;2 toxicity, or the first appearance of Grade&nbsp;3
toxicity, at any time during the treatment cycle, delay treatment until
resolved to Grade&nbsp;0&#8209;1 and then resume treatment with docetaxel
55&nbsp;mg/m&sup2;. </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>For any subsequent appearances of
toxicities, or any Grade&nbsp;4 toxicities, discontinue the docetaxel dose.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For trastuzumab dose modifications, see
trastuzumab summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If an episode of febrile neutropenia,
prolonged neutropenia or neutropenic infection occurs despite G&#8209;CSF use,
the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>. If
subsequent episodes of complicated neutropenia occur the docetaxel dose should
be reduced from 60 to 45&nbsp;mg/m<sup>2</sup>. In case of Grade&nbsp;4
thrombocytopenia the docetaxel dose should be reduced from 75 to 60&nbsp;mg/m<sup>2</sup>.
Patients should not be retreated with subsequent cycles of docetaxel until
neutrophils recover to a level &gt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup> and
platelets recover to a level &gt;&nbsp;100,000&nbsp;cells/mm<sup>3</sup>.
Discontinue treatment if these toxicities persist (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>Recommended dose modifications for toxicities
in patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
(5&#8209;FU):</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Toxicity</span></b></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Dose adjustment</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: then reduce docetaxel
  dose by 20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce docetaxel and 5&#8209;FU
  doses by 20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: discontinue treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;3 </span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: reduce 5&#8209;FU dose by
  20%.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: stop 5&#8209;FU only, at
  all subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Third episode: reduce docetaxel dose by
  20%.</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis/mucositis grade&nbsp;4</span></p>
  </td>
  <td width=384 valign=top style='width:4.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>First episode: stop 5&#8209;FU only, at all
  subsequent cycles.</span></p>
  <p class=Normal11pt><span lang=EN-GB>Second episode: reduce docetaxel dose by
  20%.</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For cisplatin and 5&#8209;fluorouracil
dose adjustments, see the corresponding summary of product characteristics.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the pivotal SCCHN studies patients who
experienced complicated neutropenia (including prolonged neutropenia, febrile
neutropenia, or infection), it was recommended to use G&#8209;CSF to provide
prophylactic coverage (eg, day&nbsp;6&#8209;15) in all subsequent cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Patients
with hepatic impairment</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Based on
pharmacokinetic data with docetaxel at 100&nbsp;mg/m&sup2; as single agent,
patients who have both elevations of transaminase (ALT and/or AST) greater than
1.5&nbsp;times the upper limit of the normal range (ULN) and alkaline
phosphatase greater than 2.5&nbsp;times the ULN, the recommended dose of
docetaxel is 75&nbsp;mg/m<sup>2</sup> (see sections 4.4 and 5.2). For those
patients with serum bilirubin &gt;&nbsp;ULN and/or ALT and
AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN associated with alkaline phosphatase
&gt;&nbsp;6&nbsp;times the ULN, no dose-reduction can be recommended and
docetaxel should not be used unless strictly indicated. </span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available
in patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of TAXOTERE in nasopharyngeal carcinoma in children aged 1 month to
less than 18 years have not yet been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There is no
relevant use of TAXOTERE in the paediatric population in the indications breast
cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head
and neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Older people</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Based on a population pharmacokinetic analysis,
there are no special instructions for use in the older people.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with capecitabine, for
patients 60&nbsp;years of age or more, a starting dose reduction of capecitabine
to 75% is recommended (see capecitabine summary of product characteristics).</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>For instructions on preparation and administration of
the product, see section</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;6.6.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section 6.1. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with baseline neutrophil count of
&lt;&nbsp;1,500&nbsp;cells/mm<sup>3</sup>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe liver impairment (see
sections 4.2 and 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Contraindications for other medicinal
products also apply, when combined with docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-top:0in'><b><span lang=EN-GB
style='font-size:11.0pt;color:windowtext;position:relative;top:-3.0pt'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For breast and non-small cell lung
cancers, premedication consisting of an oral corticosteroid, such as
dexamethasone 16&nbsp;mg per day (e.g.&nbsp;8&nbsp;mg BID) for 3&nbsp;days
starting 1&nbsp;day prior to docetaxel administration, unless contraindicated,
can reduce the incidence and severity of fluid retention as well as the
severity of hypersensitivity reactions. For prostate cancer, the premedication
is oral dexamethasone 8&nbsp;mg, 12&nbsp;hours, 3&nbsp;hours and 1&nbsp;hour
before the docetaxel infusion (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Haematology</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Neutropenia is the most frequent adverse
reaction of docetaxel. Neutrophil nadirs occurred at a median of 7&nbsp;days
but this interval may be shorter in heavily pre&#8209;treated patients.
Frequent monitoring of complete blood counts should be conducted on all patients
receiving docetaxel. Patients should be retreated with docetaxel when
neutrophils recover to a level </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1,500&nbsp;cells/mm3 (see
section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In the case of severe neutropenia
(&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup> for seven days or more) during a
course of docetaxel therapy, a reduction in dose for subsequent courses of
therapy or the use of appropriate symptomatic measures are recommended (see
section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel in
combination with cisplatin and 5&#8209;fluorouracil (TCF), febrile neutropenia
and neutropenic infection occurred at lower rates when patients received
prophylactic G&#8209;CSF. Patients treated with TCF should receive prophylactic
G&#8209;CSF to mitigate the risk of complicated neutropenia (febrile
neutropenia, prolonged neutropenia or neutropenic infection). Patients
receiving TCF should be closely monitored (see sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In patients
treated with docetaxel in combination with doxorubicin and cyclophosphamide
(TAC), febrile neutropenia and/or neutropenic infection occurred at lower rates
when patients received primary G&#8209;CSF prophylaxis. Primary G&#8209;CSF
prophylaxis should be considered in patients who receive adjuvant therapy with
TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile </span><span
lang=EN-GB style='font-size:11.0pt'>neutropenia, prolonged neutropenia or
neutropenic infection). Patients receiving TAC should be closely monitored (see
sections 4.2 and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span style='font-size:11.0pt'>Gastrointestinal reactions</span></u></p>

<p class=MsoNormal style='margin-left:15.85pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Caution is recommended for
patients with </span><span style='font-size:11.0pt'>neutropenia,</span><span
style='font-size:11.0pt'> particularly at risk for developing gastrointestinal
complications</span><span style='font-size:11.0pt'>. Although majority of cases
occurred during the first or second cycle of docetaxel containing regimen, e</span><span
lang=EN-GB style='font-size:11.0pt'>nterocolitis could develop at any time, and
could lead to death as early as on the first day of onset. Patients should be
closely monitored for early manifestations of serious gastrointestinal toxicity
(see sections 4.2, 4.4 Haematology, and 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Hypersensitivity reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients should be observed closely for
hypersensitivity reactions especially during the first and second infusions.
Hypersensitivity reactions may occur within a few minutes following the
initiation of the infusion of docetaxel, thus facilities for the treatment of
hypotension and bronchospasm should be available. If hypersensitivity reactions
occur, minor symptoms such as flushing or localised cutaneous reactions do not
require interruption of therapy. However, severe reactions, such as severe
hypotension, bronchospasm or generalised rash/erythema require immediate
discontinuation of docetaxel and appropriate therapy. Patients who have
developed severe hypersensitivity reactions should not be re-challenged with
docetaxel. </span><span lang=EN-GB>Patients who have previously experienced a
hypersensitivity reaction to paclitaxel may be at risk to develop
hypersensitivity reaction to docetaxel, including more severe hypersensitivity
reaction. These patients should be closely monitored during initiation of
docetaxel therapy</span>.</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Cutaneous reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Localised skin erythema of the extremities
(palms of the hands and soles of the feet) with oedema followed by desquamation
has been observed. Severe symptoms such as eruptions followed by desquamation
which lead to interruption or discontinuation of docetaxel treatment were
reported (see section 4.2). </span></p>

<p class=00-Paragraph><span lang=EN-GB>Severe Cutaneous Adverse Reactions (SCARs)
such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis</span><sup><span
lang=EN-GB style='font-size:10.0pt;font-family:"Arial Narrow",sans-serif'> </span></sup><span
lang=EN-GB>(TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have
been reported with docetaxel treatment. Patients should be informed about the
signs and symptoms of serious skin manifestations and closely monitored</span><strong><span
lang=EN-GB style='font-family:"Segoe UI",sans-serif;color:#444444;font-weight:
normal'>. </span></strong><span lang=EN-GB>If signs and symptoms suggestive of
these reactions appear discontinuation of docetaxel should be considered.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB>Fluid retention</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients with severe fluid retention such
as pleural effusion, pericardial effusion and ascites should be monitored
closely.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Respiratory
disorders</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung
disease, pulmonary fibrosis and respiratory failure have been reported and </span><span
class=msoins0><span lang=EN-GB style='font-size:11.0pt'>may be associated </span></span><span
lang=EN-GB style='font-size:11.0pt'>with fatal outcome. </span><span
class=BlueReplace><span lang=EN-GB style='color:windowtext'>Cases of radiation
pneumonitis have been reported in patients receiving concomitant radiotherapy.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If new or
worsening pulmonary symptoms develop, patients should be closely monitored,
promptly investigated, and appropriately treated. Interruption of docetaxel
therapy is recommended</span><span style='font-size:11.0pt'> until diagnosis is
available</span><span lang=EN-GB style='font-size:11.0pt'>. Early use of
supportive care measures may help improve the condition. The benefit of
resuming docetaxel treatment must be carefully evaluated.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Patients with liver impairment</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In patients treated with docetaxel at 100&nbsp;mg/m<sup>2</sup>
as single agent who have serum transaminase levels (ALT and/or AST) greater
than 1.5&nbsp;times the ULN concurrent with serum alkaline phosphatase levels
greater than 2.5&nbsp;times the ULN, there is a higher risk of developing
severe adverse reactions such as toxic deaths including sepsis and
gastrointestinal haemorrhage which can be fatal, febrile neutropenia,
infections, thrombocytopenia, stomatitis and asthenia. Therefore, the recommended
dose of docetaxel in those patients with elevated liver function test (LFTs) is
75&nbsp;mg/m<sup>2</sup> and LFTs should be measured at baseline and before
each cycle (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>For patients with serum bilirubin levels
&gt;&nbsp;ULN and/or ALT and AST&nbsp;&gt;&nbsp;3.5&nbsp;times the ULN
concurrent with serum alkaline phosphatase levels &gt;&nbsp;6&nbsp;times the ULN,
no dose-reduction can be recommended and docetaxel should not be used unless
strictly indicated.</span></p>

<p class=Normal11pt><span lang=EN-GB>In combination with cisplatin and 5&#8209;fluorouracil
for the treatment of patients with gastric adenocarcinoma, the pivotal clinical
study excluded patients with <span class=BlueReplace><span style='color:windowtext'>ALT
and/or</span></span> <span class=BlueReplace><span style='color:windowtext'>AST&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;ULN
associated with alkaline phosphatase &gt;&nbsp;2.5&nbsp;&times;&nbsp;ULN, and </span></span>bilirubin
&gt;&nbsp;1&nbsp;x&nbsp;ULN<span class=BlueReplace><span style='color:windowtext'>;
for these patients,</span></span> no dose-reductions can be recommended and
docetaxel should not be used unless strictly indicated. No data are available
in patients with hepatic impairment treated by docetaxel in combination in the
other indications.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with renal impairment</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>There are
no data available in patients with severely impaired renal function treated
with docetaxel. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
development of severe peripheral neurotoxicity requires a reduction of dose
(see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Cardiac
toxicity</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Heart
failure has been observed in patients receiving docetaxel in combination with
trastuzumab, particularly following anthracycline (doxorubicin or epirubicin)-containing
chemotherapy. This may be moderate to severe and has been associated with death
(see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>When patients are candidates for treatment
with docetaxel in combination with trastuzumab, they should undergo baseline cardiac
assessment. Cardiac function should be further monitored during treatment (e.g.
every three months) to help identify patients who may develop cardiac
dysfunction. For more details see summary of product characteristics of
trastuzumab.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including
ventricular tachycardia (sometimes fatal) has been reported in patients treated
with docetaxel in combination regimens including doxorubicin, 5-fluorouracil
and/ or cyclophosphamide (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>Baseline cardiac assessment is recommended.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><strong><u><span lang=EN-GB style='font-size:11.0pt;
font-weight:normal'>Eye disorders</span></u></strong></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Cystoid macular oedema (CMO) has been
reported in patients treated with docetaxel. Patients with impaired vision
should undergo a prompt and complete ophthalmologic examination. In case CMO is
diagnosed, docetaxel treatment should be discontinued and appropriate treatment
initiated (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Second primary
malignancies have been reported when docetaxel was given in combination with
anticancer treatments known to be associated with second primary malignancies. Second
primary malignancies (including acute myeloid leukaemia, myelodysplastic
syndrome and non-Hodgkin lymphoma) may occur several months or years after
docetaxel-containing therapy. Patients should be monitored for second primary
malignancies (see section 4.8).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Tumour Lysis
Syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tumour lysis
syndrome has been reported with docetaxel after the first or the second cycle
(see section 4.8). Patients at risk of tumour lysis syndrome (e.g. with renal
impairment, hyperuricemia, bulky tumour, rapid progression) should be closely
monitored. Correction of dehydration and treatment of high uric acid levels are
recommended prior to initiation of treatment.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Others</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Contraceptive measures must be
taken by both men and women during treatment and for men at least&nbsp;
6&nbsp;months after cessation of therapy (see section 4.6).</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The concomitant use of docetaxel
with strong CYP3A4 inhibitors </span><span style='font-family:"Times New Roman",serif;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole)
should be avoided (see section 4.5).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Additional cautions for use in adjuvant
treatment of breast cancer</span></u></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Complicated neutropenia</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>For patients who experience complicated
neutropenia (prolonged neutropenia, febrile neutropenia or infection), G&#8209;CSF
and dose reduction should be considered (see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Gastrointestinal
reactions</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Symptoms
such as early abdominal pain and tenderness, fever, diarrhoea, with or without
neutropenia, may be early manifestations of serious gastrointestinal toxicity
and should be evaluated and treated promptly.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><u><span lang=EN-GB>Congestive
heart failure (CHF)</span></u></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Patients
should be monitored for symptoms of congestive heart failure during therapy and
during the follow up period.</span><span lang=EN-GB> In patients treated with
the TAC regimen for node positive breast cancer, the risk of CHF has been shown
to be higher during the first year after treatment (see sections 4.8 and 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Patients with 4+ nodes</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>As the benefit observed in patient with 4+
nodes was not statistically significant on </span><span lang=EN-GB>disease&#8209;free
</span><span lang=EN-GB>survival (DFS) and overall survival (OS), the positive
benefit/risk ratio for TAC in patients with 4+&nbsp;nodes was not fully demonstrated
at the final analysis (see section 5.1).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Elderly</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in adjuvant
treatment of breast cancer</span></u></i></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There are limited data available in
patients &gt;&nbsp;70&nbsp;years of age on docetaxel use in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in castration-resistant
prostate cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Of the 333&nbsp;patients treated with docetaxel
every three weeks in a prostate cancer study </span><span lang=EN-GB>(TAX 327)</span><span
lang=EN-GB>, 209&nbsp;patients were 65&nbsp;years of age or greater and
68&nbsp;patients were older than 75&nbsp;years. In patients treated with
docetaxel every three weeks, the incidence of related nail changes occurred at
a rate </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>&nbsp;10% higher in patients who were 65&nbsp;years of age or
greater compared to younger patients. The incidence of related fever,
diarrhoea, anorexia, and peripheral oedema occurred at rates </span><span
lang=EN-GB style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10%
higher in patients who were 75&nbsp;years of age or greater versus less than
65&nbsp;years.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Cautions for use in hormone-sensitive
prostate cancer</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>Of the
</span><span style='font-size:11.0pt;color:black'>545 </span><span lang=EN-GB
style='font-size:11.0pt;color:black'>patients treated with docetaxel every 3 weeks</span><span
style='font-size:11.0pt;color:black'> in a hormone-sensitive prostate cancer
study (STAMPEDE)</span><span lang=EN-GB style='font-size:11.0pt;color:black'>, </span><span
style='font-size:11.0pt;color:black'>296 patients were 65 years of age or
older, and 48 patients were 75 years of age or older</span><span lang=EN-GB
style='font-size:11.0pt;color:black'>. </span><span style='font-size:11.0pt;
color:black'>More patients aged &#8805;65 years in the docetaxel arm reported
hypersensitivity reaction, neutropenia, anaemia, fluid retention, dyspnea, and
nail changes when compared to the patients aged less than 65 years. None of
these increases in frequency reached 10% difference with the control arm.</span><span
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>In
patients who were 75&nbsp;years of age or older, when compared to younger
patients,</span><span style='font-size:11.0pt'> neutropenia, anaemia, diarrhea,
dyspnea and upper respiratory tract infection were reported</span><span
style='font-size:11.0pt'> </span><span style='font-size:11.0pt'>with a greater
incidence (at least 10% higher)</span><span lang=EN-GB style='font-size:11.0pt'>.
</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Cautions for use in gastric
adenocarcinoma cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>Among the 300 (221&nbsp;patients in the
phase&nbsp;III part of the study and 79&nbsp;patients in the phase&nbsp;II
part) patients treated with docetaxel in combination with cisplatin and 5&#8209;fluorouracil
in the gastric cancer study, 74 were 65&nbsp;years of age or older and
4&nbsp;patients were 75&nbsp;years of age or older. The incidence of serious
adverse events was higher in older people compared to younger patients. The
incidence of the following adverse events (all grades): lethargy, stomatitis,
neutropenic infection occurred at rates </span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;10% higher in
patients who were 65&nbsp;years of age or older compared to younger patients. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Older people treated
with TCF should be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 3.16&nbsp;g ethanol anhydrous per vial, equivalent to 80&nbsp;ml of
beer or 33&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, children and high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>Consideration
should be given to possible effects on the central nervous system.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB style='font-size:
11.0pt'> studies have shown that the metabolism of docetaxel may be modified by
the concomitant administration of compounds which induce, inhibit or are
metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450&#8209;3A
such as ciclosporine, ketoconazole and erythromycin. As a result, caution
should be exercised when treating patients with these medicinal products as
concomitant therapy since there is a potential for a significant interaction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In case of
combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse
reactions may increase, as a result of reduced metabolism. If the concomitant
use of a strong CYP3A4 inhibitor </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(e.g., ketoconazole, itraconazole, clarithromycin, indinavir,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) </span><span
lang=EN-GB style='font-size:11.0pt'>cannot be avoided, a close clinical
surveillance is warranted and a dose-adjustment of docetaxel may be suitable
during the treatment with the strong CYP3A4 inhibitor (see section 4.4). </span><span
lang=EN-GB style='font-size:11.0pt'>In a pharmacokinetic study with 7 patients,
the co-administration of docetaxel with the strong CYP3A4 inhibitor
ketoconazole leads to a&nbsp;significant decrease in docetaxel clearance by
49%.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Docetaxel pharmacokinetics in the
presence of prednisone was studied in patients with metastatic prostate cancer.
Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4. No
statistically significant effect of prednisone on the pharmacokinetics of
docetaxel was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is
highly protein bound (&gt;&nbsp;95%). Although the possible <i>in vivo</i>
interaction of docetaxel with concomitantly administered medicinal product has
not been investigated formally, <i>in vitro</i> interactions with tightly
protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did
not affect protein binding of docetaxel. In addition, dexamethasone did not
affect protein binding of docetaxel. Docetaxel did not influence the binding of
digitoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not
influenced by their co&#8209;administration. Limited data from a single
uncontrolled study were suggestive of an interaction between docetaxel and
carboplatin. When combined to docetaxel, the clearance of carboplatin was about
50% higher than values previously reported for carboplatin monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><u><span style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span style='font-family:"Times New Roman",serif'>There
is no information on the use of docetaxel in pregnant women. Docetaxel has been
shown to be both embryotoxic and foetotoxic in rabbits and rats, and to reduce
fertility in rats. As with other cytotoxic medicinal products, docetaxel may cause
foetal harm when administered to pregnant women. Therefore, docetaxel must not
be used during pregnancy unless clearly indicated.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><span style='font-family:
"Times New Roman",serif'>Women of childbearing age receiving docetaxel should
be advised to avoid becoming pregnant, and to inform the treating physician
immediately should this occur.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel is a
lipophilic substance but it is not known whether it is excreted in human milk.
Consequently, because of the potential for adverse reactions in nursing
infants, breast feeding must be discontinued for the duration of docetaxel
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Contraception
in males and females</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>An effective
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>In non clinical studies, docetaxel has genotoxic
effects and may alter male fertility (see section 5.3). Therefore, men being
treated with docetaxel are advised not to father a child during and up to
6&nbsp;months after treatment and to seek advice on conservation of sperm prior
to treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>No studies on the
effects on the ability to drive and use machines have been performed. The
amount of alcohol in this </span><span lang=EN-GB style='font-size:11.0pt'>medicinal
product </span><span style='font-size:11.0pt'>and the side effects</span><span
lang=EN-GB style='font-size:11.0pt'> of the product may impair the ability to
drive or use machines (see sections 4.4</span><span style='font-size:11.0pt'>
and 4.8</span><span lang=EN-GB style='font-size:11.0pt'>). Therefore, patients
should be warned of the potential impact of the amount of alcohol and the side
effects of this medicinal product on the ability to drive or use machines, and
be advised not to drive or use machines if they experience these side effects
during treatment.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;position:relative;top:-3.0pt'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile for all indications</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The adverse
reactions considered to be possibly or probably related to the administration
of docetaxel have been obtained in: </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1312 and
     121&nbsp;patients who received 100&nbsp;mg/m&sup2;<sup> </sup>and
     75&nbsp;mg/m&sup2; of docetaxel as a single agent respectively.</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>258&nbsp;patients
     who received docetaxel in combination with doxorubicin. </span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>406&nbsp;patients
     who received docetaxel in combination with cisplatin. </span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>92&nbsp;patients
treated with docetaxel in combination with trastuzumab. </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>255&nbsp;patients
     who received docetaxel in combination with capecitabine.</span></li>
</ul>

<p class=Authors style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
auto;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>332&nbsp;patients
</span><span style='font-family:"Times New Roman",serif'>(TAX327)</span><span
style='font-family:"Times New Roman",serif'> <span lang=EN-GB>who received
docetaxel in combination with prednisone or prednisolone (clinically important
treatment related adverse events are presented).</span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1276&nbsp;patients
     (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel
     in combination with doxorubicin and cyclophosphamide (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>300&nbsp;gastric
     adenocarcinoma patients (221&nbsp;patients in the phase&nbsp;III part of
     the study and 79&nbsp;patients in the phase&nbsp;II part) who received
     docetaxel in combination with cisplatin and 5&#8209;fluorouracil
     (clinically important treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>174 and
     251&nbsp;head and neck cancer patients who received docetaxel in
     combination with cisplatin and 5&#8209;fluorouracil (clinically important
     treatment related adverse events are presented).</span></li>
 <li class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>545 patients
     (STAMPEDE study) who received docetaxel in combination with prednisone or
     prednisolone ADT.</span></li>
</ul>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>These reactions were described using the NCI Common
Toxicity Criteria (grade&nbsp;3&nbsp;=&nbsp;G3; grade&nbsp;3&#8209;4&nbsp;=&nbsp;G3/4;
grade&nbsp;4&nbsp;=&nbsp;G4), the COSTART and the MedDRA terms. Frequencies are
defined as: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to
&lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000);
not known (cannot be estimated from available data).</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse
reactions of docetaxel alone are: neutropenia (which was reversible and not
cumulative; the median day to nadir was 7&nbsp;days and the median duration of
severe neutropenia (&lt;&nbsp;500&nbsp;cells/mm<sup>3</sup>) was 7&nbsp;days), anaemia,
alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia. The severity of
adverse events of docetaxel may be increased when docetaxel is given in combination
with other chemotherapeutic agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with trastuzumab, adverse
events (all grades) reported in &#8805;&nbsp;10% are displayed. There was an
increased incidence of SAEs (40% vs. 31%) and Grade&nbsp;4 AEs (34% vs. 23%) in
the trastuzumab combination arm compared to docetaxel monotherapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For combination with capecitabine, the
most frequent treatment-related undesirable effects (&#8805;&nbsp;5%) reported
in a phase&nbsp;III study in breast cancer patients failing anthracycline
treatment are presented (see capecitabine summary of product characteristics).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For combination
with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events
occurring over the 6 cycles of treatment with docetaxel and having at least 2%
higher incidence in the docetaxel treatment arm by comparison to the control
arm, are presented, using the CTCAE grading scale.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The following adverse reactions are
frequently observed with docetaxel:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Immune system disorders</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity reactions have generally
occurred within a few minutes following the start of the infusion of docetaxel
and were usually mild to moderate. The most frequently reported symptoms were
flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea
and fever or chills. Severe reactions were characterised by hypotension and/or
bronchospasm or generalized rash/erythema (see section 4.4).</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Nervous
system disorders</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The
development of severe peripheral neurotoxicity requires a reduction of dose
(see sections 4.2 and 4.4). Mild to moderate neuro-sensory signs are
characterised by paresthesia, dysesthesia or pain including burning.
Neuro-motor events are mainly characterised by weakness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Reversible cutaneous reactions have been
observed and were generally considered as mild to moderate. Reactions were
characterised by a rash including localised eruptions mainly on the feet and
hands (including severe hand and foot syndrome), but also on the arms, face or
thorax, and frequently associated with pruritus. Eruptions generally occurred
within one week after the docetaxel infusion. Less frequently, severe symptoms
such as eruptions followed by desquamation which rarely lead to interruption or
discontinuation of docetaxel treatment were reported (see sections 4.2 and
4.4). Severe nail disorders are characterised by hypo- or hyperpigmentation and
sometimes pain and onycholysis. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>General disorders and administration
site conditions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Infusion site reactions were generally
mild and consisted of hyper pigmentation, inflammation, redness or dryness of
the skin, phlebitis or extravasation and swelling of the vein.</span></p>

<p class=Normal11pt><span lang=EN-GB>Fluid retention includes events such as
peripheral oedema and less frequently pleural effusion, pericardial effusion,
ascites and weight gain. The peripheral oedema usually starts at the lower
extremities and may become generalised with a weight gain of 3&nbsp;kg or more.
Fluid retention is cumulative in incidence and severity (see section 4.4).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for </span><span lang=EN-GB>TAXOTERE 100&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections (G3/4: 5.7%; including sepsis
  and pneumonia, fatal in 1.7%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection associated with G4 neutropenia
  (G3/4: 4.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 76.4%); <br>
  Anaemia (G3/4: 8.9%); <br>
  Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Thrombocytopenia (G4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 5.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3:
  4.1%); <br>
  Peripheral motor neuropathy (G3/4: 4%); <br>
  Dysgeusia (severe: 0.07%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension; <br>
  Hypertension;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Haemorrhage</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspnoea (severe: 2.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 5.3%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 4%); <br>
  Nausea (G3/4: 4%); <br>
  Vomiting (G3/4: 3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation (severe: 0.2%); <br>
  Abdominal pain (severe: 1%); <br>
  Gastrointestinal haemorrhage (severe: 0.3%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Oesophagitis (severe: 0.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Skin reaction (G3/4: 5.9%); <br>
  Nail disorders (severe: 2.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (severe: 1.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arthralgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (severe: 6.5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 11.2%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Non-cardiac chest pain (severe: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased
  (&lt;&nbsp;5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood alkaline phosphatase
  increased (&lt;&nbsp;4%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 AST increased (&lt;&nbsp;3%);<br>
  G3/4 ALT increased (&lt;&nbsp;2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for TAXOTERE 100 mg/m<sup>2</sup>
single agent</span></u></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare: bleeding episodes associated with
grade&nbsp;3/4 thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Reversibility data are available among
35.3% of patients who developed neurotoxicity following docetaxel treatment at
100&nbsp;mg/m&sup2; as single agent. The events were spontaneously reversible
within 3&nbsp;months.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare: one case of alopecia
non-reversible at the end of the study. 73% of the cutaneous reactions were
reversible within 21&nbsp;days.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>General disorders and administration
site conditions</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The median cumulative dose to treatment
discontinuation was more than 1,000&nbsp;mg/m<sup>2 </sup>and the median time
to fluid retention reversibility was 16.4&nbsp;weeks (range 0 to
42&nbsp;weeks). The onset of moderate and severe retention is delayed (median
cumulative dose: 818.9&nbsp;mg/m<sup>2</sup>) in patients with premedication
compared with patients without premedication (median cumulative dose:
489.7&nbsp;mg/m<sup>2</sup>); however, it has been reported in some patients
during the early courses of therapy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in non-small cell lung cancer for TAXOTERE
75&nbsp;mg/m&sup2; single agent</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  (G3/4: 5%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Neutropenia
  (G4: 54.2%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Anaemia
  (G3/4: 10.8%); Thrombocytopenia (G4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (no severe)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 2.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arrhythmia
  (no severe) </span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 3.3%); <br>
  Stomatitis (G3/4: 1.7%); <br>
  Vomiting (G3/4: 0.8%); <br>
  Diarrhoea (G3/4: 1.7%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Constipation</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Skin reaction (G3/4: 0.8%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nail
  disorders (severe: 0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Asthenia
  (severe: 12.4%); <br>
  Fluid retention (severe: 0.8%);<br>
  Pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (&lt;&nbsp;2%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 7.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 91.7%);<br>
  Anaemia (G3/4: 9.4%); <br>
  Febrile neutropenia;<br>
  Thrombocytopenia (G4: 0.8%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure; </span></p>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 5%); <br>
  Stomatitis (G3/4: 7.8%); <br>
  Diarrhoea (G3/4: 6.2%); <br>
  Vomiting (G3/4: 5%); <br>
  Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Nail disorders (severe: 0.4%); <br>
  Skin reaction (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 8.1%); <br>
  Fluid retention (severe: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood bilirubin increased (&lt;&nbsp;2.5%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 Blood alkaline phosphatase
  increased (&lt;&nbsp;2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>G3/4 AST increased (&lt;&nbsp;1%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>G3/4 ALT increased (&lt;&nbsp;1%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in non-small
cell lung cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with cisplatin</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 5.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G4: 51.5%); <br>
  Anaemia (G3/4: 6.9%); <br>
  Thrombocytopenia (G4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 2.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3:
  3.7%); <br>
  Peripheral motor neuropathy (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypotension (G3/4: 0.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 9.6%); <br>
  Vomiting (G3/4: 7.6%); <br>
  Diarrhoea (G3/4: 6.4%); <br>
  Stomatitis (G3/4: 2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Constipation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia; <br>
  Nail disorders (severe: 0.7%); <br>
  Skin reaction (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (severe: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (severe: 9.9%);<br>
  Fluid retention (severe: 0.7%);<br>
  Fever (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infusion site reaction; <br>
  Pain</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4
  Blood bilirubin increased (2.1%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>G3/4 ALT
  increased (1.3%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 AST increased (0.5%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>G3/4 Blood alkaline phosphatase increased (0.3%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for TAXOTERE 100&nbsp;mg/m&sup2; in
combination with trastuzumab</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenia (G3/4: 32%); <br>
  Febrile neutropenia (includes neutropenia associated with fever and
  antibiotic use) or neutropenic sepsis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Paresthesia; Headache; Dysgeusia;
  Hypoaesthesia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased; Conjunctivitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac failure</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lymphoedema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Epistaxis; Pharyngolaryngeal pain;
  Nasopharyngitis; Dyspnoea; <br>
  Cough; Rhinorrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea; Diarrhoea; Vomiting;
  Constipation; Stomatitis; Dyspepsia; Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Alopecia; Erythema; Rash; Nail disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia; Arthralgia; Pain in extremity; Bone
  pain; Back pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia; Oedema peripheral; Pyrexia;
  Fatigue; Mucosal inflammation; Pain; Influenza like illness; Chest pain;
  Chills</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for TAXOTERE 100&nbsp;mg/m&sup2; in
combination with trastuzumab</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very common: Haematological toxicity was
increased in patients receiving trastuzumab and docetaxel, compared with
docetaxel alone (32% grade&nbsp;3/4 neutropenia versus 22%, using NCI-CTC
criteria). Note that this is likely to be an underestimate since docetaxel
alone at a dose of 100&nbsp;mg/m<sup>2</sup> is known to result in neutropenia
in 97% of patients, 76% grade&nbsp;4, based on nadir blood counts. The
incidence of febrile neutropenia/neutropenic sepsis was also increased in
patients treated with Herceptin plus docetaxel (23% versus 17% for patients
treated with docetaxel alone).</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Cardiac disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Symptomatic cardiac failure was reported
in 2.2% of the patients who received docetaxel plus trastuzumab compared to 0%
of patients given docetaxel alone. In the docetaxel plus trastuzumab arm, 64%
had received a prior anthracycline as adjuvant therapy compared with 55% in the
docetaxel arm alone.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
breast cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with capecitabine</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Oral candidiasis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenia (G3/4: 63%); Anaemia (G3/4:
  10%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Thrombocytopenia (G3/4: 3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 1%); <br>
  Decreased appetite </span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dehydration (G3/4: 2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dysgeusia (G3/4: &lt;&nbsp;1%);<br>
  Pareaesthesia (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness; <br>
  Headache (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Neuropathy peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Pharyngolaryngeal pain (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspnoea (G3/4: 1%); <br>
  Cough (G3/4: &lt;&nbsp;1%); <br>
  Epistaxis (G3/4: &lt;&nbsp;1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 18%); <br>
  Diarrhoea (G3/4: 14%); <br>
  Nausea (G3/4: 6%); <br>
  Vomiting (G3/4: 4%); <br>
  Constipation (G3/4: 1%); <br>
  Abdominal pain (G3/4: 2%); <br>
  Dyspepsia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Abdominal pain upper; <br>
  Dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hand-foot syndrome (G3/4: 24%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 6%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Nail disorders (G3/4: 2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=FR>Dermatitis; <br>
  Rash erythematous (G3/4: &lt;&nbsp;1%); </span></p>
  <p class=Normal11pt><span lang=FR>Nail discolouration; <br>
  Onycholysis (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (G3/4: 2%); <br>
  Arthralgia (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Pain in extremity (G3/4: &lt;&nbsp;1%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Back pain (G3/4: 1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Asthenia (G3/4: 3%); <br>
  Pyrexia (G3/4: 1%); <br>
  Fatigue/weakness (G3/4: 5%); </span></p>
  <p class=Normal11pt><span lang=EN-GB>Oedema peripheral (G3/4: 1%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy;<br>
  Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight decreased;<br>
  G3/4 Blood bilirubin increased (9%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in metastatic castration-resistant prostate cancer
for TAXOTERE 75&nbsp;mg/m&sup2; in combination with prednisone or prednisolone</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA <span
   style='color:black'>system organ</span><span style='color:black'> classes</span></span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Very
   common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span lang=EN-GB
   style='font-size:11.0pt;font-family:"Times New Roman",serif;position:relative;
   top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>Common
   adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Infection
  (G3/4: 3.3%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Neutropenia
  (G3/4: 32%); <br>
  Anaemia (G3/4: 4.9%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Thrombocytopenia
  (G3/4: 0.6%);<br>
  Febrile neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
  (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Anorexia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  sensory neuropathy (G3/4: 1.2%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dysgeusia
  (G3/4: 0%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Peripheral
  motor neuropathy (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lacrimation
  increased (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Cardiac
  left ventricular function decrease (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Epistaxis
  (G3/4: 0%);<br>
  Dyspnoea (G3/4: 0.6%); <br>
  Cough (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Nausea
  (G3/4: 2.4%); <br>
  Diarrhoea (G3/4: 1.2%); <br>
  Stomatitis/Pharyngitis (G3/4: 0.9%); </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Vomiting
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia;
  <br>
  Nail disorders (no severe)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Exfoliative
  rash (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective bone disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Arthralgia
  (G3/4: 0.3%); <br>
  Myalgia (G3/4: 0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fatigue
  (G3/4: 3.9%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
  retention (severe: 0.6%)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in high-risk locally advanced or metastatic
hormone-sensitive prostate cancer for TAXOTERE 75 mg/m&sup2; in combination
with prednisone or prednisolone and ADT (STAMPEDE study) </span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:458.65pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:35.4pt'>
   <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;position:relative;top:-3.0pt'>MedDRA system organ
   classes</span></b></p>
   <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
   115%;page-break-after:avoid'><b><span style='font-size:11.0pt;line-height:
   115%'>&nbsp;</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Very common adverse reactions</span></b></p>
   </td>
   <td width=211 valign=top style='width:158.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:35.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
   line-height:115%;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;line-height:115%'>Common adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:37.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Neutropenia (G3-4: 12 %)
  Anaemia </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Febrile
  neutropenia </span><span style='font-size:11.0pt'>(G3-4: 15%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Immune
  system disorders</span><span lang=EN-GB style='font-size:11.0pt;line-height:
  115%;color:black'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Hypersensitivity (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.2pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%;color:black'>Endocrine
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><s><span style='font-size:11.0pt'><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diabetes (G3-4: 1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.8pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.8pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>Anorexia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.45pt' style='page-break-inside:
  avoid !msorm;height:20.45pt !msorm'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Psychiatric
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Insomnia (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm;height:20.45pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.15pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Nervous
  system disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Peripheral sensory
  neuropathy (&#8805;G3: 2%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Headache<br>
  <br>
  </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.15pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.5pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Eye
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.5pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Blurred vision</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.1pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Cardiac
  disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hypotension </span><span
  style='font-size:11.0pt'>(G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:43.05pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Respiratory,
  thoracic and mediastinal disorders</span><span style='font-size:11.0pt;
  line-height:115%'> </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Dyspnea (G3: 1%)<br>
  Coughing (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Upper respiratory tract
  infection (G3: 1%) </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.05pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Pharyngitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'><br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:64.3pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span style='font-size:11.0pt;line-height:115%'>Gastrointestinal
  disorders </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diarrhea (G3: 3%)<br>
  Stomatitis (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Constipation (G3: 0%)<br>
  Nausea (G3: 1%)<br>
  Dyspepsia<br>
  Abdominal pain (G3: 0%)<br>
  Flatulence</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:64.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Vomiting (G3: 1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.7pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Alopecia (G3: 3%)<sup>a</sup></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Nail changes (G3: 1%)</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.7pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  lang=FR style='font-size:11.0pt;line-height:115%'>Rash</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Myalgia </span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
  style='font-size:11.0pt;line-height:115%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.75pt'>
  <td width=192 valign=top style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal style='margin-bottom:10.0pt;text-indent:-.4pt;line-height:
  115%'><span lang=EN-GB style='font-size:11.0pt;line-height:115%'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Lethargy (G3-4: 2%)<br>
  Flu-like symptoms (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Asthenia (G3: 0%)<br>
  Fluid retention</span></p>
  </td>
  <td width=211 valign=top style='width:158.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.75pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Fever (G3: 1%)<br>
  Oral candidiasis </span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypocalcaemia (G3: 0%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypophosphataemia (G3-4:
  1%)</span></p>
  <p class=MsoNormal><span style='font-size:11.0pt'>Hypokalaemia (G3: 0%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><sup><span style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'>a</span></sup><span
style='font-size:9.0pt;font-family:"Arial Narrow",sans-serif'> </span><span
style='font-size:9.0pt;color:black'>From the GETUG AFU15 study</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions in breast cancer for </span></u><u><span lang=EN-GB>adjuvant
therapy with TAXOTERE 75&nbsp;mg/m&sup2; in combination with doxorubicin and
cyclophosphamide<b> </b>in patients with node&#8209;positive </span><span
lang=EN-GB>(TAX 316) </span></u><u><span lang=EN-GB>and node&#8209;negative </span><span
lang=EN-GB>(GEICAM 9805) </span></u><u><span lang=EN-GB>breast cancer<b> </b></span><span
lang=EN-GB>- pooled data</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>MedDRA System Organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;page-break-after:avoid;punctuation-wrap:simple;
   text-autospace:none;vertical-align:baseline'><span style='font-size:11.0pt;
   font-family:"Times New Roman",serif'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Infection (G3/4: 2.4%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Neutropenic infection </span><span lang=NL
  style='font-size:11.0pt'>(G3/4: 2.</span><span style='font-size:11.0pt'>6</span><span
  lang=NL style='font-size:11.0pt'>%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Anaemia (G3/4: 3%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Neutropenia (G3/4: 59.2%); Thrombocytopenia (G3/4:
  1.6%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Febrile neutropenia (G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypersensitivity (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Anorexia (G3/4: 1.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Dysgeusia (G3/4: 0.6%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral sensory neuropathy (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Peripheral motor neuropathy (G3/4: 0%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Syncope (G3/4: 0%); Neurotoxicity (G3/4: 0%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Somnolence (G3/4: 0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Conjunctivitis (G3/4: &lt;0.1%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lacrimation increased (G3/4: &lt;0.1%) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Arrhythmia (G3/4: 0.2%) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hot flush (G3/4: 0.5%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hypotension (G3/4: 0%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Phlebitis (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lymphoedema (G3/4: 0%)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=xCover2Answ style='margin-top:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cough (G3/4: 0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Nausea (G3/4: 5.0%); Stomatitis (G3/4: 6.0%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Vomiting (G3/4: 4.2%); </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Diarrhoea (G3/4: 3.4%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Constipation (G3/4: 0.5%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Abdominal pain (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alopecia
  (persisting: &lt;3%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin disorder
  (G3/4: 0.6%); </span></p>
  <p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nail disorders
  (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Myalgia (G3/4:
  0.7%); Arthralgia (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Reproductive system and breast disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Amenorrhoea </span><span lang=NL style='font-size:
  11.0pt'>(G3/4: NA)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Asthenia (G3/4: 10.0%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL
  style='font-size:11.0pt'>Pyrexia (G3/4: NA);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL
  style='font-size:11.0pt'>Oedema peripheral (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoFootnoteText align=left style='margin-top:0in;text-align:left;
  page-break-after:avoid'><span style='font-size:11.0pt'>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Weight increased (G3/4: 0%);</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Weight decreased (G3/4: 0.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions in breast cancer for adjuvant therapy with TAXOTERE
75&nbsp;mg/m&sup2; in combination with doxorubicin and cyclophosphamide in
patients with node&#8209;positive (TAX 316) and node&#8209;negative (GEICAM
9805) breast cancer</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Nervous system disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>peripheral sensory neuropathy </span><span style='font-size:11.0pt'>started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 84&nbsp;patients (11.3%) in TAC arm and 15
patients (2&nbsp;%) in FAC arm. At the end of the follow-up period (median
follow-up time of 8 years), p</span><span style='font-size:11.0pt'>eripheral
sensory neuropathy</span><span lang=EN-GB style='font-size:11.0pt'> was
observed to be ongoing in 10 patients (1.3</span><span style='font-size:11.0pt'>%)
in TAC arm, and in 2</span><span lang=EN-GB style='font-size:11.0pt'> patients
(0.3%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In GEICAM 9805 study peripheral sensory neuropathy
that started during the treatment period persisted into the follow-up period in
10&nbsp;patients (1.9%) in TAC arm and 4 patients (0.8&nbsp;%) in FAC arm. At
the end of the follow-up period (median follow-up time of 10 years and 5
months), peripheral sensory neuropathy was observed to be ongoing in 3 patients
(0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Cardiac disorders</span></i></p>

<p class=MsoBodyText align=left style='text-align:left;punctuation-wrap:simple;
text-autospace:none;vertical-align:baseline'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:windowtext;layout-grid-mode:
both'>In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%)
in the FAC arm experienced congestive heart failure. All except one patient in
each arm were diagnosed with CHF more than 30 days after the treatment period.&nbsp;
Two patients in the TAC arm and 4 patients in the FAC arm died because of
cardiac failure.</span></p>

<p class=MsoHeader style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In GEICAM 9805
study, 3</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
patients (0.6&nbsp;%) in TAC arm and 3 </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>patients </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(0.6&nbsp;%)
in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>FAC
arm developed congestive heart failure during the follow-up period. At the end
of the follow-up period (actual median follow-up time of 10 years and 5
months), no patients&nbsp; had CHF in TAC arm and 1 patient in TAC arm died
because of dilated cardiomyopathy, and CHF was observed to be ongoing in
1&nbsp;patient (0.2%) in FAC arm.</span></p>

<p class=MsoHeader style='text-align:justify'><s><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal style='punctuation-wrap:simple;text-autospace:none;
vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In study
TAX316 alopecia persisting into the follow-up period after the end of
chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC
patients (87.6%).<br>
At the end of the follow-up period (actual median follow-up time of</span><span
lang=EN-GB style='font-size:14.0pt;font-family:"Cambria",serif;color:#00B0F0'> </span><span
lang=EN-GB style='font-size:11.0pt'>8 years), alopecia was observed to be
ongoing in 29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>In
GEICAM 9805 study alopecia </span><span style='font-size:11.0pt'>that started
during the treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period was observed to be ongoing in 49&nbsp;patients
(9.2&nbsp;%) in TAC arm and 35 patients (6.7&nbsp;%) in FAC arm. Alopecia
related to study drug started or worsened during the follow-up period in
42&nbsp;patients (7.9&nbsp;%) in TAC arm and 30 patients (5.8&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm,
and in 1 patient (0.2%) in FAC arm.</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>Reproductive system and breast disorders</span></i></p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>In TAX316 </span>amenorrhoea <span lang=EN-GB>that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%)
and 125 of 736 FAC patients (17.0%). Amenorrhea </span>was observed to be
ongoing <span lang=EN-GB>at the end of the </span>follow-up <span lang=EN-GB>period
(median follow-up time of 8 years) </span>in 121&nbsp;<span lang=EN-GB>of 744
TAC </span>patients <span lang=EN-GB>(16.3%) and 86 FAC patients (11.7%)</span>.</p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'>In GEICAM 9805 study amenorrhoea that started during the treatment
period and persisted into the follow-up period was observed to be ongoing in
18&nbsp;patients (3.4&nbsp;%) in TAC arm and 5 patients (1.0&nbsp;%) in FAC
arm. At the end of the follow-up period (median follow-up time of 10 years and
5 months), amenorrhoea was observed to be ongoing in 7 patients (1.3%) in TAC
arm, and in 4 patients (0.8%) in FAC arm.</p>

<p class=TextTi11 align=left style='margin-bottom:0in;text-align:left;
line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><i><span
lang=EN-GB style='font-weight:normal'>General disorders and administration site
conditions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
peripheral oedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was observed in 119 of
744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), peripheral oedema was
ongoing in19&nbsp;TAC<u> </u>patients (2.6%) and 4 FAC<u> </u>patients (0.5%). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study TAX316
lymphoedema </span><span style='font-size:11.0pt'>that started during the
treatment period and </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period after the end of chemotherapy was reported in 11 of
744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%). At the end of the
follow-up period (actual median follow-up time of 8 years), lymphoedema was
observed to be ongoing in 6&nbsp;TAC patients (0.8%) and 1 FAC patient (0.1%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In study TAX316 asthenia that
started during the treatment period and persisted into the follow-up period
after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%)
and 180 of 736 FAC patients (24.5%). At the end of the follow-up period (actual
median follow-up time of 8 years), asthenia was observed to be ongoing in
29&nbsp;TAC patients (3.9%) and 16 FAC patients (2.2%).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In study GEICAM
9805 peripheral oedema </span><span style='font-size:11.0pt'>that started
during the treatment period </span><span lang=EN-GB style='font-size:11.0pt'>persisted
into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients
(0.4%) in FAC arm. At the end of the follow-up period (median follow-up time of
10 years and 5 months), no patients (0%) in TAC arm had peripheral oedema and
it was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema </span><span
style='font-size:11.0pt'>that started during the treatment period </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period in
5&nbsp;patients (0.9%) in TAC arm and 2 patients (0.4&nbsp;%) in FAC arm. At
the end of the follow-up period, lymphoedema was observed to be ongoing in 4
patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Asthenia </span><span
style='font-size:11.0pt'>that started during the treatment period and </span><span
lang=EN-GB style='font-size:11.0pt'>persisted into the follow-up period was
observed to be ongoing in 12&nbsp;patients (2.3&nbsp;%) in TAC arm and 4
patients (0.8&nbsp;%) in FAC arm. At the end of the follow-up period, asthenia
was observed to be ongoing in 2 patients (0.4%) in TAC arm, and in 2 patients
(0.4%) in FAC arm.</span></p>

<p class=MsoNormal><b><i><span style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt'>Acute leukaemia
/ Myelodysplastic syndrome.</span></i></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After 10 years of follow up in study
TAX316, acute leukaemia was reported in 3 of 744 TAC patients </span><span
style='font-weight:normal'>(0.4%)</span><span lang=EN-GB style='font-weight:
normal'> and in 1 of 736 FAC patients </span><span style='font-weight:normal'>(0.1%).</span><span
style='font-weight:normal'> </span><span style='font-weight:normal'>One TAC
patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up
period (median follow-up time of 8 years)</span><span lang=EN-GB
style='font-weight:normal'>. Myelodysplastic syndrome was reported in 2 of 744
TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%).</span></p>

<p class=Heading41 style='punctuation-wrap:hanging;text-autospace:ideograph-other'><span
lang=EN-GB style='font-weight:normal'>After</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-weight:normal'>10 years of follow-up </span><span
lang=EN-GB style='font-weight:normal'>in GEICAM 9805 study</span><span
lang=EN-GB style='font-weight:normal'>,</span><span lang=EN-GB
style='font-weight:normal'> acute leukaemia occurred in 1</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>of 532 (0.2%)</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-weight:normal'>patients </span><span
lang=EN-GB style='font-weight:normal'>in TAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No cases were reported in patients</span><span
lang=EN-GB style='font-weight:normal'> in FAC arm</span><span lang=EN-GB
style='font-weight:normal'>. No patient was diagnosed with myelodysplastic
syndrome in either treatment groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Neutropenic complications</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Table below shows that the incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in
patients who received primary G&#8209;CSF prophylaxis after it was made
mandatory in the TAC arm &#8211; GEICAM STUDY. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption><u><span lang=EN-GB style='font-size:11.0pt;font-weight:
normal'>Neutropenic complications in patients receiving TAC with or without
primary G&#8209;CSF prophylaxis (GEICAM 9805)</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=PT-BR style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Without
  primary</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF
  prophylaxis (n&nbsp;=&nbsp;111)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n&nbsp;(%)</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>With primary </span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>G-CSF </span><span
  lang=PT-BR style='font-size:11.0pt;font-family:"Times New Roman",serif'>prophylaxis</span></p>
  <p class=TableHeadCenter style='margin:0in'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(n&nbsp;=&nbsp;421)
  </span></p>
  <p class=TableHeadCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>n&nbsp;(%)</span></p>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=PT-BR style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenia&nbsp;(Grade&nbsp;4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=PT-BR
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>104 (93.7)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>135 (32.1)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=IT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Febrile
  neutropenia </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>28 (25.2)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>23 (5.5)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Neutropenic infection </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>14 (12.6)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=TableTextCenter style='margin:0in'><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>21 (5.0)</span></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:25.5pt'>
  <td width=188 valign=top style='width:140.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Neutropenic
  infection (Grade&nbsp;3-4) </span></p>
  </td>
  <td width=188 valign=top style='width:140.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2 (1.8)</span></p>
  </td>
  <td width=188 valign=top style='width:140.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoBodyText align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5 (1.2)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
gastric adenocarcinoma cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination
with cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Neutropenic infection;</span></p>
   <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 20.9%);</span></p>
   <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.2%); </span></p>
   <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4: 8.8%);</span></p>
   <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia </span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (G3/4: 1.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 11.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:40.75pt'>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=Normal11pt><span lang=EN-GB>Peripheral sensory neuropathy (G3/4:
   8.7%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
   <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.3%); </span></p>
   <p class=Normal11pt><span lang=EN-GB>Peripheral </span><span lang=EN-GB>motor
   neuropathy (G3/4: 1.3%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Lacrimation increased (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 1.0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 19.7%); </span></p>
   <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 16%); </span></p>
   <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 23.7%);</span></p>
   <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 14.3%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 1.0%);</span></p>
   <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.0%);</span></p>
   <p class=Normal11pt><span lang=EN-GB>Oesophagitis/dysphagia/odynophagia
   (G3/4: 0.7%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Rash pruritus (G3/4: 0.7%); </span></p>
   <p class=Normal11pt><span lang=EN-GB>Nail disorders (G3/4: 0.7%); </span></p>
   <p class=Normal11pt><span lang=EN-GB>Skin exfoliation (G3/4: 0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="33%" valign=top style='width:33.34%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>General disorders and administration
   site conditions</span></p>
   </td>
   <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 19.0%);</span></p>
   <p class=Normal11pt><span lang=EN-GB>Fever (G3/4: 2.3%);<br>
   Fluid retention (severe/life&#8209;threatening: 1%)</span></p>
   </td>
   <td width="33%" valign=top style='width:33.32%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Description of selected adverse reactions in gastric
adenocarcinoma cancer for TAXOTERE 75 mg/m<sup>2</sup> in combination with
cisplatin and 5-fluorouracil</span></u></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Febrile neutropenia and neutropenic
infection occurred in 17.2% and 13.5% of patients respectively, regardless of G&#8209;CSF
use. G&#8209;CSF was used for secondary prophylaxis in 19.3% of patients (10.7%
of the cycles). Febrile neutropenia and neutropenic infection occurred
respectively in 12.1% and 3.4% of patients when patients received prophylactic
G&#8209;CSF, in 15.6% and 12.9% of patients without prophylactic G&#8209;CSF
(see section 4.2).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Tabulated list of adverse reactions in
head and neck cancer for TAXOTERE 75&nbsp;mg/m&sup2; in combination with
cisplatin and 5&#8209;fluorouracil</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
radiotherapy (TAX 323)</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>MedDRA <span style='color:black'>system organ</span><span
   style='color:black'> classes</span></span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MsoToaHeading align=left style='margin-top:0in;text-align:left;
   line-height:normal;punctuation-wrap:simple;text-autospace:none;vertical-align:
   baseline'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
   position:relative;top:-3.0pt'>&nbsp;</span></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;background:white;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;color:black;
   position:relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 6.3%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Neoplasms benign, malignant and
  unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cancer pain (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 76.3%);</span></p>
  <p class=Normal11pt><span lang=IT>Anaemia (G3/4: 9.2%);</span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4: 5.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity (no severe)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.75pt'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=IT>Dysgeusia/Parosmia;</span></p>
  <p class=Normal11pt><span lang=IT>Peripheral sensory neuropathy (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:40.75pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Conjunctivitis </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Myocardial ischemia (G3/4:1.7%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia (G3/4: 0.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Venous disorder (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 0.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 2.9%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=FR>Constipation;</span></p>
  <p class=Normal11pt><span lang=FR>Esophagitis/dysphagia/ odynophagia (G3/4:
  0.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Abdominal pain;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Dyspepsia;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal haemorrhage (G3/4:
  0.6%) </span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Alopecia
  (G3/4: 10.9%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Rash
  pruritic;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Dry skin;
  </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Skin
  exfoliative (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Myalgia
  (G3/4: 0.6%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Lethargy
  (G3/4: 3.4%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pyrexia
  (G3/4: 0.6%);</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
  retention;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Oedema</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Weight
  increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction chemotherapy followed by
chemoradiotherapy (TAX 324)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>MedDRA system organ classes</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Very common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Common adverse reactions</span></b></p>
   <p class=MDSnormalsectionstyle style='margin-left:0in'><b><span lang=EN-GB
   style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>Uncommon adverse reactions</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:
   relative;top:-3.0pt'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Infection (G3/4: 3.6%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neutropenic infection</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Neoplasms benign, malignant and
  unspecified (incl cysts and polyps)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cancer pain</span><span lang=EN-GB>
  (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Neutropenia (G3/4: 83.5%);</span></p>
  <p class=Normal11pt><span lang=IT>Anaemia</span><span lang=IT> (G3/4: 12.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Thrombocytopenia (G3/4:&nbsp;4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Febrile neutropenia</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Anorexia (G3/4: 12.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=IT>Dysgeusia/Parosmia (G3/4:&nbsp;0.4%);</span></p>
  <p class=Normal11pt><span lang=IT>Peripheral sensory neuropathy (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dizziness (G3/4: 2.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Peripheral motor neuropathy (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lacrimation increased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Conjunctivitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hearing impaired (G3/4:&nbsp;1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Arrhythmia</span><span lang=EN-GB>
  (G3/4: 2.0%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Ischemia myocardial</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Venous disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Nausea (G3/4: 13.9%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Stomatitis (G3/4: 20.7%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Vomiting (G3/4: 8.4%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Diarrhoea (G3/4: 6.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Esophagitis/dysphagia/ odynophagia
  (G3/4: 12.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Constipation (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dyspepsia (G3/4: 0.8%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal pain (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Gastrointestinal haemorrhage (G3/4:
  0.4%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Alopecia (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Rash pruritic</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dry skin&nbsp;;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Desquamation</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Musculoskeletal, connective tissue bone
  disorders</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Myalgia (G3/4: 0.4%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Lethargy (G3/4: 4.0%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Pyrexia (G3/4: 3.6%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Fluid retention (G3/4: 1.2%);</span></p>
  <p class=Normal11pt><span lang=EN-GB>Oedema (G3/4: 1.2%)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight decreased</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Weight increased</span></p>
  </td>
 </tr>
</table>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Post-marketing
experience</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Neoplasms
benign, malignant and unspecified (incl cysts and polyps)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S</span><span
style='font-size:11.0pt'>econd primary malignancies (</span><span lang=EN
style='font-size:11.0pt'>frequency not known)</span><span style='font-size:
11.0pt'>, including non-Hodgkin lymphoma have been reported in association with
docetaxel when used in combination with other anticancer treatments known to be
associated with second primary malignancies</span><span lang=EN-GB
style='font-size:11.0pt'>. </span><span style='font-size:11.0pt'>Acute myeloid
leukaemia and myelodysplastic syndrome have been reported (frequency uncommon)
in pivotal clinical studies in breast cancer with TAC regimen.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Blood and lymphatic system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Bone marrow suppression and other
haematologic adverse reactions have been reported. Disseminated intravascular
coagulation (DIC), often in association with sepsis or multiorgan failure, has
been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Immune system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Some cases of anaphylactic shock,
sometimes fatal, have been reported. </span></p>

<p class=Normal11pt><span lang=EN-GB>Hypersensitivity reactions (frequency not
known) have been reported with docetaxel in patients who previously experienced
hypersensitivity reactions to paclitaxel.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Nervous system disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of convulsion or transient loss
of consciousness have been observed with docetaxel administration. These
reactions sometimes appear during the infusion of the medicinal product.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt><i><span lang=EN-GB>Eye disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>Very rare
cases of transient visual disturbances (flashes, flashing lights, scotomata)
typically occurring during infusion of the medicinal product and in association
with hypersensitivity reactions have been reported. These were reversible upon
discontinuation of the infusion. </span><span lang=EN-GB>Cases of lacrimation
with or without conjunctivitis, as cases of lacrimal duct obstruction resulting
in excessive tearing have been rarely reported. Cases of cystoid macular oedema
(CMO) have been reported in patients treated with docetaxel.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Ear and
labyrinth disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Rare cases of ototoxicity, hearing impaired
and/or hearing loss have been reported.</span></p>

<p class=Normal11pt><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
disorders</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Rare cases
of myocardial infarction have been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>Ventricular arrhythmia including
ventricular tachycardia (frequency not known), sometimes fatal, has been
reported in patients treated with docetaxel in combination regimens including
doxorubicin, 5-fluorouracil and/ or cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Vascular disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Venous thromboembolic events have rarely
been reported.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Respiratory, thoracic and mediastinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Acute respiratory
distress syndrome and cases of<b><i> </i></b>interstitial pneumonia</span><b><span
lang=EN-GB style='font-size:11.0pt'>/ </span></b><span lang=EN-GB
style='font-size:11.0pt'>pneumonitis<b>,</b></span><span lang=EN-GB
style='font-size:11.0pt'> interstitial lung disease,</span><span lang=EN-GB
style='font-size:11.0pt'> pulmonary fibrosis <span class=msoins0>and
respiratory failure </span>sometimes fatal have rarely been reported. Rare
cases of radiation pneumonitis have been reported in patients receiving
concomitant radiotherapy. </span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Gastrointestinal disorders</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Rare cases of enterocolitis, including
colitis, ischemic colitis, and neutropenic enterocolitis, have been reported
with a potential fatal outcome (frequency not known).</span></p>

<p class=Normal11pt><span lang=EN-GB>Rare occurrences of dehydration have been
reported as a consequence of gastrointestinal events including enterocolitis and
gastrointestinal perforation. </span></p>

<p class=Normal11pt><span lang=EN-GB>Rare cases of ileus and intestinal
obstruction have been reported.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatobiliary disorders</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Very rare cases of hepatitis, sometimes
fatal primarily in patients with pre&#8209;existing liver disorders, have been
reported.</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><span lang=EN-GB>Skin and subcutaneous tissue disorders </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cases of cutaneous
lupus erythematosus</span><span lang=EN-GB>, </span><span lang=EN-GB
style='font-size:11.0pt'>bullous eruptions such as erythema multiforme and </span><span
lang=EN-GB>severe cutaneous adverse reactions such as </span><span lang=EN-GB
style='font-size:11.0pt'>Stevens&#8209;Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
(TEN) and </span><span lang=EN-GB style='font-size:11.0pt'>Acute Generalized Exanthematous
Pustulosis (AGEP)</span><span lang=EN-GB style='font-size:11.0pt'> have been
reported with docetaxel. Scleroderma&#8209;like changes usually preceded by
peripheral lymphoedema have been reported with docetaxel. Cases of </span><span
lang=EN-GB style='font-size:11.0pt'>permanent</span><span lang=EN-GB
style='font-size:11.0pt'> alopecia (frequency not known) have been reported.</span></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><i><span lang=EN-GB
style='font-weight:normal'>Renal and urinary disorders</span></i></p>

<p class=MsoBodyText><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Renal insufficiency and renal failure have been reported. In
about 20% of these cases there were no risk factors for acute renal failure
such as concomitant nephrotoxic medicinal products and gastro-intestinal
disorders.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>General
disorders and administration site conditions</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Radiation
recall phenomena have rarely been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Injection site
recall reaction (recurrence of skin reaction at a site of previous
extravasation following administration of docetaxel at a different site) has
been observed at the site of previous extravasation (frequency not known).</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Fluid
retention has not been accompanied by acute episodes of oliguria or
hypotension. Dehydration and pulmonary oedema have rarely been reported.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><i>Metabolism and nutrition disorders</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Cases of electrolyte imbalance have been reported. Cases of hyponatraemia
have been reported, mostly associated with dehydration, vomiting and pneumonia.
Hypokalaemia, hypomagnesaemia, and hypocalcaemia were observed, usually in
association with gastrointestinal disorders and in particular with diarrhoea. <span
lang=EN-GB>Tumour lysis syndrome, potentially fatal, has been reported (frequency
not known).</span></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=ListBulletLevel1 style='margin-left:0in;text-indent:0in'><i>Musculoskeletal
disorder</i></p>

<p class=ListBulletLevel1 style='margin:0in;margin-bottom:.0001pt;text-indent:
0in'>Myositis has been reported with docetaxel <span lang=EN-GB>(frequency not
known)</span>.</p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>Reporting of suspected adverse reactions</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='color:black;background:#BFBFBF'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>There were a few reports of overdose.
There is no known antidote for docetaxel overdose. In case of overdose, the patient
should be kept in a specialised unit and vital functions closely monitored. In
cases of overdose, exacerbation of adverse events may be expected. The primary
anticipated complications of overdose would consist of bone marrow suppression,
peripheral neurotoxicity and mucositis. Patients should receive therapeutic G&#8209;CSF
as soon as possible after discovery of overdose. Other appropriate symptomatic
measures should be taken, as needed.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Pharmacotherapeutic group: Taxanes, ATC
Code: L01CD02</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Docetaxel
is an antineoplastic agent which acts by promoting the assembly of tubulin into
stable microtubules and inhibits their disassembly which leads to a marked
decrease of free tubulin. The binding of docetaxel to microtubules does not
alter the number of protofilaments.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown <i>in vitro</i>
to disrupt the microtubular network in cells which is essential for vital
mitotic and interphase cellular functions. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel was found to be cytotoxic <i>in
vitro</i> against various murine and human tumour cell lines and against
freshly excised human tumour cells in clonogenic assays. Docetaxel achieves
high intracellular concentrations with a long cell residence time. In addition,
docetaxel was found to be active on some but not all cell lines over expressing
the p&#8209;glycoprotein which is encoded by the multidrug resistance gene. <i>In
vivo</i>, docetaxel is schedule independent and has a broad spectrum of experimental
anti-tumour activity against advanced murine and human grafted tumours.</span></p>

<p class=Normal11pt><span lang=EN-GB>multi</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Breast cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>TAXOTERE in combination with
doxorubicin and cyclophosphamide: adjuvant therapy</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><u><span lang=EN-GB>Patients
with operable node&#8209;positive breast cancer </span></u><span lang=EN-GB>(TAX
316)</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Data from a multi-centre open label randomised
study support the use of docetaxel for the adjuvant treatment of patients with
operable node-positive breast cancer and KPS&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;80%, between 18
and 70&nbsp;years of age. After stratification according to the number of
positive lymph nodes (1&#8209;3, 4+), 1491&nbsp;patients were randomised to
receive either docetaxel 75&nbsp;mg/m<sup>2</sup> administered 1&#8209;hour
after doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup>
(TAC arm), or doxorubicin 50&nbsp;mg/m<sup>2</sup> followed by fluorouracil
500&nbsp;mg/m<sup>2</sup> and cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (FAC
arm). Both regimens were administered once every 3&nbsp;weeks for
6&nbsp;cycles. Docetaxel was administered as a 1&#8209;hour infusion, all other
medicinal products were given as intravenous bolus on day one. G&#8209;CSF was
administered as secondary prophylaxis to patients who experienced complicated
neutropenia (febrile neutropenia, prolonged neutropenia, or infection).
Patients on the TAC arm received antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg
orally twice daily for 10&nbsp;days starting on day&nbsp;5 of each cycle, or
equivalent. In both arms, after the last cycle of chemotherapy, patients with
positive eostrogen and/or progesterone receptors received tamoxifen 20&nbsp;mg
daily for up to 5&nbsp;years. Adjuvant radiation therapy was prescribed
according to guidelines in place at participating institutions and was given to
69% of patients who received TAC and 72% of patients who received FAC.</span><span
lang=EN-GB> </span><span lang=EN-GB>Two interim analyses and one final analysis
were performed. The first interim analysis was planned 3 years after the date
when half of study enrolment was done. The second interim analysis was done
after 400 DFS events had been recorded overall, which led to a median follow-up
of 55 months. The final analysis was performed when all patients had reached
their 10-year follow-up visit (unless they had a DFS event or were lost to
follow-up before). Disease-free survival (DFS) was the primary efficacy
endpoint and Overall survival (OS) was the secondary efficacy endpoint.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A final analysis was performed with an actual
median follow up of 96&nbsp;months. Significantly longer disease-free survival
for the TAC arm compared to the FAC arm was demonstrated. Incidence of relapses
at 10&nbsp;years was reduced in patients receiving TAC compared to those who
received FAC (39% versus 45%, respectively) i.e. an absolute risk reduction by 6%
(p&nbsp;=&nbsp;0.0043). Overall survival at 10&nbsp;years was also
significantly increased with TAC compared to FAC (76% versus 69%, respectively)
i.e. an absolute reduction of the risk of death by 7% (p&nbsp;=&nbsp;0.002). </span><span
lang=EN-GB>As the benefit observed in patients with 4+ nodes was not
statistically significant on DFS and OS, the positive benefit/risk ratio for
TAC in patients with 4+ nodes was not fully demonstrated at the final analysis.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>Overall,
the study results demonstrate a positive benefit risk ratio for TAC compared to
FAC. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>TAC-treated
patient subsets according to prospectively defined major prognostic factors
were analysed:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='width:104.4%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.92%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Disease free survival</span></b></p>
  </td>
  <td width="34%" colspan=3 valign=top style='width:34.6%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Overall survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>Patient subset</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Number of patients</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>Hazard ratio*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>95% CI</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>p&nbsp;=</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle style='margin-left:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='position:relative;top:-3.0pt'>No of positive nodes</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><b><span lang=EN-GB
  style='position:relative;top:-3.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>745</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.80</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.68-0.93</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0043</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.74</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.61-0.90</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0020</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>1-3</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>467</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.58-0.91</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0047</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.46-0.82</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.0008</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>4+</span></p>
  </td>
  <td width="10%" valign=top style='width:10.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>278</span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="13%" valign=top style='width:13.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.70-1.09</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2290</span></p>
  </td>
  <td width="11%" valign=top style='width:11.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.67-1.12</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MDSnormalsectionstyle align=center style='margin-left:0in;
  text-align:center;page-break-after:avoid'><span lang=EN-GB>0.2746</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>*a hazard
ratio of less than 1 indicates that TAC is associated with a longer
disease-free survival and overall survival compared to FAC</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Patients with
operable node</span><span lang=EN-GB>&#8209;</span></u><u><span lang=EN-GB
style='font-size:11.0pt'>negative breast cancer eligible to receive
chemotherapy (</span></u><span lang=EN-GB style='font-size:11.0pt'>GEICAM 9805)<u>
</u></span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Data</span><span
lang=EN-GB style='font-size:11.0pt'> from a multi-centre open label randomised
trial support the use of TAXOTERE for the adjuvant treatment of patients with
operable node&#8209;negative breast cancer eligible to receive chemotherapy<u> </u>.
1060&nbsp;patients were randomised to receive either TAXOTERE 75&nbsp;mg/m<sup>2</sup>
administered 1&#8209;hour after doxorubicin 50&nbsp;mg/m<sup>2</sup> and cyclophosphamide
500&nbsp;mg/m<sup>2</sup> (539 patients in TAC arm), or doxorubicin
50&nbsp;mg/m<sup>2</sup> followed by fluorouracil 500&nbsp;mg/m<sup>2</sup> and
cyclophosphamide 500&nbsp;mg/m<sup>2</sup> (521 patients in FAC arm), as
adjuvant treatment of operable node-negative breast cancer patients with high
risk of relapse according to 1998 St. Gallen criteria (tumour size
&gt;2&nbsp;cm and/or negative ER and PR and/or high histological/nuclear grade
(grade 2 to 3) and /or age &lt;35&nbsp;years).). Both regimens were
administered once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1&#8209;hour
infusion, all other medicinal products were given intraveinously on day 1 every
three weeks. Primary prophylactic G&#8209;CSF was made mandatory in TAC arm
after 230&nbsp;patients were randomised. The incidence of Grade&nbsp;4
neutropenia, febrile neutropenia and neutropenic infection was decreased in
patients who received primary G&#8209;CSF prophylaxis (see section 4.8). In
both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+
tumours received tamoxifen 20&nbsp;mg once a day for up to 5 years. Adjuvant
radiation therapy was administered according to guidelines in place at
participating institutions and was given to 57.3% of patients who received TAC
and 51.2% of patients who received FAC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>One primary
analysis and one updated analysis were performed. The primary analysis was done
when all patients had a follow-up of greater than 5 years (median follow-up
time of 77 months). The updated analysis was performed when all patients had
reached their 10-year (</span><span lang=EN-GB>median follow up time of 10 years
and 5&nbsp;months) </span><span lang=EN-GB>follow-up visit (unless they had a
DFS event or were lost to follow-up previously). Disease-free survival (DFS)
was the primary efficacy endpoint and Overall survival (OS) was the secondary
efficacy endpoint.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, significantly longer disease-free survival for the
TAC arm compared to the FAC arm was demonstrated. TAC&#8209;treated patients had
a 32% reduction in the risk of relapse compared to those treated with FAC (hazard
ratio&nbsp;=&nbsp;0.68, 95% CI (0.49-0.93), p&nbsp;=&nbsp;0.01). At the median
follow up time of 10 years and 5&nbsp;months, TAC&#8209;treated patients had a
16,5% reduction in the risk of relapse compared to those treated with FAC
(hazard ratio&nbsp;=&nbsp;0.84, 95% CI (0.65-1.08)</span><span
style='font-size:11.0pt'>, p=0.1646). DFS data were not statistically significant
but were still associated with a positive trend in favour of TAC.</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow-up time of 77 months, overall survival (OS) was longer in the TAC arm
with TAC-treated patients having a 24% reduction in the risk of death compared
to FAC (hazard ratio&nbsp;=&nbsp;0.76, 95% CI (0.46-1.26, p&nbsp;=&nbsp;0.29).
However, the distribution of OS was not significantly different between the 2
groups.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>At the median
follow up time of 10 years and 5&nbsp;months, TAC-treated patients had a 9%
reduction in the risk of death compared to FAC-treated patients (hazard
ratio&nbsp;=&nbsp;0.91, 95% CI (0.63-1.32)). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The survival rate
was 93.7% in the TAC arm and 91.4&nbsp;% in the FAC arm, at the 8-year
follow-up time point, and 91.3&nbsp;% in the TAC arm and 89&nbsp;% in the FAC
arm, at the 10-year follow-up time point.</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The positive benefit risk ratio for TAC compared to
FAC remained unchanged<b>. </b>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>TAC&#8209;treated
patient subsets according to prospectively defined major prognostic factors
were analysed in the primary analysis (at the median follow-up time of 77 months)
(see table below):</span></p>

<p class=MDSnormalsectionstyle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Subset Analyses-Adjuvant Therapy in Patients with Node&#8209;negative
Breast Cancer Study </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>(Intent&#8209;to&#8209;Treat Analysis)</span></u></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=558
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=258 colspan=2 valign=top style='width:193.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Disease Free Survival</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  subset</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of patients in TAC group</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio*</span></b></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>95% CI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Overall</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>539</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.49-0.93</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 1</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>260</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;50 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>279</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.05</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Age category 2</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&lt;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>42</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.31</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.11-0.89</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&#8805;35 years</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>497</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.73</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.52-1.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Hormonal receptor</span></b><span
  lang=EN-GB> <b>status</b></span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:4.6pt'>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt><span lang=EN-GB>Negative</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>195</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.7</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.6pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Positive</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>344</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.62</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.4-0.97</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Tumour size </span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB style='font-family:Symbol'>&pound;</span><span
  lang=EN-GB>2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.69</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.43-1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&gt;2&nbsp;cm</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.68</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.45-1.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Histological grade</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade1 (includes grade not assessed)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>64</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.79</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.24-2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 2</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>216</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.77</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.46-1.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Grade 3</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>259</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.59</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.39-0.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><b><span lang=EN-GB>Menopausal status</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Pre-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>285</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.64</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.40-1</span></p>
  </td>
 </tr>
 <tr>
  <td width=156 valign=top style='width:117.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Post-Menopausal</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>254</span></p>
  </td>
  <td width=129 valign=top style='width:96.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  </td>
  <td width=129 valign=top style='width:96.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.47-1.12</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*a hazard ratio
(TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease
free survival compared to FAC.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Exploratory subgroup analyses for&nbsp; disease-free
survival for&nbsp; patients who meet the 2009 St. Gallen chemotherapy criteria
&#8211; (ITT population) were performed and presented here below:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>TAC</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>FAC</span></b></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Hazard ratio</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(TAC/FAC)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Subgroups</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=539)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n=521)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Meeting
  relative indication for chemotherapy </span><sup><span lang=EN-GB
  style='font-family:"(Utiliser une police de caract&egrave;",serif'>a</span></sup></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt><span lang=EN-GB>No</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>18/214</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(8.4%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>26/227</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(11.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.796
  (0.434 - 1.459)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.4593</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>48/325</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(14.8%)</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>69/294</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(23.5%)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.606
  (0.42 - 0.877)</span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0072</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>TAC = docetaxel,
doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>FAC =
5-fluorouracil, doxorubicin and cyclophosphamide</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>CI = confidence
interval</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>ER = eostrogen
receptor</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PR = progesterone receptor</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:10.0pt;font-family:
"(Utiliser une police de caract&egrave;",serif'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> ER/PR-negative or Grade 3 or tumour size
&gt;5&nbsp;cm</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The estimated
hazard ratio was using Cox proportional hazard model with treatment group as
the factor.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
as single agent</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Two
randomised phase&nbsp;III comparative studies, involving a total of 326&nbsp;alkylating
or 392&nbsp;anthracycline failure metastatic breast cancer patients, have been
performed with docetaxel at the recommended dose and regimen of
100&nbsp;mg/m&sup2; every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In alkylating-failure patients, docetaxel
was compared to doxorubicin (75&nbsp;mg/m&sup2; every 3&nbsp;weeks). Without
affecting overall survival time (docetaxel 15&nbsp;months vs. doxorubicin
14&nbsp;months, p&nbsp;=&nbsp;0.38) or time to progression (docetaxel
27&nbsp;weeks vs. doxorubicin 23&nbsp;weeks, p&nbsp;=&nbsp;0.54), docetaxel
increased response rate (52% vs. 37%, p&nbsp;=&nbsp;0.01) and shortened time to
response (12&nbsp;weeks vs. 23&nbsp;weeks, p&nbsp;=&nbsp;0.007). Three
docetaxel patients (2%) discontinued the treatment due to fluid retention,
whereas 15&nbsp;doxorubicin patients (9%) discontinued due to cardiac toxicity
(three cases of fatal congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In anthracycline-failure patients,
docetaxel was compared to the combination of mitomycin&nbsp;C and vinblastine
(12&nbsp;mg/m&sup2; every 6&nbsp;weeks and 6&nbsp;mg/m&sup2; every
3&nbsp;weeks). Docetaxel increased response rate (33% vs. 12%,
p&nbsp;&lt;&nbsp;0.0001), prolonged time to progression (19&nbsp;weeks vs.
11&nbsp;weeks, p&nbsp;=&nbsp;0.0004) and prolonged overall survival
(11&nbsp;months vs. 9&nbsp;months, p&nbsp;=&nbsp;0.01).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During these two phase&nbsp;III studies,
the safety profile of docetaxel was consistent with the safety profile observed
in phase&nbsp;II studies (see section 4.8). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>An open-label, multi-centre, randomised
phase&nbsp;III study was conducted to compare docetaxel monotherapy and
paclitaxel in the treatment of advanced breast cancer in patients whose
previous therapy should have included an anthracycline. A total of
449&nbsp;patients were randomised to receive either docetaxel monotherapy
100&nbsp;mg/m&sup2; as a 1&nbsp;hour infusion or paclitaxel 175&nbsp;mg/m&sup2;
as a 3&nbsp;hour infusion. Both regimens were administered every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>Without affecting the primary endpoint,
overall response rate (32% vs 25%, p&nbsp;=&nbsp;0.10), docetaxel prolonged
median time to progression (24.6&nbsp;weeks vs 15.6&nbsp;weeks;
p&nbsp;&lt;&nbsp;0.01) and median survival (15.3&nbsp;months vs
12.7&nbsp;months; p&nbsp;=&nbsp;0.03).</span></p>

<p class=Normal11pt><span lang=EN-GB>More grade&nbsp;3/4 adverse events were
observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%). </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
in combination with doxorubicin</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>One large randomised
phase&nbsp;III study, involving 429 previously untreated patients with
metastatic disease, has been performed with doxorubicin (50&nbsp;mg/m&sup2;) in
combination with docetaxel (75&nbsp;mg/m&sup2;) (AT arm) versus doxorubicin
(60&nbsp;mg/m&sup2;) in combination with cyclophosphamide (600&nbsp;mg/m&sup2;)
(AC&nbsp;arm). Both regimens were administered on day&nbsp;1 every
3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Time to progression
(TTP) was significantly longer in the AT arm versus AC arm, p&nbsp;=&nbsp;0.0138.
The median TTP was 37.3&nbsp;weeks (95%&nbsp;CI: 33.4&nbsp;&#8209;&nbsp;42.1)
in AT arm and 31.9&nbsp;weeks (95%&nbsp;CI: 27.4&nbsp;&#8209;&nbsp;36.0) in AC
arm.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Overall response rate
(ORR) was significantly higher in the AT arm versus AC arm,
p&nbsp;=&nbsp;0.009. The ORR was 59.3% (95%&nbsp;CI: 52.8&nbsp;&#8209;&nbsp;65.9)
in AT arm versus 46.5% (95%&nbsp;CI: 39.8&nbsp;&#8209;&nbsp;53.2) in AC arm.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In this study, AT arm showed a higher
incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3%
versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia
(8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand,
AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT
arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive
heart failure (3.8% versus 2.8%), absolute LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;20% (13.1% versus 6.1%), absolute
LVEF decrease </span><span lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;30%
(6.2% versus 1.1%). Toxic deaths occurred in 1&nbsp;patient in the AT arm (congestive
heart failure) and in 4&nbsp;patients in the AC arm (1&nbsp;due to septic shock
and 3 due to congestive heart failure).</span></p>

<p class=Normal11pt><span lang=EN-GB>In both arms, quality of life measured by
the EORTC questionnaire was comparable and stable during treatment and follow&#8209;up.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
in combination with trastuzumab</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Docetaxel
in combination with trastuzumab was studied for the treatment of patients with
metastatic breast cancer whose tumours overexpress HER2, and who previously had
not received chemotherapy for metastatic disease. One hundred eighty six
patients were randomised to receive docetaxel (100&nbsp;mg/m<sup>2</sup>) with
or without trastuzumab; 60% of patients received prior anthracycline-based
adjuvant chemotherapy. Docetaxel plus trastuzumab was efficacious in patients
whether or not they had received prior adjuvant anthracyclines. The main test
method used to determine HER2 positivity in this pivotal study was
immunohistochemistry (IHC). A minority of patients were tested using
fluorescence in&#8209;situ hybridization (FISH). In this study, 87% of patients
had disease that was IHC 3+, and 95% of patients entered had disease that was
IHC 3+ and/or FISH positive. Efficacy results are summarized in the following
table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Parameter</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel
  plus trastuzumab<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;92</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>Docetaxel<sup>1</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;94</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Response rate </span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>61%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(50-71)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>34%</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(25-45)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(9.2-15.0)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.1</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(4.4-6.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median TTP (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>10.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.6-12.9)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>5.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(5.0-6.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=195 valign=top style='width:146.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>30.5<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(26.8-ne)</span></p>
  </td>
  <td width=196 valign=top style='width:146.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>22.1<sup>2</sup></span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(17.6-28.9)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0><span lang=EN-GB>TTP&nbsp;=&nbsp;time to progression;
&#8220;ne&#8221; indicates that it could not be estimated or it was not yet
reached.</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB>Full analysis set (intent-to-treat)</span></p>

<p class=Normal11ptGauche0><sup><span lang=EN-GB>2 </span></sup><span
lang=EN-GB>Estimated median survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Authors style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><i><span lang=EN-GB style='font-family:"Times New Roman",serif'>TAXOTERE
in combination with capecitabine</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Data from
one multi-centre, randomised, controlled phase&nbsp;III clinical study support
the use of docetaxel in combination with capecitabine for treatment of patients
with locally advanced or metastatic breast cancer after failure of cytotoxic
chemotherapy, including an anthracycline. In this study, 255&nbsp;patients were
randomised to treatment with docetaxel (75&nbsp;mg/m<sup>2</sup> as a
1&nbsp;hour intravenous infusion every 3&nbsp;weeks) and capecitabine
(1250&nbsp;mg/m<sup>2</sup> twice daily for 2&nbsp;weeks followed by 1&#8209;week
rest period). 256&nbsp;patients were randomised to treatment with docetaxel
alone (100&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour intravenous infusion every
3&nbsp;weeks). Survival was superior in the docetaxel&nbsp;+ capecitabine
combination arm (p&nbsp;=&nbsp;0.0126). Median survival was 442&nbsp;days
(docetaxel&nbsp;+ capecitabine) vs. 352&nbsp;days (docetaxel alone). The
overall objective response rates in the all&#8209;randomised population (investigator
assessment) were 41.6% (docetaxel&nbsp;+ capecitabine) vs. 29.7% (docetaxel
alone); p&nbsp;=&nbsp;0.0058. Time to progressive disease was superior in the
docetaxel&nbsp;+ capecitabine combination arm (p&nbsp;&lt;&nbsp;0.0001). The
median time to progression was 186&nbsp;days (docetaxel&nbsp;+ capecitabine)
vs. 128&nbsp;days (docetaxel alone).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Non-small cell lung cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Patients previously treated with
chemotherapy with or without radiotherapy</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>In a phase&nbsp;III study, in previously
treated patients, time to progression (12.3&nbsp;weeks versus 7&nbsp;weeks) and
overall survival were significantly longer for docetaxel at 75&nbsp;mg/m&sup2;
compared to Best Supportive Care. The 1&#8209;year survival rate was also
significantly longer in docetaxel (40%) versus BSC (16%).</span></p>

<p class=Normal11pt><span lang=EN-GB>There was less use of morphinic analgesic
(p&nbsp;&lt;&nbsp;0.01), non&#8209;morphinic analgesics
(p&nbsp;&lt;&nbsp;0.01), other disease-related medicinal products
(p&nbsp;=&nbsp;0.06) and radiotherapy (p&nbsp;&lt;&nbsp;0.01) in patients
treated with docetaxel at 75&nbsp;mg/m&sup2; compared to those with BSC.</span></p>

<p class=Normal11pt><span lang=EN-GB>The overall response rate was 6.8% in the
evaluable patients, and the median duration of response was 26.1&nbsp;weeks.</span></p>

<p class=Normal11pt><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=Normal11pt style='page-break-after:avoid'><i><span lang=EN-GB>TAXOTERE
in combination with platinum agents in chemotherapy-na&iuml;ve patients</span></i></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>In a
phase&nbsp;III study, 1218&nbsp;patients with unresectable stage&nbsp;IIIB or
IV NSCLC, with KPS of 70% or greater, and who did not receive previous
chemotherapy for this condition, were randomised to either docetaxel&nbsp;(T)
75&nbsp;mg/m<sup>2 </sup>as a 1&nbsp;hour infusion immediately followed by
cisplatin&nbsp;(Cis) 75&nbsp;mg/m<sup>2 </sup>over 30&#8209;60&nbsp;minutes
every 3&nbsp;weeks (TCis), docetaxel 75&nbsp;mg/m<sup>2</sup> as a 1&nbsp;hour
infusion in combination with carboplatin (AUC 6&nbsp;mg/ml.min) over 30&#8209;60&nbsp;minutes
every 3&nbsp;weeks, or vinorelbine&nbsp;(V) 25&nbsp;mg/m<sup>2</sup>
administered over 6&#8209;10&nbsp;minutes on days&nbsp;1, 8, 15, 22 followed by
cisplatin 100&nbsp;mg/m<sup>2</sup> administered on day&nbsp;1 of cycles repeated
every 4&nbsp;weeks (VCis).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Survival
data, median time to progression and response rates for two arms of the study
are illustrated in the following table:</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=584
 style='margin-left:17.5pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>TCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;408</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>VCis</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;404</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Statistical analysis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  survival </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(Primary
  end-point):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>Median survival (months)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>10.1</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.122</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[97.2% CI: 0.937; 1.342]*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>1-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>41</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 5.4%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: -1.1; 12.0]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>2-year Survival (%)</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>21</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 6.2%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.2; 12.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  time to progression</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(weeks):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.0</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>23.0</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard Ratio: 1.032</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.876; 1.216]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Overall
  response rate (%):</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.6</span></p>
  </td>
  <td width=83 valign=top style='width:62.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.5</span></p>
  </td>
  <td width=224 valign=top style='width:168.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Treatment difference: 7.1%</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[95% CI: 0.7; 13.5]</span></p>
  </td>
 </tr>
</table>

<p class=Normal11ptGauche0 style='page-break-after:avoid'><span lang=EN-GB>*:
Corrected for multiple comparisons and adjusted for stratification factors
(stage of disease and region of treatment), based on evaluable patient population.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Secondary end&#8209;points included change
of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom
Scale, and changes in Karnosfky performance status. Results on these end-points
were supportive of the primary end-points results. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For docetaxel/carboplatin combination,
neither equivalent nor non-inferior efficacy could be proven compared to the
reference treatment combination VCis.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Prostate cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Metastatic castration-resistant prostate cancer</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in
combination with prednisone or prednisolone in patients with metastatic castration-resistant
prostate cancer were evaluated in a randomised multi-centre phase&nbsp;III study
(TAX 327). A total of 1006&nbsp;patients with KPS&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>&nbsp;60 were randomised
to the following treatment groups:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 75&nbsp;mg/m<sup>2</sup>
every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Docetaxel 30&nbsp;mg/m<sup>2</sup>
administered weekly for the first 5&nbsp;weeks in a 6&nbsp;week cycle for
5&nbsp;cycles.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mitoxantrone
12&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 10&nbsp;cycles.</span></p>

<p class=Normal11pt><span lang=EN-GB>All 3&nbsp;regimens were administered in
combination with prednisone or prednisolone 5&nbsp;mg twice daily,
continuously.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Patients who received docetaxel every
three weeks demonstrated significantly longer overall survival compared to
those treated with mitoxantrone. The increase in survival seen in the docetaxel
weekly arm was not statistically significant compared to the mitoxantrone
control arm. Efficacy endpoints for the docetaxel arms versus the control arm
are summarized in the following table:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=608
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Endpoint</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks </span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Docetaxel </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every week</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Mitoxantrone </span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>every 3 weeks</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  survival (months)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>Hazard ratio</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=IT>p-value<sup>&#8224;</sup>*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>335</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(17.0-21.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.761</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.619-0.936)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0094</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>334</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>17.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.7-19.0)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.912</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.747-1.113)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.3624</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>337</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.4-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>PSA**
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>291</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>45.4</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(39.5-51.3)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0005</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>282</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>47.9</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(41.9-53.9)<br>
  &lt;0.0001</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>300</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(26.4-37.3)<br>
  --</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Pain
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>153</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(27.1-42.7)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0107</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>154</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(24.0-39.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0798</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>157</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.7</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(15.5-28.9)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.7pt'>
  <td width=208 valign=top style='width:155.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Number of
  patients</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Tumour
  response rate (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>95% CI</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>p-value*</span></p>
  </td>
  <td width=112 valign=top style='width:84.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>141</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(7.2-18.6)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.1112</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>134</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(4.2-14.2)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.5853</span></p>
  </td>
  <td width=175 valign=top style='width:131.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.7pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>137</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.0-12.1)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>--</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><sup><span lang=EN-GB>&#8224;</span></sup><span
lang=EN-GB>Stratified log-rank test<br>
*Threshold for statistical significance&nbsp;=&nbsp;0.0175</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**PSA:
Prostate-Specific Antigen<br>
<br>
</span></p>

<p class=Normal11pt><span lang=EN-GB>Given the fact that docetaxel every week
presented a slightly better safety profile than docetaxel every 3&nbsp;weeks,
it is possible that certain patients may benefit from docetaxel every week.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>No statistical differences were observed
between treatment groups for Global Quality of Life.</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Metastatic
hormone-sensitive prostate cancer</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>STAMPEDE </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered concomitantly with standard of care (ADT)<b> </b>in
patients with high-risk locally advanced or metastatic hormone-sensitive
prostate cancer were evaluated in a <span style='color:black'>randomised multi-centre,
multi-arm multi-stage (MAMS) study </span></span><span style='color:black'>with
a seamless phase II/III design</span><span style='font-size:11.0pt'> (STAMPEDE
&#8211; MRC PR08). A total of 1776 male patients were allocated to the
treatment armss of interest: </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>+ docetaxel
75 mg/m&sup2;, administered every 3 weeks for 6 cycles&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%'>Standard of care<b> </b>alone<span
style='background:silver'> </span></span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Docetaxel regimen was
administered in combination with prednisone or prednisolone 5 mg twice daily
continuously. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Among the 1776 randomised
patients 1086 (61%) had metastatic disease, 362 were randomised to docetaxel in
combination with standard of care, 724 received standard of care<b> </b>alone. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>In these metastatic prostate
cancer patients, the median overall survival was significantly longer in
docetaxel treatment groups than in the standard of care<b> </b>alone group,
with a median overall survival 19 months longer with the addition of docetaxel
to standard of care<b> </b>(HR =&nbsp; 0.76, 95% </span><span lang=EN-GB
style='font-size:11.0pt'>CI = 0.62-0.92,</span><span style='font-size:11.0pt'>
p=0.005). </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Efficacy results in
metastatic prostate cancer patients for </span><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span><span style='font-size:11.0pt'> arm
versus control arm are summarized in the following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Efficacy of docetaxel in combination with prednisone
or prednisolone and standard of care in the treatment of patients with
metastatic hormone-sensitive prostate cancer </span><span style='font-size:
11.0pt'>(STAMPEDE)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:maroon'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:11.0pt;
  color:black'>Endpoint</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span><span
  style='font-size:11.0pt;color:black'>+</span><span style='font-size:11.0pt;
  color:black'> standard of care</span></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Standard of care </span><span
  style='font-size:11.0pt;color:black'>alone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:54.3pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of metastatic prostate cancer
  patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months) </span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>362</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>51-73</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:54.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>724</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>43</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>40-48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>(0.62&#8209;0.92)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.005</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Failure-Free survival<i><span style='position:relative;
  top:-3.0pt'>b</span></i>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoBodyText3 style='margin-top:0in;page-break-after:avoid'><span
  lang=IT style='font-size:11.0pt;color:black;font-weight:normal;font-style:
  normal'>95% CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.8-25.2</span></p>
  </td>
  <td width=167 valign=top style='width:125.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>9.6-12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=224 valign=top style='width:168.05pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Adjusted hazard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=356 colspan=2 valign=top style='width:267.25pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.57&#8209;0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&lt; 0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.3pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>a </span></sup></i><span
  style='font-size:11.0pt;color:black'>p-value calculated from the likelihood
  ratio test and adjusted for all stratification factors (except center and
  planned hormone therapy) and stratified by trial period</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><i><sup><span
  style='font-size:11.0pt;color:black'>b</span></sup></i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'>
  Failure-free survival: time from randomization to first evidence of at least
  one of: biochemical failure (defined as a rise in PSA of 50% above the
  within-24-week nadir and above 4 ng/mL and confirmed by retest or treatment);
  progression either locally, in lymph nodes, or in distant metastases;
  skeletal-related event; or death from prostate cancer.</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:1.7pt;layout-grid-mode:char'><span style='font-size:11.0pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:115%'><span style='font-size:11.0pt;
line-height:115%;color:maroon'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>CHAARTED </span></i><i><span lang=EN-GB style='font-size:11.0pt'>study</span></i></p>

<p class=MsoNormal><span style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The safety and efficacy of </span><span
lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span style='font-size:
11.0pt'> administered at the beginning of androgen-deprivation therapy (ADT) in
patients with metastatic hormone-sensitive prostate cancer were evaluated in a randomised
Phase III multi-centre study (CHAARTED). A total of 790 male patients were
allocated to the 2 treatment groups. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT + docetaxel
75 mg/m&sup2; given at the beginning of ADT, administered every 3 weeks for 6
cycles</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;line-height:
115%'><span style='font-size:11.0pt;line-height:115%;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;line-height:115%'>ADT alone<sup> </sup>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'><br>
The median overall survival was significantly longer in docetaxel treatment
group than in the ADT alone group, with a median overall survival 13.6
months&nbsp; longer with the addition of docetaxel to ADT (hazard ratio (HR) =
0.61, 95% </span><span lang=EN-GB style='font-size:11.0pt'>confidence interval
(CI)&nbsp;= 0.47-0.80, </span><span style='font-size:11.0pt'>p=0.0003). <br>
<br>
Efficacy results or the </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> arm versus the control arm are summarized in the
following table:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>Efficacy
of </span><span lang=EN-GB style='font-size:11.0pt'>docetaxel</span><span
style='font-size:11.0pt'> and ADT in the treatment of patients with metastatic
hormone-sensitive prostate cancer (CHAARTED)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>Endpoint</span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=178 valign=top style='width:133.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt;color:black'>Docetaxel<i> </i></span></b><b><span
   style='font-size:11.0pt;color:black'>+ADT </span></b></p>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width=112 valign=top style='width:83.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
   margin-bottom:3.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='font-size:11.0pt;color:black'>ADT alone</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Number of patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>Median overall survival (months)</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:11.0pt;color:black'>All patients</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><i><span
  lang=IT style='font-size:11.0pt;color:black'>95% CI</span></i></b><span
  style='color:black'>Adjusted </span><span style='font-size:11.0pt;color:black'>hazard
  ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>397</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>57.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>49.1-72.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>393</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>44.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>34.4-49.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.47&#8209;0.80)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.0003</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Progression Free Survival</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value*</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>16.7-22.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.60</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.51-0.72</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>P&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.6</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>10.8-14.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 6 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>127 (32.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>77 (19.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>PSA response** at 12 months &#8211; N(%)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>110 (27.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>66 (16.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to castration-resistant prostate cancer<i><span
  style='position:relative;top:-3.0pt'>b</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months) </span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>20.2</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.2&#8209;23.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>11.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(10.8-14.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.51&#8209;0.72)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Time to clinical progression</span><i><span style='font-size:
  11.0pt;color:black;position:relative;top:-3.0pt'>c</span></i><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>Median (months)<i><span style='position:relative;top:-3.0pt'> </span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>33.0</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>19.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(27.3-41.2)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(17.9-22.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Adjusted
  h</span><span style='font-size:11.0pt;color:black'>azard ratio</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>0.61</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>95% CI</span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>(0.50-0.75)</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=329 valign=top style='width:246.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:11.0pt;
  color:black'>p-value<i><span style='position:relative;top:-3.0pt'>a*</span></i></span></p>
  </td>
  <td width=178 valign=top style='width:133.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>&lt;0.0001</span></p>
  </td>
  <td width=112 valign=top style='width:83.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt;color:black'>--</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.3pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>a</span></i><span style='font-size:11.0pt;color:black'>&nbsp;</span><span
  style='font-size:11.0pt;color:black'>Time to event variables: Stratified
  log-rank test. <br>
  &nbsp; Response rate variables: Fisher's Exact test</span><i><span
  style='font-size:11.0pt;color:black;position:relative;top:-3.0pt'> </span></i></p>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>* p-value for
  descriptive purpose.</span></p>
  <p class=MsoCommentText><span style='font-size:11.0pt;color:black'>** </span><span
  lang=EN-GB style='color:black'>PSA r</span><span style='font-size:11.0pt;
  color:black'>esponse</span><span lang=EN-GB style='font-size:11.0pt;
  color:black'>: Prostate-Specific Antigen response: </span><span
  style='font-size:11.0pt;color:black'>PSA level &lt;0.2 ng/mL measured for two
  consecutive measurements at least 4 weeks apart.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>b </span></i><span style='font-size:11.0pt;color:black'>Time
  to castration-resistant prostate cancer = time from randomization to PSA progression
  </span><span lang=EN-GB style='color:black'>or clinical progression (i.e.,
  increasing symptomatic bone metastases, progression per </span><span
  style='font-size:11.0pt;color:black'>Response Evaluation Criteria in Solid
  Tumours (</span><span lang=EN-GB style='color:black'>RECIST) criteria, or
  clinical deterioration due to cancer per the Investigator&#8217;s opinion),
  whichever occurred first.</span></p>
  <p class=MsoNormal><i><span style='font-size:11.0pt;color:black;position:
  relative;top:-3.0pt'>c</span></i><span style='font-size:11.0pt;color:black'>&nbsp;The
  time to clinical progression = the time from randomization until clinical
  progression (i.e., increased symptoms of bone metastases; progression
  according to RECIST; or clinical deterioration due to cancer according to the
  investigator&#8217;s opinion).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11pt><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Gastric adenocarcinoma</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>A multi-centre, open-label, randomised
study was conducted to evaluate the safety and efficacy of docetaxel for the
treatment of patients with metastatic gastric adenocarcinoma, including
adenocarcinoma of the gastroesophageal junction, who had not received prior
chemotherapy for metastatic disease. A total of 445&nbsp;patients with
KPS&nbsp;&gt;&nbsp;70 were treated with either docetaxel&nbsp;(T) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) in combination with cisplatin&nbsp;(C) (75&nbsp;mg/m<sup>2</sup>
on day&nbsp;1) and 5&#8209;fluorouracil&nbsp;(F) (750&nbsp;mg/m<sup>2</sup> per
day for 5&nbsp;days) or cisplatin (100&nbsp;mg/m<sup>2</sup> on day&nbsp;1) and
5&#8209;fluorouracil (1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days). The
length of a treatment cycle was 3&nbsp;weeks for the TCF arm and 4&nbsp;weeks
for the CF arm. The median number of cycles administered per patient was 6 (with
a range of 1&#8209;16) for the TCF arm compared to 4 (with a range of 1&#8209;12)
for the CF arm. Time to progression (TTP) was the primary endpoint. The risk
reduction of progression was 32.1% and was associated with a significantly
longer TTP (p&nbsp;=&nbsp;0.0004) in favour of the TCF arm. Overall survival
was also significantly longer (p&nbsp;=&nbsp;0.0201) in favor of the TCF arm
with a risk reduction of mortality of 22.7%. Efficacy results are summarized in
the following table:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the treatment of patients with gastric adenocarcinoma</span></u></p>

<p align=center style='margin:0in;text-align:center;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>TCF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;221</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CF</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;224</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median TTP (months)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>5.6</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>3.7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(4.86-5.91)</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(3.45-4.47)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.473</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.189-1.825)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Median survival (months)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.2</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(8.38-10.58)</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(7.16-9.46)</span></p>
  </td>
 </tr>
 <tr>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>2-year estimate (%)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18.4</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>8.8</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Hazard ratio</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.293</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(1.041-1.606)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>*p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0201</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall response rate (CR+PR) (%)</span></p>
  </td>
  <td width=133 valign=top style='width:99.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36.7</span></p>
  </td>
  <td width=133 valign=top style='width:99.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>p-value</span></p>
  </td>
  <td width=266 colspan=2 valign=top style='width:199.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0106</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 valign=top style='width:254.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progressive disease as best overall response (%)</span></p>
  </td>
  <td width=133 style='width:99.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.7</span></p>
  </td>
  <td width=133 style='width:99.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>25.9</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Unstratified
logrank test</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Subgroup analyses across age, gender and
race consistently favoured the TCF arm compared to the CF arm.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>A survival update analysis conducted with
a median follow-up time of 41.6&nbsp;months no longer showed a statistically
significant difference although always in favour of the TCF regimen and showed
that the benefit of TCF over CF is clearly observed between 18 and
30&nbsp;months of follow up.</span></p>

<p class=Normal11pt><b><i><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></i></b></p>

<p class=Normal11pt><span lang=EN-GB>Overall, quality of life (QoL) and
clinical benefit results consistently indicated improvement in favour of the
TCF arm. Patients treated with TCF had a longer time to 5% definitive<b> </b>deterioration
of global health status on the QLQ&#8209;C30 questionnaire
(p&nbsp;=&nbsp;0.0121) and a longer time to definitive worsening<b> </b>of
Karnofsky performance status (p&nbsp;=&nbsp;0.0088) compared to patients
treated with CF.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Head and neck cancer</span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Induction</span><span lang=EN-GB
style='font-size:11.0pt'> chemotherapy followed by radiotherapy (TAX323)</span></p>

<p class=Normal11pt><span lang=EN-GB>The safety and efficacy of docetaxel in
the induction treatment of patients with squamous cell carcinoma of the head
and neck (SCCHN) was evaluated in a phase&nbsp;III, multi-centre, open-label, randomised
study (TAX323). In this study, 358&nbsp;patients with inoperable locally
advanced SCCHN, and WHO performance status&nbsp;0 or 1, were randomised to one
of two treatment arms. Patients on the docetaxel arm received
docetaxel&nbsp;(T) 75&nbsp;mg/m<sup>2</sup> followed by cisplatin&nbsp;(P)
75&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
750&nbsp;mg/m<sup>2</sup> per day as a continuous infusion for 5&nbsp;days.
This regimen was administered every three weeks for 4&nbsp;cycles in case at
least a minor response (&#8805;&nbsp;25% reduction in bidimensionally measured
tumour size) was observed after 2&nbsp;cycles. At the end of chemotherapy, with
a minimal interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks,
patients whose disease did not progress received radiotherapy (RT) according to
institutional guidelines for 7&nbsp;weeks (TPF/RT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m<sup>2</sup> followed by 5&#8209;fluorouracil&nbsp;(F)
1000&nbsp;mg/m<sup>2</sup> per day for 5&nbsp;days. This regimen was
administered every three weeks for 4&nbsp;cycles in case at least a minor
response (&#8805;&nbsp;25% reduction in bidimensionally measured tumour size)
was observed after 2&nbsp;cycles. At the end of chemotherapy, with a minimal
interval of 4&nbsp;weeks and a maximal interval of 7&nbsp;weeks, patients whose
disease did not progress received radiotherapy&nbsp;(RT) according to
institutional guidelines for 7&nbsp;weeks (PF/RT). Locoregional therapy with
radiation was delivered either with a conventional fraction (1.8&nbsp;Gy&nbsp;&#8209;&nbsp;2.0&nbsp;Gy
once a day, 5&nbsp;days per week for a total dose of 66 to 70&nbsp;Gy), or
accelerated/hyperfractionated regimens of radiation therapy (twice a day, with
a minimum interfraction interval of 6&nbsp;hours, 5&nbsp;days per week). A
total of 70&nbsp;Gy was recommended for accelerated regimens and 74&nbsp;Gy for
hyperfractionated schemes. Surgical resection was allowed following
chemotherapy, before or after radiotherapy. Patients on the TPF arm received
antibiotic prophylaxis with ciprofloxacin 500&nbsp;mg orally twice daily for
10&nbsp;days starting on day&nbsp;5 of each cycle, or equivalent. The primary
endpoint in this study, progression-free survival (PFS), was significantly
longer in the TPF arm compared to the PF arm, p&nbsp;=&nbsp;0.0042 (median PFS:
11.4 vs. 8.3&nbsp;months respectively) with an overall median follow up time of
33.7&nbsp;months. Median overall survival was also significantly longer in favour
of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5&nbsp;months
respectively) with a 28% risk reduction of mortality, p&nbsp;=&nbsp;0.0128.
Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Efficacy of docetaxel in the induction
treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat
Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 style='margin-top:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;text-transform:none'>Endpoint</span></h1>
  </td>
  <td width=128 valign=top style='width:96.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;177</span></b></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=&nbsp;181</span></b></p>
  </td>
 </tr>
 <tr style='height:22.0pt'>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt><span lang=EN-GB>Median progression free survival
  (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.4</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.1-14.0)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>8.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(7.4-9.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Adjusted hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>*p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.55-0.89)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0042</span></p>
  </td>
 </tr>
 <tr style='height:20.65pt'>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt><span lang=EN-GB>Median survival (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>18.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(15.7-24.0)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.65pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>14.5</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(11.6-18.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.56-0.93)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0128</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to chemotherapy
  (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>67.8</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(60.4-74.6)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>53.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(46.0-61.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Best overall response to study treatment
  [chemotherapy +/- radiotherapy] (%)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>72.3</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(65.1-78.8)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>58.6</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(51.0-65.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.006</span></p>
  </td>
 </tr>
 <tr>
  <td width=338 valign=top style='width:253.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Median duration of response to
  chemotherapy&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>&plusmn;</span><span
  lang=EN-GB> radiotherapy (months)</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=128 valign=top style='width:96.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;128</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>15.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(13.4-24.6)</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>n&nbsp;=&nbsp;106</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>11.7</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(10.2-17.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=338 valign=top style='width:253.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Hazard ratio</span></p>
  <p class=Normal11pt><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  <p class=Normal11pt><span lang=EN-GB>**p-value</span></p>
  </td>
  <td width=256 colspan=2 valign=top style='width:192.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.72</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>(0.52-0.99)</span></p>
  <p class=Normal11pt align=center style='text-align:center'><span lang=EN-GB>0.0457</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>A hazard
ratio of less than&nbsp;1 favours docetaxel&nbsp;+ cisplatin&nbsp;+ 5&#8209;FU</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>*Cox model
(adjustment for Primary tumour site, T and N clinical stages and PSWHO)</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>**Logrank
test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in'><span lang=EN-GB>***
Chi-square test</span></p>

<p class=MsoNormal style='margin-left:.5in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Normal11pt><i><span lang=EN-GB>Quality of life parameters</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Patients treated with TPF experienced
significantly less deterioration of their Global health score compared to those
treated with PF (p&nbsp;=&nbsp;0.01, using the EORTC QLQ&#8209;C30 scale). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Clinical benefit parameters</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The performance status scale, for head and
neck (PSS&#8209;HN) subscales designed to measure understandability of speech,
ability to eat in public, and normalcy of diet, was significantly in favour of
TPF as compared to PF.</span></p>

<p class=Normal11pt><span lang=EN-GB>Median time to first deterioration of WHO
performance status was significantly longer in the TPF arm compared to PF.</span><span
lang=EN-GB style='layout-grid-mode:line'> Pain intensity score improved during
treatment in both groups indicating adequate pain management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:
line'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Induction
</span><span lang=EN-GB style='font-size:11.0pt'>chemotherapy</span><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'> followed by
chemoradiotherapy (TAX324)</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of docetaxel in the induction treatment of patients with locally
advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in
a randomised, multi-centre open-label, phase&nbsp;III study (TAX324). In this
study, 501&nbsp;patients, with locally advanced SCCHN, and a WHO performance
status of 0 or 1, were randomised to one of two arms. The study population
comprised patients with technically unresectable disease, patients with low
probability of surgical cure and patients aiming at organ preservation. The efficacy
and safety evaluation solely addressed survival endpoints and the success of
organ preservation was not formally addressed. Patients on the docetaxel arm
received docetaxel&nbsp;(T) 75&nbsp;mg/m&sup2; by intravenous infusion on day 1
followed by cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; administered as a 30&#8209;minute
to three-hour intravenous infusion, followed by the continuous intravenous
infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day from
day&nbsp;1 to day&nbsp;4. The cycles were repeated every 3 weeks for 3 cycles.
All patients who did not have progressive disease were to receive
chemoradiotherapy (CRT) as per protocol (TPF/CRT). Patients on the comparator
arm received cisplatin&nbsp;(P) 100&nbsp;mg/m&sup2; as a 30&#8209;minute to
three&#8209;hour intravenous infusion on day&nbsp;1 followed by the continuous
intravenous infusion of 5&#8209;fluorouracil&nbsp;(F) 1000&nbsp;mg/m&sup2;/day
from day&nbsp;1 to day&nbsp;5. The cycles were repeated every 3&nbsp;weeks for
3&nbsp;cycles. All patients who did not have progressive disease were to
receive CRT as per protocol (PF/CRT). </span></p>

<p class=Normal11pt><span lang=EN-GB>Patients in both treatment arms were to receive
7&nbsp;weeks of CRT following induction chemotherapy with a minimum interval of
3&nbsp;weeks and no later than 8&nbsp;weeks after start of the last cycle
(day&nbsp;22 to day&nbsp;56 of last cycle). During radiotherapy, carboplatin
(AUC&nbsp;1.5) was given weekly as a one&#8209;hour intravenous infusion for a
maximum of 7&nbsp;doses. Radiation was delivered with megavoltage equipment
using once daily fractionation (2&nbsp;Gy per day, 5&nbsp;days per week for
7&nbsp;weeks, for a total dose of 70&#8209;72&nbsp;Gy). Surgery on the primary
site of disease and/or neck could be considered at any time following
completion of CRT. All patients on the docetaxel-containing arm of the study
received prophylactic antibiotics. The primary efficacy endpoint in this study,
overall survival (OS) was significantly longer (log-rank test,
p&nbsp;=&nbsp;0.0058) with the docetaxel-containing regimen compared to PF
(median OS: 70.6 versus 30.1&nbsp;months respectively), with a 30% risk
reduction in mortality compared to PF (hazard ratio (HR)&nbsp;=&nbsp;0.70, 95%
confidence interval (CI)&nbsp;=&nbsp;0.54&#8209;0.90) with an overall median
follow up time of 41.9&nbsp;months. The secondary endpoint, PFS, demonstrated a
29% risk reduction of progression or death and a 22&nbsp;month improvement in
median PFS (35.5&nbsp;months for TPF and 13.1 for PF). This was also
statistically significant with an HR of 0.71; 95% CI 0.56-0.90; log-rank test
p&nbsp;=&nbsp;0.004. Efficacy results are presented in the table below:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of docetaxel in the induction treatment of patients with locally advanced SCCHN
(Intent-to-Treat Analysis)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Endpoint</span></b></p>
  </td>
  <td width=166 valign=bottom style='width:124.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Docetaxel&nbsp;+
  Cis&nbsp;+ 5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  255</span></b></p>
  </td>
  <td width=166 valign=bottom style='width:124.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Cis&nbsp;+
  5&#8209;FU</span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>n&nbsp;=
  246</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  overall survival (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>70.6</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(49.0-NA)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>30.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(20.9-51.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 style='width:202.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>*p-value </span></p>
  </td>
  <td width=333 colspan=2 valign=top style='width:249.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.70</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.54-0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0058</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 style='width:202.2pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  PFS (months) </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>35.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(19.3-NA)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.1</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(10.6 - 20.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio:</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>**p-value
  </span></p>
  </td>
  <td width=333 colspan=2 valign=bottom style='width:249.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.71</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.56 - 0.90)</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to chemotherapy (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.8</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.8-77.2)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>64.2</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(57.9-70.2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=333 colspan=2 style='width:249.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.070</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Best
  overall response (CR + PR) to study treatment [chemotherapy +/-
  chemoradiotherapy] (%)</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95%CI)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>76.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(70.8-81.5)</span></p>
  </td>
  <td width=166 valign=top style='width:124.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71.5</span></p>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(65.5-77.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=270 valign=top style='width:202.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>***p-value</span></p>
  </td>
  <td width=333 colspan=2 style='width:249.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.209</span></p>
  </td>
 </tr>
</table>

</div>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>A hazard ratio of less than 1 favours docetaxel&nbsp;+
cisplatin&nbsp;+ fluorouracil</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>*un-adjusted log-rank test</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>**un-adjusted log-rank test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>***Chi square test, not adjusted for multiple comparisons</span></p>

<p class=Normal11ptGauche0 style='margin-left:0in;page-break-after:avoid'><span
lang=EN-GB>NA-not applicable</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The European
Medicines Agency has waived the obligation to submit the results of studies
with TAXOTERE in all subsets of the paediatric population in breast cancer,
non-small cell lung cancer, prostate cancer, gastric carcinoma and head and
neck cancer, not including type II and III less differentiated nasopharyngeal
carcinoma (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;position:relative;
top:-3.0pt'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Absorption</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The pharmacokinetics of docetaxel have
been evaluated in cancer patients after administration of 20&#8209;115&nbsp;mg/m<sup>2</sup>
in phase&nbsp;I studies. The kinetic profile of docetaxel is dose independent
and consistent with a three-compartment pharmacokinetic model with half-lives
for the </span><span lang=EN-GB>a</span><span lang=EN-GB>, </span><span lang=EN-GB>b</span><span lang=EN-GB> and </span><span
lang=EN-GB>g</span><span lang=EN-GB>&nbsp;phases of 4&nbsp;min, 36&nbsp;min and
11.1&nbsp;h, respectively. The late phase is due, in part, to a relatively slow
efflux of docetaxel from the peripheral compartment. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Distribution</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Following the administration of a
100&nbsp;mg/m<sup>2</sup> dose given as a one&#8209;hour infusion a mean peak
plasma level of 3.7&nbsp;&micro;g/ml was obtained with a corresponding AUC of
4.6&nbsp;h.&micro;g/ml. Mean values for total body clearance and steady-state
volume of distribution were 21&nbsp;l/h/m<sup>2</sup> and 113&nbsp;l,
respectively. Inter individual variation in total body clearance was
approximately 50%. Docetaxel is more than 95% bound to plasma proteins.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>A study of <sup>14</sup>C&#8209;docetaxel
has been conducted in three cancer patients. Docetaxel was eliminated in both
the urine and faeces following cytochrome P450&#8209;mediated oxidative
metabolism of the tert-butyl ester group, within seven days, the urinary and
faecal excretion accounted for about 6% and 75% of the administered
radioactivity, respectively. About 80% of the radioactivity recovered in faeces
is excreted during the first 48&nbsp;hours as one major inactive metabolite and
3&nbsp;minor inactive metabolites and very low amounts of unchanged medicinal
product.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Special populations</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Age and gender</span></i></p>

<p class=Normal11pt><span lang=EN-GB>A population pharmacokinetic analysis has
been performed with docetaxel in 577&nbsp;patients. Pharmacokinetic parameters
estimated by the model were very close to those estimated from phase&nbsp;I
studies. The pharmacokinetics of docetaxel were not altered by the age or sex
of the patient. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=Normal11pt><span lang=EN-GB>In a small number of patients
(n&nbsp;=&nbsp;23) with clinical chemistry data suggestive of mild to moderate
liver function impairment (ALT, AST&nbsp;</span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;1.5&nbsp;times the ULN
associated with alkaline phosphatase </span><span
lang=EN-GB>&sup3;</span><span lang=EN-GB>&nbsp;2.5&nbsp;times the ULN), total
clearance was lowered by 27% on average (see section 4.2). </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Fluid retention</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel clearance was not modified in
patients with mild to moderate fluid retention and there are no data available
in patients with severe fluid retention.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Combination therapy</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Doxorubicin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>When used in combination, docetaxel does
not influence the clearance of doxorubicin and the plasma levels of
doxorubicinol (a doxorubicin metabolite). The pharmacokinetics of docetaxel,
doxorubicin and cyclophosphamide were not influenced by their co&#8209;administration.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Capecitabine</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Phase&nbsp;I study evaluating the effect
of capecitabine on the pharmacokinetics of docetaxel and vice versa showed no
effect by capecitabine on the pharmacokinetics of docetaxel (Cmax and AUC) and
no effect by docetaxel on the pharmacokinetics of a relevant capecitabine
metabolite 5&#8217;&#8209;DFUR.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>Cisplatin</span></i></p>

<p class=Normal11pt><span lang=EN-GB>Clearance of docetaxel in combination
therapy with cisplatin was similar to that observed following monotherapy. <span
style='layout-grid-mode:line'>The pharmacokinetic profile of cisplatin
administered shortly after docetaxel infusion is similar to that observed with
cisplatin alone.</span></span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Cisplatin
and 5-fluorouracil</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The combined administration of docetaxel,
cisplatin and 5&#8209;fluorouracil in 12&nbsp;patients with solid tumours had
no influence on the pharmacokinetics of each individual medicinal product.</span></p>

<p class=Normal11pt><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone
and dexamethasone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>The effect of prednisone on the
pharmacokinetics of docetaxel administered with standard dexamethasone
premedication has been studied in 42&nbsp;patients. </span></p>

<p class=Normal11pt><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Normal11pt><i><span lang=EN-GB style='layout-grid-mode:line'>Prednisone</span></i></p>

<p class=Normal11pt><span lang=EN-GB>No effect of prednisone on the
pharmacokinetics of docetaxel was observed.</span></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=MsoBodyText><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext;position:relative;top:-3.0pt'>5.3&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The carcinogenic potential of docetaxel
has not been studied.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel has been shown to be mutagenic
in the <i>in vitro</i> micronucleus and chromosome aberration test in CHO&#8209;K1
cells and in the <i>in vivo</i> micronucleus test in the mouse. However, it did
not induce mutagenicity in the Ames test or the CHO/HGPRT gene mutation assay.
These results are consistent with the pharmacological activity of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Undesirable effects on the testis observed
in rodent toxicity studies suggest that docetaxel may impair male fertility.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp; List of
excipients</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=Normal11pt><span lang=EN-GB>Ethanol anhydrous</span></p>

<p class=Normal11pt><span lang=EN-GB>Citric acid</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>This medicinal product must not be mixed
with other medicinal products except those mentioned in section 6.6.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp; Shelf-life</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Unopened vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>3&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>After opening
of the vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is for
single use and should be used immediately after opening. If not used
immediately, in&#8209;use storage times and conditions are the responsibility
of the user. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TblTextLeft style='margin:0in;page-break-after:avoid'><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Once added to the </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>infusion </span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>bag</span></u><u><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>From a
microbiological point of view,</span><span lang=EN-GB style='font-size:11.0pt'>
reconstitution/dilution must take place in controlled and aseptic conditions</span><span
lang=EN-GB style='font-size:11.0pt'> and the medicinal product should be used
immediately. If not used immediately, in&#8209;use storage times and conditions
are the responsibility of the user.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Once added as
recommended into the infusion bag, the docetaxel infusion solution, if stored
below 25&deg;C, is stable for 6 hours. It should be used within 6 hours
(including the one hour infusion intravenous administration). </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>In addition,
physical and chemical in-use stability of the infusion solution prepared as
recommended has been demonstrated in non&#8209;PVC bags up to 48 hours when
stored between 2 to 8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel infusion
solution is supersaturated, therefore may crystallize over time. If crystals
appear, the solution must no longer be used and shall be discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not
store above 25&deg;C. </span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Store in
the original package in order to protect from light.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>For storage
conditions of the diluted medicinal product, see section 6.3.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>15&nbsp;ml
clear glass (type I) vial with a blue aluminium seal and blue plastic flip&#8209;off
cap containing 8&nbsp;ml of concentrate.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Each box contains one vial.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it and preparing TAXOTERE solutions. The use of gloves is recommended.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion
solution should come into contact with skin, wash immediately and thoroughly
with soap and water. If TAXOTERE concentrate or infusion solution should come
into contact with mucous membranes, wash immediately and thoroughly with water.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation for the intravenous
administration</span></u></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2 vials (concentrate and
solvent) with this medicinal product (TAXOTERE 160&nbsp;mg/8&nbsp;ml
concentrate for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE
160&nbsp;mg/8&nbsp;ml </span></b><b><span lang=EN-GB style='font-size:11.0pt'>concentrate
for solution for infusion </span></b><b><span lang=EN-GB style='font-size:11.0pt'>requires
NO prior dilution with a solvent and is ready to add to the infusion solution.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each vial is of
single use and should be used immediately.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><span lang=EN-GB>If the vials are stored under
refrigeration, allow the required number of boxes of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> to
stand below 25&deg;C for 5&nbsp;minutes before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>More than one vial of TAXOTERE </span><span
lang=EN-GB>concentrate for solution for infusion</span><span lang=EN-GB> may be
necessary to obtain the required dose for the patient. Aseptically withdraw the
required amount of TAXOTERE concentrate for solution for infusion using a
calibrated syringe fitted with a 21G needle.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 160&nbsp;mg/8&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=Normal11pt><span lang=EN-GB>The required volume of TAXOTERE
concentrate </span><span lang=EN-GB>for solution for infusion</span><span
lang=EN-GB> must be injected via a single injection (one shot) into a
250&nbsp;ml infusion bag or bottle containing either 5% glucose solution or
sodium chloride 9&nbsp;mg/ml (0.9%) solution for infusion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If a dose greater than 190&nbsp;mg of
docetaxel is required, use a larger volume of the infusion vehicle so that a
concentration of 0.74&nbsp;mg/ml docetaxel is not exceeded. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Mix the infusion bag or bottle manually
using a rocking motion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The infusion bag solution should be used
within 6 hours below 25&deg;C including the one hour infusion to the patient.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>As with all parenteral products, TAXOTERE
infusion solution should be visually inspected prior to use, solutions
containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>8.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EU/1/95/002/005</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>9.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: </span><span lang=EN-GB
style='font-size:11.0pt'>27 November 1995</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Date of latest renewal: 27 November 2005</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>10.&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <u>http://www.ema.europa.eu.</u> </span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:-23.75pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>ANNEX II</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:81.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><b><span
lang=EN-GB style='font-size:11.0pt'>A.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:81.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:81.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><b><span
lang=EN-GB style='font-size:11.0pt'>B.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:.75in;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:81.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><b><span
lang=EN-GB style='font-size:11.0pt'>C.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>OTHER CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:67.35pt'><b><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:67.35pt;margin-bottom:
0in;margin-left:81.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><a
name="OLE_LINK8"></a><a name="OLE_LINK9"><b><span lang=EN-GB style='font-size:
11.0pt'>D.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>conditions or restrictions with regard to the safe and effective use
of the medicinal product</span></b></a></p>

<p class=MsoNormal style='margin-right:67.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:67.35pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEA2><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><u><span
lang=EN-GB style='font-size:11.0pt'>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
color:black'>65926 Frankfurt am Main</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
  color:black'>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
style='font-size:11.0pt'>Sanofi-Aventis Zrt.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
style='font-size:11.0pt'>(Harbor Park) 1, Campona utca</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=SV style='font-size:11.0pt'>Budapest 1225</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=SV style='font-size:11.0pt'>Hungary</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=SV style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>The printed package leaflet of the
medicinal product must state the name and address of the</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=SV style='font-size:11.0pt'>manufacturer responsible for the release of
the concerned batch.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=SV style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Medicinal product subject to
restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:27.0pt;margin-bottom:.0001pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:13.0pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Periodic Safety
Update Reports </span></b><b><span lang=EN-GB style='color:black'>(PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>The marketing authorisation holder shall submit PSUR
for this product in accordance with the requirements set out in the list of
Union reference dates (EURD list) provided for under Article 107c(7) of
Directive 2001/83</span><span lang=EN-GB style='font-size:11.0pt'>/EC and&nbsp;
published on the European medicines web-portal.</span></p>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:35.45pt;text-indent:-35.45pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b><b><span
lang=EN-GB>&nbsp; </span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
13.0pt'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
style='font-size:11.0pt;color:black'>The marketing authorisation holder (MAH)
shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the marketing
authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
style='font-size:11.0pt;color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:41.4pt;text-indent:-.25in;line-height:
13.0pt;text-autospace:none'><span style='font-size:11.0pt;font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>At the request of the
European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:41.4pt;text-indent:-.25in;line-height:
13.0pt;text-autospace:none'><span style='font-size:11.0pt;font-family:Symbol;
color:black'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Whenever the risk
management system is modified, especially as the result of new information
being received that may lead to a significant change to the benefit/risk
profile or as the result of an important (pharmacovigilance or risk
minimisation) milestone being reached.</span></p>

<p class=Header1><span lang=PT-BR>&nbsp;</span></p>

<p class=Header1><span lang=PT-BR>&nbsp;</span></p>

<p class=Header1><span lang=EN-GB style='color:black'>An updated RMP shall be
submitted by 31 October 2019.</span><span lang=PT-BR><br clear=all
style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='margin-right:-24.0pt'><span lang=PT-BR
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:2.8pt;text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=EMEA1><span lang=EN-GB>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>PARTICULARS TO APPEAR ON OUTER PACKAGING AND THE
IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>CARTON/TAXOTERE 20 mg/0.5&nbsp;ml </span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 20 mg/0.5&nbsp;ml concentrate and solvent for
solution for infusion</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:5.65pt;text-indent:-5.65pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>1&nbsp;vial of TAXOTERE 20 mg/0.5&nbsp;ml concentrate
for solution for infusion</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20
mg docetaxel in 0.5&nbsp;ml polysorbate&nbsp;80 (40&nbsp;mg/ml)</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill:
24.4&nbsp;mg/0.61&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>1&nbsp;vial of solvent for TAXOTERE</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13%
(w/w) ethanol 95% in water for injections </span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill:
1.98<b><i>&nbsp;</i></b>ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE vial: polysorbate&nbsp;80, citric acid.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Solvent vial: ethanol 95% </span><span lang=EN-GB>(see
leaflet for further information)</span><span lang=EN-GB style='font-size:11.0pt'>,
water for injections.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each blister pack
of TAXOTERE 20 mg/0.5&nbsp;ml concentrate and solvent for solution for infusion
contains:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
concentrate,</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
solvent.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>CAUTION: Dilution required with the entire contents of
the solvent vial.&nbsp; See accompanying preparation guide.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Intravenous use</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>CYTOTOXIC</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>To be administered under the supervision of a
physician experienced in the use of cytotoxic agents.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not store above 25&deg;C or below 2&deg;C.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 3.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Single-use vials - discard unused contents
appropriately.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/001</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Information in braille</span></span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black;background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span><span lang=EN-GB style='font-size:
11.0pt;color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>CONCENTRATE and SOLVENT/TAXOTERE </span></b><b><span
style='font-size:11.0pt'>20 mg/0.5&nbsp;ml </span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=Heading41 style='margin-right:170.1pt;page-break-after:auto'><i><span
lang=EN-GB style='font-weight:normal'>&nbsp;</span></i></p>

<p class=Heading41 style='margin-right:3.55pt;page-break-after:auto'><span
lang=EN-GB style='font-weight:normal'>TAXOTERE 20 mg/0.5&nbsp;ml concentrate
and solvent for solution for infusion</span></p>

<p class=MsoNormal style='margin-right:170.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:170.1pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP </span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=FR style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>TAXOTERE concentrate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-weight:normal'>SOLVENT for TAXOTERE</span><span lang=EN-GB> </span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>VIAL</span></b><b><span lang=EN-GB style='font-size:
11.0pt'>/TAXOTERE 20 mg/0.5&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 20 mg/0.5&nbsp;ml concentrate for solution
for infusion</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>intravenous use</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>0.5&nbsp;ml (Fill
0.61&nbsp;ml)</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>VIAL</span></b><b><span lang=EN-GB style='font-size:
11.0pt'>/SOLVENT FOR TAXOTERE 20 mg/0.5&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>SOLVENT for TAXOTERE 20 mg/0.5&nbsp;ml</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>13% (w/w) ethanol 95% in water for injections (see
leaflet for further information)</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>1.5&nbsp;ml (Fill 1.98&nbsp;ml)</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE
IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>CARTON/TAXOTERE 80 mg/2&nbsp;ml </span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 80 mg/2&nbsp;ml concentrate and solvent for
solution for infusion</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:5.65pt;text-indent:-5.65pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>1&nbsp;vial of TAXOTERE 80 mg/2&nbsp;ml concentrate
for solution for infusion</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80
mg docetaxel in 2&nbsp;ml polysorbate&nbsp;80 (40&nbsp;mg/ml)</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill:
94.4&nbsp;mg/2.36&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>1&nbsp;vial of solvent for TAXOTERE</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13%
(w/w) ethanol 95% in water for injections </span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill:
7.33&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE vial: polysorbate&nbsp;80, citric acid.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Solvent vial: ethanol 95% </span><span lang=EN-GB>(see
leaflet</span><span lang=EN-GB style='font-size:11.0pt'> for further
information), </span><span lang=EN-GB style='font-size:11.0pt'>water for
injections.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each blister pack
of TAXOTERE 80 mg/2&nbsp;ml concentrate and solvent for solution for infusion
contains:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
concentrate,</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>one single-dose vial of
solvent.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>CAUTION: Dilution required with the entire contents of
the solvent vial.&nbsp; See accompanying preparation guide.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Intravenous use</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>CYTOTOXIC</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>To be administered under the supervision of a
physician experienced in the use of cytotoxic agents.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not store above 25&deg;C or below 2&deg;C.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Single-use vials - discard unused contents
appropriately.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP, 54
rue La Bo&eacute;tie, 75008 Paris, France</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/002</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Information in braille</span></span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span><span lang=EN-GB style='font-size:
11.0pt;color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>CONCENTRATE and SOLVENT/TAXOTERE 80 mg/2&nbsp;ml </span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=Heading41 style='margin-right:170.1pt;page-break-after:auto'><i><span
lang=EN-GB style='font-weight:normal'>&nbsp;</span></i></p>

<p class=Heading41 style='margin-right:3.55pt;page-break-after:auto'><span
lang=EN-GB style='font-weight:normal'>TAXOTERE 80 mg/2&nbsp;ml</span><span
lang=EN-GB style='font-weight:normal'> </span><span lang=EN-GB
style='font-weight:normal'>concentrate and solvent for solution for infusion</span></p>

<p class=MsoNormal style='margin-right:170.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:170.1pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP </span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=FR style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=FR style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE concentrate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>SOLVENT for
TAXOTERE </span><span lang=EN-GB style='font-size:11.0pt'><br clear=all
style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>VIAL</span></b><b><span lang=EN-GB style='font-size:
11.0pt'>/TAXOTERE 80 mg/2&nbsp;ml</span></b></p>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 80 mg/2&nbsp;ml concentrate for solution for
infusion</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>docetaxel</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>intravenous use</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>2&nbsp;ml (Fill
2.36&nbsp;ml)</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>VIAL/</span></b><b><span lang=EN-GB style='font-size:
11.0pt'>SOLVENT FOR TAXOTERE 80 mg/2&nbsp;ml</span></b><b><span lang=EN-GB
style='font-size:11.0pt'> </span></b></p>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>SOLVENT for TAXOTERE 80 mg/2&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Batch:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>13% (w/w) ethanol
95% in water for injections (see leaflet for further information)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>6&nbsp;ml (Fill
7.33&nbsp;ml)</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

<p class=MsoNormal style='page-break-before:always;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>OUTER CARTON / TAXOTERE 20&nbsp;mg/1&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 20&nbsp;mg/1&nbsp;ml concentrate
for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:5.65pt;text-indent:-5.65pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each ml of
concentrate contains 20&nbsp;mg docetaxel as trihydrate.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One&nbsp;vial of 1&nbsp;ml of concentrate
contains 20&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Excipients: polysorbate&nbsp;80, ethanol
anhydrous (see leaflet for further information) and citric acid. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>1 vial</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Ready to add to infusion solution.</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>CAUTION</span></b><span lang=EN-GB>:
Withdraw the required amount of this docetaxel concentrate (<b>20&nbsp;mg/ml</b>)
from the vial and add it directly into the infusion solution. See accompanying
preparation guide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Single-use vial.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>SIGHT AND </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>REACH OF CHILDREN</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>CYTOTOXIC</span></p>

<p class=Normal11pt><span lang=EN-GB>To be administered under the supervision
of a physician experienced in the use of cytotoxic agents.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Shelf life in infusion bag: see the
leaflet.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 3.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>EU/1/95/002/003</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Information in braille</span></span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span><span lang=EN-GB style='font-size:
11.0pt;color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span style='font-size:
11.0pt'>VIAL LABEL </span></b><b><span style='font-size:11.0pt'>/ TAXOTERE
20&nbsp;mg/1&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=IT>TAXOTERE 20&nbsp;mg/1&nbsp;ml sterile
concentrate</span></p>

<p class=Normal11pt><span lang=IT>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEA10 align=left style='text-align:left'><span lang=EN-GB
style='font-weight:normal'>Contains anhydrous ethanol (see leaflet)<br
clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>PARTICULARS TO APPEAR ON OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>OUTER CARTON / TAXOTERE 80&nbsp;mg/4&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 80&nbsp;mg/4&nbsp;ml concentrate
for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:5.65pt;text-indent:-5.65pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each ml of
concentrate contains 20&nbsp;mg docetaxel as trihydrate.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One vial of 4&nbsp;ml of concentrate
contains 80&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Excipients: polysorbate&nbsp;80, ethanol
anhydrous (see leaflet for further information) and citric acid. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>1 vial</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Ready to add to infusion solution.</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>CAUTION</span></b><span lang=EN-GB>: Withdraw
the required amount of this docetaxel concentrate (<b>20&nbsp;mg/ml</b>) from
the vial and add it directly into the infusion solution. See accompanying
preparation guide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Single-use vial.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>SIGHT AND </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>REACH OF CHILDREN</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>CYTOTOXIC</span></p>

<p class=Normal11pt><span lang=EN-GB>To be administered under the supervision
of a physician experienced in the use of cytotoxic agents.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Shelf life in infusion bag: see the
leaflet.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 3.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><a name="OLE_LINK2"></a><a
name="OLE_LINK7"><span lang=EN-GB style='font-size:11.0pt'>EU/1/95/002/004</span></a></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Information in braille</span></span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span><span lang=EN-GB style='font-size:
11.0pt;color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span style='font-size:
11.0pt'>VIAL LABEL </span></b><b><span style='font-size:11.0pt'>/ TAXOTERE
80&nbsp;mg/4&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=IT>TAXOTERE 80&nbsp;mg/4&nbsp;ml sterile
concentrate</span></p>

<p class=Normal11pt><span lang=IT>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-weight:normal'>Contains anhydrous ethanol (see leaflet)</span><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>PARTICULARS TO APPEAR ON OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>OUTER CARTON / TAXOTERE 160&nbsp;mg/8&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE 160&nbsp;mg/8&nbsp;ml concentrate
for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:5.65pt;text-indent:-5.65pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each ml of
concentrate contains 20&nbsp;mg docetaxel as trihydrate.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>One&nbsp;vial of 8&nbsp;ml of concentrate
contains 160&nbsp;mg of docetaxel.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Excipients: polysorbate&nbsp;80, ethanol
anhydrous (see leaflet for further information) and citric acid. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=Normal11pt><span lang=EN-GB>1 vial</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b><span lang=EN-GB style='font-size:
11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Ready to add to infusion solution.</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>CAUTION</span></b><span lang=EN-GB>:
Withdraw the required amount of this docetaxel concentrate (<b>20&nbsp;mg/ml</b>)
from the vial and add it directly into the infusion solution. See accompanying
preparation guide.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Single-use vial.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>SIGHT AND </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>REACH OF CHILDREN</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>CYTOTOXIC<br>
<br>
</span></p>

<p class=Normal11pt><span lang=EN-GB>To be administered under the supervision
of a physician experienced in the use of cytotoxic agents.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Shelf life in infusion bag: see the
leaflet.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 3.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>10.&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Discard unused contents appropriately in
accordance with local requirements.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>France</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<p class=Normal11pt><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EU/1/95/002/005</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:5.65pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>Information in braille</span></span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB style='background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span><span lang=EN-GB style='font-size:
11.0pt;color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>Not applicable.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span style='font-size:
11.0pt'>VIAL LABEL </span></b><b><span style='font-size:11.0pt'>/ TAXOTERE
160&nbsp;mg/8&nbsp;ml</span></b></p>

</div>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=IT>TAXOTERE 160&nbsp;mg/8&nbsp;ml sterile
concentrate</span></p>

<p class=Normal11pt><span lang=IT>docetaxel</span></p>

<p class=Normal11pt><span lang=EN-GB>Intravenous use</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>EXP:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-weight:normal'>Contains anhydrous ethanol (see leaflet)</span><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=EMEA1><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient</span></b></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>&nbsp;</span></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>TAXOTERE 20 mg/0.5&nbsp;ml
concentrate </span><span style='font-family:"Times New Roman",serif;text-transform:
none'>and solvent </span><span style='font-family:"Times New Roman",serif;
text-transform:none'>for solution for infusion</span></p>

<p class=Titre0 style='margin:0in;page-break-before:auto'><span
style='font-family:"Times New Roman",serif;text-transform:none'>docetaxel</span></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal style='margin-right:2.8pt'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor, hospital pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects talk to your doctor, hospital pharmacist or nurse.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>What is in this
leaflet</span></b><span lang=EN-GB style='font-size:11.0pt'>:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use TAXOTERE</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to use TAXOTERE</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store TAXOTERE</span></p>

<p class=MsoDate><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The name of this medicine is TAXOTERE. Its common name
is docetaxel. Docetaxel is a substance derived from the needles of yew trees.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Docetaxel belongs to the group of anti-cancer
medicines called taxoids.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE has been prescribed by your doctor for the
treatment of breast cancer, special forms of lung cancer (non-small cell lung
cancer), prostate cancer, gastric cancer or head and neck cancer: </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of advanced breast cancer,
TAXOTERE could be administered either alone or in combination with doxorubicin,
or trastuzumab, or capecitabine.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of early breast cancer with <a
name="OLE_LINK1">or without </a>lymph node involvement, TAXOTERE could be administered
in combination with doxorubicin and cyclophosphamide.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of lung cancer, TAXOTERE could be
administered either alone or in combination with cisplatin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the
treatment of prostate cancer, TAXOTERE is administered in combination with
prednisone or prednisolone.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the
treatment of metastatic gastric cancer, TAXOTERE is administered in combination
with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the
treatment of head and neck cancer, TAXOTERE is administered in combination with
cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Heading51 style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-top:0in;punctuation-wrap:simple;text-autospace:
none;vertical-align:baseline'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use TAXOTERE</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>You must not be given TAXOTERE:</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic
(hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE (listed
in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if the number of white
blood cells is too low.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you</span><span
lang=EN-GB style='font-size:11.0pt'> have a severe liver disease.</span></p>

<p class=Retrait1 style='margin-left:0in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Warnings and precautions</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Before each treatment with TAXOTERE, you will have
blood tests to check that you have enough blood cells and sufficient liver
function to receive TAXOTERE. In case of white blood cells disturbances, you
may experience associated fever or infections.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist, or nurse
immediately if you have abdominal pain or tenderness, diarrhoea, rectal
haemorrhage, blood in stool or fever. These symptoms may be the first signs of
a serious gastrointestinal toxicity, which could be fatal. Your doctor should
address them immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you
have vision problems. In case of vision problems, in particular blurred vision,
you should immediately have your eyes and vision examined. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin-top:2.9pt;margin-right:0in;margin-bottom:0in;margin-left:0in;
text-align:justify;punctuation-wrap:simple;vertical-align:baseline'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tell your doctor,
hospital pharmacist or nurse if you have experienced an allergic reaction to
previous paclitaxel therapy.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>Tell
your doctor, hospital pharmacist or nurse if you have heart problems. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you develop acute or worsening problems with your
lungs (fever, shortness of breath or cough), please tell your doctor, hospital
pharmacist or nurse immediately. Your doctor may stop your treatment
immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You will be asked to take premedication consisting of
an oral corticosteroid such as dexamethasone, one day prior to TAXOTERE administration
and to continue for one or two days after it in order to minimise certain undesirable
effects which may occur after the infusion of TAXOTERE in particular allergic
reactions and fluid retention (swelling of the hands, feet, legs or weight gain).</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>During treatment,
you may be given other medicines to maintain the number of your blood cells.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Severe skin problems such as
Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute
Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: </span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SJS/TEN symptoms may include blistering, peeling
or bleeding on any part of your skin (including your lips, eyes, mouth, nose,
genitals, hands or feet) with or without a rash. You may also have flu-like
symptoms at the same time, such as fever, chills or aching muscles.</span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>AGEP symptoms may include a red, scaly
widespread rash with bumps under the swollen skin (including your skin folds,
trunk, and upper extremities) and blisters accompanied by fever. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you develop severe skin reactions or any
of the reactions listed above, immediately contact your doctor or healthcare
professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have kidney problems or high levels of uric acid in your blood
before intiating TAXOTERE.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE contains alcohol. Discuss with
your doctor if you suffer from alcohol dependency, epilepsy or liver
impairment. See also section &#8220; TAXOTERE contains ethanol (alcohol)&#8221;
below.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Other medicines and TAXOTERE</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Please tell your doctor or hospital pharmacist if you
are taking or have recently taken any other medicine, including medicines
obtained without a prescription. This is because TAXOTERE or the other medicine
may not work as well as expected and you may be more likely to get a side effect.
<br>
</span><span lang=EN-GB style='font-size:11.0pt'>The amount of alcohol in this
medicinal product may alter the effects of other medicines.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy, breast-feeding and fertility</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ask your doctor
for advice before being given any medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE must <u>NOT</u> be administered if you are
pregnant unless clearly indicated by your doctor. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You must not become pregnant during treatment with
this medicine and must use an effective method of contraception during therapy,
because TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during
your treatment, you must immediately inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You must not breast-feed
while you are treated with TAXOTERE.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you are a man
being treated with TAXOTERE you are advised not to father a child during and up
to 6&nbsp;months after treatment and to seek advice on conservation of sperm
prior to treatment because docetaxel may alter male fertility.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;font-variant:small-caps'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
impair your ability to drive or use machines. </span><span lang=EN-GB
style='font-size:11.0pt'>You may experience side effects of this</span><span
lang=EN-GB style='font-size:11.0pt'> medicine</span><span lang=EN-GB
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>that
may impair your ability to drive, use tools or operate machines </span><span
lang=EN-GB style='font-size:11.0pt'>(see section 4 Possible side effects). If
this happens, do not drive or use any tools or machines before discussing with
your doctor, nurse or hospital pharmacist.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>TAXOTERE contains ethanol (alcohol)</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
style='font-size:11.0pt'>13% (w/w) ethanol 95% v/v (alcohol), i.e. up to 252 mg
ethanol 95% v/v per solvent vial, equivalent to 6 ml of beer or 2.6 ml wine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. <br>
To be taken into account in pregnant or breast&#8209;feeding women, in children
and in high&#8209;risk groups such as patients with liver disease, or epilepsy.<br>
<br>
</span><span style='font-size:11.0pt'>The amount of alcohol in this medicinal product
may have effects on the central nervous system (the part of the nervous system
that includes the brain and spinal cord).</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to use TAXOTERE</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE will be administered to you by a healthcare
professional.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Usual dose</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The dose will depend on your weight and your general
condition. Your doctor will calculate your body surface area in square meters
(m&sup2;) and will determine the dose you should receive.<s> </s></span></p>

<p class=MsoNormal style='margin-right:2.8pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Method and route of administration</span></b></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.85pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE will be given by infusion into one of your
veins (intravenous use). The infusion will last approximately one hour during
which you will be in the hospital.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Frequency of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You should usually
receive your infusion once every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Your doctor may change the dose and frequency of
dosing depending on your blood tests, your general condition and your response
to <span style='text-transform:uppercase'>t</span>AXOTERE. In particular, please
inform your doctor in case of diarrhoea, sores in the mouth, feeling of
numbness or pins and needles, fever and give her/him results of your blood tests.
Such information will allow her/him to decide whether a dose reduction is needed.
If you have any further questions on the use of this medicine, ask your doctor,
or hospital pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Like all medicines, this medicine </span><span
style='font-size:11.0pt'>can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Your doctor will discuss these with you and will explain
the </span><span style='font-size:11.0pt'>potential </span><span lang=EN-GB
style='font-size:11.0pt'>risks and benefits of your treatment.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The most commonly reported adverse reactions of
TAXOTERE alone are: decrease in the number of red blood cells or white blood
cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The severity of adverse events of TAXOTERE may be
increased when TAXOTERE is given in combination with other chemotherapeutic
agents.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>During the infusion at the hospital the following
allergic reactions may occur </span><span style='font-size:11.0pt'>(may affect
more than 1&nbsp;in 10 people)</span><span lang=EN-GB style='font-size:11.0pt'>:
</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>flushing, skin reactions, itching</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>chest tightness; difficulty in
breathing </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>fever or chills</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>back pain </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>low blood pressure.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>More
severe reactions may occur</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span style='font-size:11.0pt'>If
you had an allergic reaction to paclitaxel, you may also experience an allergic
reaction to docetaxel, which may be more severe.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The hospital staff will
monitor your condition closely during treatment.&nbsp; Tell them immediately if
you notice any of these effects.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Between infusions of TAXOTERE the following may occur,
</span><span style='font-size:11.0pt'>and the frequency may vary with the combinations
of medicines that are received</span><span lang=EN-GB style='font-size:11.0pt'>:</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Very common (</span></b><span
style='font-size:11.0pt'>may affect more than 1 in 10&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infections, decrease in the number
of red (anaemia), or white blood cells (which are important in fighting
infection) and platelets</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>fever: if this happens you must
tell your doctor immediately</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>allergic reactions as described
above</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>loss of appetite (anorexia) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>insomnia</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>feeling of numbness or pins and needles
or pain in the joints or muscles</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>headache </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>alteration in sense of taste </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the eye or increased
tearing of the eyes </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>swelling caused by faulty
lymphatic drainage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>shortness of breath </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>nasal drainage; inflammation of
the throat and nose; cough</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>bleeding from the nose </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>sores in the mouth </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>stomach upsets including nausea,
vomiting and diarrhoea, constipation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>indigestion</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hair loss: in most cases normal
hair growth should return. In some cases (frequency not known) permanent hair
loss has been observed</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>redness and swelling of the palms
of your hands or soles of your feet which may cause your skin to peel (this may
also occur on the arms, face, or body)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>change in the colour of your
nails, which may detach </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>muscle aches and pains; back pain
or bone pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>change or absence of menstrual
period</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>swelling of the hands, feet, legs </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>tiredness; or flu-like symptoms</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>weight gain or loss</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infection of the upper respiratory
tract.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Common </span></b><span
style='font-size:11.0pt'>(may affect </span><span style='font-size:11.0pt'>up
to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>oral candidiasis</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dehydration</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dizziness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hearing impaired</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease in blood pressure;
irregular or rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>heart failure</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>oesophagitis </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>difficulty or painful swallowing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>haemorrhage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>raised liver enzymes (hence the
need for regular blood tests)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>rises in blood sugar levels
(diabetes)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease of the potassium, calcium
and/or phosphate in your blood. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Uncommon</span></b><span
style='font-size:11.0pt'> (may affect up to 1 in 100&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fainting</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>at the injection site, skin
reactions, phlebitis (inflammation of the vein) or swelling </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>blood clots.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>acute myeloid leukaemia and
myelodysplastic syndrome (types of blood cancer) may occur in patients who are
treated with docetaxel together with certain other anticancer treatments</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Rare</span></b><b><span
style='font-size:11.0pt'> </span></b><span style='font-size:11.0pt'>(may affect
up to 1 in 1,000 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the colon, small
intestine, which could be fatal (frequency not known); intestinal perforation.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Frequency not known</span></b><span
lang=EN-GB style='font-size:11.0pt'> (cannot be estimated from the available
data):</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>interstitial lung
disease (inflammation of the lungs causing coughing and difficulty breathing.
Inflammation of the lungs can also develop when docetaxel therapy is used with
radiotherapy)</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pneumonia (infection of
the lungs)</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pulmonary fibrosis
(scarring and thickening in the lungs with shortness of breath)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision due to swelling of the retina
within the eye (cystoid macular oedema)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease of the sodium and/or magnesium in your
blood (electrolyte balance disorders)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ventricular arrhythmia or ventricular
tachycardia (manifested as irregular and/or rapid heartbeat, severe shortness
of breath, dizziness, and/or fainting). Some of these symptoms can be serious.
If this happens, you must tell your doctor immediately</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injection site reactions at the site of a previous reaction<span
lang=EN-GB>.</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>n</span>on-Hodgkin lymphoma (a cancer affecting
the immune system) and other cancers may occur in patients who are treated with
docetaxel together with certain other anticancer treatments.</p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens-Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN) (blistering, peeling or bleeding on any part of your
skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or
without a rash. You may also have flu-like symptoms at the same time, such as
fever, chills or aching muscles.)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute Generalized Exanthematous Pustulosis
(AGEP) (red, scaly widespread rash with bumps under the swollen skin (including
your skin folds, trunk, and upper extremities) and blisters accompanied by
fever.)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>tumour lysis syndrome is a serious condition
revealed by changes in blood test such as increased level of uric acid,
potassium, phosphorus and decreased level of calcium; and results in symptoms such
as seizures, kidney failure </span><span lang=EN-GB>(reduced amount or darkening
of urine) <span style='color:black'>and heart rhythm disturbance. &nbsp;If this
happens, you must tell your doctor immediately.</span></span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>myositis (inflammation of the
muscles -hot, red and swollen- which produces muscle pain and weakness) </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Reporting of
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you get any
side effects talk to your doctor, hospital pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. </span><span lang=EN-GB
style='font-size:11.0pt'>You can also report side effects directly via the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB style='font-size:11.0pt'>. By reporting side
effects you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store TAXOTERE</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal;page-break-after:auto'><span
style='font-size:11.0pt;font-weight:normal'>Keep this medicine out of the sight
and reach of children.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>This
medicine should not be used after the expiry date shown on the carton, blister
pack and vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not store above 25&deg;C or below 2&deg;C.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Store in the original package in order to protect from
light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The premix
solution should be used immediately after preparation. However the chemical and
physical stability of the premix solution has been demonstrated for 8&nbsp;hours
when stored either between 2&deg;C and 8&deg;C or at room temperature (below
25&deg;C).</span></p>

<p class=paragraph align=left style='margin-top:0in;margin-right:.55pt;
margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph align=left style='margin-top:0in;margin-right:.55pt;
margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>The infusion solution should be used within
4&nbsp;hours at room temperature (below 25&deg;C).</span></p>

<p class=MsoNormal style='margin-right:-19.9pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-19.9pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-19.9pt;text-align:justify;page-break-after:
avoid;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><b><span
lang=EN-GB style='font-size:11.0pt'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-19.9pt;text-align:justify;page-break-after:
avoid;punctuation-wrap:simple;text-autospace:none;vertical-align:baseline'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-20.15pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>What TAXOTERE concentrate vial contains</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The active substance is docetaxel (as trihydrate).
Each ml of docetaxel solution contains 40&nbsp;mg of docetaxel (anhydrous). One
vial contains 20 mg/0.5&nbsp;ml docetaxel. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The other ingredients are polysorbate&nbsp;80 and
citric acid.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-20.15pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>What solvent vial contains</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>13% (w/w) ethanol 95% </span><span lang=EN-GB
style='font-size:11.0pt'>(see section 2) </span><span lang=EN-GB
style='font-size:11.0pt'>in water for injections. </span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph align=left style='margin-top:0in;margin-right:-20.15pt;
margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:left;
page-break-after:avoid'><b><span style='font-size:11.0pt'>What TAXOTERE looks like
and contents of the pack</span></b></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE
20 mg/0.5&nbsp;ml concentrate for solution for infusion is a clear viscous,
yellow to brown-yellow solution.</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Each
blister pack contains:</span></p>

<p class=MsoBodyText align=left style='margin-left:.25in;text-align:left;
text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;
color:windowtext'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>one single-dose vial of concentrate and,</span></p>

<p class=MsoBodyText align=left style='margin-left:.25in;text-align:left;
text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;
color:windowtext'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>one single-dose vial of solvent.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>France</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><b><span lang=PT-BR
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><b><span lang=PT-BR style='font-size:
11.0pt'>Manufacturers</span></b></p>

<p class=MsoNormal style='margin-right:-19.9pt'><span lang=DE style='font-size:
11.0pt'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='margin-right:-19.9pt'><span lang=DE style='font-size:
11.0pt'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='margin-right:-19.9pt'><span style='font-size:11.0pt'>65926
Frankfurt am Main</span></p>

<p class=MsoNormal style='margin-right:-19.9pt'><span style='font-size:11.0pt'>Germany</span></p>

<p class=MsoNormal style='margin-right:-19.9pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>For any information about this medicinal product,
please contact the local representative of the Marketing Authorisation Holder. </span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Belgi&euml;/Belgique</span></b><b><span
  lang=MT style='font-size:11.0pt'>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>UAB </span><span
  lang=FR style='font-size:11.0pt;letter-spacing:-.05pt'>&laquo;SANOFI-AVENTIS
  LIETUVA&raquo;</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=IT
  style='font-family:"Times New Roman",serif'>SANOFI BULGARIA EOOD</span></p>
  <p class=MsoNormal><span lang=BG style='font-size:11.0pt'>&#1058;&#1077;&#1083;</span><span
  lang=IT style='font-size:11.0pt'>.</span><span lang=BG style='font-size:11.0pt'>:
  +</span><span lang=IT style='font-size:11.0pt'>359 (0)2</span><span lang=IT
  style='font-size:11.0pt'> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis,
  s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +420 233 086
  111</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU style='font-size:11.0pt'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  zrt., Magyarorsz&aacute;g</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel.: +36 1 </span><span
  lang=HU style='font-size:11.0pt'>505 0050</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tlf: +45 45 16 70
  00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: </span><span
  lang=FR style='font-size:11.0pt'>+39. 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi-Aventis
  Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: </span><span
  lang=FR style='font-size:10.0pt;font-family:"Arial",sans-serif'>0800 04 36
  996</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'>Tel.
  aus dem Ausland: +49 69 305 70 13</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +31 </span><span
  lang=NL style='font-size:11.0pt'>&nbsp; </span><span lang=CS
  style='font-size:11.0pt'>20 245 4000</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  Estonia O&Uuml;</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  Norge AS</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tlf: +47 67 10 71
  00</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;</span><span
  lang=CS style='font-size:11.0pt'>: +30 210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +43 1 80 185
  &#8211; 0</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='font-size:11.0pt'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>sanofi-aventis,
  S.A.</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +34 93 485 94
  00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis Sp.
  z o.o.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel.: +48 22&nbsp;</span><span
  lang=EN-GB style='font-size:11.0pt'>280 00 00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:56.0pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.0pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>sanofi-aventis
  France</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l: 0 800 222
  555</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Appel depuis
  l&#8217;&eacute;tranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.0pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi -
  Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +351 21 35 89 </span><span
  lang=FR style='font-size:11.0pt'>400</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT
  style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +385 1 600 34
  00</span></p>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL style='font-size:11.0pt'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>Tel: +40 </span><span
  lang=FR style='font-size:11.0pt'>(0) 21 317 31 36</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Ireland Ltd. </span><span lang=FR style='font-size:11.0pt'>T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +353 (0) 1 403
  56 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +386 1 560 48
  00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS style='font-size:11.0pt'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=IS style='font-size:11.0pt'>S&iacute;mi</span><span
  lang=CS style='font-size:11.0pt'>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK style='font-size:11.0pt'>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>sanofi-</span><span
  lang=CS style='font-size:11.0pt'>aventis Slovakia </span><span lang=SK
  style='font-size:11.0pt'>s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +421 2
  33&nbsp;100 100</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: 800536389</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi </span><span
  lang=SV style='font-size:11.0pt'>Oy</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Puh/Tel: +358 (0)
  201 200 300</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +</span><span lang=FR style='font-size:11.0pt'>357 22 871600</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi </span><span
  lang=SV style='font-size:11.0pt'>AB</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +46 (0)8 634
  50 00</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +371 67 33 24
  51</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +44 (0)
  845&nbsp;372 7101</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>This leaflet was last revised in .</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Detailed information on this medicine is
available on the European Medicines Agency web site: <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu/</a>.</span></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div class=WordSection2>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>The following information is intended for healthcare
professionals only:</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt'>PREPARATION GUIDE FOR USE WITH TAXOTERE 20&nbsp;mg/0.5&nbsp;ml
CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BodyText21 align=left style='margin-left:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB>It is important that you read the
entire contents of this guide prior to the preparation of either the TAXOTERE
premix solution or the TAXOTERE infusion solution</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FORMULATION</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BodyText21 align=left style='margin-left:0in;text-align:left;
line-height:normal'><span lang=EN-GB>TAXOTERE 20 mg/0.5&nbsp;ml concentrate for
solution for infusion is a clear viscous, yellow to brown-yellow solution containing
40&nbsp;mg/ml docetaxel (anhydrous) in polysorbate&nbsp;80 and citric acid. The
solvent for TAXOTERE is a 13% w/w solution of ethanol 95% in water for
injections.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PRESENTATION</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE is
supplied as single-dose vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each box contains
one TAXOTERE vial (20 mg/0.5&nbsp;ml) and one corresponding solvent for
TAXOTERE vial in a blister pack.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE vials
should be stored between 2&deg;C and 25&deg;C and protected from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE should
not be used after the expiry date shown on the carton, blister pack and vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>2.1&nbsp;&nbsp;&nbsp;&nbsp; TAXOTERE 20 mg/0.5&nbsp;ml
vial</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE 20 mg/0.5&nbsp;ml
vial is a 7&nbsp;ml clear glass vial with a green flip-off cap.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE 20 mg/0.5&nbsp;ml
vial contains a solution of docetaxel in polysorbate&nbsp;80 at a concentration
of 40&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each TAXOTERE 20 mg/0.5&nbsp;ml
vial contains 0.5&nbsp;ml of a 40&nbsp;mg/ml solution of docetaxel in
polysorbate&nbsp;80 (fill volume: 24.4&nbsp;mg/0.61&nbsp;ml). This volume has
been established during the development of TAXOTERE to compensate for liquid
loss during preparation of the premix (see section 4) due to foaming, adhesion
to the walls of the vial and &quot;dead-volume&quot;. This overfill ensures
that after dilution with the entire contents of the accompanying solvent for
TAXOTERE vial, there is a minimal extractable premix volume of 2&nbsp;ml
containing 10&nbsp;mg/ml docetaxel which corresponds to the labelled amount of 20
mg/0.5&nbsp;ml per vial.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>2.2&nbsp;&nbsp;&nbsp;&nbsp; Solvent for TAXOTERE 20
mg/0.5&nbsp;ml vial</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The solvent for
TAXOTERE 20 mg/0.5&nbsp;ml vial is a 7&nbsp;ml clear glass vial with a
transparent colourless flip-off cap.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The solvent for
TAXOTERE composition is a 13% w/w solution of ethanol 95% in water for
injections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each solvent for
TAXOTERE 20 mg/0.5&nbsp;ml vial contains 1.98&nbsp;ml. This volume has been
established based on the fill volume of the TAXOTERE 20 mg/0.5&nbsp;ml vial.
The addition of the entire contents of the solvent vial to the contents of the
TAXOTERE 20 mg/0.5&nbsp;ml vial ensures a premix concentration of 10&nbsp;mg/ml
docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RECOMMENDATIONS
FOR THE SAFE HANDLING</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE is an
antineoplastic agent and, as with other potentially toxic compounds, caution should
be exercised when handling it<span style='position:relative;top:-3.0pt'> </span>and
preparing TAXOTERE solutions. The use of gloves is recommended. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
skin, wash immediately and thoroughly with soap and water. If TAXOTERE concentrate,
premix solution or infusion solution should come into contact with mucous
membranes, wash immediately and thoroughly with water.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PREPARATION
FOR THE INTRAVENOUS ADMINISTRATION</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Preparation of the
TAXOTERE<span style='position:relative;top:-3.0pt'> </span>premix solution (10&nbsp;mg
docetaxel/ml)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.05pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=41 valign=top style='width:30.6pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.1</span></b></p>
  </td>
  <td width=380 colspan=3 valign=top style='width:284.8pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If the vials are
  stored under refrigeration, allow the required number of TAXOTERE boxes to
  stand at room temperature (below 25&deg;C) for 5&nbsp;minutes.</span></p>
  </td>
  <td width=187 valign=top style='width:140.45pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=131 height=130 src="Taxoter_files/image001.jpg"></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=187 valign=top style='width:140.45pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.45pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.2</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:284.15pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Using a syringe
  fitted with a needle, aseptically withdraw the entire contents of the solvent
  for TAXOTERE vial by partially inverting the vial.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=126 height=132 src="Taxoter_files/image002.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.45pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:284.15pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.3</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.7pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
  entire contents of the syringe into the corresponding TAXOTERE vial.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=123 height=134 src="Taxoter_files/image003.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.7pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  <br clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.4</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.7pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Remove the
  syringe and needle and mix manually by repeated inversions for at least
  45&nbsp;seconds. Do not shake.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=131 height=131 src="Taxoter_files/image004.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=378 valign=top style='width:283.7pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.45pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.5</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:284.15pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Allow the premix
  vial to stand for 5&nbsp;minutes at room temperature (below 25&deg;C) and
  then check that the solution is homogenous and clear (foaming is normal even
  after 5&nbsp;minutes due to the presence of polysorbate&nbsp;80 in the formulation).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The premix
  solution contains 10&nbsp;mg/ml docetaxel and should be used immediately
  after preparation. However the chemical and physical stability of the premix
  solution has been demonstrated for 8&nbsp;hours when stored either between +&nbsp;2&deg;C
  and +&nbsp;8&deg;C or at room temperature (below 25&deg;C).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=137 height=152 src="Taxoter_files/image005.jpg"></span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=41 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=378 style='border:none'></td>
  <td width=187 style='border:none'></td>
  <td width=2 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Preparation of the
infusion solution</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.05pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.1</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>More than one
  premix vial may be necessary to obtain the required dose for the patient.
  Based on the required dose for the patient expressed in mg, aseptically
  withdraw the corresponding premix volume containing 10&nbsp;mg/ml docetaxel
  from the appropriate number of premix vials using graduated syringes fitted
  with a needle. For example, a dose of 140&nbsp;mg docetaxel would require
  14&nbsp;ml docetaxel premix solution.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'><img border=0
  width=131 height=144 src="Taxoter_files/image006.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.2</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
  required premix volume into a 250&nbsp;ml infusion bag or bottle containing
  either 5% glucose solution or sodium chloride </span><span lang=EN-GB
  style='font-size:11.0pt'>9&nbsp;mg/ml (0.9%) </span><span lang=EN-GB
  style='font-size:11.0pt'>solution</span><span lang=EN-GB style='font-size:
  11.0pt'> for infusion</span><span lang=EN-GB style='font-size:11.0pt'>. If a
  dose greater than 200&nbsp;mg of docetaxel is required, use a larger volume
  of the infusion vehicle so that a concentration of 0.74&nbsp;mg/ml docetaxel
  is not exceeded.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=132 height=123 src="Taxoter_files/image007.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.3</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Mix the infusion
  bag or bottle manually using a rocking motion.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=133 height=135 src="Taxoter_files/image008.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.4</span></b></p>
  </td>
  <td width=567 colspan=3 valign=top style='width:425.25pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE
  infusion solution should be used within 4&nbsp;hours and should be aseptically
  administered as a 1&#8209;hour infusion under room temperature (below
  25&deg;C) and normal lighting conditions.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=2 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=567 colspan=3 valign=top style='width:425.25pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Authors style='margin-top:0in;page-break-after:auto'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=1><p class='MsoNormal'>&nbsp;</td>
  <td width=42 valign=top style='width:31.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-3.75pt'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-3.75pt;margin-bottom:
  0in;margin-left:-2.6pt;margin-bottom:.0001pt'><b><span lang=EN-GB
  style='font-size:11.0pt'>4.2.5</span></b></p>
  </td>
  <td width=387 colspan=2 valign=top style='width:290.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>As with all
  parenteral products, TAXOTERE premix solution and infusion solution should be
  visually inspected prior to use, solutions containing a precipitate should be
  discarded.</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=121 height=124 src="Taxoter_files/image009.jpg"></span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=1 style='border:none'></td>
  <td width=42 style='border:none'></td>
  <td width=378 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=180 style='border:none'></td>
 </tr>
</table>

<p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 align=left style='text-align:left;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DISPOSAL</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>All
materials that have been utilised for dilution and administration should be
disposed of according to standard procedures. Do not throw away any medicines
via wastewater. Ask your pharmacist how to throw away medicines you no longer
use. These measures will help protect the environment.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoBodyText align=left style='text-align:left'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient</span></b></p>

<p class=Heading11 align=center style='margin-left:17.85pt;text-align:center;
text-indent:-17.85pt;page-break-after:auto'><span lang=EN-GB>TAXOTERE 80 mg/2&nbsp;ml
concentrate and solvent for solution for infusion</span></p>

<p class=Titre0 style='margin:0in;page-break-before:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:none'>docetaxel</span></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal style='margin-right:2.8pt'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Heading41 style='page-break-after:auto;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>Read all of this
leaflet carefully before you start using this medicine because it contains
important information for you.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor, hospital pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects talk to your doctor, hospital pharmacist or nurse.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>What is in this
leaflet</span></b><span lang=EN-GB style='font-size:11.0pt'>:</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use TAXOTERE</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to use TAXOTERE</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store TAXOTERE</span></p>

<p class=MsoDate><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The name of this medicine is TAXOTERE. Its common name
is docetaxel. Docetaxel is a substance derived from the needles of yew trees.</span></p>

<p class=paragraph align=left style='margin-top:0in;margin-right:.55pt;
margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>Docetaxel belongs to the group of
anti-cancer medicines called taxoids.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE has been prescribed by your doctor for the
treatment of breast cancer, special forms of lung cancer (non-small cell lung
cancer), prostate cancer, gastric cancer or head and neck cancer: </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of advanced breast cancer,
TAXOTERE could be administered either alone or in combination with doxorubicin,
or trastuzumab, or capecitabine.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of early breast cancer with or without
lymph node involvement, TAXOTERE could be administered in combination with
doxorubicin and cyclophosphamide.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- For the treatment of lung cancer, TAXOTERE could be
administered either alone or in combination with cisplatin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the
treatment of prostate cancer, TAXOTERE is administered in combination with
prednisone or prednisolone.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the
treatment of metastatic gastric cancer, TAXOTERE is administered in combination
with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>- For the treatment
of head and neck cancer, TAXOTERE is administered in combination with cisplatin
and 5&#8209;fluorouracil.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use TAXOTERE</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>You must not be given TAXOTERE:</span></b></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.85pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic
(hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE (listed
in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if the number of white
blood cells is too low.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have a severe
liver disease.</span></p>

<p class=Retrait1 style='margin-left:0in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Warnings and precautions</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Before each treatment with TAXOTERE, you will have
blood tests to check that you have enough blood cells and sufficient liver
function to receive TAXOTERE. In case of white blood cells </span><span
lang=EN-GB style='font-size:11.0pt'>disturbances, you may experience associated
fever or infections.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist, or nurse
immediately if you have abdominal pain or tenderness, diarrhoea, rectal
haemorrhage, blood in stool or fever. These symptoms may be the first signs of
a serious gastrointestinal toxicity, which could be fatal. Your doctor should
address them immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you have
vision problems. In case of vision problems<u>,</u> in particular blurred
vision, you should immediately have your eyes and vision examined. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you
have experienced an allergic reaction to previous paclitaxel therapy.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>Tell
your doctor, hospital pharmacist or nurse if you have heart problems. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you develop acute or worsening problems with your
lungs (fever, shortness of breath or cough), please tell your doctor, hospital
pharmacist or nurse immediately. Your doctor may stop your treatment
immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You will be asked to take premedication consisting of
an oral corticosteroid such as dexamethasone, one day prior to TAXOTERE
administration and to continue for one or two days after it in order to minimise
certain undesirable effects which may occur after the infusion of TAXOTERE in
particular allergic reactions and fluid retention (swelling of the hands, feet,
legs or weight gain).</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=TableTextLeft style='margin:0in;text-align:justify;page-break-after:
auto'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>During
treatment, you may be given other medicines to maintain the number of your
blood cells.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Severe skin problems such as
Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute
Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: </span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SJS/TEN symptoms may include blistering, peeling
or bleeding on any part of your skin (including your lips, eyes, mouth, nose,
genitals, hands or feet) with or without a rash. You may also have flu-like
symptoms at the same time, such as fever, chills or aching muscles.</span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>AGEP symptoms may include a red, scaly widespread
rash with bumps under the swollen skin (including your skin folds, trunk, and
upper extremities) and blisters accompanied by fever. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you develop severe skin reactions or
any of the reactions listed above, immediately contact your doctor or healthcare
professional.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have kidney problems or high levels of uric acid in your blood before
intiating TAXOTERE. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE contains alcohol. Discuss with
your doctor if you suffer from alcohol dependency, epilepsy or liver
impairment. See also section &#8220; TAXOTERE contains ethanol (alcohol)&#8221;
below.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Other medicines and TAXOTERE</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>Please tell your doctor or hospital pharmacist if you
are taking or have recently taken any other medicine, including medicines obtained
without a prescription.&nbsp; This is because TAXOTERE or the other medicine
may not work as well as expected and you may be more likely to get a side effect.
<br>
</span><span lang=EN-GB style='font-size:11.0pt'>The amount of alcohol in this
medicinal product may alter the effects of other medicines.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy, breast-feeding and fertility</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ask your doctor
for advice before being given any medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE must <u>NOT</u> be administered if you are
pregnant unless clearly indicated by your doctor. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You must not become pregnant during treatment with
this medicine and must use an effective method of contraception during therapy ,
because TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during
your treatment, you must immediately inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You must not
breast&#8209;feed while you are treated with TAXOTERE.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you are a man
being treated with TAXOTERE you are advised not to father a child during and up
to 6&nbsp;months after treatment and to seek advice on conservation of sperm
prior to treatment because docetaxel may alter male fertility.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;font-variant:small-caps'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
impair your ability to drive or use machines. You may </span><span
style='font-size:11.0pt'>experience side effects of this </span><span
lang=EN-GB style='font-size:11.0pt'>medicine </span><span style='font-size:
11.0pt'>that may impair your ability to drive, use tools or operate machines
(see section 4 Possible side effects). If this happens, do not drive or use any
tools or machines before discussing with your </span><span lang=EN-GB
style='font-size:11.0pt'>doctor, nurse or hospital pharmacist</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>TAXOTERE contains ethanol (alcohol)</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
style='font-size:11.0pt'>13% (w/w) ethanol 95% v/v (alcohol), i.e. up to 932 mg
ethanol 95% v/v per solvent vial, equivalent to 23 ml of beer or 9.5 ml wine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, in children and in high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;font-family:TimesNewRoman'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>The
amount of alcohol in this medicinal product may have effects on the central
nervous system (the part of the nervous system that includes the brain and
spinal cord).</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to use TAXOTERE</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE will be administered to you by a healthcare
professional.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Usual dose</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The dose will depend on your weight and your general
condition. Your doctor will calculate your body surface area in square meters
(m&sup2;) and will determine the dose you should receive.<s> </s></span></p>

<p class=MsoNormal style='margin-right:2.8pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Method and route of administration</span></b></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.85pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE will be given by infusion into one of your
veins (intravenous use). The infusion will last approximately one hour during
which you will be in the hospital.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.85pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Frequency of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You should usually
receive your infusion once every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Your doctor may change the dose and frequency of
dosing depending on your blood tests, your general condition and your response
to <span style='text-transform:uppercase'>t</span>AXOTERE. In particular,
please inform your doctor in case of diarrhoea, sores in the mouth, feeling of
numbness or pins and needles, fever and give her/him results of your blood
tests. Such information will allow her/him to decide whether a dose reduction is
needed. If you have any further questions on the use of this medicine, ask your
doctor, or hospital pharmacist.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Like all medicines, this medicine </span><span
style='font-size:11.0pt'>can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Your doctor will discuss these with you and will
explain the </span><span style='font-size:11.0pt'>potential </span><span
lang=EN-GB style='font-size:11.0pt'>risks and benefits of your treatment.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The most commonly reported adverse reactions of
TAXOTERE alone are: decrease in the number of red blood cells or white blood
cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>The severity of adverse events of TAXOTERE may be
increased when TAXOTERE is given in combination with other chemotherapeutic
agents.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>During the infusion at the hospital the following
allergic reactions may occur </span><span style='font-size:11.0pt'>(may affect
more than 1&nbsp; in 10 people)</span><span lang=EN-GB style='font-size:11.0pt'>:
</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>flushing, skin reactions, itching</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>chest tightness; difficulty in breathing
</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>fever or chills</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>back pain </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>low blood pressure.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>More
severe reactions may occur</span><span lang=EN-GB style='font-size:11.0pt'>. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you had an allergic reaction to paclitaxel, you may
also experience an allergic reaction to docetaxel, which may be </span><span
style='font-size:11.0pt'>more severe</span><span lang=EN-GB style='font-size:
11.0pt'>.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>The hospital staff will monitor
your condition closely during treatment. Tell them immediately if you notice
any of these effects.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Between infusions of TAXOTERE the following may occur,
</span><span style='font-size:11.0pt'>and the frequency may vary with the
combinations of medicines that are received</span><span lang=EN-GB
style='font-size:11.0pt'>:</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Very common (</span></b><span
style='font-size:11.0pt'>may affect more than 1 in 10&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infections, decrease in the number
of red (anaemia), or white blood cells (which are important in fighting infection)
and platelets</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>fever: if this happens you must
tell your doctor immediately</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>allergic reactions as described above</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>loss of appetite (anorexia) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>insomnia</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>feeling of numbness or pins and
needles or pain in the joints or muscles</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>headache </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>alteration in sense of taste </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the eye or
increased tearing of the eyes </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>swelling caused by faulty
lymphatic drainage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>shortness of breath </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>nasal drainage; inflammation of
the throat and nose; cough</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>bleeding from the nose </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>sores in the mouth </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>stomach upsets including nausea,
vomiting and diarrhoea, constipation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>indigestion</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hair loss: in most cases normal hair
growth should return. In some cases (frequency not known) permanent hair loss
has been observed</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>redness and swelling of the palms
of your hands or soles of your feet which may cause your skin to peel (this may
also occur on the arms, face, or body)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>change in the colour of your
nails, which may detach </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>muscle aches and pains; back pain
or bone pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>change or absence of menstrual
period</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>swelling of the hands, feet, legs </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>tiredness; or flu-like symptoms</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>weight gain or loss.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infection of the upper respiratory
tract.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Common </span></b><span
style='font-size:11.0pt'>(may affect </span><span style='font-size:11.0pt'>up
to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>oral candidiasis</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dehydration</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dizziness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hearing impaired</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease in blood pressure; irregular
or rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>heart failure</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>oesophagitis </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>difficulty or painful swallowing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>haemorrhage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>raised liver enzymes (hence the
need for regular blood tests)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>rises in blood sugar levels
(diabetes)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>decrease of the
potassium, calcium and/or phosphate in your blood.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Uncommon</span></b><span
style='font-size:11.0pt'> (may affectup to 1 in 100&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fainting</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>at the injection site, skin reactions,
phlebitis (inflammation of the vein) or swelling</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>blood clots</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>acute myeloid leukaemia and
myelodysplastic syndrome (types of blood cancer) may occur in patients who are
treated with docetaxel together with certain other anticancer treatments</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Rare</span></b><b><span
style='font-size:11.0pt'> </span></b><span style='font-size:11.0pt'>(may affect
up to 1 in 1,000 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the colon, small
intestine, which could be fatal (frequency not known); intestinal perforation.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Frequency not known
</span></b><span lang=EN-GB style='font-size:11.0pt'>(cannot be estimated from
the available data):</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>interstitial lung
disease (inflammation of the lungs causing coughing and difficulty breathing.
Inflammation of the lungs can also develop when docetaxel therapy is used with
radiotherapy)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pneumonia (infection of
the lungs)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pulmonary fibrosis
(scarring and thickening in the lungs with shortness of breath)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision due to swelling of the retina
within the eye (cystoid macular oedema)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease of the sodium and/or magnesium in your
blood (electrolyte balance disorders)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ventricular arrhythmia or ventricular
tachycardia (manifested as irregular and/or rapid heartbeat, severe shortness
of breath, dizziness, and/or fainting). Some of these symptoms can be serious.
If this happens, you must tell your doctor immediately </span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injection site reactions at the site of a previous reaction<span
lang=EN-GB>.</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>n</span>on-Hodgkin lymphoma (a cancer affecting
the immune system) and other cancers may occur in patients who are treated with
docetaxel together with certain other anticancer treatments.</p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens-Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN) (blistering, peeling or bleeding on any part of your
skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or
without a rash. You may also have flu-like symptoms at the same time, such as
fever, chills or aching muscles.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute Generalized Exanthematous Pustulosis
(AGEP) (red, scaly widespread rash with bumps under the swollen skin (including
your skin folds, trunk, and upper extremities) and blisters accompanied by
fever.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>tumour lysis syndrome is a
serious condition revealed by changes in blood test such as increased level of
uric acid, potassium, phosphorus and decreased level of calcium; and results in
symptoms such as seizures, kidney failure </span><span lang=EN-GB>(reduced
amount or darkening of urine) <span style='color:black'>and heart rhythm
disturbance. &nbsp;If this happens, you must tell your doctor immediately.</span></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>myositis (inflammation
of the muscles -hot, red and swollen- which produces muscle pain and weakness) </span></p>

<p class=Normal11pt style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Reporting of
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you get any
side effects talk to your doctor, hospital pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. </span><span lang=EN-GB
style='font-size:11.0pt'>You can also report side effects directly via the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB style='font-size:11.0pt'>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 style='line-height:normal'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store TAXOTERE</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>This
medicine should not be used after the expiry date shown on the carton, blister
pack and vials.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not store above 25&deg;C or below 2&deg;C.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Store in the original package in order to protect from
light.</span></p>

<p class=TextTi11 style='margin-bottom:0in;line-height:normal;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The premix
solution should be used immediately after preparation. However the chemical and
physical stability of the premix solution has been demonstrated for 8&nbsp;hours
when stored either between 2&deg;C and 8&deg;C or at room temperature (below 25&deg;C).</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>The
infusion solution should be used within 4&nbsp;hours at room temperature (below
25&deg;C).</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Questiontext style='margin:0in;page-break-after:auto'><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Questiontext style='margin:0in'><span style='font-family:"Times New Roman",serif'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-19.9pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>What TAXOTERE concentrate vial contains</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The active substance is docetaxel (as trihydrate).
Each ml of docetaxel solution contains 40&nbsp;mg of docetaxel (anhydrous). One
vial contains 80 mg/2&nbsp;ml docetaxel. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The other ingredients are polysorbate&nbsp;80 and
citric acid.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-19.9pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>What solvent vial contains</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='font-size:11.0pt'>13% (w/w) ethanol 95% </span><span lang=EN-GB
style='font-size:11.0pt'>(see section 2) </span><span lang=EN-GB
style='font-size:11.0pt'>in water for injections. </span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><b><span
style='font-size:11.0pt'>What TAXOTERE looks like and contents of the pack</span></b></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>TAXOTERE
80 mg/2&nbsp;ml concentrate for solution for infusion is a clear viscous,
yellow to brown-yellow solution.</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText align=left style='text-align:left'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Each
blister pack contains:</span></p>

<p class=MsoBodyText align=left style='margin-left:.25in;text-align:left;
text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;
color:windowtext'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>one single-dose vial of concentrate and,</span></p>

<p class=MsoBodyText align=left style='margin-left:.25in;text-align:left;
text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;
color:windowtext'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>one single-dose vial of solvent.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=FR style='font-size:
11.0pt'>France</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><b><span lang=PT-BR
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><b><span
lang=PT-BR style='font-size:11.0pt'>Manufacturers</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=DE style='font-size:
11.0pt'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=DE style='font-size:
11.0pt'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span style='font-size:11.0pt'>65926
Frankfurt am Main</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span style='font-size:11.0pt'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>For any information about this medicinal product, please
contact the local representative of the Marketing Authorisation Holder.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Belgi&euml;/Belgique</span></b><b><span
  lang=MT style='font-size:11.0pt'>/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>UAB </span><span
  lang=FR style='font-size:11.0pt;letter-spacing:-.05pt'>&laquo;SANOFI-AVENTIS
  LIETUVA&raquo;</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>SANOFI BULGARIA EOOD</span></p>
  <p class=MsoNormal><span lang=BG style='font-size:11.0pt'>&#1058;&#1077;&#1083;</span><span
  lang=IT style='font-size:11.0pt'>.</span><span lang=BG style='font-size:11.0pt'>:
  +</span><span lang=IT style='font-size:11.0pt'>359 (0)2</span><span lang=IT
  style='font-size:11.0pt'> 970 53 00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis,
  s.r.o.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +420 233 086
  111</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU style='font-size:11.0pt'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis zrt.,
  Magyarorsz&aacute;g</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel.: +36 1 </span><span
  lang=HU style='font-size:11.0pt'>505 0050</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tlf: +45 45 16 70
  00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi S.r.l. </span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: </span><span
  lang=FR style='font-size:11.0pt'>+39. 02 39394275</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi-Aventis
  Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: 0800 04 36 996</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel. aus dem
  Ausland: +49 69 305 70 13</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +31 20 245
  4000</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  Estonia O&Uuml;</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  Norge AS</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tlf: +47 67 10 71
  00</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;</span><span
  lang=CS style='font-size:11.0pt'>: +30 210 900 16 00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS style='font-size:11.0pt'>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +43 1 80 185
  &#8211; 0</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='font-size:11.0pt'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>sanofi-aventis,
  S.A.</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +34 93 485 94
  00</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis Sp.
  z o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel.: +48 22&nbsp;</span><span
  lang=EN-GB style='font-size:11.0pt'>280 00 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR-BE style='font-size:11.0pt'>sanofi-aventis
  France</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l: 0 800 222
  555</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Appel depuis
  l&#8217;&eacute;tranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi -
  Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +351 21 35 89
  400</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT
  style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +385 1 600 34
  00</span></p>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL style='font-size:11.0pt'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>Tel: +40 </span><span
  lang=FR style='font-size:11.0pt'>(0) 21 317 31 36</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Ireland Ltd.</span><span lang=FR style='font-size:11.0pt'> T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +353 (0) 1 403
  56 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>sanofi-aventis
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: +386 1 560 48
  00</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS style='font-size:11.0pt'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=IS style='font-size:11.0pt'>S&iacute;mi</span><span
  lang=CS style='font-size:11.0pt'>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK style='font-size:11.0pt'>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>sanofi-</span><span
  lang=CS style='font-size:11.0pt'>aventis Slovakia </span><span lang=SK
  style='font-size:11.0pt'>s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +421 2
  33&nbsp;100 100</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: 800536389</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Puh/Tel: +358 (0)
  201 200 300</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +</span><span lang=FR style='font-size:11.0pt'>357 22 871600</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +46 (0)8 634
  50 00</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +371 67 33 24
  51</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +44 (0)
  845&nbsp;372 7101</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt'>This leaflet was last revised in .</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Detailed information on this medicine is
available on the European Medicines Agency web site: <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu/</a>.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>The following information is intended for healthcare
professionals only:</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt'>PREPARATION GUIDE FOR USE WITH TAXOTERE 80&nbsp;mg/2&nbsp;ml
CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BodyText21 align=left style='margin-left:0in;text-align:left;
line-height:normal'><i><span lang=EN-GB>It is important that you read the
entire contents of this guide prior to the preparation of either the TAXOTERE
premix solution or the TAXOTERE infusion solution</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FORMULATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BodyText21 align=left style='margin-left:0in;text-align:left;
line-height:normal'><span lang=EN-GB>TAXOTERE 80 mg/2&nbsp;ml concentrate for
solution for infusion is a clear viscous, yellow to brown-yellow solution
containing 40&nbsp;mg/ml docetaxel (anhydrous) in polysorbate&nbsp;80 and
citric acid. The solvent for TAXOTERE is a 13% w/w solution of ethanol 95% in
water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PRESENTATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE is
supplied as single-dose vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Each box contains
one TAXOTERE vial (80 mg/2&nbsp;ml) and one corresponding solvent for TAXOTERE
vial in a blister pack.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE vials
should be stored between 2&deg;C and 25&deg;C and protected from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE should
not be used after the expiry date shown on the carton, blister pack and vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>2.1&nbsp;&nbsp;&nbsp;&nbsp; TAXOTERE 80 mg/2&nbsp;ml
vial</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE 80 mg/2&nbsp;ml
vial is a 15&nbsp;ml clear glass vial with a red flip-off cap.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE 80 mg/2&nbsp;ml
vial contains a solution of docetaxel in polysorbate&nbsp;80 at a concentration
of&nbsp;40&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each TAXOTERE 80 mg/2&nbsp;ml
vial contains 2.0&nbsp;ml of a 40&nbsp;mg/ml solution of docetaxel in
polysorbate&nbsp;80 (fill volume: 94.4&nbsp;mg/2.36&nbsp;ml). This volume has
been established during the development of TAXOTERE to compensate for liquid
loss during preparation of the premix (see section 4) due to foaming, adhesion
to the walls of the vial and &quot;dead-volume&quot;. This overfill ensures
that after dilution with the entire contents of the accompanying solvent for
TAXOTERE vial, there is a minimal extractable premix volume of 8&nbsp;ml
containing 10&nbsp;mg/ml docetaxel which corresponds to the labelled amount of 80
mg/2&nbsp;ml per vial.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>2.2&nbsp;&nbsp;&nbsp;&nbsp; Solvent for TAXOTERE 80
mg/2&nbsp;ml vial</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The solvent for
TAXOTERE 80 mg/2&nbsp;ml vial is a 15&nbsp;ml clear glass vial with a
transparent colourless flip-off cap.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The solvent for
TAXOTERE composition is a 13% w/w solution of ethanol 95% in water for
injections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each solvent for
TAXOTERE 80 mg/2&nbsp;ml vial contains 7.33&nbsp;ml. This volume has been
established based on the fill volume of the TAXOTERE 80 mg/2&nbsp;ml vial. The
addition of the entire contents of the solvent vial to the contents of the
TAXOTERE 80 mg/2&nbsp;ml vial ensures a premix concentration of 10&nbsp;mg/ml
docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RECOMMENDATIONS
FOR THE SAFE HANDLING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE is an
antineoplastic agent and, as with other potentially toxic compounds, caution
should be exercised when handling it and preparing TAXOTERE solutions. The use
of gloves is recommended. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If TAXOTERE
concentrate, premix solution or infusion solution should come into contact with
skin, wash immediately and thoroughly with soap and water. If TAXOTERE concentrate,
premix solution or infusion solution should come into contact with mucous
membranes, wash immediately and thoroughly with water.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 align=left style='margin:0in;margin-bottom:.0001pt;
text-align:left;text-indent:0in;line-height:normal;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PREPARATION
FOR THE INTRAVENOUS ADMINISTRATION</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Preparation of the
TAXOTERE<span style='position:relative;top:-3.0pt'> </span>premix solution
(10&nbsp;mg docetaxel/ml)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.05pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.1</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If the vials are
  stored under refrigeration, allow the required number of TAXOTERE boxes to
  stand at room temperature (below 25&deg;C) for 5&nbsp;minutes.</span></p>
  </td>
  <td width=187 valign=top style='width:140.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=131 height=130 src="Taxoter_files/image010.jpg"></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=187 valign=top style='width:140.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 valign=top style='width:31.25pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.2</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:284.1pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Using a syringe
  fitted with a needle, aseptically withdraw the entire contents of the solvent
  for TAXOTERE vial by partially inverting the vial.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=126 height=132 src="Taxoter_files/image011.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 valign=top style='width:31.25pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:284.1pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.3</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
  entire contents of the syringe into the corresponding TAXOTERE vial.</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=123 height=134 src="Taxoter_files/image003.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  <br clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.4</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Remove the
  syringe and needle and mix manually by repeated inversions for at least 45&nbsp;seconds.
  Do not shake.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=131 height=131 src="Taxoter_files/image004.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 colspan=2 valign=top style='width:31.85pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=42 valign=top style='width:31.45pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.1.5</span></b></p>
  </td>
  <td width=379 colspan=2 valign=top style='width:283.95pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Allow the premix
  vial to stand for 5&nbsp;minutes at room temperature (below 25&deg;C) and
  then check that the solution is homogenous and clear (foaming is normal even
  after 5&nbsp;minutes due to the presence of polysorbate&nbsp;80 in the formulation).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The premix
  solution contains 10&nbsp;mg/ml docetaxel and should be used immediately
  after preparation. However the chemical and physical stability of the premix
  solution has been demonstrated for 8&nbsp;hours when stored either between
  +&nbsp;2&deg;C and +&nbsp;8&deg;C or at room temperature (below 25&deg;C).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 colspan=2 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=137 height=152 src="Taxoter_files/image005.jpg"></span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=42 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=378 style='border:none'></td>
  <td width=187 style='border:none'></td>
  <td width=2 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Preparation of the
infusion solution</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.05pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.1</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>More than one
  premix vial may be necessary to obtain the required dose for the patient.
  Based on the required dose for the patient expressed in mg, aseptically withdraw
  the corresponding premix volume containing 10&nbsp;mg/ml docetaxel from the
  appropriate number of premix vials using graduated syringes fitted with a
  needle. For example, a dose of 140&nbsp;mg docetaxel would require 14&nbsp;ml
  docetaxel premix solution.</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'><img border=0
  width=125 height=138 src="Taxoter_files/image012.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.2</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Inject the
  required premix volume into a 250&nbsp;ml infusion bag or bottle containing
  either 5% glucose solution or sodium chloride </span><span lang=EN-GB
  style='font-size:11.0pt'>9&nbsp;mg/ml (0.9%) </span><span lang=EN-GB
  style='font-size:11.0pt'>solution</span><span lang=EN-GB style='font-size:
  11.0pt'> for infusion</span><span lang=EN-GB style='font-size:11.0pt'>. If a
  dose greater than 200&nbsp;mg of docetaxel is required, use a larger volume
  of the infusion vehicle so that a concentration of 0.74&nbsp;mg/ml docetaxel
  is not exceeded.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=132 height=123 src="Taxoter_files/image007.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=43 colspan=3 valign=top style='width:31.9pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.55pt 0in 3.55pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=41 colspan=2 valign=top style='width:30.6pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.3</span></b></p>
  </td>
  <td width=380 colspan=2 valign=top style='width:284.8pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Mix the infusion
  bag or bottle manually using a rocking motion.</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=133 height=135 src="Taxoter_files/image008.jpg"></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=41 colspan=2 valign=top style='width:30.6pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=380 colspan=2 valign=top style='width:284.8pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=41 colspan=2 valign=top style='width:30.6pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4.2.4</span></b></p>
  </td>
  <td width=569 colspan=3 valign=top style='width:426.55pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The TAXOTERE
  infusion solution should be used within 4&nbsp;hours and should be aseptically
  administered as a 1&#8209;hour infusion under room temperature (below
  25&deg;C) and normal lighting conditions.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=41 colspan=2 valign=top style='width:30.6pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=380 colspan=2 valign=top style='width:284.8pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=1><p class='MsoNormal'>&nbsp;</td>
  <td width=42 colspan=2 valign=top style='width:31.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-3.75pt;margin-bottom:
  0in;margin-left:-2.6pt;margin-bottom:.0001pt'><b><span lang=EN-GB
  style='font-size:11.0pt'>4.2.5</span></b></p>
  </td>
  <td width=378 valign=top style='width:283.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>As with all
  parenteral products, TAXOTERE premix solution and infusion solution should be
  visually inspected prior to use, solutions containing a precipitate should be
  discarded.</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'><img border=0
  width=121 height=124 src="Taxoter_files/image013.jpg"></span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=1 style='border:none'></td>
  <td width=40 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=378 style='border:none'></td>
  <td width=189 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading51 align=left style='margin:0in;margin-bottom:.0001pt;
text-align:left;text-indent:0in;line-height:normal;punctuation-wrap:hanging;
text-autospace:ideograph-numeric ideograph-other'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DISPOSAL</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>All materials that have been utilised for
dilution and administration should be disposed of according to standard
procedures. </span><span lang=EN-GB>Do not throw away any medicines via
wastewater. Ask your pharmacist how to throw away medicines you no longer use.
These measures will help protect the environment.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>TAXOTERE
20&nbsp;mg/1&nbsp;ml concentrate for solution for infusion</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>docetaxel</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=Normal11pt style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Read all of this leaflet carefully
before you start using this medicine because it contains important information
for you.</span></b></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, ask your doctor, hospital pharmacist or nurse.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any side
effects talk to your doctor, hospital pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=Normal11pt><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=Normal11pt><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What<span style='text-transform:uppercase'> TAXOTERE </span>is
and what it is used for</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The name of this medicine is TAXOTERE. Its
common name is docetaxel. Docetaxel is a substance derived from the needles of
yew trees.</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel belongs to the group of
anti-cancer medicines called taxoids.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE has been prescribed by your
doctor for the treatment of breast cancer, special forms of lung cancer
(non-small cell lung cancer), prostate cancer, gastric cancer or head and neck
cancer: </span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of advanced breast
cancer, TAXOTERE could be administered either alone or in combination with
doxorubicin, or trastuzumab, or capecitabine.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of early breast cancer
with or without lymph node involvement, TAXOTERE could be administered in
combination with doxorubicin and cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of lung cancer,
TAXOTERE could be administered either alone or in combination with cisplatin.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of prostate cancer, TAXOTERE
is administered in combination with prednisone or prednisolone.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of metastatic gastric
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of head and neck
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What you need to know before you use<span
style='text-transform:uppercase'> <a name="OLE_LINK13"></a><a name="OLE_LINK14">TAXOTERE</a></span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>You must not be given TAXOTERE:</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:23.2pt;margin-bottom:.0001pt;text-indent:-23.2pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic
(hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE (listed
in section&nbsp;6.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if the number of white
blood cells is too low.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have a severe
liver disease.</span></p>

<p class=Retrait1 style='margin-left:0in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Before each
treatment with TAXOTERE, you will have blood tests to check that you have
enough blood cells and sufficient liver function to receive TAXOTERE. In case
of white blood cells disturbances, you may experience associated fever or
infections.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist, or
nurse immediately if you have abdominal pain or tenderness, diarrhoea, rectal
haemorrhage, blood in stool or fever. These symptoms may be the first signs of
a serious gastrointestinal toxicity, which could be fatal. Your doctor should
address them immediately.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have vision problems. In case of vision problems<u>, </u>in
particular blurred vision, you should immediately have your eyes and vision
examined.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you
have experienced an allergic reaction to previous paclitaxel therapy.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>Tell
your doctor, hospital pharmacist or nurse if you have heart problems. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you develop acute or worsening problems with your
lungs (fever, shortness of breath or cough), please tell your doctor, hospital
pharmacist or nurse immediately. Your doctor may stop your treatment immediately.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You will be asked to take premedication
consisting of an oral corticosteroid such as dexamethasone, one day prior to
TAXOTERE administration and to continue for one or two days after it in order
to minimise certain undesirable effects which may occur after the infusion of
TAXOTERE in particular allergic reactions and fluid retention (swelling of the
hands, feet, legs or weight gain).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During treatment, you may be given other
medicines to maintain the number of your blood cells.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Severe skin problems such as
Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute
Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: </span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SJS/TEN symptoms may include blistering, peeling
or bleeding on any part of your skin (including your lips, eyes, mouth, nose,
genitals, hands or feet) with or without a rash. You may also have flu-like
symptoms at the same time, such as fever, chills or aching muscles.</span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>AGEP symptoms may include a red, scaly
widespread rash with bumps under the swollen skin (including your skin folds,
trunk, and upper extremities) and blisters accompanied by fever. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you develop severe skin reactions or
any of the reactions listed above, immediately contact your doctor or
healthcare professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have kidney problems or high levels of uric acid in your blood before
intiating TAXOTERE. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE contains alcohol. Discuss with
your doctor if you suffer from alcohol dependency, epilepsy or liver
impairment. See also section &#8220; TAXOTERE contains ethanol (alcohol)&#8221;
below.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Other medicines and TAXOTERE</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Please tell your doctor or hospital
pharmacist if you are taking or have recently taken any other medicine,
including medicines obtained without a prescription. This is because TAXOTERE
or the other medicine may not work as well as expected and you may be more
likely to get a side effect.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>The amount of alcohol in this medicinal product may
alter the effects of other medicines.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy, breast-feeding and fertility</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ask your doctor
for advice before being given any medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE must <u>NOT</u> be administered if you are
pregnant unless clearly indicated by your doctor. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You must not become pregnant during treatment with
this medicine and must use an effective method of contraception during therapy,
because TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during
your treatment, you must immediately inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You must not
breast&#8209;feed while you are treated with TAXOTERE.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you are a man being
treated with TAXOTERE you are advised not to father a child during and up to
6&nbsp;months after treatment and to seek advice on conservation of sperm prior
to treatment because docetaxel may alter male fertility.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The amount
of alcohol in this medicinal product may impair your ability to drive or use
machines. You may experience side effects </span>of this <span lang=EN-GB>medicine
</span>that may impair your ability to drive, use tools or operate machines
(see section 4 Possible side effects). If this happens, do not drive or use any
tools or machines before discussing with your <span lang=EN-GB>doctor, nurse or
hospital pharmacist</span>.</p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>TAXOTERE contains ethanol (alcohol)</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 395&nbsp;mg ethanol anhydrous per vial, equivalent to 10&nbsp;ml of
beer or 4&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, in children and high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt>The amount of alcohol in this medicinal product may have
effects on the central nervous system (the part of the nervous system that
includes the brain and spinal cord).</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to use <span style='text-transform:uppercase'>TAXOTERE</span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be administered to you by a
healthcare professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Usual dose</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The dose
will depend on your weight and your general condition. Your doctor will
calculate your body surface area in square meters (m&sup2;) and will determine
the dose you should receive.<s> </s></span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Method and route of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be given by infusion into one
of your veins (intravenous use). The infusion will last approximately one hour
during which you will be in the hospital.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Frequency of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You should usually receive your infusion
once every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor may change the dose and frequency
of dosing depending on your blood tests, your general condition and your
response to TAXOTERE. In particular, please inform your doctor in case of
diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever
and give her/him results of your blood tests. Such information will allow
her/him to decide whether a dose reduction is needed. If you have any further
questions on the use of this medicine, ask your doctor, or hospital pharmacist.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>Possible side effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor will discuss these with you and
will explain the potential risks and benefits of your treatment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse
reactions of TAXOTERE alone are: decrease in the number of red blood cells or
white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea
and tiredness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The severity of adverse events of TAXOTERE
may be increased when TAXOTERE is given in combination with other chemotherapeutic
agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During the infusion at the hospital the
following allergic reactions may occur (may affect more than 1&nbsp;in 10
people): </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>flushing, skin
reactions, itching</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>chest tightness;
difficulty in breathing </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever or chills</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>back pain </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>low blood pressure.</span></p>

<p class=Normal11pt><span lang=EN-GB>More severe reactions may occur. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you had an allergic reaction to
paclitaxel, you may also experience an allergic reaction to docetaxel, which
may be </span>more severe<span lang=EN-GB>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The hospital staff will monitor your
condition closely during treatment. Tell them immediately if you notice any of
these effects.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Between infusions of TAXOTERE the
following may occur, and the frequency may vary with the combinations of
medicines that are received</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Very common </span></b><span lang=EN-GB
style='font-size:11.0pt'>(</span><span lang=EN-GB>may affect</span><span
lang=EN-GB style='font-size:11.0pt'> more than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>infections, decrease in
the number of red (anaemia), or white blood cells (which are important in
fighting infection) and platelets</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever: if this happens
you must tell your doctor immediately</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>allergic reactions as
described above</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>loss of appetite
(anorexia) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>insomnia</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>feeling of numbness or
pins and needles or pain in the joints or muscles</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>headache </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>alteration in sense of
taste </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>inflammation of the eye
or increased tearing of the eyes </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling caused by
faulty lymphatic drainage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>shortness of breath </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>nasal drainage; inflammation
of the throat and nose; cough</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>bleeding from the nose </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>sores in the mouth </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>stomach upsets
including nausea, vomiting and diarrhoea, constipation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>indigestion</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hair loss: in most cases normal
hair growth should return. In some cases (frequency not known) permanent hair
loss has been observed</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>redness and swelling of
the palms of your hands or soles of your feet which may cause your skin to peel
(this may also occur on the arms, face, or body)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change in the colour of
your nails, which may detach </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>muscle aches and pains;
back pain or bone pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change or absence of
menstrual period</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling of the hands,
feet, legs </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>tiredness; or flu-like
symptoms</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>weight gain or loss.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infection of the upper respiratory
tract.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> (may
affect up to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oral candidiasis</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dehydration</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dizziness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>hearing impaired</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>decrease in blood
pressure; irregular or rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>heart failure</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oesophagitis </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>difficulty or painful
swallowing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>haemorrhage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>raised liver enzymes
(hence the need for regular blood tests)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>rises in blood sugar levels
(diabetes)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease of the potassium, calcium
and/or phosphate in your blood. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> (may
affect up to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fainting</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>at the injection site,
skin reactions, phlebitis (inflammation of the vein) or swelling</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>blood clots.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>acute myeloid leukaemia and
myelodysplastic syndrome (types of blood cancer) may occur in patients who are
treated with docetaxel together with certain other anticancer treatments</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Rare</span></b><b><span
style='font-size:11.0pt'> </span></b><span style='font-size:11.0pt'>(may affect
up to 1 in 1,000 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the colon, small
intestine, which could be fatal (frequency not known); intestinal perforation.</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Frequency not known </span></b><span lang=EN-GB
style='font-size:11.0pt'>(cannot be estimated from the available data):</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>interstitial lung disease (inflammation of
the lungs causing coughing and difficulty breathing. Inflammation of the lungs
can also develop when docetaxel therapy is used with radiotherapy)</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>pneumonia (infection of the lungs)</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>pulmonary fibrosis (scarring and thickening
in the lungs with shortness of breath)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision due to swelling of the retina
within the eye (cystoid macular oedema)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease of the sodium and/or magnesium in your
blood (electrolyte balance disorders)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ventricular arrhythmia or ventricular
tachycardia (manifested as irregular and/or rapid heartbeat, severe shortness
of breath, dizziness, and/or fainting). Some of these symptoms can be serious.
If this happens, you must tell your doctor immediately</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injection site reactions at the site of a previous reaction<span
lang=EN-GB>.</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>n</span>on-Hodgkin lymphoma (a cancer affecting
the immune system) and other cancers may occur in patients who are treated with
docetaxel together with certain other anticancer treatments.</p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens-Johnson Syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN) (blistering, peeling or bleeding on any part of your skin (including
your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash.
You may also have flu-like symptoms at the same time, such as fever, chills or
aching muscles.)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute Generalized Exanthematous Pustulosis
(AGEP) (red, scaly widespread rash with bumps under the swollen skin (including
your skin folds, trunk, and upper extremities) and blisters accompanied by
fever.)</span></p>

<p class=Normal11pt style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>tumour lysis syndrome is a serious condition
revealed by changes in blood test such as increased level of uric acid, potassium,
phosphorus and decreased level of calcium; and results in symptoms such as
seizures, kidney failure </span><span lang=EN-GB>(reduced amount or darkening
of urine) <span style='color:black'>and heart rhythm disturbance. &nbsp;If this
happens, you must tell your doctor immediately.</span></span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>myositis (inflammation of the
muscles -hot, red and swollen- which produces muscle pain and weakness) </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Reporting of
side effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>If you get any side effects talk to your
doctor, hospital pharmacist or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>. By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to store<span style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the outer carton and on the
label of the vial after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use the vial immediately after its
opening. If not used immediately, in&#8209;use storage times and conditions are
the responsibility of the user.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>From a microbiological point of view,
reconstitution/dilution must take place in controlled and aseptic conditions.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use immediately the medicine once added
into the infusion bag<u>.</u> If not used immediately, in&#8209;use storage
times and conditions are the responsibility of the user and would normally not
be longer than 6&nbsp;hours below 25&deg;C including the one hour infusion.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Physical and
chemical in-use stability of the infusion solution prepared as recommended has
been demonstrated in non-PVC bags up to 48 hours when stored between 2 to
8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel infusion solution is
supersaturated, therefore may cristallize over time. If crystals appear, the
solution must no longer be used and shall be discarded.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><span lang=EN-GB>Do not throw away any medicines via wastewater.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-19.85pt;text-align:justify;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>Contents of the pack and other information</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE contains</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The active substance is docetaxel (as trihydrate).
Each ml of concentrate for solution for infusion contains 20&nbsp;mg docetaxel.
</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span style='font-size:11.0pt'>- The
other ingredients are polysorbate&nbsp;80, ethanol anhydrous (see section 2) and
citric acid.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE looks like and contents
of the pack</span></b></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE concentrate for solution for infusion
is a pale yellow to brownish&#8209;yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is supplied in a 7&nbsp;ml
clear colourless glass vial with a green aluminium seal and a green plastic
flip&#8209;off cap.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each box
contains one vial of 1&nbsp;ml concentrate (20&nbsp;mg docetaxel).</span></p>

<p class=TblTextLeft style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=Normal11pt><span lang=FR>France</span></p>

<p class=Normal11pt><b><span lang=PT-BR>&nbsp;</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=PT-BR>Manufacturers</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
color:black'>65926 Frankfurt am Main</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
  color:black'>Germany</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Or</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Sanofi-Aventis
Zrt.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>(Harbor Park)
1, Campona utca</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Budapest</span><span
lang=EN-GB> 1225</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hungary</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder. </span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>UAB <span
  style='letter-spacing:-.05pt'>&laquo;SANOFI-AVENTIS LIETUVA&raquo;</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=IT
  style='font-family:"Times New Roman",serif'>SANOFI BULGARIA EOOD</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#1058;&#1077;&#1083;</span><span
  lang=IT style='font-size:11.0pt'>.: +359 (0)2 970 53 00</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis,
  s.r.o.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +420 233 086
  111</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  zrt., Magyarorsz&aacute;g</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel.: +36 1 505
  0050</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>SanofiA/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 45 16
  70 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi S.r.l. </span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +39. 02 39394275</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi-Aventis
  Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: 0800 04 36 996</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel. aus dem
  Ausland: +49 69 305 70 13</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +31 </span><span
  lang=CS style='font-size:11.0pt'>20 245 4000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Estonia O&Uuml;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>sanofi-aventis Norge
   AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +47 67 10 71
  00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;</span><span
  lang=FR style='font-size:11.0pt'>: +30 210 900 16 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +43 1 80 185
  &#8211; 0</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +34 93 485
  94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis Sp.
  z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel.: +48
  22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  France</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l: 0 800 222
  555</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Appel depuis
  l&#8217;&eacute;tranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi -
  Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +351 21 35
  89 400</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT
  style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +385 1 600 34
  00</span></p>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +40 </span><span
  lang=FR style='font-size:11.0pt'>(0) 21 317 31 36</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +353 (0) 1
  403 56 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +386 1 560
  48 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S&iacute;mi</span><span
  lang=EN-GB style='font-size:11.0pt'>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis
  Slovakia s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +421 2
  33&nbsp;100 100</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: 800536389</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Puh/Tel: +358 (0)
  201 200 300</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;:
  +357 22 871600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +46 (0)8 634
  50 00</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +371 67 33 24
  51</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +44 (0)
  845&nbsp;372 7101</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:.05in'><span class=Normal11ptCar><b><span
lang=EN-GB style='font-size:11.0pt'>This leaflet was last revised in </span></b></span></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>Other sources of information </span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed information on this medicine is available on
the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div class=WordSection4>

<p class=Normal11pt><span lang=EN-GB>The following information is intended for healthcare
professionals only:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>PREPARATION GUIDE FOR USE
WITH TAXOTERE 20&nbsp;</span></b><b><span lang=EN-GB style='font-size:11.0pt'>mg/1&nbsp;ml<span
style='text-transform:uppercase'> </span></span></b><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>CONCENTRATE FOR SOLUTION FOR
INFUSION</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>It is important that you read the
entire contents of this guide prior to the preparation of the TAXOTERE infusion
solution.</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Recommendations for the safe handling</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it<span style='position:relative;top:-3.0pt'> </span>and preparing its
solutions. The use of gloves is recommended. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion solution
should come into contact with skin, wash immediately and thoroughly with soap
and water. If it should come into contact with mucous membranes, wash
immediately and thoroughly with water.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation of the intravenous administration</span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2 vials (concentrate and
solvent) with this medicinal product (TAXOTERE 20&nbsp;mg/1&nbsp;ml concentrate
for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 20&nbsp;mg/1&nbsp;ml concentrate for solution
for infusion requires NO prior dilution with a solvent and is ready to add to
the infusion solution.</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each vial is for single
use and should be used immediately after opening. If not used immediately, in&#8209;use
storage times and conditions are the responsibility of the user. </span><span
lang=EN-GB style='font-size:11.0pt'>More than one vial of </span><span
lang=EN-GB style='font-size:11.0pt'>concentrate for solution for infusion</span><span
lang=EN-GB style='font-size:11.0pt'> may be necessary to obtain the required
dose for the patient. For example, a dose of 140&nbsp;mg docetaxel would
require 7&nbsp;ml docetaxel concentrate for solution.</span></p>

<p class=Normal11pt style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptically withdraw the required amount of
concentrate for solution for infusion with a calibrated syringe fitted with a
21G needle.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 20&nbsp;mg/1&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Then, inject via a single
injection (one shot) into a 250&nbsp;ml infusion bag or bottle containing
either 5% glucose solution or sodium chloride 9&nbsp;mg/ml (0.9%) solution for infusion.
If a dose greater than 190&nbsp;mg of docetaxel is required, use a larger
volume of the infusion vehicle so that a concentration of 0.74&nbsp;mg/ml
docetaxel is not exceeded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mix the infusion bag or
bottle manually using a rocking motion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>From a microbiological
point of view, reconstitution /dilution must take place in controlled and
aseptic conditions</span><span lang=EN-GB style='font-size:11.0pt'> and the infusion
solution</span><span lang=EN-GB style='font-size:11.0pt'> should be used
immediately. If not used immediately, in&#8209;use storage times and conditions
are the responsibility of the user</span><span lang=EN-GB style='font-size:
11.0pt'>.</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Once added as recommended into the infusion bag, the
docetaxel infusion solution, if stored below 25&deg;C, is stable for 6 hours.
It should be used within 6 hours (including the one hour infusion intravenous administration).
</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>In addition, physical and chemical in-use stability of
the infusion solution prepared as recommended has been demonstrated in non-PVC
bags up to 48 hours when stored between 2&deg;C to 8&deg;C. </span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Docetaxel infusion solution is supersaturated,
therefore may crystallize over time. If crystals appear, the solution must no
longer be used and shall be discarded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As with all parenteral
products, infusion solution should be visually inspected prior to use,
solutions containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Disposal</span></u></p>

<p class=Normal11pt><span lang=EN-GB>All materials that have been utilised for
dilution and administration should be disposed of according to standard
procedures. Do not throw away any medicines via wastewater. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment. </span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>TAXOTERE
80&nbsp;mg/4&nbsp;ml concentrate for solution for infusion</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>docetaxel</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=Normal11pt style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Read all of this leaflet carefully
before you start using this medicine because it contains important information
for you.</span></b></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, ask your doctor, hospital pharmacist or nurse.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any side
effects talk to your doctor, hospital pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=Normal11pt><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=Normal11pt><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and otherinformation</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What<span style='text-transform:uppercase'> TAXOTERE </span>is
and what it is used for</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The name of this medicine is TAXOTERE. Its
common name is docetaxel. Docetaxel is a substance derived from the needles of
yew trees.</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel belongs to the group of
anti-cancer medicines called taxoids.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE has been prescribed by your
doctor for the treatment of breast cancer, special forms of lung cancer
(non-small cell lung cancer), prostate cancer, gastric cancer or head and neck
cancer: </span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of advanced breast
cancer, TAXOTERE could be administered either alone or in combination with
doxorubicin, or trastuzumab, or capecitabine.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of early breast cancer
with or without lymph node involvement, TAXOTERE could be administered in
combination with doxorubicin and cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of lung cancer,
TAXOTERE could be administered either alone or in combination with cisplatin.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of prostate cancer,
TAXOTERE is administered in combination with prednisone or prednisolone.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of metastatic gastric
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of head and neck
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What you need to know before you use<span
style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>You must not be given TAXOTERE: </span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:23.2pt;margin-bottom:.0001pt;text-indent:-23.2pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic
(hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE </span><span
lang=EN-GB>(listed in section&nbsp;6)</span><span lang=EN-GB style='font-size:
11.0pt'>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if the number of white
blood cells is too low.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have a severe
liver disease.</span></p>

<p class=Retrait1 style='margin-left:0in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Before each
treatment with TAXOTERE, you will have blood tests to check that you have enough
blood cells and sufficient liver function to receive TAXOTERE. In case of white
blood cells disturbances, you may experience associated fever or infections.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist, or nurse
immediately if you have abdominal pain or tenderness, diarrhoea, rectal
haemorrhage, blood in stool or fever. These symptoms may be the first signs of
a serious gastrointestinal toxicity, which could be fatal. Your doctor should
address them immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you have
vision problems. In case of vision problems, in particular blurred vision, you
should immediately have your eyes and vision examined. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have experienced an allergic reaction to previous paclitaxel therapy.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>Tell
your doctor, hospital pharmacist or nurse if you have heart problems. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you develop acute or worsening problems with your
lungs (fever, shortness of breath or cough), please tell your doctor, hospital
pharmacist or nurse immediately. Your doctor may stop your treatment
immediately.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You will be asked to take premedication
consisting of an oral corticosteroid such as dexamethasone, one day prior to
TAXOTERE administration and to continue for one or two days after it in order
to minimise certain undesirable effects which may occur after the infusion of
TAXOTERE in particular allergic reactions and fluid retention (swelling of the
hands, feet, legs or weight gain).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During treatment, you may be given other
medicines to maintain the number of your blood cells.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Severe skin problems such as
Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute
Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: </span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SJS/TEN symptoms may include blistering, peeling
or bleeding on any part of your skin (including your lips, eyes, mouth, nose,
genitals, hands or feet) with or without a rash. You may also have flu-like
symptoms at the same time, such as fever, chills or aching muscles.</span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>AGEP symptoms may include a red, scaly widespread
rash with bumps under the swollen skin (including your skin folds, trunk, and
upper extremities) and blisters accompanied by fever. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you develop severe skin reactions or
any of the reactions listed above, immediately contact your doctor or healthcare
professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have kidney problems or high levels of uric acid in your blood before
intiating TAXOTERE. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE contains alcohol. Discuss with
your doctor if you suffer from alcohol dependency, epilepsy or liver
impairment. See also section &#8220;TAXOTERE contains ethanol (alcohol)&#8221;
below.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Other medicines and TAXOTERE</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Please tell your doctor or hospital
pharmacist if you are taking or have recently taken any other medicine, including
medicines obtained without a prescription. This is because TAXOTERE or the
other medicine may not work as well as expected and you may be more likely to get
a side effect.</span></p>

<p class=Normal11pt><span lang=EN-GB>The amount of alcohol in this medicinal
product may alter the effects of other medicines.</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy, breast-feeding and fertility</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ask your doctor
for advice before being given any medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE must <u>NOT</u> be administered if you are pregnant
unless clearly indicated by your doctor. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You must not become pregnant during treatment with
this medicine and must use an effective method of contraception during therapy,
because TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during
your treatment, you must immediately inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You must not
breast&#8209;feed while you are treated with TAXOTERE.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you are a man
being treated with TAXOTERE you are advised not to father a child during and up
to 6&nbsp;months after treatment and to seek advice on conservation of sperm
prior to treatment because docetaxel may alter male fertility.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The amount of alcohol in this medicinal
product may impair your ability to drive or use machines. You may </span><span
style='font-size:11.0pt'>experience side effects of this </span><span
lang=EN-GB style='font-size:11.0pt'>medicine </span><span style='font-size:
11.0pt'>that may impair your ability to drive, use tools or operate machines (see
section 4 Possible side effects). If this happens, do not drive or use any
tools or machines before discussing with your </span><span lang=EN-GB
style='font-size:11.0pt'>doctor, nurse or hospital pharmacist</span><span
style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>TAXOTERE contains ethanol (alcohol)</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 1.58&nbsp;g ethanol anhydrous per vial, equivalent to 40&nbsp;ml of
beer or 17&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>H</span><span lang=EN-GB style='font-size:11.0pt'>armful
for those suffering from alcoholism. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>To be taken into account in pregnant or breast&#8209;feeding
women, in children and high&#8209;risk groups such as patients with liver disease,
or epilepsy.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=Normal11pt>The amount of alcohol in this medicinal product may have
effects on the central nervous system (the part of the nervous system that
includes the brain and spinal cord).</p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to use<span style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be administered to you by a
healthcare professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Usual dose</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The dose
will depend on your weight and your general condition. Your doctor will calculate
your body surface area in square meters (m&sup2;) and will determine the dose
you should receive.<s> </s></span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Method and route of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be given by infusion into
one of your veins (intravenous use). The infusion will last approximately one
hour during which you will be in the hospital.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Frequency of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You should usually receive your infusion
once every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor may change the dose and
frequency of dosing depending on your blood tests, your general condition and your
response to </span><span lang=EN-GB style='font-family:"(Utiliser une police de caract&egrave;",serif'>TAXOTERE</span><span
lang=EN-GB>. In particular, please inform your doctor in case of diarrhoea,
sores in the mouth, feeling of numbness or pins and needles, fever and give
her/him results of your blood tests. Such information will allow her/him to
decide whether a dose reduction is needed. If you have any further questions on
the use of this medicine, ask your doctor, or hospital pharmacist.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>Possible side effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor will discuss these with you
and will explain the potential risks and benefits of your treatment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse reactions
of TAXOTERE alone are: decrease in the number of red blood cells or white blood
cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The severity of adverse events of TAXOTERE
may be increased when TAXOTERE is given in combination with other
chemotherapeutic agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During the infusion at the hospital the
following allergic reactions may occur (may affect more than 1&nbsp;in 10
people): </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>flushing, skin
reactions, itching</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>chest tightness;
difficulty in breathing </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever or chills</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>back pain </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>low blood pressure.</span></p>

<p class=Normal11pt><span lang=EN-GB>More severe reactions may occur. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you had an allergic reaction to
paclitaxel, you may also experience an allergic reaction to docetaxel, which
may be </span>more severe<span lang=EN-GB>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The hospital staff will monitor your condition
closely during treatment. Tell them immediately if you notice any of these
effects.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Between infusions of TAXOTERE the following
may occur, and the frequency may vary with the combinations of medicines that
are received</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Very common </span></b><span lang=EN-GB
style='font-size:11.0pt'>(</span><span lang=EN-GB>may affect</span><span
lang=EN-GB style='font-size:11.0pt'> more than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>infections, decrease in
the number of red (anaemia), or white blood cells (which are important in
fighting infection) and platelets</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever: if this happens
you must tell your doctor immediately</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>allergic reactions as
described above</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>loss of appetite
(anorexia) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>insomnia</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>feeling of numbness or
pins and needles or pain in the joints or muscles</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>headache </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>alteration in sense of
taste </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>inflammation of the eye
or increased tearing of the eyes </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling caused by
faulty lymphatic drainage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>shortness of breath </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>nasal drainage;
inflammation of the throat and nose; cough</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>bleeding from the nose </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>sores in the mouth </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>stomach upsets
including nausea, vomiting and diarrhoea, constipation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>indigestion</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hair loss: in most cases normal
hair growth should return. In some cases (frequency not known) permanent hair
loss has been observed</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>redness and swelling of
the palms of your hands or soles of your feet which may cause your skin to peel
(this may also occur on the arms, face, or body)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change in the colour of
your nails, which may detach </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>muscle aches and pains;
back pain or bone pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change or absence of
menstrual period</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling of the hands,
feet, legs </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>tiredness; or flu-like
symptoms</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>weight gain or loss.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infection of the upper respiratory
tract.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> (may
affect up to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oral candidiasis</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dehydration</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dizziness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>hearing impaired</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>decrease in blood
pressure; irregular or rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>heart failure</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oesophagitis </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>difficulty or painful
swallowing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>haemorrhage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>raised liver enzymes
(hence the need for regular blood tests)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>rises in blood sugar levels
(diabetes)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease of the potassium, calcium
and/or phosphate in your blood. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> (may
affect up to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fainting</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>at the injection site,
skin reactions, phlebitis (inflammation of the vein) or swelling</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>blood clots.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>acute myeloid leukaemia and
myelodysplastic syndrome (types of blood cancer) may occur in patients who are
treated with docetaxel together with certain other anticancer treatments</span><span
style='font-size:11.0pt'>.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Rare</span></b><b><span
style='font-size:11.0pt'> </span></b><span style='font-size:11.0pt'>(may affect
up to 1 in 1,000 people):</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the colon, small
intestine, which could be fatal (frequency not known); intestinal perforation.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Frequency not known
</span></b><span lang=EN-GB style='font-size:11.0pt'>(cannot be estimated from
the available data):</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>interstitial lung
disease (inflammation of the lungs causing coughing and difficulty breathing.
Inflammation of the lungs can also develop when docetaxel therapy is used with
radiotherapy)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pneumonia (infection of
the lungs)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pulmonary fibrosis
(scarring and thickening in the lungs with shortness of breath)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision due to swelling of the retina
within the eye (cystoid macular oedema)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease of the sodium and/or magnesium in your
blood (electrolyte balance disorders)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ventricular arrhythmia or ventricular
tachycardia (manifested as irregular and/or rapid heartbeat, severe shortness
of breath, dizziness, and/or fainting). Some of these symptoms can be serious.
If this happens, you must tell your doctor immediately</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injection site reactions at the site of a previous reaction<span
lang=EN-GB>.</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>n</span>on-Hodgkin lymphoma (a cancer affecting
the immune system) and other cancers may occur in patients who are treated with
docetaxel together with certain other anticancer treatments.</p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stevens-Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN) (blistering, peeling or bleeding on any part of your
skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or
without a rash. You may also have flu-like symptoms at the same time, such as
fever, chills or aching muscles.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute Generalized Exanthematous Pustulosis (AGEP)
(red, scaly widespread rash with bumps under the swollen skin (including your
skin folds, trunk, and upper extremities) and blisters accompanied by fever.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>tumour lysis syndrome is a
serious condition revealed by changes in blood test such as increased level of
uric acid, potassium, phosphorus and decreased level of calcium; and results in
symptoms such as seizures, kidney failure </span><span lang=EN-GB>(reduced
amount or darkening of urine)<span style='color:black'> and heart rhythm
disturbance. &nbsp;If this happens, you must tell your doctor immediately.</span></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>myositis (inflammation
of the muscles -hot, red and swollen- which produces muscle pain and weakness) </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Reporting of adverse effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>If you get any side effects talk to your
doctor, hospital pharmacist or nurse. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via the
national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>. By reporting side effects you can help provide more information on the
safety of this medicine.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to store<span style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the outer carton and on the label
of the vial after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use the vial immediately after its
opening. If not used immediately, in&#8209;use storage times and conditions are
the responsibility of the user. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>From a microbiological point of view, reconstitution/dilution
must take place in controlled and aseptic conditions.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use immediately the medicine once added
into the infusion bag<u>.</u> If not used immediately, in&#8209;use storage times
and conditions are the responsibility of the user and would normally not be
longer than 6&nbsp;hours below 25&deg;C including the one hour infusion. </span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Physical and
chemical in-use stability of the infusion solution prepared as recommended has been
demonstrated in non-PVC bags up to 48 hours when stored between 2 to 8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel infusion solution is
supersaturated, therefore may cristallize over time. If crystals appear, the
solution must no longer be used and shall be discarded.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><span lang=EN-GB>Do not throw away any medicines via
wastewater. Ask your pharmacist how to throw away medicines you no longer use.
These measures will help protect the environment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-19.85pt;text-align:justify;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>Contents of the pack and other information</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE contains</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The active substance is docetaxel (as trihydrate).
Each ml of concentrate for solution for infusion contains 20&nbsp;mg docetaxel.
</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span style='font-size:11.0pt'>- The
other ingredients are polysorbate&nbsp;80, ethanol anhydrous (see section 2) and
citric acid.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE looks like and contents
of the pack</span></b></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE concentrate for solution for
infusion is a pale yellow to brownish&#8209;yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is supplied in a 7&nbsp;ml
clear colourless glass vial with a magenta aluminium seal and a magenta plastic
flip&#8209;off cap.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each box
contains one vial of 4&nbsp;ml concentrate (80&nbsp;mg docetaxel).</span></p>

<p class=TblTextLeft style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=FR>France</span></p>

<p class=Normal11pt><b><span lang=PT-BR>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=PT-BR>Manufacturers</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
color:black'>65926 Frankfurt am Main</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt;text-autospace:none'><span style='font-size:11.0pt;color:black'>Germany</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Or</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Sanofi-Aventis
Zrt.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>(Harbor Park) 1,
Campona utca</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Budapest</span><span
lang=EN-GB> 1225</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hungary</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder. </span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>UAB <span
  style='letter-spacing:-.05pt'>&laquo;SANOFI-AVENTIS LIETUVA&raquo;</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=IT
  style='font-family:"Times New Roman",serif'>SANOFI BULGARIA EOOD</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#1058;&#1077;&#1083;</span><span
  lang=IT style='font-size:11.0pt'>.: +359 (0)2 970 53 00</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis,
  s.r.o.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +420 233 086
  111</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis zrt.,
  Magyarorsz&aacute;g</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel.: +36 1 505
  0050</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 45 16
  70 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi S.r.l. </span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +39. 02
  39394275</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi-Aventis
  Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: 0800 04 36 996</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel. aus dem
  Ausland: +49 69 305 70 13</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +</span><span
  lang=CS style='font-size:11.0pt'>20 245 4000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Estonia O&Uuml;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>sanofi-aventis Norge
   AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +47 67 10
  71 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;</span><span
  lang=FR style='font-size:11.0pt'>: +30 210 900 16 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +43 1 80 185
  &#8211; 0</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +34 93 485
  94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis Sp.
  z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel.: +48
  22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  France</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l: 0 800 222
  555</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Appel depuis
  l&#8217;&eacute;tranger : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi -
  Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +351 21 35
  89 400</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT
  style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +385 1 600 34
  00</span></p>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +40 </span><span
  lang=EN-GB style='font-size:11.0pt'>(0) 21 317 31 36</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +353 (0) 1
  403 56 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +386 1 560
  48 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S&iacute;mi</span><span
  lang=EN-GB style='font-size:11.0pt'>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis
  Slovakia s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +421 2
  33&nbsp;100 100</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: 800536389</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi </span><span
  lang=FR style='font-size:11.0pt'>Oy</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Puh/Tel: +358 (0)
  201 200 300</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;:
  +357 22 871600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi </span><span
  lang=EN-GB style='font-size:11.0pt'>AB</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +46 (0)8
  634 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +371 67 33 24
  51</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>United
    Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sanofi</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +44 (0) </span><span
  lang=SV style='font-size:11.0pt'>845&nbsp;372 7101</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:.05in'><span class=Normal11ptCar><b><span
lang=EN-GB style='font-size:11.0pt'>This leaflet was last revised in</span></b></span><b><span
lang=EN-GB style='font-size:11.0pt'> </span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>Other sources of information </span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed information on this medicine is available on
the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div class=WordSection5>

<p class=Normal11pt><span lang=EN-GB>The following information is intended for healthcare
professionals only:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>PREPARATION GUIDE FOR USE
WITH TAXOTERE 80&nbsp;</span></b><b><span lang=EN-GB style='font-size:11.0pt'>mg/4&nbsp;ml<span
style='text-transform:uppercase'> </span></span></b><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>CONCENTRATE FOR SOLUTION FOR
INFUSION</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>It is important that you read the
entire contents of this guide prior to the preparation of the TAXOTERE infusion
solution.</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Recommendations for the safe handling</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it<span style='position:relative;top:-3.0pt'> </span>and preparing its
solutions. The use of gloves is recommended. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion solution
should come into contact with skin, wash immediately and thoroughly with soap
and water. If it should come into contact with mucous membranes, wash
immediately and thoroughly with water.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation of the intravenous administration</span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2 vials (concentrate and
solvent) with this medicinal product (TAXOTERE 80&nbsp;mg/4&nbsp;ml concentrate
for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE 80&nbsp;mg/4&nbsp;ml concentrate for solution
for infusion requires NO prior dilution with a solvent and is ready to add to
the infusion solution.</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each vial is for single
use and should be used immediately after opening. If not used immediately, in&#8209;use
storage times and conditions are the responsibility of the user. </span><span
lang=EN-GB style='font-size:11.0pt'>More than one vial of </span><span
lang=EN-GB style='font-size:11.0pt'>concentrate for solution for infusion</span><span
lang=EN-GB style='font-size:11.0pt'> may be necessary to obtain the required
dose for the patient. For example, a dose of 140&nbsp;mg docetaxel would
require 7&nbsp;ml docetaxel concentrate for solution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Aseptically withdraw
the required amount of concentrate for solution for infusion with a calibrated
syringe fitted with a 21G needle.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 80&nbsp;mg/4&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Then, inject via a single
injection (one shot) into a 250&nbsp;ml infusion bag or bottle containing
either 5% glucose solution or sodium chloride 9&nbsp;mg/ml (0.9%) solution for infusion.
If a dose greater than 190&nbsp;mg of docetaxel is required, use a larger
volume of the infusion vehicle so that a concentration of 0.74&nbsp;mg/ml
docetaxel is not exceeded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mix the infusion bag or
bottle manually using a rocking motion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>From a microbiological
point of view, reconstitution /dilution must take place in controlled and
aseptic conditions and </span><span lang=EN-GB style='font-size:11.0pt'>the</span><span
lang=EN-GB style='font-size:11.0pt'> infusion solution</span><span lang=EN-GB
style='font-size:11.0pt'> should be used immediately. If not used immediately,
in&#8209;use storage times and conditions are the responsibility of the user.</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Once added as recommended into the infusion bag, the
docetaxel infusion solution, if stored below 25&deg;C, is stable for 6 hours.
It should be used within 6 hours (including the one hour infusion intravenous administration).
</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>In addition, physical and chemical in-use stability of
the infusion solution prepared as recommended has been demonstrated in non-PVC
bags up to 48 hours when stored between 2&deg;C to 8&deg;C. </span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt'>Docetaxel infusion solution is supersaturated,
therefore may crystallize over time. If crystals appear, the solution must no
longer be used and shall be discarded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As with all parenteral
products, infusion solution should be visually inspected prior to use,
solutions containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Disposal</span></u></p>

<p class=Normal11pt><span lang=EN-GB>All materials that have been utilised for
dilution and administration should be disposed of according to standard
procedures. Do not throw away any medicines via wastewater. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>Package
Leaflet: Information for the patient</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>TAXOTERE
160&nbsp;mg/8&nbsp;ml concentrate for solution for infusion</span></b></p>

<p class=Normal11pt align=center style='text-align:center'><b><span lang=EN-GB>docetaxel</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=Normal11pt style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Read all of this leaflet carefully
before you start using this medicine because it contains important information
for you.</span></b></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, ask your doctor, hospital pharmacist or nurse.</span></p>

<p class=Normal11pt style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any side
effects talk to your doctor, hospital pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
TAXOTERE is and what it is used for</span></p>

<p class=Normal11pt><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
use TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=Normal11pt><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store TAXOTERE</span></p>

<p class=Normal11pt><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What<span style='text-transform:uppercase'> TAXOTERE </span>is
and what it is used for</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The name of this medicine is TAXOTERE. Its
common name is docetaxel. Docetaxel is a substance derived from the needles of
yew trees.</span></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel belongs to the group of
anti-cancer medicines called taxoids.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE has been prescribed by your
doctor for the treatment of breast cancer, special forms of lung cancer
(non-small cell lung cancer), prostate cancer, gastric cancer or head and neck
cancer: </span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of advanced breast
cancer, TAXOTERE could be administered either alone or in combination with
doxorubicin, or trastuzumab, or capecitabine.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of early breast cancer
with or without lymph node involvement, TAXOTERE could be administered in
combination with doxorubicin and cyclophosphamide.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of lung cancer,
TAXOTERE could be administered either alone or in combination with cisplatin.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of prostate cancer,
TAXOTERE is administered in combination with prednisone or prednisolone.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of metastatic gastric
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>- For the treatment of head and neck
cancer, TAXOTERE is administered in combination with cisplatin and 5&#8209;fluorouracil.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>What you need to know before you use<span
style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>You must not be given TAXOTERE: </span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:23.2pt;margin-bottom:.0001pt;text-indent:-23.2pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic
(hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE (listed
in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if the number of white
blood cells is too low.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.8pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have a severe
liver disease.</span></p>

<p class=Retrait1 style='margin-left:0in;text-align:justify'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Before each
treatment with TAXOTERE, you will have blood tests to check that you have enough
blood cells and sufficient liver function to receive TAXOTERE. In case of white
blood cells disturbances, you may experience associated fever or infections.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist, or nurse
immediately if you have abdominal pain or tenderness, diarrhoea, rectal
haemorrhage, blood in stool or fever. These symptoms may be the first signs of
a serious gastrointestinal toxicity, which could be fatal. Your doctor should
address them immediately.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you
have vision problems. In case of vision problems, in particular blurred vision,
you should immediately have your eyes and vision examined. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor, hospital pharmacist or nurse if you
have experienced an allergic reaction to previous paclitaxel therapy.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span style='font-size:11.0pt'>Tell
your doctor, hospital pharmacist or nurse if you have heart problems. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>If you develop acute or worsening problems with your
lungs (fever, shortness of breath or cough), please tell your doctor, hospital
pharmacist or nurse immediately. Your doctor may stop your treatment
immediately.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You will be asked to take premedication consisting
of an oral corticosteroid such as dexamethasone, one day prior to TAXOTERE
administration and to continue for one or two days after it in order to minimise
certain undesirable effects which may occur after the infusion of TAXOTERE in
particular allergic reactions and fluid retention (swelling of the hands, feet,
legs or weight gain).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During treatment, you may be given other
medicines to maintain the number of your blood cells.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Severe skin problems such as
Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute
Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: </span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>SJS/TEN symptoms may include blistering, peeling
or bleeding on any part of your skin (including your lips, eyes, mouth, nose,
genitals, hands or feet) with or without a rash. You may also have flu-like
symptoms at the same time, such as fever, chills or aching muscles.</span></p>

<p class=Normal11pt style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>AGEP symptoms may include a red, scaly
widespread rash with bumps under the swollen skin (including your skin folds,
trunk, and upper extremities) and blisters accompanied by fever. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you develop severe skin reactions or
any of the reactions listed above, immediately contact your doctor or
healthcare professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Tell your doctor, hospital pharmacist or
nurse if you have kidney problems or high levels of uric acid in your blood before
intiating TAXOTERE. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE contains alcohol. Discuss with
your doctor if you suffer from alcohol dependency, epilepsy or liver
impairment. See also section &#8220;TAXOTERE contains ethanol (alcohol)&#8221;
below.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Other medicines and TAXOTERE</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Please tell your doctor or hospital
pharmacist if you are taking or have recently taken any other medicine,
including medicines obtained without a prescription. This is because TAXOTERE
or the other medicine may not work as well as expected and you may be more
likely to get a side effect.</span></p>

<p class=Normal11pt><span lang=EN-GB>The amount of alcohol in this medicinal
product may alter the effects of other medicines.</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Heading31 style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;text-align:justify;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy</span><span style='font-size:11.0pt'>,
breast-feeding and fertility</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ask your doctor
for advice before being given any medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>TAXOTERE must <u>NOT</u> be administered if you are pregnant
unless clearly indicated by your doctor. </span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>You must not become pregnant during treatment with
this medicine and must use an effective method of contraception during therapy,
because TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during
your treatment, you must immediately inform your doctor.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>You must not
breast&#8209;feed while you are treated with TAXOTERE.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>If you are a man
being treated with TAXOTERE you are advised not to father a child during and up
to 6&nbsp;months after treatment and to seek advice on conservation of sperm
prior to treatment because docetaxel may alter male fertility.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>The amount of alcohol in this medicinal
product may impair your ability to drive or use machines. You may </span><span
style='font-size:11.0pt'>experience side effects of this</span><span
style='font-size:11.0pt'> <span lang=EN-GB>medicine </span></span><span
style='font-size:11.0pt'>that may impair your ability to drive, use tools or
operate machines (see section 4 Possible side effects). If this happens, do not
drive or use any tools or machines before discussing with your </span><span
lang=EN-GB style='font-size:11.0pt'>doctor, nurse or hospital pharmacist</span><span
style='font-size:11.0pt'>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>TAXOTERE contains ethanol (alcohol)</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>This medicinal product contains </span><span
lang=EN-GB style='font-size:11.0pt'>50&nbsp;vol % ethanol anhydrous (alcohol),
i.e. up to 3.16&nbsp;g ethanol anhydrous per vial, equivalent to 80&nbsp;ml of
beer or 33&nbsp;ml wine</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'><br>
H</span><span lang=EN-GB style='font-size:11.0pt'>armful for those suffering
from alcoholism. </span></p>

<p class=Normal11pt><span lang=EN-GB>To be taken into account in pregnant or
breast&#8209;feeding women, in children and high&#8209;risk groups such as
patients with liver disease, or epilepsy.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;font-family:TimesNewRoman'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt'>The
amount of alcohol in this medicinal product may have effects on the central
nervous system (the part of the nervous system that includes the brain and spinal
cord).</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to use<span style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be administered to you by a
healthcare professional.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Usual dose</span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>The dose
will depend on your weight and your general condition. Your doctor will
calculate your body surface area in square meters (m&sup2;) and will determine
the dose you should receive.<s> </s></span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>Method and route of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE will be given by infusion into
one of your veins (intravenous use). The infusion will last approximately one
hour during which you will be in the hospital.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Frequency of administration</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>You should usually receive your infusion
once every 3&nbsp;weeks.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor may change the dose and
frequency of dosing depending on your blood tests, your general condition and
your response to </span><span lang=EN-GB style='font-family:"(Utiliser une police de caract&egrave;",serif'>TAXOTERE</span><span
lang=EN-GB>. In particular, please inform your doctor in case of diarrhoea,
sores in the mouth, feeling of numbness or pins and needles, fever and give
her/him results of your blood tests. Such information will allow her/him to
decide whether a dose reduction is needed. If you have any further questions on
the use of this medicine, ask your doctor, or hospital pharmacist.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>Possible side effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Your doctor will discuss these with you
and will explain the potential risks and benefits of your treatment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The most commonly reported adverse
reactions of TAXOTERE alone are: decrease in the number of red blood cells or
white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea
and tiredness.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The severity of adverse events of TAXOTERE
may be increased when TAXOTERE is given in combination with other
chemotherapeutic agents.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>During the infusion at the hospital the
following allergic reactions may occur (may affect more than 1&nbsp; in 10
people): </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>flushing, skin
reactions, itching</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>chest tightness;
difficulty in breathing </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever or chills</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>back pain </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>low blood pressure.</span></p>

<p class=Normal11pt><span lang=EN-GB>More severe reactions may occur. </span></p>

<p class=Normal11pt><span lang=EN-GB>If you had an allergic reaction to paclitaxel,
you may also experience an allergic reaction to docetaxel, which may be </span>more
severe<span lang=EN-GB>.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>The hospital staff will monitor your condition
closely during treatment. Tell them immediately if you notice any of these
effects.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Between infusions of TAXOTERE the
following may occur, and the frequency may vary with the combinations of
medicines that are received</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Very common </span></b><span lang=EN-GB
style='font-size:11.0pt'>(</span><span lang=EN-GB>may affect</span><span
lang=EN-GB style='font-size:11.0pt'> more than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>infections, decrease in
the number of red (anaemia), or white blood cells (which are important in fighting
infection) and platelets</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fever: if this happens
you must tell your doctor immediately</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>allergic reactions as
described above</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>loss of appetite
(anorexia) </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>insomnia</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>feeling of numbness or
pins and needles or pain in the joints or muscles</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>headache </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>alteration in sense of
taste </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>inflammation of the eye
or increased tearing of the eyes </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling caused by
faulty lymphatic drainage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>shortness of breath </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>nasal drainage;
inflammation of the throat and nose; cough</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>bleeding from the nose </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>sores in the mouth </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>stomach upsets including
nausea, vomiting and diarrhoea, constipation</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>indigestion</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>hair loss: in most cases normal
hair growth should return. In some cases (frequency not known) permanent hair
loss has been observed</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>redness and swelling of
the palms of your hands or soles of your feet which may cause your skin to peel
(this may also occur on the arms, face, or body)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change in the colour of
your nails, which may detach </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>muscle aches and pains;
back pain or bone pain</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>change or absence of
menstrual period</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling of the hands,
feet, legs </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>tiredness; or flu-like
symptoms</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>weight gain or loss.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>infection of the upper respiratory
tract.</span></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> (may
affectup to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oral candidiasis</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dehydration</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dizziness</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>hearing impaired</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>decrease in blood pressure;
irregular or rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>heart failure</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>oesophagitis </span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>dry mouth</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>difficulty or painful
swallowing</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>haemorrhage</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>raised liver enzymes
(hence the need for regular blood tests)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>rises in blood sugar levels
(diabetes)</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>decrease of the potassium, calcium
and/or phosphate in your blood. </span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> (may
affectup to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>fainting</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>at the injection site,
skin reactions, phlebitis (inflammation of the vein) or swelling</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>blood clots.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>acute myeloid leukaemia and
myelodysplastic syndrome (types of blood cancer) may occur in patients who are
treated with docetaxel together with certain other anticancer treatments</span><span
style='font-size:11.0pt'>.</span></p>

<p class=Normal11pt>&nbsp;</p>

<p class=MsoNormal><b><span style='font-size:11.0pt'>Rare</span></b><b><span
style='font-size:11.0pt'> </span></b><span style='font-size:11.0pt'>(may affect
up to 1 in 1,000 people):</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
style='font-size:11.0pt;font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>inflammation of the colon, small
intestine, which could be fatal (frequency not known); intestinal perforation.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Frequency not known
</span></b><span lang=EN-GB style='font-size:11.0pt'>(cannot be estimated from the
available data):</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>interstitial lung
disease (inflammation of the lungs causing coughing and difficulty breathing.
Inflammation of the lungs can also develop when docetaxel therapy is used with
radiotherapy)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pneumonia (infection of
the lungs)</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pulmonary fibrosis
(scarring and thickening in the lungs with shortness of breath)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision due to swelling of the retina
within the eye (cystoid macular oedema)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease of the sodium and/or magnesium in your
blood (electrolyte balance disorders)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ventricular arrhythmia or ventricular
tachycardia (manifested as irregular and/or rapid heartbeat, severe shortness
of breath, dizziness, and/or fainting). Some of these symptoms can be serious.
If this happens, you must tell your doctor immediately</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>injection site reactions at the site of a previous reaction<span
lang=EN-GB>.</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>n</span>on-Hodgkin lymphoma (a cancer affecting
the immune system) and other cancers may occur in patients who are treated with
docetaxel together with certain other anticancer treatments.</p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stevens-Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN) (blistering, peeling or bleeding on any part of your
skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or
without a rash. You may also have flu-like symptoms at the same time, such as
fever, chills or aching muscles.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute Generalized Exanthematous Pustulosis (AGEP)
(red, scaly widespread rash with bumps under the swollen skin (including your
skin folds, trunk, and upper extremities) and blisters accompanied by fever.)</span></p>

<p class=Normal11pt style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>tumour lysis syndrome is a
serious condition revealed by changes in blood test such as increased level of
uric acid, potassium, phosphorus and decreased level of calcium; and results in
symptoms such as seizures, kidney failure </span><span lang=EN-GB>(reduced
amount or darkening of urine) <span style='color:black'>and heart rhythm
disturbance. &nbsp;If this happens, you must tell your doctor immediately.</span></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>myositis (inflammation
of the muscles -hot, red and swollen- which produces muscle pain and weakness) </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=Normal11pt><span lang=EN-GB>If you get any side effects talk to your
doctor, hospital pharmacist or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national
reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>. By reporting side effects you can help provide more information on the
safety of this medicine.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>How to store<span style='text-transform:uppercase'> TAXOTERE</span></span></b></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the outer carton and on the
label of the vial after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Do not store above 25&deg;C.</span></p>

<p class=Normal11pt><span lang=EN-GB>Store in the original package in order to
protect from light.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use the vial immediately after its opening.
If not used immediately, in&#8209;use storage times and conditions are the
responsibility of the user. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>From a microbiological point of view, reconstitution/dilution
must take place in controlled and aseptic conditions.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>Use immediately the medicine once added
into the infusion bag<u>.</u> If not used immediately, in&#8209;use storage
times and conditions are the responsibility of the user and would normally not
be longer than 6&nbsp;hours below 25&deg;C including the one hour infusion. </span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Physical and
chemical in-use stability of the infusion solution prepared as recommended has
been demonstrated in non-PVC bags up to 48 hours when stored between 2 to
8&deg;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Docetaxel infusion
solution is supersaturated, therefore may cristallize over time. If crystals
appear, the solution must no longer be used and shall be discarded. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;Do not throw
away any medicines via wastewater. Ask your pharmacist how to throw away
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-19.85pt;text-align:justify;punctuation-wrap:
simple;text-autospace:none;vertical-align:baseline'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>Contents of the pack and other information</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE contains</span></b></p>

<p class=MsoNormal style='margin-right:2.8pt'><span lang=EN-GB
style='font-size:11.0pt'>- The active substance is docetaxel (as trihydrate).
Each ml of concentrate for solution for infusion contains 20&nbsp;mg docetaxel.
</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span style='font-size:11.0pt'>- The
other ingredients are polysorbate&nbsp;80, ethanol anhydrous (see section 2) and
citric acid.</span></p>

<p class=paragraph style='margin-top:0in;margin-right:.55pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><b><span lang=EN-GB>What TAXOTERE looks like and contents of
the pack</span></b></p>

<p class=Normal11pt><span lang=EN-GB>TAXOTERE concentrate for solution for
infusion is a pale yellow to brownish&#8209;yellow solution.</span></p>

<p class=Normal11pt><span lang=EN-GB>The concentrate is supplied in a <a
name="OLE_LINK3"></a><a name="OLE_LINK4">15</a>&nbsp;ml clear colourless glass
vial with a blue aluminium seal and a blue plastic flip&#8209;off cap.</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='text-align:justify'><span lang=EN-GB>Each box
contains one vial of 8&nbsp;ml concentrate (160&nbsp;mg docetaxel).</span></p>

<p class=TblTextLeft style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Sanofi Mature IP</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>54 rue La
Bo&eacute;tie</span></p>

<p class=MsoNormal><span lang=FR style='font-size:11.0pt'>75008 Paris</span></p>

<p class=Normal11pt><span lang=FR>France</span><span lang=FR> </span></p>

<p class=Normal11pt><b><span lang=PT-BR>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=PT-BR>&nbsp;</span></b></p>

<p class=Normal11pt><b><span lang=PT-BR>Manufacturers</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Sanofi-Aventis Deutschland GmbH</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=DE style='font-size:
11.0pt;color:black'>Industriepark H&ouml;chst</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
color:black'>65926 Frankfurt am Main</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;
  color:black'>Germany</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Or</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>Sanofi-Aventis
Zrt.</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=SV>(Harbor Park)
1, Campona utca</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Budapest</span><span
lang=EN-GB> 1225</span></p>

<p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Hungary</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>For any information about this medicine, please
contact the local representative of the Marketing Authorisation Holder. </span></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>UAB <span
  style='letter-spacing:-.05pt'>&laquo;SANOFI-AVENTIS LIETUVA&raquo;</span></span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +370 5 2755224</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=Authors style='margin-top:0in;page-break-after:auto'><span lang=IT
  style='font-family:"Times New Roman",serif'>SANOFI BULGARIA EOOD</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#1058;&#1077;&#1083;</span><span
  lang=IT style='font-size:11.0pt'>.: +359 (0)2 970 53 00</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt;layout-grid-mode:
  line'>Sanofi Belgium </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>T&eacute;l/Tel: <span
  style='layout-grid-mode:line'>+32 (0)2 710 54 00 (</span>Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis,
  s.r.o.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +420 233 086
  111</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  zrt., Magyarorsz&aacute;g</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel.: +36 1 505
  0050</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Sanofi A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 45 16
  70 00</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +39. 02
  39394275</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Sanofi-Aventis
  Deutschland GmbH</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel: 0800 04 36 996</span></p>
  <p class=MsoNormal><span lang=CS style='font-size:11.0pt'>Tel. aus dem
  Ausland: +49 69 305 70 13</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL style='font-size:11.0pt'>Genzyme Europe B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +31 </span><span
  lang=CS style='font-size:11.0pt'>20 245 4000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Estonia O&Uuml;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +372 627 34 88</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>sanofi-aventis Norge
   AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +47 67 10
  71 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis AEBE</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;</span><span
  lang=FR style='font-size:11.0pt'>: +30 210 900 16 00</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>sanofi-aventis GmbH</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +43 1 80 185
  &#8211; 0</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +34 93 485
  94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis Sp.
  z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel.: +48
  22&nbsp;280 00 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  France</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>T&eacute;l: 0 800 222
  555</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Appel depuis l&#8217;&eacute;tranger
  : +33 1 57 63 23 23</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:11.0pt'>Sanofi -
  Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +351 21 35
  89 400</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT
  style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Croatia d.o.o.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +385 1 600 34
  00</span></p>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Romania SRL</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +40 </span><span
  lang=FR style='font-size:11.0pt'>(0) 21 317 31 36</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Ireland Ltd. T/A SANOFI</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +353 (0) 1
  403 56 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +386 1 560
  48 00</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>S&iacute;mi</span><span
  lang=EN-GB style='font-size:11.0pt'>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>sanofi-aventis
  Slovakia s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +421 2 33
  100 100</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi S.r.l.</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: 800536389</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Sanofi Oy</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Puh/Tel: +358 (0)
  201 200 300</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>sanofi-aventis
  Cyprus Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;:
  +357 22 871600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Sanofi AB</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +46 (0)8 634
  50 00</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>sanofi-aventis
  Latvia SIA</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Tel: +371 67 33 24
  51</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sanofi</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>Tel: +44 (0)
  845&nbsp;372 7101</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:.05in'><span class=Normal11ptCar><b><span
lang=EN-GB style='font-size:11.0pt'>This leaflet was last revised in</span></b></span></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>Other sources of information </span></b></p>

<p class=MsoNormal style='margin-right:.05in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.05in'><span lang=EN-GB
style='font-size:11.0pt'>Detailed information on this medicine is available on
the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div class=WordSection6>

<p class=Normal11pt><span lang=EN-GB>The following information is intended for
healthcare professionals only:</span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>PREPARATION GUIDE FOR USE
WITH TAXOTERE 160&nbsp;</span></b><b><span lang=EN-GB style='font-size:11.0pt'>mg/8&nbsp;ml<span
style='text-transform:uppercase'> </span></span></b><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>CONCENTRATE FOR SOLUTION FOR
INFUSION</span></b></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Normal11pt><i><span lang=EN-GB>It is important that you read the
entire contents of this guide prior to the preparation of the TAXOTERE infusion
solution.</span></i></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><u><span lang=EN-GB>Recommendations for the safe handling</span></u></p>

<p class=Normal11pt><span lang=EN-GB>Docetaxel is an antineoplastic agent and,
as with other potentially toxic compounds, caution should be exercised when
handling it<span style='position:relative;top:-3.0pt'> </span>and preparing its
solutions. The use of gloves is recommended. </span></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt><span lang=EN-GB>If TAXOTERE concentrate or infusion solution
should come into contact with skin, wash immediately and thoroughly with soap
and water. If it should come into contact with mucous membranes, wash
immediately and thoroughly with water.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Preparation of the intravenous administration</span></u></p>

<p class=Normal11pt><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Normal11pt><i><u><span lang=EN-GB>Preparation of the infusion solution</span></u></i></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>DO NOT use
other docetaxel medicinal products consisting of 2 vials (concentrate and
solvent) with this medicinal product (TAXOTERE 160&nbsp;mg/8&nbsp;ml
concentrate for solution for infusion, which contains only 1&nbsp;vial).</span></b></p>

<p class=Normal11pt><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>TAXOTERE 160&nbsp;mg/8&nbsp;ml
concentrate for solution for infusion requires NO prior dilution with a solvent
and is ready to add to the infusion solution.</span></b><span lang=EN-GB
style='font-size:11.0pt'> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Each vial is for single
use and should be used immediately after opening. If not used immediately, in&#8209;use
storage times and conditions are the responsibility of the user. </span><span
lang=EN-GB style='font-size:11.0pt'>More than one vial of </span><span
lang=EN-GB style='font-size:11.0pt'>concentrate for solution for infusion</span><span
lang=EN-GB style='font-size:11.0pt'> may be necessary to obtain the required
dose for the patient. For example, a dose of 140&nbsp;mg docetaxel would
require 7&nbsp;ml docetaxel concentrate for solution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Aseptically withdraw
the required amount of concentrate for solution for infusion with a calibrated
syringe fitted with a 21G needle.</span></p>

<p class=Normal11pt><b><span lang=EN-GB>In TAXOTERE 160&nbsp;mg/8&nbsp;ml vial
the concentration of docetaxel is 20&nbsp;mg/ml.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Then, inject via a single
injection (one shot) into a 250&nbsp;ml infusion bag or bottle containing
either 5% glucose solution or sodium chloride 9&nbsp;mg/ml (0.9%) solution for
infusion. If a dose greater than 190&nbsp;mg of docetaxel is required, use a
larger volume of the infusion vehicle so that a concentration of 0.74&nbsp;mg/ml
docetaxel is not exceeded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Mix the infusion bag or
bottle manually using a rocking motion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>From a microbiological
point of view, reconstitution /dilution must take place in controlled and
aseptic conditions and the infusion solution should be used immediately. If not
used immediately, in&#8209;use storage times and conditions are the
responsibility of the user.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>Once added as recommended into the infusion bag, the
docetaxel infusion solution, if stored below 25&deg;C, is stable for 6 hours. It
should be used within 6 hours (including the one hour infusion intravenous administration).
</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>In addition, physical and chemical in-use stability of
the infusion solution prepared as recommended has been demonstrated in non-PVC
bags up to 48 hours when stored between 2&deg;C to 8&deg;C. </span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>Docetaxel infusion solution is supersaturated,
therefore may crystallize over time. If crystals appear, the solution must no
longer be used and shall be discarded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As with all parenteral
products, infusion solution should be visually inspected prior to use,
solutions containing a precipitate should be discarded.</span></p>

<p class=Normal11pt><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Normal11pt><u><span lang=EN-GB>Disposal</span></u></p>

<p class=Normal11pt><span lang=EN-GB>All materials that have been utilised for
dilution and administration should be disposed of according to standard
procedures. Do not throw away any medicines via wastewater. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment. </span></p>

</div>

</body>

</html>
